表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験:[redacted]

試験番号・ 被験者識別コード	MT-5199-J02・ [redacted]	投与群 （最終時投与量）	MT-5199 40 mg 群 （40 mg/日）
年齢・性別	6[redacted]歳・女性	体重・BMI ［ベースライン時］	6[redacted] kg，21.0 kg/m^2
遅発性ジスキネジア 発症年齢	6[redacted] 歳	基礎疾患区分 （発症年齢）	抑うつ障害 （5[redacted] 歳）
死亡に至った有害事象 （MedDRA 基本語）・ 発現時期	死亡・ Day 268～Day 268	死亡時期・ 治験薬との因果関係	Day 268・ Reasonable possibility
合併症	遅発性ジスキネジア，抑うつ障害，過敏性腸症候群，メニエール病，椎間板突出，関節痛，尿路結石，アレルギー性鼻炎，頭痛，不眠症，糖尿病，アカシジア，感音性難聴		
治験担当医師コメント	治験医師は診療情報提供書より死因が不明で治験薬との因果関係が否定できない為、因果関係はありと評価した		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	40 (mg)/QID	遅発性ジスキネジア	死亡 (Day 268)
ETIZOLAM	3.0 (mg) /QID	基礎疾患	
DULOXETINE HYDROCHLORIDE	60 (mg) /QD	基礎疾患	
MIRTAZAPINE	45 (mg) /QD	基礎疾患	
TRIAZOLAM	0.5 (mg) /QD	基礎疾患	
FLUNITRAZEPAM	3 (mg) /QD	基礎疾患	
OLANZAPINE	10 (mg) /QD	基礎疾患	
OLANZAPINE	20 (mg) /QD	基礎疾患	
CHLORPROMAZINE HYDROCHLORIDE	200 (mg) /QD	基礎疾患	
CHLORPROMAZINE HYDROCHLORIDE	150 (mg) /QD	基礎疾患	
BIFIDOBACTERIUM NOS	36 (mg) /TID	合併症	
RAMOSETRON HYDROCHLORIDE	2.5 (ug) /QD	合併症	
HYOSCINE BUTYLBROMIDE	30 (mg) /TID	合併症	
DIFENIDOL HYDROCHLORIDE	50 (mg) /BID	合併症	
LOPERAMIDE HYDROCHLORIDE	2 (mg) /BID	合併症	
APRONAL;CAFFEINE;PARACETAMOL;PROPYPHENAZONE	3 (g) /TID	合併症	
KETOPROFEN	1 (PATCH) /QD	合併症	
LORATADINE	10 (mg) /QD	合併症	
ADENOSINE TRIPHOSPHATE, DISODIUM SALT	200 (mg) /BID	合併症	
LOXOPROFEN SODIUM DIHYDRATE	60 (mg) /PRN	合併症	
ACETYLSALICYLIC ACID	1 (TABLET) /PRN	合併症	
CHONDROITIN SULFATE SODIUM	3 (TABLET) /QD	合併症	
FAMOTIDINE	20 (mg) /BID	胃炎予防	
CAFFEINE;PARACETAMOL;PROMETHAZINE METHYLENE DISALICYLATE;SALICYLAMIDE	1 (g) /PRN	有害事象	
BETAHISTINE MESILATE	36 (mg) /TID	有害事象	
ADENOSINE TRIPHOSPHATE, DISODIUM SALT	300 (mg) /TID	有害事象	
OTHER CARDIAC GLYCOSIDES	2 (TABLET) /PRN	有害事象	
EPINEPHRINE	Unknown /	有害事象	
CHLORPROMAZINE HYDROCHLORIDE	250 (mg) /QD	有害事象，合併症，基礎疾患	
CHLORPROMAZINE HYDROCHLORIDE	150 (mg) /QD	有害事象，合併症，基礎疾患	
APRONAL;CAFFEINE;PARACETAMOL;PROPYPHENAZONE	4 (g) /QID	有害事象，合併症	
ALPRAZOLAM	0.4 (mg) /QD	有害事象，合併症	
CLONAZEPAM	1 (mg) /QD	有害事象，合併症	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
死亡	高度	重篤	死亡 (Day 268)
上咽頭炎	軽度	非重篤	
頭痛	軽度	非重篤	
糖尿病	軽度	非重篤	
感音性難聴	軽度	非重篤	
浮動性めまい	軽度	非重篤	
動悸	軽度	非重篤	
呼吸困難	軽度	非重篤	
流涎過多	軽度	非重篤	
浮動性めまい	中等度	非重篤	
不眠症	中等度	非重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 2：8.33 h, Week 4: 5.45 h, Week 6: 5.13 h, Week 16: 3.83 h, Week 32: 2.42 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験：[redacted]（続き）

治験依頼者の見解

被験者[redacted]は，MT-5199-J02 試験の Day 268 に死亡した（死因は不明）．本被験者は，抗精神病薬としてオランザピンを Day 1～Day 44 まで併用し，Day 45～Day 164 までクロルプロマジン 150 mg/日に変更され，その後 Day 165～Day 188 まではクロルプロマジン 250 mg/日に増量された後、Day 188 から死亡日まではクロルプロマジン 150 mg/日に減量されている．治験薬服用期間に，器官別大分類「精神障害」又は「神経系障害」の有害事象に該当する浮動性めまい及び不眠症が認められたがいずれも死亡に至る有害事象とは考えにくい．本被験者は，QT 延長作用を有することが知られている薬剤としてミルタザピン，オランザピン，クロルプロマジン，ファモチジン，ロペラミド及びプロメタジンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．また本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤は併用していなかった．また Day 241 から服用されている市販薬の救心については作用の強度から死亡の原因とは考えにくい．今回あらためて合併症・有害事象と併用薬との関連を考察したが特に死亡の要因となるものはなく，MT-5199 との関連は不明であるが，併用薬と死亡の関連性は否定できると考える．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験：[redacted]

試験番号・ 被験者識別コード	MT-5199-J02・ [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （80 mg/日）
年齢・性別	7[redacted]歳・男性	体重・BMI ［ベースライン時］	4[redacted] kg，16.9 kg/m^2
遅発性ジスキネジア 発症年齢	6[redacted]歳	基礎疾患区分 （発症年齢）	統合失調症 （2[redacted]歳）
死亡に至った有害事象 （MedDRA 基本語）・ 発現時期	死亡・ Day 270～Day 270	死亡時期・ 治験薬との因果関係	Day 270・ No reasonable possibility
合併症	遅発性ジスキネジア，統合失調症，２型糖尿病，高血圧，便秘，筋肉痛，脂質異常症，浮動性めまい		
治験担当医師コメント	治験医師は、突然死であり原因不明だが，治験薬投与前と比べ、V11 と V13 では上室性期外収縮が発現しているが発現開始時期も継続投与期開始以降、半年以上経過していること、V12 では上室性期外収縮が見られなかったこと、その他自覚症状等もないため臨床上問題ないとした。上室性期外収縮が原因とは考えにくく、その他発現した咳払い、疲労感、傾眠も回復していることから偶発的な事象であり、治験又は治験薬との因果関係は否定できると評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡 (Day 270)
ETIZOLAM	1 (mg) /BID	基礎疾患	
MIANSERIN HYDROCHLORIDE	20 (mg) /QD	基礎疾患	
FLUNITRAZEPAM	2 (mg) /QD	基礎疾患	
BROTIZOLAM	0.25 (mg) /QD	基礎疾患	
LORAZEPAM	0.5 (mg) /QD	基礎疾患	
ETIZOLAM	1 (mg) /QD	基礎疾患	
SENNOSIDE A+B CALCIUM	12 (mg) /QD	合併症	
MIGLITOL	150 (mg) /TID	合併症	
BETAHISTINE MESILATE	18 (mg) /TID	合併症	
ENALAPRIL MALEATE	5 (mg) /QD	合併症	
PITAVASTATIN CALCIUM	1 (mg) /QD	合併症	
PIOGLITAZONE HYDROCHLORIDE	15 (mg) /QD	合併症	
AMLODIPINE BESILATE	10 (mg) /QD	合併症	
SENNOSIDE A+B CALCIUM	24 (mg) /QD	合併症	
AZULENE SODIUM SULFONATE;LEVOGLUTAMIDE	2.01 (g) /TID	胃粘膜保護	
URSODEOXYCHOLIC ACID	100 (mg) /BID	肝臓保護	
GLYCERYL TRINITRATE	27 (mg) /QD	合併症，狭心症の予防	
CALCIUM CHLORIDE DIHYDRATE;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	500 (mL) /ONCE	補液	
CALCIUM CHLORIDE DIHYDRATE;GLUCOSE;POTASSIUM CHLORIDE;SODIUM ACETATE;SODIUM CHLORIDE	500 (mL) /ONCE	補液	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
死亡	高度	重篤	死亡 (Day 270)
咳払い	軽度	非重篤	
傾眠	軽度	非重篤	
疲労	軽度	非重篤	
よだれ	軽度	非重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 2：4.33 h, Week 4: 3.75 h, Week 6: 4.88 h, Week 16: 4.75 h, Week 32: 4.33 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す．

治験依頼者の見解

被験者[redacted]は，MT-5199-J02 試験の Day 270 に死亡した．治験担当医は死因については不明で突然死であると判断されている．本被験者は，抗精神病薬を併用していなかった．本被験者は QT 延長作用を有することが知られている薬剤としてミアンセリンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．

，また本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．Day 1 時点で併用していた基礎疾患治療薬については全て死亡時まで MT-5199 と併用されており，治験薬服用期間には器官別大分類「精神障害」又は「神経系障害」の有害事象に該当する傾眠，よだれが認められたが，それらと死亡との関連性は低いと考えられる．本被験者は，投与 28

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験：[redacted]（続き）

週後と投与 36 週後に上室性期外収縮を認めたが，MT-5199 投与開始から半年以上経過していること，投与 32 週後には所見が認められなかったこと，また自覚症状等もなかったことから，治験担当医師は上室性期外収縮が死因とは考えにくいことを報告している．なお，本被験者はベースライン時の BMI が 16.9 kg/m^2 と低く，一般的に死亡リスク因子といわれている低 BMI に該当していた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験:[redacted]

試験番号・ 被験者識別コード	MT-5199-J02・ [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （80 mg/日）
年齢・性別	7[redacted] 歳・男性	体重・BMI ［ベースライン時］	4[redacted] kg，17.7 kg/m^2
遅発性ジスキネジア 発症年齢	7[redacted]歳	基礎疾患区分 （発症年齢）	統合失調症 （3[redacted] 歳）
死亡に至った有害事象 （MedDRA 基本語）・ 発現時期	誤嚥性肺炎・ Day 212～Day 216	死亡時期・ 治験薬との因果関係	Day 216・ No reasonable possibility
合併症	遅発性ジスキネジア，統合失調症，足部白癬，ラクナ梗塞，慢性副鼻腔炎，甲状腺新生物，失語症，流涎過多，便秘，食欲減退，振戦，慢性気管支炎，嚥下困難		
治験担当医師コメント	治験医師は，嚥下困難は治験の参加前より認め，合併症として報告している。また，嚥下困難による誤嚥性肺炎も治験の参加前より発症することがあった。そのため今回の誤嚥性肺炎に関しても治験薬との因果関係は否定できると評価した。		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡 (Day 216)
BLONANSERIN	16 (mg) /TID	基礎疾患	
TRAZODONE HYDROCHLORIDE	150 (mg) /QD	基礎疾患に伴ううつ症状	
BROTIZOLAM	0.25 (mg) /QD	基礎疾患に伴う不眠	
ZOLPIDEM	5 (mg) /QD	基礎疾患に伴う不眠	
ZOLPIDEM	5 (mg) /PRN	基礎疾患に伴う不眠	
PANTETHINE	300 (mg) /TID	合併症	
CARBOCISTEINE	1500 (mg) /TID	合併症	
PROMETHAZINE HYDROCHLORIDE	100 (mg) /QD	合併症	
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	7.5 (g) /TID	合併症	
CLONAZEPAM	1 (mg) /BID	合併症	
TEMOCAPRIL HYDROCHLORIDE	2 (mg) /QD	合併症	
TULOBUTEROL	1 (PATCH) /QD	合併症	
LULICONAZOLE	Unknown /QD	合併症	
SODIUM PICOSULFATE	Unknown /PRN	合併症	
PARACETAMOL	0.5 (g) /ONCE	有害事象	
AMOXICILLIN TRIHYDRATE;CLAVULANATE POTASSIUM	4 (TABLET) /QID	有害事象	
LOXOPROFEN SODIUM DIHYDRATE	60 (mg) /ONCE	有害事象	
ASARUM SPP. ROOT;CINNAMOMUM CASSIA BARK;EPHEDRA SPP. HERB;GLYCYRRHIZA SPP. ROOT;PAEONIA LACTIFLORA ROOT;PINELLIA TERNATA TUBER;SCHISANDRA CHINENSIS FRUIT;ZINGIBER OFFICINALE PROCESSED RHIZOME	9 (g) /TID	有害事象	
AMOXICILLIN TRIHYDRATE;CLAVULANATE POTASSIUM	4 (TABLET) /QID	有害事象	
TRIHEXYPHENIDYL HYDROCHLORIDE	6 (mg) /TID	有害事象	
AMPICILLIN SODIUM;SULBACTAM SODIUM	6 (g) /BID	有害事象	
CALCIUM GLUCONATE;GLUCOSE;MAGNESIUM CHLORIDE;POTASSIUM CHLORIDE;POTASSIUM PHOSPHATE MONOBASIC;SODIUM ACETATE;SODIUM CHLORIDE	1000 (mL) /BID	有害事象	
CALCIUM CHLORIDE DIHYDRATE;MALTOSE;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	500 (mL) /ONCE	有害事象	
CARBOHYDRATES NOS;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	500 (mL) /ONCE	有害事象	
AMOXICILLIN TRIHYDRATE;CLAVULANATE POTASSIUM	4 (TABLET) /QID	有害事象	
TRAZODONE HYDROCHLORIDE	25 (mg) /PRN	有害事象	
RAMELTEON	8 (mg) /QD	有害事象	
ACHYRANTHES BIDENTATA ROOT;ACONITUM SPP. PROCESSED ROOT;ALISMA PLANTAGO-AQUATICA VAR. ORIENTALE TUBER;CINNAMOMUM CASSIA BARK;CORNUS OFFICINALIS FRUIT;DIOSCOREA SPP. RHIZOME;PAEONIA X SUFFRUTICOSA ROOT BARK;PLANTAGO ASIATICA SEED;PORIA COCOS SCLEROTIUM;RUEHMANNIA GLUTINOSA ROOT	7.5 (g) /TID	有害事象	
CALCIUM GLUCONATE;GLUCOSE;MAGNESIUM CHLORIDE;POTASSIUM CHLORIDE;POTASSIUM PHOSPHATE MONOBASIC;SODIUM ACETATE;SODIUM CHLORIDE	500 (mL) /QD	有害事象	
CARBOHYDRATES NOS;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM LACTATE	1,000 (mL) /BID	有害事象	
AMPICILLIN SODIUM;SULBACTAM SODIUM	6 (g) /BID	有害事象	
CALCIUM GLUCONATE;GLUCOSE;MAGNESIUM CHLORIDE;POTASSIUM CHLORIDE;POTASSIUM PHOSPHATE MONOBASIC;SODIUM ACETATE;SODIUM CHLORIDE	1,000 (mL) /BID	有害事象	
EPINEPHRINE	4 (mg) /Fourtimes a day	有害事象	
SODIUM BICARBONATE	250 (mL) /ONCE	有害事象	
DOPAMINE HYDROCHLORIDE	200 (mL) /ONCE	有害事象	
ENTEROCOCCUS FAECALIS	3 (g) /TID	腸調整	
ENTEROCOCCUS FAECALIS	3 (g) /TID	腸調整	
ENTEROCOCCUS FAECALIS	3 (g) /TID	腸調整	
INFLUENZA VACCINE	0.5 (mL) /ONCE	インフルエンザ予防	


有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
誤嚥性肺炎	中等度	非重篤	死亡 (Day 216)
誤嚥性肺炎	高度	非重篤	
誤嚥性肺炎	高度	重篤	
気管支炎	軽度	非重篤	
流涎過多	軽度	非重篤	
胸水	軽度	非重篤	
譫妄	軽度	非重篤	
夜間頻尿	軽度	非重篤	

次ページへ続く

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験:[redacted]（続き）



治験依頼者の見解

被験者[redacted]は，MT-5199-J02 試験の Day 216 に「誤嚥性肺炎」により死亡した．本被験者は，抗精神病薬としてブロナンセリンを Day 1～Day 211 に併用しており，ブロナンセリンの併用期間に器官別大分類「精神障害」又は「神経系障害」の有害事象に該当する譫妄が認められたが死亡に至った有害事象である誤嚥性肺炎との関連性は低いと考えられる．本被験者は，QT 延長作用を有することが知られている薬剤としてプロメタジン，トラゾドン及びブロナンセリンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤は併用していなかった．治験担当医師は，被験者が治験参加前より嚥下困難による誤嚥性肺炎を発症していたことを報告しており，また本被験者は MT-5199 投与期間中にも誤嚥性肺炎を複数回発現していることを踏まえると，MT-5199 と併用薬がこれらの経過に影響を及ぼした可能性は低いと考えられた．

表 2.7.4.7－39 死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験:[redacted]

試験番号・被験者識別コード	MT-5199-J02・[redacted]	投与群（最終時投与量）	MT-5199 40 mg 群（40 mg/日）
年齢・性別	6[redacted] 歳・男性	体重・BMI［ベースライン時］	5[redacted] kg，17.1 kg/m^2
遅発性ジスキネジア発症年齢	4[redacted]歳	基礎疾患区分（発症年齢）	双極性障害（3[redacted] 歳）
死亡に至った有害事象（MedDRA 基本語）・発現時期	心筋虚血・Day 152～Day 152	死亡時期・治験薬との因果関係	Day 152・No reasonable possibility
合併症	遅発性ジスキネジア，双極性障害，白内障，くも膜嚢胞，脂質異常症，てんかん，ジストニア，便秘，食欲減退		
治験担当医師コメント	治験医師は、治験参加以前より頻脈傾向の被験者で、治験中の心電図においては右房拡大を認めていた。直接死因は、急性虚血性心疾患によるもので、治験薬との因果関係は、合理的な可能性なしと評価した.		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	40 (mg)/QID	遅発性ジスキネジア	死亡 (Day 152)
NITRAZEPAM	5 (mg) /QD	基礎疾患	
TRAZODONE HYDROCHLORIDE	50 (mg) /QD	基礎疾患	
BROTIZOLAM	0.25 (mg) /QD	基礎疾患	
LORAZEPAM	3 (mg) /TID	基礎疾患	
LITHIUM CARBONATE	600 (mg) /TID	基礎疾患	
BACLOFEN	10 (mg) /BID	合併症	
MECOBALAMIN	1 (mg) /BID	合併症	
EICOSAPENTAENOIC ACID ETHYL ESTER	1200 (mg) /BID	合併症	
LEVETIRACETAM	1000 (mg) /BID	合併症	
CLOSTRIDIUM BUTYRICUM	2 (TABLET) /BID	合併症	
ANGELICA ACUTILOBA ROOT;ASTRAGALUS SPP. ROOT;ATRACTYLODES LANCEA RHIZOME;BUPLEURUM FALCATUM ROOT;CIMICIFUGA SPP. RHIZOME;CITRUS RETICULATA PEEL;GLYCYRRHIZA SPP. ROOT;PANAX GINSENG ROOT;ZINGIBER OFFICINALE RHIZOME;ZIZIPHUS JUJUBA VAR. INERMIS FRUIT	2.5 (g) /QD	合併症	
NEPAFENAC	3 (gtt) /TID	合併症	
EICOSAPENTAENOIC ACID ETHYL ESTER	1800 (mg) /BID	合併症	
ASCORBIC ACID;BIOTIN;CALCIUM CARBONATE;CALCIUM PANTOTHENATE;CARBOHYDRATES NOS;COPPER SULFATE;CYANOCOBALAMIN;ERGOCALCIFEROL;FATS NOS;FERROUS SULFATE;FOLIC ACID;LINOLEIC ACID;MAGNESIUM CHLORIDE;MANGANESE CHLORIDE;NICOTINAMIDE;PHYTOMENADIONE;POTASSIUM CHLORIDE;POTASSIUM CITRATE;POTASSIUM IODIDE;PROTEIN;PYRIDOXINE HYDROCHLORIDE;RETINOL PALMITATE;RIBOFLAVIN;SODIUM POLYMETAPHOSPHATE;THIAMINE HYDROCHLORIDE;TOCOPHERYL ACETATE;ZINC SULFATE	250 (mL) /ONCE	有害事象	
CARBOHYDRATES NOS;ELECTROLYTES NOS;LIPIDS NOS;PROTEINS NOS;VITAMINS NOS	400 (mL) /BID	有害事象	
MONTELUKAST SODIUM	10 (mg) /QD	有害事象	
FLUTICASONE FUROATE;VILANTEROL TRIFENATATE	1 (inhalation) /QD	有害事象	
L-CARBOCYSTEINE	1500 (mg) /TID	有害事象	
CARBOHYDRATES NOS;ELECTROLYTES NOS;LIPIDS NOS;PROTEINS NOS;VITAMINS NOS	600 (mL) /TID	有害事象	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
心筋虚血	高度	重篤	死亡 (Day 152)
自殺念慮	軽度	非重篤	
瞼下障害	中等度	非重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 2：8.52 h, Week 4: 9.53 h, Week 6: 7.02 h, Week 16: 11.88 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す.

治験依頼者の見解

被験者[redacted]は，MT-5199-J02 試験の Day 152 に「心筋虚血」により死亡した．本被験者は，抗精神病薬として炭酸リチウムを Day 1～Day 152 に併用しており，炭酸リチウムの併用期間に器官別大分類「精神障害」又は「神経系障害」の有害事象に該当する自殺念慮が認められたが，自殺念慮と死亡に至った有害事象である心筋虚血との関連性は低いと考えられる．本被験者は，QT 延長作用を有することが知られている薬剤としてレベチラセタム，トラゾドン及び炭酸リチウムを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

MT-5199-J02 試験：[redacted]（続き）

CYP3A4 阻害剤又は強力な CYP2D6 阻害剤は併用していなかった．なお，本被験者はベースライン時の BMI が 17.1 kg/m^2 と低く，一般的に死亡リスク因子といわれている低 BMI に該当していた．

表 2.7.4.7－39 死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1202 試験:[redacted]

試験番号・被験者識別コード	NBI-98854-1202 [redacted]	投与群（最終時投与量）	プラセボ群（プラセボ）
年齢・性別	5[redacted]歳・女性	体重・BMI［ベースライン時］	5[redacted] kg・21.6 kg/m²
遅発性ジスキネジア発症年齢	不明	基礎疾患区分（発症年齢）	統合失調症又は統合失調感情障害（3[redacted]歳）
死亡に至った有害事象（MedDRA 基本語）・発現時期	心筋梗塞・Day 10～Day 10	死亡時期・治験薬との因果関係	Day 10・Not related
合併症・既往歴	近視，眼乾燥，てんかん，骨粗鬆症，胃食道逆流性疾患，関節炎，甲状腺機能低下症，腹式子宮全摘，不眠症，喘息，下垂体機能低下症，高血圧性心疾患，心不全		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても虚血性心疾患およびアテローム動脈硬化性心疾患の既往歴があることから本剤との関連性は否定できると考え，因果関係なしと評価した		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
Placebo		遅発性ジスキネジア	死亡
CHLORPROMAZINE	300 (mg) /HS	統合失調症/統合失調感情障害	（Day 10）
QUETIAPINE	200 (mg) /HS	統合失調症/統合失調感情障害	
RISEDRONATE SODIUM	35 (mg) /OTH	合併症	
HYDROCORTISONE	20 (mg) /BID	合併症	
LEVETIRACETAM	500 (mg) /BID	合併症	
LEVOTHYROXINE	200 (mcg) /QD	合併症	
NAPROXEN	500 (mg) /BID	合併症	
OMEPRAZOLE	20 (mg) /QD	合併症	
PHENYTOIN	100 (mg) /BID	合併症	
ZOLPIDEM	10 (mg) /HS	合併症	
POLYVINYL ALCOHOL	1.4 (%) /QID	合併症	
CELLUVISC	1 (%) /HS	合併症	
TRAZODONE	100 (mg) /HS	錐体外路障害	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
心筋梗塞	高度	重篤	死亡
痙攣	中等度	重篤	（Day 10）
痙攣	高度	重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本被験者はプラセボ群であり，血漿中濃度データは取得されていない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1202 試験の Day 10 に「心筋梗塞」により死亡した．本被験者はプラセボ群であり，本剤を服用していなかったため，「心筋梗塞」と本剤との因果関係はない．本被験者は，抗精神病薬としてクロルプロマジンを併用しており，器官別大分類「神経系障害」の有害事象に該当する痙攣が Day 9 及び Day 10 に認められたが，治験担当医師により本剤との因果関係は not related と判断されている．また，合併症にてんかんがあり，これが痙攣の一因となった可能性は否定できないと考えられた．本被験者は，QT 延長作用を有することが知られているレベチラセタム，クロルプロマジン及びオメプラゾールを併用していた．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが予想される強力な CYP3A4 阻害剤又は CYP2D6 阻害剤を併用していなかった．

本被験者は高血圧性心疾患や心不全といった死亡リスクを上昇させることが知られている疾患の既往歴があることから，これらが死亡の一因となった可能性は否定できないと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1304 試験：[redacted]

試験番号・被験者識別コード	NBI-98854-1304 [redacted]	投与群（最終時投与量）	MT-5199 80 mg 群（80 mg/日）・
年齢・性別	7[redacted]歳・男性	体重・BMI［ベースライン時］	10[redacted] kg・33.6 kg/m^2
遅発性ジスキネジア発症年齢	7[redacted]歳	基礎疾患区分（発症年齢）	統合失調症又は統合失調感情障害（3[redacted]歳）
死亡に至った有害事象（MedDRA 基本語）・発現時期	突然死・Day 33～Day 33	死亡時期・治験薬との因果関係	Day 33・Unlikely
合併症・既往歴	糖尿病，高コレステロール血症，高血圧，肥満，爪真菌症，ビタミンＤ欠乏，胆嚢切除，急性胆嚢炎，発疹		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡（Day 33）
FLUPHENAZINE	20 (mg) /QD	統合失調症/統合失調感情障害	
METFORMIN	500 (mg) /BID	合併症	
METOPROLOL	50 (mg) /BID	合併症	
AMLODIPINE	10 (mg) /QD	合併症	
ZESTORETIC	10/12.5 (mg) /QD	合併症	
SIMVASTATIN	20 (mg) /QD	合併症	
COLECALCIFEROL	2000 (IU) /QD	合併症	
NYSTATIN	1 (APPLICATION) /QD	合併症	
CLOBETASOL	1 (APPLICATION) /BID	合併症	
ACETYLSALICYLIC ACID	81 (mg) /QD	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
突然死	高度	重篤	死亡（Day 33）

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 2：4.88 h, Week 4: 4.12 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1304 試験の Day 33 に「突然死」により死亡した．本被験者は，抗精神病薬としてフルフェナジンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤を併用していなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．

本被験者は合併症に高血圧，高コレステロール血症，糖尿病及び肥満といった生活習慣病等，死亡リスクを上昇させることが知られている疾患を複数罹患しており，これらが死亡の一因となった可能性は否定できないと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1304 試験：[redacted]

試験番号・被験者識別コード	NBI-98854-1304 [redacted]	投与群（最終時投与量）	MT-5199 80 mg 群（80 mg/日）
年齢・性別	5[redacted] 歳・男性	体重・BMI［ベースライン時］	6[redacted] kg・23.2 kg/m²
遅発性ジスキネジア発症年齢	不明	基礎疾患区分（発症年齢）	統合失調症又は統合失調感情障害（不明）
死亡に至った有害事象（MedDRA 基本語）・発現日	心不全，肝不全，糖尿病，高カリウム血症，代謝性アシドーシス，胸水・全て Day 327～Day 327	死亡時期・治験薬との因果関係	Day 327・Not related
合併症・既往歴	冠動脈硬化症，喘息，良性前立腺肥大症，便秘，胃食道逆流性疾患，高血圧，2 型糖尿病		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	
HALOPERIDOL	5 (mg) /QAM	統合失調症/統合失調感情障害	死亡 (Day 327)
HALOPERIDOL	10 (mg) /HS	統合失調症/統合失調感情障害	
RISPERIDONE	2 (mg) /BID	統合失調症/統合失調感情障害	
CLONAZEPAM	0.5 (mg) /BID	統合失調症/統合失調感情障害	
HALOPERIDOL	5 (mg) /BID	統合失調症/統合失調感情障害	
TEMAZEPAM	30 (mg) /HS	統合失調症/統合失調感情障害	
IBUPROFEN	800 (mg) /TID	合併症	
OMEPRAZOLE	20 (mg) /BID	合併症	
METFORMIN	500 (mg) /BID	合併症	
BUDESONIDE W/FORMOTEROL FUMARATE	160-4.5 (mcg) /BID	合併症	
SITAGLIPTIN	100 (mg) /QD	合併症	
DOCUSATE	100 (mg) /QD	合併症	
NOVOLOG MIX	20 (UNIT) /QAM	合併症	
NOVOLOG MIX	15 (UNIT) /QPM	合併症	
LACTULOSE	10/15 (G/ML) /QD	合併症	
HUMAN MIXTARD	20 (UNIT) /BID	合併症	
OMEPRAZOLE	40 (mg) /QD	合併症	
BENZATROPINE	2 (mg) /QD	錐体外路障害	
BENZATROPINE	1 (mg) /BID	錐体外路障害	
GLUCOSE	50 (mL) /OTHER :UNK	有害事象	
SODIUM BICARBONATE	1 AMP /OTHER :UNK	有害事象	
INSULIN ASPART	10 (UNIT) /OTHER :UNK	有害事象	
EPINEPHRINE	UNK /OTHER :UNK	有害事象	
ACETYLSALICYLIC ACID	81 (mg) /QD	その他	
FERROUS SULFATE	325 (mg) /QD	その他	
SODIUM CHLORIDE	1 (GM) /QAM	その他	
THIAMINE	100 (mg) /QD	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
高カリウム血症	高度	重篤	
心不全	高度	重篤	
肝不全	高度	重篤	
糖尿病	高度	重篤	
代謝性アシドーシス	高度	重篤	
胸水	高度	重篤	
血中ブドウ糖増加	軽度	非重篤	死亡 (Day 327)
尿中ブドウ糖陽性	軽度	非重篤	
グリコヘモグロビン増加	軽度	非重篤	
尿路感染	軽度	非重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 2：6.75 h, Week 4: 30.58 h, Week 6: 6.55 h, Week 8: 6.00 h, Week 16: 6.82 h, Week 24: 7.35 h, Week 32: 5.80 h, Week 40: 6.33 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1304 試験:[redacted]（続き）

治験依頼者の見解

被験者[redacted]は，NBI-98854-1304 試験の Day 327 に「高カリウム血症」，「心不全」，「肺不全」，「糖尿病」，「代謝性アシドーシス」及び「胸水」により死亡した．本被験者は，抗精神病薬としてハロペリドールとリスペリドンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤としてハロペリドール，リスペリドン及びオメプラゾールを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は CYP2D6 阻害剤を併用していなかった．

本被験者は合併症に高血圧，2 型糖尿病といった生活習慣病や，冠動脈硬化症といった心血管系疾患等，死亡リスクを上昇させることが知られている疾患を複数罹患していたこと，また喘息もあったことから，これらが死亡の一因となった可能性は否定できないと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1402 試験：[redacted]

試験番号・ 被験者識別コード	NBI-98854-1402 [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （80 mg/日）
年齢・性別	4[redacted] 歳・女性	体重・BMI ［ベースライン時］	11[redacted] kg・41.7 kg/m^2
遅発性ジスキネジア 発症年齢	4[redacted] 歳	基礎疾患区分 （発症年齢）	統合失調症又は統合失調感情障害（2[redacted] 歳）
死亡に至った有害事象 （MedDRA 基本語）・ 発現時期	乳癌・ Day55～Day55	死亡時期・ 治験薬との因果関係	Day 55・ Not related
合併症・既往歴	喘息，子宮頸管炎，慢性閉塞性肺疾患，薬物過敏症，高血圧，肥満， 腹部ヘルニア修復，皮膚裂傷		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）


MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡（Day 55）
ZIPRASIDONE	60 (mg) /HS	統合失調症/統合失調感情障害	
AMLODIPINE	10 (mg) /QD	合併症	
BENZATROPINE	1 (mg) /BID	錐体外路障害	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
乳癌	高度	重篤	死亡（Day 55）

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度



各 Visit における直前の投与から採血までの経過時間 － Week 4：6.37 h
青丸は 40 mg 投与，赤丸は 80 mg 投与時のデータを示す．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1402 試験の Day 55 に「乳癌」により死亡した．本被験者は，抗精神病薬としてジプラシドンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤としてジプラシドンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．

本剤の作用機序，並びに蓄積された安全性データに基づいて特定したリスクを踏まえると，本剤が「乳癌」の原因となった可能性は低いと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1506 試験:[redacted]

試験番号・ 被験者識別コード	NBI-98854-1506 [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （80 mg/日）
年齢・性別	[redacted]歳・男性	体重・BMI [ベースライン時]	[redacted] kg・34.3 kg/m^2
遅発性ジスキネジア 発症年齢	不明	基礎疾患区分 （発症年齢）	統合失調症又は統合失調感情障害（[redacted]歳）
死亡に至った有害事象 （MedDRA 基本語）・ 死亡時期	慢性閉塞性肺疾患・ Day 332～Day334	死亡時期・ 治験薬との因果関係	Day 334・ Not related
合併症・既往歴	慢性閉塞性肺疾患，緑内障，高血圧，冠動脈硬化症，胃食道逆流性疾患，便秘，不眠症，双極性障害，健忘，甲状腺機能低下症，脂質異常症，2 型糖尿病，関節リウマチ，皮膚乾燥，爪真菌症，良性前立腺肥大症，虫垂炎		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QD	遅発性ジスキネジア	死亡
QUETIAPINE	800 (mg) /HS	統合失調症/統合失調感情障害	(Day 334)
AMMONIUM LACTATE	1 (APPLICATION) /BID	合併症	
ATORVASTATIN	40 (mg) /HS	合併症	
CARVEDILOL	3.125 (mg) /BID	合併症	
CICLOPIROX	1 (APPLICATION) /QD	合併症	
CLONAZEPAM	0.5 (mg) /BID	合併症	
DILTIAZEM	300 (mg) /QD	合併症	
DOCUSATE	100 (mg) /BID	合併症	
DONEPEZIL	5 (mg) /HS	合併症	
GABAPENTIN	800 (mg) /TID	合併症	
INSULIN LISPRO	15 (IU) /BID	合併症	
KETOCONAZOLE	1 (APPLICATION) /BID	合併症	
KETOROLAC	1 (gtt) /BID	合併症	
INSULIN GLARGINE	40 (IU) /QD	合併症	
LATANOPROST	1 (gtt) /HS	合併症	
LEVOTHYROXINE	25 (ug) /QD	合併症	
METHOTREXATE	12.5 (mg) /EVERY WEEK	合併症	
OMEPRAZOLE	20 (mg) /QD	合併症	
PREDNISONE	5 (mg) /PRN	合併症	
SALBUTAMOL	90 (ug) /BID	合併症	
VALSARTAN	160 (mg) /QD	合併症	
METHYLPREDNISOLONE	4 (mg) /QD	合併症	
FINASTERIDE	5 (mg) /QD	合併症	
FUROSEMIDE	20 (mg) /QD	合併症	
LOSARTAN	25 (mg) /QD	合併症	
PREDNISONE	20 (mg) /QD	有害事象	
ACETYLSALICYLIC ACID	81 (mg) /QD	その他	
FERROUS SULFATE	325 (mg) /BID	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
慢性閉塞性肺疾患	軽度	非重篤	
慢性閉塞性肺疾患	高度	重篤	死亡 (Day 334)

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本試験においては，血漿中濃度データを取得していない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1402 試験（48 週間）を完遂した後，NBI-98854-1506 試験の Day 334 に「慢性閉塞性肺疾患」により死亡した．本被験者は，抗精神病薬としてクエチアピンを服用していたが，器官別大分類「神経障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤としてドネペジル，ケトコナゾール，クエチアピン，オメプラゾール及びフロセミドを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤としてケトコナゾールを併用していた．ただし，ケトコナゾールは合併症である爪真菌症に対する処置として外用剤で使用されており，生体内への移行率は低いと考えられる．NBI-98854-1506 試験では血漿中薬物濃度測定を実施していないが，本剤との薬物相互作用により MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇した可能性は低いと考えられた．

本被験者は，慢性閉塞性肺疾患の既往があったことから，これが死亡の一因となった可能性は否定できないと考えられた．なお，合併症に高血圧，脂質異常症及び 2 型糖尿病といった生活習慣病や，冠動脈硬化症といった心血管系疾患等，死亡リスクを上昇させることが知られている疾患を複数罹患していた．

表 2.7.4.7－39 死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1506 試験 [redacted]

試験番号・被験者識別コード	NBI-98854-1506 [redacted]	投与群（最終時投与量）	MT-5199 80 mg 群（80 mg/日）
年齢・性別	6[redacted] 歳・男性	体重・BMI［ベースライン時］	8[redacted] kg・27.0 kg/m^2
遅発性ジスキネジア発症年齢	5[redacted]歳	基礎疾患区分（発症年齢）	統合失調症又は統合失調感情障害（2[redacted] 歳）
死亡に至った有害事象（MedDRA 基本語）・死亡時期	敗血症症候群・Day 207～Day 217	死亡時期・治験薬との因果関係	Day 217・Not related
合併症・既往歴	胃食道逆流性疾患，C 型肝炎，慢性閉塞性肺疾患，骨関節炎，感覚鈍麻，坐骨神経痛，植物アレルギー，湿疹，過体重，義歯使用者，季節性アレルギー		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡 (Day 217)
PROPRANOLOL	10 (mg) /Q6H	遅発性ジスキネジア	
PYRIDOXINE	300 (mg) /BID	遅発性ジスキネジア	
CITALOPRAM	40 (mg) /QD	統合失調症/統合失調感情障害	
VALPROATE SEMISODIUM	500 (mg) /QD	統合失調症/統合失調感情障害	
VALPROATE SODIUM	500 (mg) /HS	統合失調症/統合失調感情障害	
COMBIVENT	1 (PUFF) /Q4H	合併症	
LORATADINE	10 (mg) /QD	合併症	
NORTRIPTYLINE	50 (mg) /BID	合併症	
PANTOPRAZOLE	40 (mg) /QD	合併症	
RANITIDINE	150 (mg) /QD	合併症	
FAMOTIDINE	20 (mg) /BID	合併症	
PANTOPRAZOLE	40 (mg) /QD	合併症	
SODIUM BICARBONATE	50 (mEq) /ONCE	合併症	
SODIUM BICARBONATE	150 (mEq) /CONTINUOUS	合併症	
FAMOTIDINE	20 (mg) /BID	合併症	
ATORVASTATIN	20 (mg) /QD	有害事象	
KETOCONAZOLE	2 (%) /QD	有害事象	
PARACETAMOL	1500 (mg) /Q8H	有害事象	
IBUPROFEN	600 (mg) /Q6H	有害事象	
PARACETAMOL	500 (mg) /Q6H	有害事象	
VICODIN	5/325 (mg/mg) /Q6H	有害事象	
MUPIROCIN	1 (APPLICATION) /TID	有害事象	
BACTRIM	800/160 (mg/mg) /Q12H	有害事象	
TIZANIDINE	4 (mg) /Q8H	有害事象	
PARACETAMOL	500 (mg) /QD	有害事象	
IBUPROFEN	400 (mg) /QD	有害事象	
SALBUTAMOL	5 (g/L) /PRN	有害事象	
IPRATROPIUM	500/2.5 (ug/mL) /ONCE	有害事象	
METHYLPREDNISOLONE SODIUM SUCCINATE	125 (mg) /ONCE	有害事象	
CEFTRIAXONE	2 (g) /ONCE	有害事象	
PANADEINE CO	300/30 (mg/mg) /PRN	有害事象	
COMBIVENT	3 (mL) /Q6H	有害事象	
ALLOPURINOL	300 (mg) /ONCE	有害事象	
BUDESONIDE	0.5 (mg) /BID	有害事象	
PIPERACILLIN W/TAZOBACTAM	3.375 (g) /Q8H	有害事象	
PIPERACILLIN W/TAZOBACTAM	4.5 (g) /ONCE	有害事象	
RASBURICASE	6 (mg) /ONCE	有害事象	
VANCOMYCIN	1250 (mg) /Q12H	有害事象	
PARACETAMOL	650 (mg) /Q6H	有害事象	
IPRATROPIUM W/SALBUTAMOL	3 (mL) /TID	有害事象	
PIPERACILLIN W/TAZOBACTAM	3.375 (mg) /Q4H	有害事象	
AMPICILLIN	2 (g) /6 TIMES PER DAY	有害事象	
FENTANYL	25-250 (ug/h) /TITRATED	有害事象	
NOREPINEPHRINE	1-30 (ug/min) /TITRATED	有害事象	
CEFTRIAXONE	2 (g) /BID	有害事象	
ACICLOVIR	700 (mg) /BID	有害事象	
COMBIVENT	3 (mL) /Q6H	有害事象	
DOPAMINE	5-10 (ug/kg/min) /CONTINU	有害事象	
FLUCONAZOLE	400 (mg) /QD	有害事象	
MAGNESIUM SULFATE	2 (g) /PRN	有害事象	
VANCOMYCIN	1250 (mg) /QAM	有害事象	
VANCOMYCIN	1250 (mg) /QPM	有害事象	
VASOPRESSIN	0.01-.0.3 (U/min) /TITRATE	有害事象	
AMIODARONE	0.5-1 (mg/min) /TITRATED	有害事象	
AMIODARONE	150 (mg) /ONCE	有害事象	
AMPICILLIN	2 (g) /Q6H	有害事象	
MAGNESIUM SULFATE	2 (g) /PRN	有害事象	
METHYLPREDNISOLONE SODIUM SUCCINATE	125 (mg) /TID	有害事象	
METRONIDAZOLE	500 (mg) /QID	有害事象	
CEFTRIAXONE	2 (g) /QD	有害事象	
SODIUM PHOSPHATE	30 (mmol) /PRN	有害事象	
VANCOMYCIN	1250 (mg) /PRN	有害事象	
INSULIN LISPRO	0-18 (U) /Q12H	有害事象	
INSULIN GLARGINE	28 (U) /QD	有害事象	
VANCOMYCIN	1 (g) /Q12H	有害事象	

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1506 試験：[redacted]（続き）

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）（続き）

MT-5199，併用薬（続き）

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
DIGOXIN	125 (ug) /Q6H	有害事象	死亡
FISH OIL	1000 (mg) /QD	その他	(Day 217)
GLUCOSAMINE	1500 (mg) /QD	その他	
MULTIVITAMINS	1 (TABLET) /QD	その他	
VITAMIN B COMPLEX	1 (TABLET) /QD	その他	
TOCOPHEROL	400 (IU) /BID	その他	
PNEUMOCOCCAL VACCINE	0.5 (mL) /ONCE	その他	
VARICELLA ZOSTER VACCINE	0.65 (mL) /ONCE	その他	
MACROSALB (99MTC)	6.4 (mCi) /ONCE	その他	
XENON (133 XE)	17 (mCi) /ONCE	その他	
HEPARIN	5000 (U) /BID	その他	
LORAZEPAM	2 (mg) /ONCE	その他	
LORAZEPAM	2 (mg) /Q2H	その他	
GLUCOSE	100 (mL/h) /CONTINUOUS	その他	
GLUCOSE	12.5 (g) /PRN	その他	
GLUCOSE	25 (g) /ONCE	その他	
PROPOFOL	10-70 (ug/kg/min) /TITRATE	その他	
ALBUMIN HUMAN	25 (g) /QID	その他	
ALTEPLASE	1 (mg) /QD	その他	
CALCIUM GLUCONATE	2 (g) /PRN	その他	
GLUCOSE	75 (mL) /ONCE	その他	
GLUCOSE	150 (mL) /CONTINUOUS	その他	
LIDOCAINE	5 (mL) /PRN	その他	
ALBUMIN HUMAN	25 (g) /PRN	その他	
POLYVINYL ALCOHOL	1 (APPLICATION) /PRN	その他	
CALCIUM GLUCONATE	3-4 (g) /PRN	その他	
DIPHENHYDRAMINE	50 (mg) /ONCE	その他	
HEPARIN	2600 (U) /PRN	その他	
INTRALIPID	250 (mL) /ONCE	その他	
HEPARIN	2800 (U) /ONCE	その他	
GLUCOSE	60 (mL/h) /CONTINUOUS	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
敗血症症候群	高度	重篤	死亡
高コレステロール血症	軽度	非重篤	(Day 217)
皮膚真菌感染	軽度	非重篤	
腰痛症	軽度	非重篤	
背部痛	高度	重篤	
リンパ節症	軽度	非重篤	
γ－グルタミルトランスフェラーゼ増加	中等度	非重篤	
肺炎	高度	重篤	
貧血	軽度	非重篤	
血中乳酸脱水素酵素増加	中等度	非重篤	
脳虚血	軽度	非重篤	
高尿酸血症	軽度	非重篤	
脾腫	軽度	非重篤	
転倒・転落	軽度	非重篤	
頭部損傷	軽度	非重篤	
腎不全	高度	重篤	
電解質失調	軽度	非重篤	
壊疽	中等度	非重篤	
心房細動	軽度	非重篤	
高血糖	軽度	非重篤	
出血性卒中	中等度	重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本試験においては，血漿中濃度データを取得していない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1402 試験（48 週間）を完遂した後，NBI-98854-1506 試験の Day 217 に「敗血症症候群」により死亡した．本被験者は，抗精神病薬を併用していなかった．本被験者は，QT 延長作用を有することが知られている薬剤として，プロポフォール，アミオダロン，シタロプラム，ノルトリプチリン，ケトコナゾール，フルコナゾール，ファモチジン，バントフラゾール，ジフェンヒドラミン，チザニジン及びメトロニダゾールを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤としてケトコナゾールを併用していた．ケトコナゾールは，有害事象である皮膚真菌感染に対する処置として Day 110 から Day 189 まで外用剤で使用されており，生体内への移行率は低いと考えられる．NBI-98854-1506 試験では血漿中薬物測定を実施していないが，本剤との薬物相互作用により MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇した可能性は低いと考えられた．

本被験者は，Day 206 に重篤な有害事象「肺炎」を発現しており，「敗血症症候群」に繋がった可能性がある．本剤の作用機序，並びに蓄積された安全性データに基づいて特定したリスクを踏まえると，本剤が「肺炎」や「敗血症症候群」の原因となった可能性は低いと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1506 試験：[redacted]

試験番号・ 被験者識別コード	NBI-98854-1506 [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （80 mg/日）
年齢・性別	5[redacted] 歳・男性	体重・BMI ［ベースライン時］	8[redacted] kg・29.6 kg/m^2
遅発性ジスキネジア 発症年齢	3[redacted]歳	基礎疾患区分 （発症年齢）	統合失調症又は統合失調感情障害（1[redacted] 歳）
死亡に至った有害事象 （MedDRA 基本語）・ 死亡時期	昏睡・ Day 33～Day 49	死亡時期・ 治験薬との因果関係	Day 49・ Not related
合併症・既往歴	不眠症，不安，うつ病，胃食道逆流性疾患，便秘，乾癬， 陰嚢水瘤，骨折の変形治癒		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	[redacted] 死亡（Day 49）
OLANZAPINE	20 (mg) /HS	統合失調症/統合失調感情障害	
QUETIAPINE	200 (mg) /HS	統合失調症/統合失調感情障害	
QUETIAPINE	400 (mg) /HS	統合失調症/統合失調感情障害	
BUSPIRONE	30 (mg) /BID	合併症	
DIPHENHYDRAMINE	100 (mg) /HS	合併症	
OMEPRAZOLE	40 (mg) /QAM	合併症	
VENLAFAXINE	75 (mg) /QAM	合併症	
SENNOSIDE A+B	17.2 (mg) /HS	合併症	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
昏睡	高度	重篤	[redacted] 死亡（Day 49）

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本試験においては，血漿中濃度データを取得していない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1304 試験（48 週間）を完遂した後，NBI-98854-1506 試験の Day 49 に「昏睡」により死亡した．本被験者は，抗精神病薬としてオランザピン及びクエチアピンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤としてベンラファキシン，オランザピン，クエチアピン，オメプラゾール及びジフェンヒドラミンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．

本被験者の死亡に至った有害事象の報告名は「アルコール性昏睡」であることから，本剤や併用薬の影響で本被験者が死亡に至った可能性は低いと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-1506 試験:[redacted]

試験番号・ 被験者識別コード	NBI-98854-1506 [redacted]	投与群 （最終時投与量）	MT-5199 80 mg 群 （40 mg/日）
年齢・性別	6[redacted] 歳・男性	体重・BMI ［ベースライン時］	10[redacted] kg・31.9 kg/m^2
遅発性ジスキネジア 発症年齢	3[redacted] 歳	基礎疾患区分 （発症年齢）	統合失調症又は統合失調感情障害（1[redacted] 歳）
死亡に至った有害事象 （MedDRA 基本語）・ 死亡時期	高血圧性心疾患・ Day 87～Day 87	死亡時期・ 治験薬との因果関係	Day 87・ Not related
合併症・既往歴	便秘，高血圧，慢性閉塞性肺疾患，脂質異常症，骨関節炎，2 型糖尿病，尿路感染，糖尿，糖尿病，冠動脈硬化症，皮膚炎		
治験担当医師コメント	死亡原因は高血圧性心疾患であり，他の重要な要因に糖尿病や肥満がある．治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡
MT-5199	40 (mg)/QID	遅発性ジスキネジア	(Day 87)
CLOZAPINE	300 (mg) /BID	統合失調症/統合失調感情障害	
LUBIPROSTONE	24 (ug) /BID	合併症	
ATORVASTATIN	20 (mg) /QD	合併症	
FENOFIBRATE	48 (mg) /QD	合併症	
SITAGLIPTIN	100 (mg) /QD	合併症	
LISINOPRIL	5 (mg) /QD	合併症	
METOPROLOL	100 (mg) /QD	合併症	
MONTELUKAST	10 (mg) /QD	合併症	
SALBUTAMOL	2 (PUFF) /TID	合併症	
METOPROLOL	200 (mg) /QD	合併症	
METOPROLOL	100 (mg) /QD	有害事象	
ACETYLSALICYLIC ACID	81 (mg) /QD	その他	
CLOPIDOGREL	75 (mg) /QD	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
高血圧性心疾患	高度	重篤	死亡
流涎過多	中等度	非重篤	(Day 87)
喘息	中等度	非重篤	
胸部不快感	中等度	非重篤	

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本試験においては，血漿中濃度データを取得していない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-1402 試験（48 週間）を完遂した後，NBI-98854-1506 試験の投 Day 87 に「高血圧性心疾患」により死亡した．本被験者は，抗精神病薬としてクロザピンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られている薬剤としてクロザピンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．

本被験者は合併症に高血圧，脂質異常症及び 2 型糖尿病といった生活習慣病等，死亡リスクを上昇させることが知られている疾患を複数罹患しており，これらが死亡の一因となった可能性は否定できないと考えられた．

表 2.7.4.7－39　死亡例の経過図：国内外臨床試験（続き）

NBI-98854-TD4002 試験：[redacted]

試験番号・ 被験者識別コード	NBI-98854-TD4002 [redacted]	投与群 （最終時投与量）	非盲検期本剤群 （80 mg/日）
年齢・性別	4[redacted]歳・男性	体重・BMI ［ベースライン時］	[redacted] kg・28.4 kg/m^2
遅発性ジスキネジア 発症年齢	4[redacted]歳	基礎疾患区分 （発症年齢）	統合失調症又は統合失調感情障害（2[redacted]歳）
死亡に至った有害事象 （MedDRA 基本語） 死亡時期	偶発的過量投与・ Day 44～Day 44	死亡時期・ 治験薬との因果関係	Day 44・ Not related
合併症・既往歴	高血圧，高脂血症，2 型糖尿病，背部痛， 腰椎椎間板ヘルニア，慢性咳嗽		
治験担当医師コメント	治験医師は本剤との因果関係を否定した．企業としても本剤との関連性は否定できると考え，因果関係なしと評価した．		

MT-5199 及び併用薬の投与状況，有害事象の発現状況（Day -30～死亡時）

MT-5199，併用薬

薬剤	用量（単位）/頻度	投与理由	MT-5199投与開始日（太線箇所）をDay 1とした場合の投与期間
MT-5199	80 (mg)/QID	遅発性ジスキネジア	死亡（Day 44）
BENZATROPINE	2 (mg) /HS	遅発性ジスキネジア	
OLANZAPINE	5 (mg) /QD	統合失調症/統合失調感情障害	
ARIPIPRAZOLE	5 (mg) /QD	統合失調症/統合失調感情障害	
ARIPIPRAZOLE	10 (mg) /QD	統合失調症/統合失調感情障害	
CITALOPRAM	20 (mg) /HS	統合失調症/統合失調感情障害	
VALPROATE SEMISODIUM	500 (mg) /BID	統合失調症/統合失調感情障害	
OLANZAPINE	20 (mg) /BID	統合失調症/統合失調感情障害	
TEMAZEPAM	15 (mg) /HS	統合失調症/統合失調感情障害	
ATORVASTATIN	20 (mg) /QD	合併症	
GLIPIZIDE	10 (mg) /BID	合併症	
HYDROCODONE;PARACETAMOL	5-325 (mg) /BID	合併症	
LISINOPRIL	10 (mg) /QD	合併症	
MELOXICAM	15 (mg) /QD	合併症	
METFORMIN	1000 (mg) /BID	合併症	
TIZANIDINE	2 (mg) /TID	合併症	
NICOTINE	21 / 24 (mg/h) /QD	その他	

有害事象

MedDRA基本語	程度	重篤度	MT-5199投与開始日（太線箇所）をDay 1とした場合の発現期間
偶発的過量投与	高度	重篤	死亡（Day 44）

MT-5199 未変化体及び活性代謝物 NBI-98782 の血漿中薬物濃度

本被験者における PK 用採血は，Day 1 の投与前のみの実施であり，投与後の血漿中濃度データは取得されていない．

治験依頼者の見解

被験者[redacted]は，NBI-98854-TD4002 試験の Day 44 に「偶発的過量投与」により死亡した．本被験者の死亡は，ヒドロコドン，メトルファン，オランザピン，シタロプラム，ガバペンチン，トラマドール及びテマゼパムの「複合的及び混合的な影響による偶発的なもの」であったと報告されており，複数の併用薬の処方量超の服用が原因と考えられる．本被験者は，抗精神病薬としてオランザピンを併用していたが，器官別大分類「精神障害」又は「神経系障害」に該当する有害事象は認められなかった．本被験者は，QT 延長作用を有することが知られているオランザピン及びチザニジンを併用していたが，治験期間中，臨床上問題となる QT 延長の心電図所見は認められなかった．本被験者は，本剤との併用により，MT-5199 未変化体又は活性代謝物 NBI-98782 の血漿中濃度が上昇することが想定される強力な CYP3A4 阻害剤又は強力な CYP2D6 阻害剤を併用していなかった．

本被験者の死亡は，ヒドロコドン，オランザピン，シタロプラム，ガバペンチン，トラマドール及びテマゼパムを含む薬剤の「複合的及び混合的な影響による偶発的なもの」であり，安全性評価から自殺の可能性は否定できると治験担当医師により報告されており，複数の併用薬の処方量超の服用が原因と考えられる．また，本被験者は合併症に高血圧，高脂血症及び 2 型糖尿病といった生活習慣病等，死亡リスクを上昇させることが知られている疾患を複数罹患しており，これらが死亡の一因となった可能性は否定できないと考えられた．

表 2.7.4.7－40　死亡に至った有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Any Adverse Event Leading to Death	n (%)	0	0	1(0.9)	0	1(0.4)	1(0.6)
心臓障害	n (%)	0	0	0	0	0	1(0.6)
心筋梗塞	n (%)	0	0	0	0	0	1(0.6)
全身障害および投与局所様態	n (%)	0	0	1(0.9)	0	1(0.4)	0
突然死	n (%)	0	0	1(0.9)	0	1(0.4)	0

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－2 Table 1.2.5.2 より引用（一部改変）

表 2.7.4.7－41　死亡に至った有害事象の内訳：MT-5199 長期投与期間（海外試験_120-Day Safety Update）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Any Adverse Event Leading to Death	n (%)	0	3(1.3)	3(1.4)	3(0.7)
心臓障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
心不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
全身障害および投与局所様態	n (%)	0	1(0.4)	1(0.5)	1(0.2)
突然死	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝胆道系障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
代謝および栄養障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
糖尿病	n (%)	0	1(0.4)	1(0.5)	1(0.2)
高カリウム血症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
代謝性アシドーシス	n (%)	0	1(0.4)	1(0.5)	1(0.2)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	n (%)	0	1(0.4)	1(0.5)	1(0.2)
乳癌	n (%)	0	1(0.4)	1(0.5)	1(0.2)
呼吸器、胸郭および縦隔障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胸水	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－3 Table 1.2.5.3 より引用（一部改変）

表 2.7.4.7－42　死亡例及び非死亡例の主要な人口統計学的特性：MT-5199-J02 試験

	Statistics	Death (N=8) n(%)	Non-death (N=245) n(%)
Age (years)	n	8	245
	Mean	67.9	58.6
	SD	5.9	13.8
	Median	70.0	60.0
	(Min, Max)	(57, 75)	(21, 85)
<65	n(%)	2 (25.0)	151 (61.6)
>=65	n(%)	6 (75.0)	94 (38.4)
65 to <75	n(%)	5 (62.5)	63 (25.7)
>=75	n(%)	1 (12.5)	31 (12.7)
Gender			
Male	n(%)	6 (75.0)	121 (49.4)
Female	n(%)	2 (25.0)	124 (50.6)
Race			
Japanese	n(%)	8 (100.0)	245 (100.0)
Non-Japanese	n(%)	0 (0.0)	0 (0.0)
Ethnicity			
Hispanic or Latino	n(%)	0 (0.0)	0 (0.0)
Not Hispanic or Latino	n(%)	8 (100.0)	245 (100.0)
Body Mass Index (kg/m2)	n	8	245
	Mean	18.80	23.90
	SD	1.59	4.01
	Median	18.80	23.60
	(Min, Max)	(16.9, 21.0)	(16.4, 35.2)
<18.5	n(%)	3 (37.5)	19 (7.8)
18.5 to <25	n(%)	5 (62.5)	134 (54.7)
25 to <30	n(%)	0 (0.0)	74 (30.2)
>=30	n(%)	0 (0.0)	18 (7.3)
CYP2D6 Phenotype Classification			
Ultra-rapid Metabolizer (UM)	n(%)	0 (0.0)	4 (1.6)
Extensive Metabolizer (EM)	n(%)	5 (62.5)	167 (68.2)
Intermediate Metabolizer (IM)	n(%)	3 (37.5)	63 (25.7)
Poor Metabolizer (PM)	n(%)	0 (0.0)	0 (0.0)
Not Reported	n(%)	0 (0.0)	11 (4.5)

Hepatic abnormality is defined as baseline GGT, ALT, or AST > ULN.

表 2.7.4.7－42　死亡例及び非死亡例の主要な人口統計学的特性：MT-5199-J02 試験（続き）

	Statistics	Death (N=8) n(%)	Non-death (N=245) n(%)
Hepatic Abnormality			
Yes	n(%)	2 (25.0)	40 (16.3)
No	n(%)	6 (75.0)	205 (83.7)
Medical History			
Yes	n(%)	8 (100.0)	238 (97.1)
No	n(%)	0 (0.0)	7 (2.9)

Hepatic abnormality is defined as baseline GGT, ALT, or AST > ULN.

5.3.5.3－5 Table 1.2.1.1.1 より引用

表 2.7.4.7－43　死亡例及び非死亡例のベースライン疾患特性：MT-5199-J02 試験

	Statistics	Death (N=8) n(%)	Non-death (N=245) n(%)
Age at Tardive Dyskinesia Diagnosis (years)	n	8	245
	Mean	63.6	55.1
	SD	9.3	14.2
	Median	67.5	55.0
	(Min, Max)	(47, 74)	(20, 83)
Duration of Tardive Dyskinesia (years)			
<2	n(%)	3 (37.5)	115 (46.9)
>=2	n(%)	5 (62.5)	130 (53.1)
Disease Category			
Schizophrenia/Schizoaffective Disorder	n(%)	4 (50.0)	158 (64.5)
Bipolar Disorder/Depressive Disorder	n(%)	4 (50.0)	87 (35.5)
Age at Schizophrenia/Schizoaffective Disorder Diagnosis (years)	n	4	158
	Mean	43.3	39.7
	SD	21.3	15.7
	Median	41.0	36.5
	(Min, Max)	(22, 69)	(14, 76)
Age at Bipolar Disorder/Depressive Disorder Diagnosis (years)	n	4	87
	Mean	51.3	46.0
	SD	12.0	14.5
	Median	51.0	48.0
	(Min, Max)	(37, 66)	(16, 79)
Use of Antipsychotic Medication at Baseline			
Yes	n(%)	5 (62.5)	187 (76.3)
No	n(%)	3 (37.5)	58 (23.7)
Number of Antipsychotic Medication			
1	n(%)	5 (62.5)	125 (51.0)
2	n(%)	0 (0.0)	55 (22.4)
>=3	n(%)	0 (0.0)	7 (2.9)
Atypical vs Typical Antipsychotic Medication			
Atypical only	n(%)	5 (62.5)	148 (60.4)
Typical or both Typical and Atypical	n(%)	0 (0.0)	39 (15.9)
Dose Equivalent to 100mg of chlorpromazine at Baseline			
< 600 mg	n(%)	4 (50.0)	137 (55.9)
>= 600 mg	n(%)	1 (12.5)	50 (20.4)

表 2.7.4.7－43　死亡例及び非死亡例のベースライン疾患特性：MT-5199-J02 試験（続き）

	Statistics	Death (N=8) n(%)	Non-death (N=245) n(%)
Use of Anticholinergic Medication at Baseline			
Yes	n(%)	2 (25.0)	107 (43.7)
No	n(%)	6 (75.0)	138 (56.3)
Suicidality During Lifetime			
Yes	n(%)	3 (37.5)	100 (40.8)
No	n(%)	5 (62.5)	145 (59.2)
Suicidality Within 3 Months Prior to Screening			
Yes	n(%)	0 (0.0)	19 (7.8)
No	n(%)	8 (100.0)	226 (92.2)
Baseline AIMS Dyskinesia Total Score (Central Assessment)	n	8	245
	Mean	7.4	7.7
	SD	4.7	4.1
	Median	6.0	8.0
	(Min, Max)	(3, 18)	(0, 20)

5.3.5.3－5 Table 1.2.1.2.1 より引用

表 2.7.4.7－44　死亡例及び非死亡例の主要な人口統計学的特性：海外臨床試験

	Statistics	Death (N=9) n(%)	Non-death (N=812) n(%)
Age (years)	n	9	812
	Mean	59.9	56.4
	SD	11.0	9.6
	Median	59.0	57.0
	(Min, Max)	(48, 80)	(26, 84)
<65	n(%)	7 (77.8)	662 (81.5)
>=65	n(%)	2 (22.2)	150 (18.5)
Gender			
Male	n(%)	7 (77.8)	452 (55.7)
Female	n(%)	2 (22.2)	360 (44.3)
Race			
American Indian or Alaska Native	n(%)	0 (0.0)	4 (0.5)
Asian	n(%)	0 (0.0)	3 (0.4)
Black or African American	n(%)	3 (33.3)	292 (36.0)
White	n(%)	6 (66.7)	492 (60.6)
Native Hawaiian or Other Pacific Islander	n(%)	0 (0.0)	4 (0.5)
Multiple	n(%)	0 (0.0)	6 (0.7)
Other	n(%)	0 (0.0)	11 (1.4)
Ethnicity			
Hispanic or Latino	n(%)	4 (44.4)	278 (34.2)
Not Hispanic or Latino	n(%)	5 (55.6)	534 (65.8)
Body Mass Index (kg/m2)	n	9	811
	Mean	29.9	28.6
	SD	6.3	5.5
	Median	28.4	28.2
	(Min, Max)	(22, 42)	(14, 47)
<18.5	n(%)	0 (0.0)	14 (1.7)
18.5 to <25	n(%)	2 (22.2)	204 (25.1)
25 to <30	n(%)	3 (33.3)	267 (32.9)
>=30	n(%)	4 (44.4)	326 (40.1)

N1 : The subjects in NBI-98854-TD4001 and TD4002 were not included in this item.
Hepatic abnormality is defined as baseline GGT, ALT, or AST > ULN.

表 2.7.4.7－44　死亡例及び非死亡例の主要な人口統計学的特性：海外臨床試験（続き）

	Statistics	Death (N=9) n(%)	Non-death (N=812) n(%)
CYP2D6 Genotype			
Poor Metabolizer	n(%)	0 (0.0)	39 (4.8)
Ultra Rapid	n(%)	0 (0.0)	19 (2.3)
Extensive	n(%)	5 (55.6)	331 (40.8)
Intermediate	n(%)	3 (33.3)	209 (25.7)
Intermediate or Extensive	n(%)	0 (0.0)	13 (1.6)
Extensive or Ultra Rapid	n(%)	0 (0.0)	7 (0.9)
Normal Metabolizer	n(%)	1 (11.1)	186 (22.9)
Unable to assign status	n(%)	0 (0.0)	6 (0.7)
Not Reported	n(%)	0 (0.0)	2 (0.2)
Hepatic Abnormality	N1	8	592
Yes	n(%)	1 (12.5)	61 (10.3)
No	n(%)	7 (87.5)	531 (89.7)
Medical History			
Yes	n(%)	9 (100.0)	789 (97.2)
No	n(%)	0 (0.0)	23 (2.8)

N1 : The subjects in NBI-98854-TD4001 and TD4002 were not included in this item.
Hepatic abnormality is defined as baseline GGT, ALT, or AST > ULN.

5.3.5.3－5 Table 1.2.1.1.2 より引用

表 2.7.4.7－45　死亡例及び非死亡例のベースライン疾患特性：海外臨床試験

	Statistics	Death (N=9) n(%)	Non-death (N=812) n(%)
Age at Tardive Dyskinesia Diagnosis (years)	n	6	627
	Mean	46.2	48.2
	SD	15.3	11.4
	Median	42.0	50.0
	(Min, Max)	(31, 72)	(16, 81)
Psychiatric Diagnosis Group			
Schizophrenia or Schizoaffective Disorder	n(%)	9 (100.0)	580 (71.4)
Mood Disorder	n(%)	0 (0.0)	228 (28.1)
Gastrointestinal Disorder	n(%)	0 (0.0)	4 (0.5)
Age at Schizophrenia or Schizoaffective Disorder (years)	n	8	524
	Mean	30.4	29.1
	SD	13.6	12.4
	Median	26.0	26.0
	(Min, Max)	(17, 59)	(6, 68)
Age at Mood Disorder (years)	n	0	208
	Mean	-	35.5
	SD	-	13.7
	Median	-	35.5
	(Min, Max)	(-, -)	(10, 66)
Use of Antipsychotic Medication at Baseline	N1	8	592
Yes	n(%)	7 (87.5)	495 (83.6)
No	n(%)	1 (12.5)	97 (16.4)
Atypical vs Typical Antipsychotic Medication	N1	8	592
Atypical only	n(%)	4 (50.0)	392 (66.2)
Typical or both Typical and Atypical	n(%)	3 (37.5)	103 (17.4)
Suicidality During Lifetime	N1	8	592
Yes	n(%)	1 (12.5)	237 (40.0)
No	n(%)	7 (87.5)	355 (60.0)
Suicidality Within 3 Months Prior to Screening	N1	8	592
Yes	n(%)	0 (0.0)	22 (3.7)
No	n(%)	8 (100.0)	570 (96.3)

N1 : The subjects in NBI-98854-TD4001 and TD4002 were not included in this item.

5.3.5.3－5 Table 1.2.1.2.2 より引用

表 2.7.4.7－46　死亡例及び非死亡例の合併症の内訳：MT-5199-J02 試験

System Organ Class (MedDRA)	System Organ Class (MedDRA) in Japanese	Death (N=8) n(%)	Non-death (N=245) n(%)
Any Medical History		8 (100.0)	238 (97.1)
Infections and infestations	感染症および寄生虫症	1 (12.5)	40 (16.3)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (12.5)	0 (0.0)
Blood and lymphatic system disorders	血液およびリンパ系障害	0 (0.0)	13 (5.3)
Immune system disorders	免疫系障害	0 (0.0)	25 (10.2)
Endocrine disorders	内分泌障害	0 (0.0)	20 (8.2)
Metabolism and nutrition disorders	代謝および栄養障害	5 (62.5)	108 (44.1)
Psychiatric disorders	精神障害	2 (25.0)	70 (28.6)
Nervous system disorders	神経系障害	4 (50.0)	90 (36.7)
Eye disorders	眼障害	1 (12.5)	30 (12.2)
Ear and labyrinth disorders	耳および迷路障害	1 (12.5)	5 (2.0)
Cardiac disorders	心臓障害	0 (0.0)	10 (4.1)
Vascular disorders	血管障害	3 (37.5)	61 (24.9)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	3 (37.5)	29 (11.8)
Gastrointestinal disorders	胃腸障害	6 (75.0)	156 (63.7)
Hepatobiliary disorders	肝胆道系障害	0 (0.0)	16 (6.5)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	1 (12.5)	44 (18.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	3 (37.5)	83 (33.9)
Renal and urinary disorders	腎および尿路障害	2 (25.0)	22 (9.0)
Reproductive system and breast disorders	生殖系および乳房障害	1 (12.5)	17 (6.9)
Congenital, familial and genetic disorders	先天性、家族性および遺伝性障害	0 (0.0)	1 (0.4)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	7 (2.9)
Investigations	臨床検査	0 (0.0)	17 (6.9)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	9 (3.7)
Surgical and medical procedures	外科および内科処置	0 (0.0)	1 (0.4)
Social circumstances	社会環境	0 (0.0)	10 (4.1)
Product issues	製品の問題	0 (0.0)	1 (0.4)

MedDRA Version 23.0.

5.3.5.3－5 Table 1.3.2.1 より引用

表 2.7.4.7－47　死亡例及び非死亡例の合併症の内訳：海外臨床試験（P4 以外）

System Organ Class (MedDRA)	System Organ Class (MedDRA) in Japanese	Death (N=8) n(%)	Non-death (N=592) n(%)
Any Medical History		8 (100.0)	577 (97.5)
Infections and infestations	感染症および寄生虫症	6 (75.0)	134 (22.6)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (12.5)	39 (6.6)
Blood and lymphatic system disorders	血液およびリンパ系障害	0 (0.0)	62 (10.5)
Immune system disorders	免疫系障害	3 (37.5)	132 (22.3)
Endocrine disorders	内分泌障害	2 (25.0)	83 (14.0)
Metabolism and nutrition disorders	代謝および栄養障害	6 (75.0)	333 (56.3)
Psychiatric disorders	精神障害	4 (50.0)	413 (69.8)
Nervous system disorders	神経系障害	4 (50.0)	216 (36.5)
Eye disorders	眼障害	2 (25.0)	86 (14.5)
Ear and labyrinth disorders	耳および迷路障害	0 (0.0)	19 (3.2)
Cardiac disorders	心臓障害	4 (50.0)	72 (12.2)
Vascular disorders	血管障害	5 (62.5)	325 (54.9)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	6 (75.0)	192 (32.4)
Gastrointestinal disorders	胃腸障害	6 (75.0)	290 (49.0)
Hepatobiliary disorders	肝胆道系障害	1 (12.5)	22 (3.7)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	5 (62.5)	67 (11.3)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	5 (62.5)	256 (43.2)
Renal and urinary disorders	腎および尿路障害	1 (12.5)	60 (10.1)
Pregnancy, puerperium and perinatal conditions	妊娠、産褥および周産期の状態	0 (0.0)	2 (0.3)
Reproductive system and breast disorders	生殖系および乳房障害	2 (25.0)	74 (12.5)
Congenital, familial and genetic disorders	先天性、家族性および遺伝性障害	1 (12.5)	15 (2.5)
General disorders and administration site conditions	全身障害および投与局所様態	0 (0.0)	42 (7.1)
Investigations	臨床検査	0 (0.0)	55 (9.3)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	3 (37.5)	86 (14.5)
Surgical and medical procedures	外科および内科処置	4 (50.0)	207 (35.0)
Social circumstances	社会環境	2 (25.0)	71 (12.0)

MedDRA Version 12.0.

5.3.5.3－5 Table 1.3.2.2 より引用

表 2.7.4.7－48　死亡例及び非死亡例の合併症の内訳：海外臨床試験（P4）

System Organ Class (MedDRA)	System Organ Class (MedDRA) in Japanese	Death (N=1) n(%)	Non-death (N=220) n(%)
Any Medical History		1 (100.0)	212 (96.4)
Infections and infestations	感染症および寄生虫症	0 (0.0)	35 (15.9)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0 (0.0)	11 (5.0)
Blood and lymphatic system disorders	血液およびリンパ系障害	0 (0.0)	26 (11.8)
Immune system disorders	免疫系障害	0 (0.0)	45 (20.5)
Endocrine disorders	内分泌障害	0 (0.0)	26 (11.8)
Metabolism and nutrition disorders	代謝および栄養障害	1 (100.0)	127 (57.7)
Psychiatric disorders	精神障害	0 (0.0)	163 (74.1)
Nervous system disorders	神経系障害	0 (0.0)	89 (40.5)
Eye disorders	眼障害	0 (0.0)	33 (15.0)
Ear and labyrinth disorders	耳および迷路障害	0 (0.0)	5 (2.3)
Cardiac disorders	心臓障害	0 (0.0)	20 (9.1)
Vascular disorders	血管障害	1 (100.0)	130 (59.1)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	1 (100.0)	72 (32.7)
Gastrointestinal disorders	胃腸障害	0 (0.0)	107 (48.6)
Hepatobiliary disorders	肝胆道系障害	0 (0.0)	7 (3.2)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	0 (0.0)	8 (3.6)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	1 (100.0)	93 (42.3)
Renal and urinary disorders	腎および尿路障害	0 (0.0)	18 (8.2)
Pregnancy, puerperium and perinatal conditions	妊娠、産褥および周産期の状態	0 (0.0)	1 (0.5)
Reproductive system and breast disorders	生殖系および乳房障害	0 (0.0)	21 (9.5)
Congenital, familial and genetic disorders	先天性、家族性および遺伝性障害	0 (0.0)	3 (1.4)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	16 (7.3)
Investigations	臨床検査	0 (0.0)	9 (4.1)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	20 (9.1)
Surgical and medical procedures	外科および内科処置	0 (0.0)	71 (32.3)
Social circumstances	社会環境	0 (0.0)	30 (13.6)

MedDRA Version 21.0.

5.3.5.3－5 Table 1.3.2.3 より引用

表 2.7.4.7－49　死亡例及び非死亡例の併用薬（抗精神病薬）の内訳：MT-5199-J02 試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
Any Concomitant Medications	6 (75.0)	193 (78.8)
ANTIPSYCHOTICS	6 (75.0)	193 (78.8)
ARIPIPRAZOLE	2 (25.0)	36 (14.7)
ASENAPINE	0 (0.0)	1 (0.4)
ASENAPINE MALEATE	0 (0.0)	10 (4.1)
BLONANSERIN	1 (12.5)	17 (6.9)
BREXPIPRAZOLE	0 (0.0)	13 (5.3)
BROMPERIDOL	0 (0.0)	1 (0.4)
CHLORPROMAZINE HYDROCHLORIDE	1 (12.5)	10 (4.1)
CLOZAPINE	0 (0.0)	2 (0.8)
FLUPHENAZINE DECANOATE	0 (0.0)	2 (0.8)
HALOPERIDOL	0 (0.0)	9 (3.7)
HALOPERIDOL DECANOATE	0 (0.0)	4 (1.6)
LEVOMEPROMAZINE	0 (0.0)	3 (1.2)
LEVOMEPROMAZINE HYDROCHLORIDE	0 (0.0)	2 (0.8)
LEVOMEPROMAZINE MALEATE	0 (0.0)	12 (4.9)
LITHIUM CARBONATE	1 (12.5)	17 (6.9)
MOSAPRAMINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
OLANZAPINE	1 (12.5)	61 (24.9)
OXYPERTINE	0 (0.0)	1 (0.4)
PALIPERIDONE	0 (0.0)	8 (3.3)
PALIPERIDONE PALMITATE	0 (0.0)	9 (3.7)
PERICIAZINE	0 (0.0)	1 (0.4)
PEROSPIRONE	0 (0.0)	1 (0.4)
PEROSPIRONE HYDROCHLORIDE	0 (0.0)	7 (2.9)
PERPHENAZINE MALEATE	0 (0.0)	1 (0.4)
PROCHLORPERAZINE MALEATE	0 (0.0)	1 (0.4)
QUETIAPINE	0 (0.0)	3 (1.2)
QUETIAPINE FUMARATE	2 (25.0)	35 (14.3)
RISPERIDONE	0 (0.0)	46 (18.8)
SULPIRIDE	0 (0.0)	6 (2.4)
TIAPRIDE	0 (0.0)	1 (0.4)
TIAPRIDE HYDROCHLORIDE	0 (0.0)	9 (3.7)
ZOTEPINE	0 (0.0)	4 (1.6)

5.3.5.3－5 Table 1.4.2.1 より引用

表 2.7.4.7－50　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：MT-5199-J02 試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
Any Concomitant Medications	8 (100.0)	226 (92.2)
ANESTHETICS, GENERAL	0 (0.0)	3 (1.2)
PROPOFOL	0 (0.0)	3 (1.2)
SEVOFLURANE	0 (0.0)	1 (0.4)
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	0 (0.0)	3 (1.2)
CANDESARTAN CILEXETIL;HYDROCHLOROTHIAZIDE	0 (0.0)	2 (0.8)
HYDROCHLOROTHIAZIDE;TELMISARTAN	0 (0.0)	1 (0.4)
ANTIARRHYTHMICS, CLASS I AND III	0 (0.0)	1 (0.4)
DISOPYRAMIDE	0 (0.0)	1 (0.4)
ANTIDEPRESSANTS	6 (75.0)	60 (24.5)
AMITRIPTYLINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
CLOMIPRAMINE HYDROCHLORIDE	0 (0.0)	2 (0.8)
ESCITALOPRAM	0 (0.0)	1 (0.4)
ESCITALOPRAM OXALATE	1 (12.5)	13 (5.3)
FLUVOXAMINE MALEATE	0 (0.0)	3 (1.2)
MAPROTILINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
MIANSERIN HYDROCHLORIDE	1 (12.5)	7 (2.9)
MIRTAZAPINE	1 (12.5)	23 (9.4)
SERTRALINE HYDROCHLORIDE	0 (0.0)	6 (2.4)
TRAZODONE	0 (0.0)	1 (0.4)
TRAZODONE HYDROCHLORIDE	2 (25.0)	18 (7.3)
VENLAFAXINE	0 (0.0)	1 (0.4)
VENLAFAXINE HYDROCHLORIDE	1 (12.5)	6 (2.4)
ANTIEPILEPTICS	1 (12.5)	1 (0.4)
LEVETIRACETAM	1 (12.5)	1 (0.4)
ANTIFUNGALS FOR TOPICAL USE	0 (0.0)	4 (1.6)
KETOCONAZOLE	0 (0.0)	4 (1.6)
ANTIHISTAMINES FOR SYSTEMIC USE	0 (0.0)	4 (1.6)
CALCIUM BROMIDE;DIPHENHYDRAMINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
HYDROXYZINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
PROMETHAZINE METHYLENE DISALICYLATE	0 (0.0)	2 (0.8)

表 2.7.4.7－50　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：MT-5199-J02 試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
ANTIINFECTIVES	1 (12.5)	13 (5.3)
GATIFLOXACIN	0 (0.0)	4 (1.6)
LEVOFLOXACIN	1 (12.5)	4 (1.6)
MOXIFLOXACIN HYDROCHLORIDE	0 (0.0)	1 (0.4)
OFLOXACIN	0 (0.0)	5 (2.0)
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	0 (0.0)	2 (0.8)
METRONIDAZOLE	0 (0.0)	2 (0.8)
ANTIPROPULSIVES	1 (12.5)	2 (0.8)
LOPERAMIDE HYDROCHLORIDE	1 (12.5)	2 (0.8)
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	0 (0.0)	5 (2.0)
CAMPHOR;DIPHENHYDRAMINE;ENOXOLONE;LEVOMENTHOL;THYMOL	0 (0.0)	1 (0.4)
DIPHENHYDRAMINE	0 (0.0)	4 (1.6)

表 2.7.4.7－50　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：MT-5199-J02 試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
ANTIPSYCHOTICS	6 (75.0)	188 (76.7)
ARIPIPRAZOLE	2 (25.0)	36 (14.7)
ASENAPINE	0 (0.0)	1 (0.4)
ASENAPINE MALEATE	0 (0.0)	10 (4.1)
BLONANSERIN	1 (12.5)	17 (6.9)
CHLORPROMAZINE HYDROCHLORIDE	1 (12.5)	10 (4.1)
CLOZAPINE	0 (0.0)	2 (0.8)
HALOPERIDOL	0 (0.0)	9 (3.7)
HALOPERIDOL DECANOATE	0 (0.0)	4 (1.6)
LEVOMEPROMAZINE	0 (0.0)	3 (1.2)
LEVOMEPROMAZINE HYDROCHLORIDE	0 (0.0)	2 (0.8)
LEVOMEPROMAZINE MALEATE	0 (0.0)	12 (4.9)
LITHIUM CARBONATE	1 (12.5)	17 (6.9)
OLANZAPINE	1 (12.5)	61 (24.9)
PALIPERIDONE	0 (0.0)	8 (3.3)
PALIPERIDONE PALMITATE	0 (0.0)	9 (3.7)
PERPHENAZINE MALEATE	0 (0.0)	1 (0.4)
QUETIAPINE	0 (0.0)	3 (1.2)
QUETIAPINE FUMARATE	2 (25.0)	35 (14.3)
RISPERIDONE	0 (0.0)	46 (18.8)
SULPIRIDE	0 (0.0)	6 (2.4)
TIAPRIDE	0 (0.0)	1 (0.4)
TIAPRIDE HYDROCHLORIDE	0 (0.0)	9 (3.7)
ZOTEPINE	0 (0.0)	4 (1.6)
ANTITHROMBOTIC AGENTS	0 (0.0)	2 (0.8)
CILOSTAZOL	0 (0.0)	2 (0.8)
ANXIOLYTICS	0 (0.0)	5 (2.0)
HYDROXYZINE EMBONATE	0 (0.0)	5 (2.0)
HYDROXYZINE HYDROCHLORIDE	0 (0.0)	1 (0.4)
DOPAMINERGIC AGENTS	0 (0.0)	8 (3.3)
AMANTADINE HYDROCHLORIDE	0 (0.0)	8 (3.3)

表 2.7.4.7－50　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：MT-5199-J02 試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	3 (37.5)	28 (11.4)
ESOMEPRAZOLE MAGNESIUM	0 (0.0)	7 (2.9)
FAMOTIDINE	2 (25.0)	8 (3.3)
LANSOPRAZOLE	0 (0.0)	12 (4.9)
OMEPRAZOLE	1 (12.5)	1 (0.4)
HIGH-CEILING DIURETICS	0 (0.0)	4 (1.6)
FUROSEMIDE	0 (0.0)	4 (1.6)
HYPNOTICS AND SEDATIVES	2 (25.0)	15 (6.1)
PROMETHAZINE	0 (0.0)	1 (0.4)
PROMETHAZINE HYDROCHLORIDE	2 (25.0)	14 (5.7)
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	0 (0.0)	10 (4.1)
AZITHROMYCIN	0 (0.0)	1 (0.4)
CLARITHROMYCIN	0 (0.0)	9 (3.7)
ROXITHROMYCIN	0 (0.0)	1 (0.4)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	0 (0.0)	15 (6.1)
EPERISONE HYDROCHLORIDE	0 (0.0)	7 (2.9)
TIZANIDINE HYDROCHLORIDE	0 (0.0)	9 (3.7)
OPIOIDS	0 (0.0)	3 (1.2)
PARACETAMOL;TRAMADOL HYDROCHLORIDE	0 (0.0)	2 (0.8)
TRAMADOL HYDROCHLORIDE	0 (0.0)	1 (0.4)
OTHER ANALGESICS AND ANTIPYRETICS	1 (12.5)	31 (12.7)
CAFFEINE;PARACETAMOL;PROMETHAZINE METHYLENE DISALICYLATE;SALICYLAMIDE	1 (12.5)	31 (12.7)
OTHER DERMATOLOGICAL PREPARATIONS	0 (0.0)	3 (1.2)
TACROLIMUS	0 (0.0)	3 (1.2)
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	0 (0.0)	2 (0.8)
DIPHENHYDRAMINE SALICYLATE;DIPROPHYLLINE	0 (0.0)	2 (0.8)
PROPULSIVES	0 (0.0)	11 (4.5)
DOMPERIDONE	0 (0.0)	5 (2.0)
METOCLOPRAMIDE	0 (0.0)	5 (2.0)
METOCLOPRAMIDE HYDROCHLORIDE	0 (0.0)	3 (1.2)
QUINOLONE ANTIBACTERIALS	0 (0.0)	13 (5.3)
GARENOXACIN MESILATE	0 (0.0)	1 (0.4)
LEVOFLOXACIN	0 (0.0)	12 (4.9)
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	0 (0.0)	2 (0.8)
NICARDIPINE HYDROCHLORIDE	0 (0.0)	2 (0.8)

表 2.7.4.7－50　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：MT-5199-J02 試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
STOMATOLOGICAL PREPARATIONS	0 (0.0)	1 (0.4)
BENZALKONIUM CHLORIDE;CHLORHEXIDINE HYDROCHLORIDE;DIPHENHYDRAMINE SALICYLATE;HYDROCORTISONE ACETATE	0 (0.0)	1 (0.4)
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	0 (0.0)	6 (2.4)
CAMPHOR;DIPHENHYDRAMINE;MENTHA X PIPERITA OIL;METHYL SALICYLATE;THYMOL	0 (0.0)	6 (2.4)
UROLOGICALS	0 (0.0)	7 (2.9)
MIRABEGRON	0 (0.0)	6 (2.4)
SOLIFENACIN SUCCINATE	0 (0.0)	2 (0.8)

5.3.5.3－5 Table 1.4.3.1 より引用

表 2.7.4.7－51　死亡例及び非死亡例の併用薬（強力な CYP3A4/5 阻害剤又は強力な CYP2D6 阻害剤）の内訳：MT-5199-J02 試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=8) n(%)	Non-death (N=245) n(%)
Any Concomitant Medications	0 (0.0)	13 (5.3)
ANTIFUNGALS FOR TOPICAL USE	0 (0.0)	4 (1.6)
KETOCONAZOLE	0 (0.0)	4 (1.6)
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	0 (0.0)	9 (3.7)
CLARITHROMYCIN	0 (0.0)	9 (3.7)

5.3.5.3－5 Table 1.4.4.1 より引用

表 2.7.4.7－52　死亡例及び非死亡例の併用薬（抗精神病薬）の内訳：海外臨床試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
Any Concomitant Medications	8 (88.9)	703 (86.6)
ANTIPSYCHOTICS	8 (88.9)	703 (86.6)
ARIPIPRAZOLE	0 (0.0)	111 (13.7)
ASENAPINE	0 (0.0)	4 (0.5)
BREXPIPRAZOLE	0 (0.0)	4 (0.5)
CARIPRAZINE	0 (0.0)	1 (0.1)
CHLORPROMAZINE	1 (11.1)	15 (1.8)
CLOZAPINE	1 (11.1)	31 (3.8)
FLUPENTIXOL	0 (0.0)	1 (0.1)
FLUPHENAZINE	2 (22.2)	23 (2.8)
HALOPERIDOL	1 (11.1)	84 (10.3)
ILOPERIDONE	0 (0.0)	8 (1.0)
LITHIUM	0 (0.0)	30 (3.7)
LITHIUM CARBONATE	0 (0.0)	8 (1.0)
LOXAPINE	0 (0.0)	6 (0.7)
LURASIDONE	0 (0.0)	41 (5.0)
OLANZAPINE	2 (22.2)	103 (12.7)
PALIPERIDONE	0 (0.0)	24 (3.0)
PERPHENAZINE	0 (0.0)	20 (2.5)
QUETIAPINE	2 (22.2)	197 (24.3)
RISPERIDONE	1 (11.1)	140 (17.2)
TIOTIXENE	0 (0.0)	1 (0.1)
TRIFLUOPERAZINE	0 (0.0)	8 (1.0)
ZIPRASIDONE	1 (11.1)	37 (4.6)

5.3.5.3－5 Table 1.4.2.2 より引用

表 2.7.4.7－53　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：海外臨床試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
Any Concomitant Medications	8 (88.9)	793 (97.7)
ACE INHIBITORS, COMBINATIONS	0 (0.0)	7 (0.9)
BENAZEPRIL;HYDROCHLOROTHIAZIDE	0 (0.0)	2 (0.2)
ENALAPRIL;HYDROCHLOROTHIAZIDE	0 (0.0)	1 (0.1)
HYDROCHLOROTHIAZIDE;LISINOPRIL	0 (0.0)	4 (0.5)
ANESTHETICS, GENERAL	1 (11.1)	3 (0.4)
PROPOFOL	1 (11.1)	3 (0.4)
SEVOFLURANE	0 (0.0)	1 (0.1)
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	0 (0.0)	3 (0.4)
HYDROCHLOROTHIAZIDE W/LOSARTAN	0 (0.0)	1 (0.1)
HYDROCHLOROTHIAZIDE;LOSARTAN	0 (0.0)	1 (0.1)
HYDROCHLOROTHIAZIDE;LOSARTAN POTASSIUM	0 (0.0)	1 (0.1)
ANTI-DEMENTIA DRUGS	1 (11.1)	32 (3.9)
DONEPEZIL	1 (11.1)	22 (2.7)
MEMANTINE	0 (0.0)	14 (1.7)
ANTIARRHYTHMICS, CLASS I AND III	1 (11.1)	1 (0.1)
AMIODARONE	1 (11.1)	1 (0.1)
ANTIDEPRESSANTS	4 (44.4)	471 (58.0)
AMITRIPTYLINE	0 (0.0)	13 (1.6)
CITALOPRAM	2 (22.2)	78 (9.6)
CLOMIPRAMINE	0 (0.0)	1 (0.1)
DESIPRAMINE	0 (0.0)	2 (0.2)
DESVENLAFAXINE	0 (0.0)	1 (0.1)
DOXEPIN	0 (0.0)	10 (1.2)
ESCITALOPRAM	0 (0.0)	48 (5.9)
FLUOXETINE	0 (0.0)	60 (7.4)
FLUVOXAMINE	0 (0.0)	3 (0.4)
IMIPRAMINE	0 (0.0)	1 (0.1)
MIRTAZAPINE	0 (0.0)	73 (9.0)
NORTRIPTYLINE	1 (11.1)	5 (0.6)
PAROXETINE	0 (0.0)	19 (2.3)
SERTRALINE	1 (11.1)	87 (10.7)
TRAZODONE	0 (0.0)	183 (22.5)
VENLAFAXINE	1 (11.1)	31 (3.8)

表 2.7.4.7－53　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：海外臨床試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
ANTIEMETICS AND ANTINAUSEANTS	0 (0.0)	13 (1.6)
ONDANSETRON	0 (0.0)	12 (1.5)
PROMETHAZINE	0 (0.0)	2 (0.2)
ANTIEPILEPTICS	1 (11.1)	6 (0.7)
LEVETIRACETAM	1 (11.1)	6 (0.7)
ANTIFUNGALS FOR TOPICAL USE	2 (22.2)	3 (0.4)
KETOCONAZOLE	2 (22.2)	3 (0.4)
ANTIHISTAMINES FOR SYSTEMIC USE	1 (11.1)	20 (2.5)
DIPHENHYDRAMINE	1 (11.1)	16 (2.0)
HYDROXYZINE	0 (0.0)	2 (0.2)
PROMETHAZINE	0 (0.0)	2 (0.2)
ANTIINFECTIVES	1 (11.1)	3 (0.4)
CIPROFLOXACIN	1 (11.1)	2 (0.2)
ERYTHROMYCIN	0 (0.0)	1 (0.1)
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	0 (0.0)	18 (2.2)
CIPROFLOXACIN	0 (0.0)	18 (2.2)
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS	0 (0.0)	1 (0.1)
HYDROXYCHLOROQUINE	0 (0.0)	1 (0.1)
ANTIMETABOLITES	0 (0.0)	1 (0.1)
FLUOROURACIL	0 (0.0)	1 (0.1)
ANTIMYCOTICS FOR SYSTEMIC USE	1 (11.1)	1 (0.1)
FLUCONAZOLE	1 (11.1)	1 (0.1)
ANTIPROPULSIVES	0 (0.0)	8 (1.0)
LOPERAMIDE	0 (0.0)	8 (1.0)

表 2.7.4.7－53　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：海外臨床試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
ANTIPSYCHOTICS	7 (77.8)	685 (84.4)
ARIPIPRAZOLE	0 (0.0)	111 (13.7)
ASENAPINE	0 (0.0)	4 (0.5)
CHLORPROMAZINE	1 (11.1)	15 (1.8)
CLOZAPINE	1 (11.1)	31 (3.8)
FLUPENTIXOL	0 (0.0)	1 (0.1)
HALOPERIDOL	1 (11.1)	84 (10.3)
ILOPERIDONE	0 (0.0)	8 (1.0)
LITHIUM	0 (0.0)	30 (3.7)
LITHIUM CARBONATE	0 (0.0)	8 (1.0)
LURASIDONE	0 (0.0)	41 (5.0)
OLANZAPINE	2 (22.2)	103 (12.7)
PALIPERIDONE	0 (0.0)	24 (3.0)
PERPHENAZINE	0 (0.0)	20 (2.5)
QUETIAPINE	2 (22.2)	197 (24.3)
RISPERIDONE	1 (11.1)	140 (17.2)
ZIPRASIDONE	1 (11.1)	37 (4.6)
ANTITHROMBOTIC AGENTS	0 (0.0)	1 (0.1)
CILOSTAZOL	0 (0.0)	1 (0.1)
ANXIOLYTICS	0 (0.0)	75 (9.2)
HYDROXYZINE	0 (0.0)	74 (9.1)
HYDROXYZINE EMBONATE	0 (0.0)	1 (0.1)
BETA BLOCKING AGENTS AND THIAZIDES	0 (0.0)	3 (0.4)
ATENOLOL W/HYDROCHLOROTHIAZIDE	0 (0.0)	1 (0.1)
BISOPROLOL W/HYDROCHLOROTHIAZIDE	0 (0.0)	1 (0.1)
BISOPROLOL;HYDROCHLOROTHIAZIDE	0 (0.0)	1 (0.1)
CHEMOTHERAPEUTICS FOR TOPICAL USE	0 (0.0)	1 (0.1)
METRONIDAZOLE	0 (0.0)	1 (0.1)
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	0 (0.0)	2 (0.2)
HYDROCHLOROTHIAZIDE;TRIAMTERENE	0 (0.0)	2 (0.2)
DOPAMINERGIC AGENTS	0 (0.0)	6 (0.7)
AMANTADINE	0 (0.0)	6 (0.7)

表 2.7.4.7－53　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：海外臨床試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	5 (55.6)	224 (27.6)
DEXLANSOPRAZOLE	0 (0.0)	1 (0.1)
ESOMEPRAZOLE	0 (0.0)	24 (3.0)
FAMOTIDINE	1 (11.1)	23 (2.8)
LANSOPRAZOLE	0 (0.0)	5 (0.6)
OMEPRAZOLE	4 (44.4)	147 (18.1)
PANTOPRAZOLE	1 (11.1)	36 (4.4)
DRUGS USED IN ADDICTIVE DISORDERS	0 (0.0)	3 (0.4)
BUPRENORPHINE W/NALOXONE	0 (0.0)	1 (0.1)
METHADONE	0 (0.0)	2 (0.2)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	0 (0.0)	2 (0.2)
ALFUZOSIN	0 (0.0)	2 (0.2)
HIGH-CEILING DIURETICS	1 (11.1)	26 (3.2)
FUROSEMIDE	1 (11.1)	26 (3.2)
HYPNOTICS AND SEDATIVES	2 (22.2)	65 (8.0)
DIPHENHYDRAMINE	2 (22.2)	61 (7.5)
DOXEPIN	0 (0.0)	5 (0.6)
LOW-CEILING DIURETICS, EXCL. THIAZIDES	0 (0.0)	1 (0.1)
INDAPAMIDE	0 (0.0)	1 (0.1)
LOW-CEILING DIURETICS, THIAZIDES	0 (0.0)	59 (7.3)
HYDROCHLOROTHIAZIDE	0 (0.0)	59 (7.3)
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	0 (0.0)	16 (2.0)
AZITHROMYCIN	0 (0.0)	14 (1.7)
ERYTHROMYCIN	0 (0.0)	2 (0.2)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	2 (22.2)	6 (0.7)
TIZANIDINE	2 (22.2)	6 (0.7)
OPIOIDS	0 (0.0)	24 (3.0)
TRAMADOL	0 (0.0)	24 (3.0)
OTHER ANALGESICS AND ANTIPYRETICS	0 (0.0)	1 (0.1)
DIPHENHYDRAMINE;PARACETAMOL;PHENYLEPHRINE	0 (0.0)	1 (0.1)
OTHER ANTIBACTERIALS	1 (11.1)	4 (0.5)
METRONIDAZOLE	1 (11.1)	4 (0.5)
OTHER NERVOUS SYSTEM DRUGS	0 (0.0)	2 (0.2)
DEUTETRABENAZINE	0 (0.0)	1 (0.1)
TETRABENAZINE	0 (0.0)	1 (0.1)

表 2.7.4.7－53　死亡例及び非死亡例の併用薬（QT 延長作用を有することが知られている薬剤）の内訳：海外臨床試験（続き）

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
PERIPHERAL VASODILATORS	0 (0.0)	1 (0.1)
CILOSTAZOL	0 (0.0)	1 (0.1)
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	0 (0.0)	2 (0.2)
ATOMOXETINE	0 (0.0)	2 (0.2)
QUINOLONE ANTIBACTERIALS	0 (0.0)	21 (2.6)
CIPROFLOXACIN	0 (0.0)	10 (1.2)
LEVOFLOXACIN	0 (0.0)	10 (1.2)
MOXIFLOXACIN	0 (0.0)	1 (0.1)
UROLOGICALS	0 (0.0)	13 (1.6)
MIRABEGRON	0 (0.0)	4 (0.5)
SOLIFENACIN	0 (0.0)	5 (0.6)
SOLIFENACIN SUCCINATE	0 (0.0)	1 (0.1)
TOLTERODINE	0 (0.0)	3 (0.4)

5.3.5.3－5 Table 1.4.3.2 より引用

表 2.7.4.7－54　死亡例及び非死亡例の併用薬（強力な CYP3A4/5 阻害剤又は強力な CYP2D6 阻害剤）の内訳：海外臨床試験

WHO Drug ATC Category (Level 3) Preferred Term	Death (N=9) n(%)	Non-death (N=812) n(%)
Any Concomitant Medications	2 (22.2)	145 (17.9)
ANTIDEPRESSANTS	0 (0.0)	145 (17.9)
BUPROPION	0 (0.0)	69 (8.5)
FLUOXETINE	0 (0.0)	60 (7.4)
PAROXETINE	0 (0.0)	19 (2.3)
ANTIFUNGALS FOR SYSTEMIC USE	0 (0.0)	2 (0.2)
TERBINAFINE	0 (0.0)	2 (0.2)
ANTIFUNGALS FOR TOPICAL USE	2 (22.2)	3 (0.4)
KETOCONAZOLE	2 (22.2)	3 (0.4)

5.3.5.3－5 Table 1.4.4.2 より引用

表 2.7.4.7－55　重篤な有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Any Serious Adverse Event	n (%)	0	6(5.5)	6(5.4)	0	12(4.7)	6(3.4)
心臓障害	n (%)	0	0	0	0	0	1(0.6)
心筋梗塞	n (%)	0	0	0	0	0	1(0.6)
全身障害および投与局所様態	n (%)	0	1(0.9)	1(0.9)	0	2(0.8)	0
胸痛	n (%)	0	1(0.9)	0	0	1(0.4)	0
突然死	n (%)	0	0	1(0.9)	0	1(0.4)	0
肝胆道系障害	n (%)	0	0	1(0.9)	0	1(0.4)	0
急性肝炎	n (%)	0	0	1(0.9)	0	1(0.4)	0
感染症および寄生虫症	n (%)	0	2(1.8)	0	0	2(0.8)	0
ウイルス性胃腸炎	n (%)	0	1(0.9)	0	0	1(0.4)	0
急性腎盂腎炎	n (%)	0	1(0.9)	0	0	1(0.4)	0
傷害、中毒および処置合併症	n (%)	0	1(0.9)	0	0	1(0.4)	0
転倒・転落	n (%)	0	1(0.9)	0	0	1(0.4)	0
神経系障害	n (%)	0	0	0	0	0	1(0.6)
痙攣	n (%)	0	0	0	0	0	1(0.6)
精神障害	n (%)	0	3(2.7)	4(3.6)	0	7(2.8)	4(2.2)
双極１型障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
うつ病	n (%)	0	0	1(0.9)	0	1(0.4)	0
敵意	n (%)	0	1(0.9)	0	0	1(0.4)	0

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表 2.7.4.7－55 重篤な有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
精神状態変化	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
統合失調感情障害	n (%)	0	0	1(0.9)	0	1(0.4)	1(0.6)
統合失調症	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
自殺念慮	n (%)	0	0	1(0.9)	0	1(0.4)	0
自殺企図	n (%)	0	0	1(0.9)	0	1(0.4)	0
統合失調症、妄想型	n (%)	0	0	0	0	0	1(0.6)
腎および尿路障害	n (%)	0	0	0	0	0	1(0.6)
尿閉	n (%)	0	0	0	0	0	1(0.6)
呼吸器、胸郭および縦隔障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
慢性閉塞性肺疾患	n (%)	0	1(0.9)	0	0	1(0.4)	0

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－2 Table 1.2.6.2より引用（一部改変）

表 2.7.4.7－56　重篤な副作用の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
Any Serious Treatment-Related Adverse Event[b]	n (%)	0	0	1(0.9)	0	1(0.4)	0
肝胆道系障害	n (%)	0	0	1(0.9)	0	1(0.4)	0
急性肝炎	n (%)	0	0	1(0.9)	0	1(0.4)	0

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] Treatment-Related AEs are defined as AEs possibly or definitely related to study drug.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－2 Table 1.2.8.2より引用（一部改変）

表2.7.4.7－57　重篤な有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Any Serious Adverse Event	n (%)	23(11.5)	38(16.5)	37(17.6)	61(14.2)
心臓障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
心不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胃腸障害	n (%)	2(1.0)	4(1.7)	4(1.9)	6(1.4)
腹痛	n (%)	1(0.5)	2(0.9)	2(1.0)	3(0.7)
便秘	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胃炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胃腸出血	n (%)	1(0.5)	0	0	1(0.2)
食道狭窄	n (%)	1(0.5)	0	0	1(0.2)
直腸出血	n (%)	1(0.5)	0	0	1(0.2)
全身障害および投与局所様態	n (%)	1(0.5)	2(0.9)	2(1.0)	3(0.7)
胸痛	n (%)	1(0.5)	0	0	1(0.2)
非心臓性胸痛	n (%)	0	1(0.4)	1(0.5)	1(0.2)
突然死	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝胆道系障害	n (%)	0	3(1.3)	3(1.4)	3(0.7)
胆石症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性肝炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
感染症および寄生虫症	n (%)	4(2.0)	2(0.9)	2(1.0)	6(1.4)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表2.7.4.7－57　重篤な有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	 All NBI-98854 (N=430)
憩室炎	n (%)	0	2(0.9)	2(1.0)	2(0.5)
気管支炎	n (%)	1(0.5)	0	0	1(0.2)
ブドウ球菌性蜂巣炎	n (%)	1(0.5)	0	0	1(0.2)
ウイルス性胃腸炎	n (%)	1(0.5)	0	0	1(0.2)
急性腎盂腎炎	n (%)	1(0.5)	0	0	1(0.2)
傷害、中毒および処置合併症	n (%)	3(1.5)	5(2.2)	4(1.9)	8(1.9)
転倒・転落	n (%)	2(1.0)	0	0	2(0.5)
交通事故	n (%)	0	2(0.9)	2(1.0)	2(0.5)
異物による損傷	n (%)	0	1(0.4)	1(0.5)	1(0.2)
頭部損傷	n (%)	1(0.5)	0	0	1(0.2)
関節脱臼	n (%)	0	1(0.4)	0	1(0.2)
四肢外傷性切断	n (%)	1(0.5)	0	0	1(0.2)
治療薬毒性	n (%)	0	1(0.4)	1(0.5)	1(0.2)
代謝および栄養障害	n (%)	0	2(0.9)	2(1.0)	2(0.5)
糖尿病	n (%)	0	1(0.4)	1(0.5)	1(0.2)
高カリウム血症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
低ナトリウム血症候群	n (%)	0	1(0.4)	1(0.5)	1(0.2)
代謝性アシドーシス	n (%)	0	1(0.4)	1(0.5)	1(0.2)
筋骨格系および結合組織障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
骨関節炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表2.7.4.7－57　重篤な有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	n (%)	0	2(0.9)	2(1.0)	2(0.5)
乳癌	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肺新生物	n (%)	0	1(0.4)	1(0.5)	1(0.2)
神経系障害	n (%)	3(1.5)	3(1.3)	3(1.4)	6(1.4)
失神	n (%)	2(1.0)	1(0.4)	1(0.5)	3(0.7)
一過性脳虚血発作	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
脳症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
鎮静	n (%)	0	1(0.4)	1(0.5)	1(0.2)
妊娠、産褥および周産期の状態	n (%)	0	1(0.4)	1(0.5)	1(0.2)
自然流産	n (%)	0	1(0.4)	1(0.5)	1(0.2)
精神障害	n (%)	12(6.0)	11(4.8)	11(5.2)	23(5.3)
統合失調症	n (%)	3(1.5)	2(0.9)	2(1.0)	5(1.2)
自殺念慮	n (%)	2(1.0)	3(1.3)	3(1.4)	5(1.2)
うつ病	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
精神状態変化	n (%)	2(1.0)	0	0	2(0.5)
統合失調感情障害	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
自殺企図	n (%)	0	2(0.9)	2(1.0)	2(0.5)
双極１型障害	n (%)	1(0.5)	0	0	1(0.2)
錯乱状態	n (%)	1(0.5)	0	0	1(0.2)
譫妄	n (%)	1(0.5)	0	0	1(0.2)
敵意	n (%)	1(0.5)	0	0	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表2.7.4.7－57　重篤な有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
躁病	n (%)	0	1(0.4)	1(0.5)	1(0.2)
精神病性障害	n (%)	1(0.5)	0	0	1(0.2)
自殺行為	n (%)	0	1(0.4)	1(0.5)	1(0.2)
腎および尿路障害	n (%)	2(1.0)	1(0.4)	1(0.5)	3(0.7)
血尿	n (%)	1(0.5)	0	0	1(0.2)
腎結石症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性腎不全	n (%)	1(0.5)	0	0	1(0.2)
呼吸器、胸郭および縦隔障害	n (%)	1(0.5)	3(1.3)	3(1.4)	4(0.9)
慢性閉塞性肺疾患	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
胸水	n (%)	0	1(0.4)	1(0.5)	1(0.2)
嚥下性肺炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
社会環境	n (%)	1(0.5)	0	0	1(0.2)
社会的入院	n (%)	1(0.5)	0	0	1(0.2)
血管障害	n (%)	0	2(0.9)	2(1.0)	2(0.5)
深部静脈血栓症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
高血圧	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－3 Table 1.2.6.3より引用（一部改変）

表 2.7.4.7－58　重篤な副作用の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	 All NBI-98854 (N=430)
Any Serious Treatment-Related Adverse Event[c]	n (%)	1(0.5)	2(0.9)	2(1.0)	3(0.7)
肝胆道系障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性肝炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
精神障害	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
錯乱状態	n (%)	1(0.5)	0	0	1(0.2)
自殺念慮	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] Treatment-Related AEs are defined as AEs possibly or definitely related to study drug.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－3 Table 1.2.8.3より引用（一部改変）

表 2.7.4.7－59　投与中止に至った有害事象（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Any System Organ Class		5 (12.2)	18 (21.2)	14 (35.9)	22 (26.2)
Infections and infestations	感染症および寄生虫症	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.6)
Cellulitis	蜂巣炎	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Pneumonia	肺炎	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)
Metabolism and nutrition disorders	代謝および栄養障害	0 (0.0)	2 (2.4)	1 (2.6)	1 (1.2)
Dehydration	脱水	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Marasmus	マラスムス	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Decreased appetite	食欲減退	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Psychiatric disorders	精神障害	2 (4.9)	8 (9.4)	3 (7.7)	4 (4.8)
Anxiety	不安	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Delusion	妄想	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Depression	うつ病	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Hypomania	軽躁	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Insomnia	不眠症	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Middle insomnia	中期不眠症	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Schizophrenia	統合失調症	1 (2.4)	4 (4.7)	0 (0.0)	0 (0.0)
Suicidal ideation	自殺念慮	0 (0.0)	3 (3.5)	0 (0.0)	0 (0.0)
Suicide attempt	自殺企図	1 (2.4)	1 (1.2)	0 (0.0)	1 (1.2)
Major depression	大うつ病	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)

MedDRA Version 23.0.

表 2.7.4.7－59　投与中止に至った有害事象（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Nervous system disorders	神経系障害	1 (2.4)	3 (3.5)	6 (15.4)	8 (9.5)
Akathisia	アカシジア	1 (2.4)	1 (1.2)	0 (0.0)	3 (3.6)
Bradykinesia	運動緩慢	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Disturbance in attention	注意力障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (1.2)	0 (0.0)	1 (1.2)
Hypoaesthesia	感覚鈍麻	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Movement disorder	運動障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Parkinsonism	パーキンソニズム	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Somnolence	傾眠	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Stupor	昏迷	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Tremor	振戦	0 (0.0)	1 (1.2)	0 (0.0)	1 (1.2)
Cardiac disorders	心臓障害	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Myocardial ischaemia	心筋虚血	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Vascular disorders	血管障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension	高血圧	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	0 (0.0)	0 (0.0)	1 (2.6)	2 (2.4)
Pneumonia aspiration	誤嚥性肺炎	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Respiratory failure	呼吸不全	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Gastrointestinal disorders	胃腸障害	1 (2.4)	0 (0.0)	0 (0.0)	2 (2.4)
Dry mouth	口内乾燥	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dysphagia	嚥下障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

MedDRA Version 23.0.

表 2.7.4.7－59　投与中止に至った有害事象（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	0 (0.0)	1 (1.2)	2 (5.1)	1 (1.2)
Rash	発疹	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Rash erythematous	紅斑性皮疹	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Toxic skin eruption	中毒性皮疹	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Rhabdomyolysis	横紋筋融解症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	3 (3.5)	1 (2.6)	3 (3.6)
Death	死亡	0 (0.0)	1 (1.2)	0 (0.0)	1 (1.2)
Feeling abnormal	異常感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Gait disturbance	歩行障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Malaise	倦怠感	0 (0.0)	2 (2.4)	0 (0.0)	2 (2.4)
Investigations	臨床検査	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Weight decreased	体重減少	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	1 (2.4)	1 (1.2)	0 (0.0)	1 (1.2)
Head injury	頭部損傷	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Intentional overdose	企図的過量投与	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Contusion	挫傷	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

MedDRA Version 23.0.

5.3.5.3－5 Table 3.1.1 より引用

表 2.7.4.7－60　投与中止に至った副作用（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Any System Organ Class		2 (4.9)	10 (11.8)	12 (30.8)	12 (14.3)
Metabolism and nutrition disorders	代謝および栄養障害	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Decreased appetite	食欲減退	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	3 (3.5)	3 (7.7)	1 (1.2)
Depression	うつ病	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Hypomania	軽躁	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Insomnia	不眠症	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Middle insomnia	中期不眠症	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Schizophrenia	統合失調症	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Suicidal ideation	自殺念慮	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Major depression	大うつ病	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Nervous system disorders	神経系障害	1 (2.4)	3 (3.5)	5 (12.8)	7 (8.3)
Akathisia	アカシジア	1 (2.4)	1 (1.2)	0 (0.0)	2 (2.4)
Bradykinesia	運動緩慢	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Disturbance in attention	注意力障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (1.2)	0 (0.0)	1 (1.2)
Hypoaesthesia	感覚鈍麻	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Movement disorder	運動障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Somnolence	傾眠	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Stupor	昏迷	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Tremor	振戦	0 (0.0)	1 (1.2)	0 (0.0)	1 (1.2)

MedDRA Version 23.0.

表 2.7.4.7－60　投与中止に至った副作用（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Gastrointestinal disorders	胃腸障害	1 (2.4)	0 (0.0)	0 (0.0)	2 (2.4)
Dry mouth	口内乾燥	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dysphagia	嚥下障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	0 (0.0)	1 (1.2)	2 (5.1)	1 (1.2)
Rash	発疹	0 (0.0)	0 (0.0)	1 (2.6)	1 (1.2)
Rash erythematous	紅斑性皮疹	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Toxic skin eruption	中毒性皮疹	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Rhabdomyolysis	横紋筋融解症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	3 (3.5)	1 (2.6)	2 (2.4)
Death	死亡	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Feeling abnormal	異常感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Gait disturbance	歩行障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Malaise	倦怠感	0 (0.0)	2 (2.4)	0 (0.0)	2 (2.4)
Investigations	臨床検査	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Weight decreased	体重減少	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.

5.3.5.3－5 Table 3.1.2 より引用

表 2.7.4.7－61　発現時期別の投与中止に至った有害事象の内訳（P-40 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

Placebo - MT-5199 40 mg		Timing of Onset						
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 2 (N=41) n(%)	Post Week 2 to Week 4 (N=37) n(%)	Post Week 4 to Week 6 (N=37) n(%)	Post Week 6 to Week 12 (N=36) n(%)	Post Week 12 to Week 24 (N=33) n(%)	Post Week 24 to Week 36 (N=32) n(%)	Post Week 36 to Week 48 (N=29) n(%)
Any System Organ Class		2 (4.9)	1 (2.7)	0 (0.0)	0 (0.0)	1 (3.0)	1 (3.1)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	1 (3.1)	0 (0.0)
Schizophrenia	統合失調症	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	0 (0.0)	0 (0.0)
Nervous system disorders	神経系障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Akathisia	アカシジア	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Vascular disorders	血管障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension	高血圧	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	0 (0.0)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dysphagia	嚥下障害	0 (0.0)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	0 (0.0)	0 (0.0)
Intentional overdose	企図的過量投与	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.1 より引用（一部改変）

表 2.7.4.7－62　発現時期別の投与中止に至った有害事象の内訳（40-40 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

MT-5199 40 mg - MT-5199 40 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=67) n(%)	Post Week 12 to Week 24 (N=60) n(%)	Post Week 24 to Week 36 (N=51) n(%)	Post Week 36 to Week 48 (N=44) n(%)
Any System Organ Class		6 (7.1)	3 (4.5)	5 (8.3)	4 (7.8)	1 (2.3)
Metabolism and nutrition disorders	代謝および栄養障害	1 (1.2)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)
Marasmus	マラスムス	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)
Decreased appetite	食欲減退	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Psychiatric disorders	精神障害	1 (1.2)	2 (3.0)	3 (5.0)	2 (3.9)	0 (0.0)
Depression	うつ病	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)
Middle insomnia	中期不眠症	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)
Schizophrenia	統合失調症	1 (1.2)	1 (1.5)	2 (3.3)	0 (0.0)	0 (0.0)
Suicidal ideation	自殺念慮	0 (0.0)	0 (0.0)	1 (1.7)	2 (3.9)	0 (0.0)
Suicide attempt	自殺企図	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)
Nervous system disorders	神経系障害	1 (1.2)	0 (0.0)	1 (1.7)	1 (2.0)	0 (0.0)
Akathisia	アカシジア	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)
Tremor	振戦	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Cardiac disorders	心臓障害	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Myocardial ischaemia	心筋虚血	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash erythematous	紅斑性皮疹	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	2 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.3)
Death	死亡	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.3)
Malaise	倦怠感	2 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

表 2.7.4.7－62　発現時期別の投与中止に至った有害事象の内訳（40-40 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

MT-5199 40 mg - MT-5199 40 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=67) n(%)	Post Week 12 to Week 24 (N=60) n(%)	Post Week 24 to Week 36 (N=51) n(%)	Post Week 36 to Week 48 (N=44) n(%)
Investigations	臨床検査	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)
Weight decreased	体重減少	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Head injury	頭部損傷	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.1 より引用（一部改変）

表 2.7.4.7－63　発現時期別の投与中止に至った有害事象の内訳（P-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

Placebo - MT-5199 80 mg		Timing of Onset						
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 2 (N=39) n(%)	Post Week 2 to Week 4 (N=35) n(%)	Post Week 4 to Week 6 (N=30) n(%)	Post Week 6 to Week 12 (N=29) n(%)	Post Week 12 to Week 24 (N=25) n(%)	Post Week 24 to Week 36 (N=21) n(%)	Post Week 36 to Week 48 (N=18) n(%)
Any System Organ Class		5 (12.8)	3 (8.6)	1 (3.3)	1 (3.4)	2 (8.0)	1 (4.8)	1 (5.6)
Metabolism and nutrition disorders	代謝および栄養障害	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	食欲減退	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Psychiatric disorders	精神障害	1 (2.6)	0 (0.0)	1 (3.3)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
Depression	うつ病	0 (0.0)	0 (0.0)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Insomnia	不眠症	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Major depression	大うつ病	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
Nervous system disorders	神経系障害	1 (2.6)	2 (5.7)	0 (0.0)	0 (0.0)	2 (8.0)	1 (4.8)	0 (0.0)
Bradykinesia	運動緩慢	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)
Disturbance in attention	注意力障害	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)
Movement disorder	運動障害	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Parkinsonism	パーキンソニズム	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.8)	0 (0.0)
Somnolence	傾眠	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stupor	昏迷	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.6)
Pneumonia aspiration	誤嚥性肺炎	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.6)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	1 (2.6)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash	発疹	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Toxic skin eruption	中毒性皮疹	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gait disturbance	歩行障害	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.1 より引用（一部改変）

表 2.7.4.7－64　発現時期別の投与中止に至った有害事象の内訳（80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

MT-5199 80 mg - MT-5199 80 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=56) n(%)	Post Week 12 to Week 24 (N=49) n(%)	Post Week 24 to Week 36 (N=40) n(%)	Post Week 36 to Week 48 (N=36) n(%)
Any System Organ Class		14 (16.7)	4 (7.1)	1 (2.0)	1 (2.5)	2 (5.6)
Infections and infestations	感染症および寄生虫症	1 (1.2)	1 (1.8)	1 (2.0)	0 (0.0)	0 (0.0)
Cellulitis	蜂巣炎	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Pneumonia	肺炎	1 (1.2)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	代謝および栄養障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dehydration	脱水	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Psychiatric disorders	精神障害	3 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)
Anxiety	不安	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Delusion	妄想	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypomania	軽躁	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)
Nervous system disorders	神経系障害	8 (9.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Akathisia	アカシジア	3 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	浮動性めまい	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypoaesthesia	感覚鈍麻	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Somnolence	傾眠	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tremor	振戦	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	呼吸器、胸郭および縦隔障害	0 (0.0)	1 (1.8)	0 (0.0)	1 (2.5)	0 (0.0)
Pneumonia aspiration	誤嚥性肺炎	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.5)	0 (0.0)
Respiratory failure	呼吸不全	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

表 2.7.4.7－64　発現時期別の投与中止に至った有害事象の内訳（80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

MT-5199 80 mg - MT-5199 80 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=56) n(%)	Post Week 12 to Week 24 (N=49) n(%)	Post Week 24 to Week 36 (N=40) n(%)	Post Week 36 to Week 48 (N=36) n(%)
Gastrointestinal disorders	胃腸障害	2 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dry mouth	口内乾燥	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Skin and subcutaneous tissue disorders	皮膚および皮下組織障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash	発疹	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Rhabdomyolysis	横紋筋融解症	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	1 (1.2)	1 (1.8)	0 (0.0)	0 (0.0)	1 (2.8)
Death	死亡	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)
Feeling abnormal	異常感	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Malaise	倦怠感	1 (1.2)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Contusion	挫傷	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.1 より引用（一部改変）

表2.7.4.7－65　投与中止に至った有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
Any Adverse Event Leading to Study Discontinuation	n (%)	0	4(3.6)	5(4.5)	1(3.7)	10(3.9)	8(4.5)
心臓障害	n (%)	0	0	0	0	0	1(0.6)
心筋梗塞	n (%)	0	0	0	0	0	1(0.6)
先天性、家族性および遺伝性障害	n (%)	0	0	0	0	0	1(0.6)
トゥレット病	n (%)	0	0	0	0	0	1(0.6)
胃腸障害	n (%)	0	0	0	0	0	1(0.6)
悪心	n (%)	0	0	0	0	0	1(0.6)
全身障害および投与局所様態	n (%)	0	0	1(0.9)	0	1(0.4)	0
突然死	n (%)	0	0	1(0.9)	0	1(0.4)	0
肝胆道系障害	n (%)	0	0	1(0.9)	0	1(0.4)	0
急性肝炎	n (%)	0	0	1(0.9)	0	1(0.4)	0
黄疸	n (%)	0	0	1(0.9)	0	1(0.4)	0
感染症および寄生虫症	n (%)	0	1(0.9)	0	1(3.7)	2(0.8)	0
体部白癬	n (%)	0	1(0.9)	0	0	1(0.4)	0
尿路感染	n (%)	0	0	0	1(3.7)	1(0.4)	0
臨床検査	n (%)	0	0	0	0	0	1(0.6)
血中ビリルビン増加	n (%)	0	0	0	0	0	1(0.6)
肝酵素上昇	n (%)	0	0	0	0	0	1(0.6)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表2.7.4.7－65　投与中止に至った有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
神経系障害	n (%)	0	1(0.9)	0	1(3.7)	2(0.8)	1(0.6)
アカシジア	n (%)	0	1(0.9)	0	0	1(0.4)	0
失神	n (%)	0	0	0	1(3.7)	1(0.4)	0
痙攣	n (%)	0	0	0	0	0	1(0.6)
精神障害	n (%)	0	3(2.7)	3(2.7)	0	6(2.4)	3(1.7)
不安	n (%)	0	1(0.9)	0	0	1(0.4)	0
双極１型障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
敵意	n (%)	0	1(0.9)	0	0	1(0.4)	0
精神状態変化	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
統合失調感情障害	n (%)	0	0	1(0.9)	0	1(0.4)	1(0.6)
自殺念慮	n (%)	0	0	1(0.9)	0	1(0.4)	0
自殺企図	n (%)	0	0	1(0.9)	0	1(0.4)	0
統合失調症、妄想型	n (%)	0	0	0	0	0	1(0.6)
腎および尿路障害	n (%)	0	0	0	0	0	1(0.6)
尿閉	n (%)	0	0	0	0	0	1(0.6)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－2 Table 1.2.9.2より引用（一部改変）

表 2.7.4.7－66　投与中止に至った有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Any Adverse Event Leading to Study Discontinuation	n (%)	32(16.0)	31(13.5)	26(12.4)	63(14.7)
血液およびリンパ系障害	n (%)	1(0.5)	0	0	1(0.2)
貧血	n (%)	1(0.5)	0	0	1(0.2)
心臓障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
心不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胃腸障害	n (%)	0	2(0.9)	2(1.0)	2(0.5)
便秘	n (%)	0	1(0.4)	1(0.5)	1(0.2)
流涎過多	n (%)	0	1(0.4)	1(0.5)	1(0.2)
全身障害および投与局所様態	n (%)	3(1.5)	6(2.6)	3(1.4)	9(2.1)
疲労	n (%)	3(1.5)	1(0.4)	1(0.5)	4(0.9)
無力症	n (%)	0	2(0.9)	0	2(0.5)
歩行障害	n (%)	0	1(0.4)	0	1(0.2)
末梢性浮腫	n (%)	0	1(0.4)	1(0.5)	1(0.2)
突然死	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝胆道系障害	n (%)	0	2(0.9)	2(1.0)	2(0.5)
肝不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性肝炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
黄疸	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表 2.7.4.7－66　投与中止に至った有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
感染症および寄生虫症	n (%)	3(1.5)	0	0	3(0.7)
ダニ皮膚炎	n (%)	1(0.5)	0	0	1(0.2)
体部白癬	n (%)	1(0.5)	0	0	1(0.2)
尿路感染	n (%)	1(0.5)	0	0	1(0.2)
傷害、中毒および処置合併症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
交通事故	n (%)	0	1(0.4)	1(0.5)	1(0.2)
臨床検査	n (%)	3(1.5)	1(0.4)	1(0.5)	4(0.9)
心電図ＱＴ延長	n (%)	0	1(0.4)	1(0.5)	1(0.2)
グリコヘモグロビン増加	n (%)	1(0.5)	0	0	1(0.2)
ヘモグロビン減少	n (%)	1(0.5)	0	0	1(0.2)
肝酵素上昇	n (%)	1(0.5)	0	0	1(0.2)
代謝および栄養障害	n (%)	0	3(1.3)	3(1.4)	3(0.7)
食欲減退	n (%)	0	1(0.4)	1(0.5)	1(0.2)
糖尿病	n (%)	0	1(0.4)	1(0.5)	1(0.2)
高カリウム血症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
低ナトリウム血症候群	n (%)	0	1(0.4)	1(0.5)	1(0.2)
代謝性アシドーシス	n (%)	0	1(0.4)	1(0.5)	1(0.2)
筋骨格系および結合組織障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
骨関節炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表 2.7.4.7－66　投与中止に至った有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	n (%)	0	2(0.9)	2(1.0)	2(0.5)
乳癌	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肺新生物	n (%)	0	1(0.4)	1(0.5)	1(0.2)
神経系障害	n (%)	8(4.0)	8(3.5)	5(2.4)	16(3.7)
傾眠	n (%)	0	3(1.3)	1(0.5)	3(0.7)
失神	n (%)	2(1.0)	1(0.4)	1(0.5)	3(0.7)
振戦	n (%)	2(1.0)	1(0.4)	0	3(0.7)
アカシジア	n (%)	2(1.0)	0	0	2(0.5)
一過性脳虚血発作	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
注意力障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
脳症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
頭痛	n (%)	1(0.5)	0	0	1(0.2)
鎮静	n (%)	0	1(0.4)	1(0.5)	1(0.2)
精神障害	n (%)	14(7.0)	8(3.5)	8(3.8)	22(5.1)
自殺念慮	n (%)	4(2.0)	3(1.3)	3(1.4)	7(1.6)
統合失調症	n (%)	2(1.0)	1(0.4)	1(0.5)	3(0.7)
うつ病	n (%)	2(1.0)	0	0	2(0.5)
精神状態変化	n (%)	2(1.0)	0	0	2(0.5)
統合失調感情障害	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
自殺企図	n (%)	0	2(0.9)	2(1.0)	2(0.5)
不安	n (%)	1(0.5)	0	0	1(0.2)
双極１型障害	n (%)	1(0.5)	0	0	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表 2.7.4.7－66 投与中止に至った有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
錯乱状態	n (%)	1(0.5)	0	0	1(0.2)
敵意	n (%)	1(0.5)	0	0	1(0.2)
妄想症	n (%)	1(0.5)	0	0	1(0.2)
精神病性障害	n (%)	1(0.5)	0	0	1(0.2)
自殺行為	n (%)	0	1(0.4)	1(0.5)	1(0.2)
トランス	n (%)	1(0.5)	0	0	1(0.2)
腎および尿路障害	n (%)	3(1.5)	0	0	3(0.7)
血尿	n (%)	2(1.0)	0	0	2(0.5)
急性腎不全	n (%)	1(0.5)	0	0	1(0.2)
呼吸器、胸郭および縦隔障害	n (%)	0	2(0.9)	2(1.0)	2(0.5)
慢性閉塞性肺疾患	n (%)	0	1(0.4)	1(0.5)	1(0.2)
胸水	n (%)	0	1(0.4)	1(0.5)	1(0.2)
皮膚および皮下組織障害	n (%)	5(2.5)	0	0	5(1.2)
アレルギー性皮膚炎	n (%)	1(0.5)	0	0	1(0.2)
そう痒症	n (%)	1(0.5)	0	0	1(0.2)
発疹	n (%)	1(0.5)	0	0	1(0.2)
全身性皮疹	n (%)	1(0.5)	0	0	1(0.2)
斑状丘疹状皮疹	n (%)	1(0.5)	0	0	1(0.2)
社会環境	n (%)	1(0.5)	0	0	1(0.2)
社会的入院	n (%)	1(0.5)	0	0	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

表 2.7.4.7－66　投与中止に至った有害事象の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
血管障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
深部静脈血栓症	n (%)	0	1(0.4)	1(0.5)	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－3 Table 1.2.9.3より引用（一部改変）

表 2.7.4.7－67　減量に至った有害事象（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Any System Organ Class		8 (19.5)	8 (9.4)	19 (48.7)	20 (23.8)
Metabolism and nutrition disorders	代謝および栄養障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Decreased appetite	食欲減退	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	2 (2.4)	4 (10.3)	3 (3.6)
Anxiety	不安	0 (0.0)	0 (0.0)	2 (5.1)	0 (0.0)
Bruxism	歯ぎしり	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Flat affect	感情の平板化	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Insomnia	不眠症	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Restlessness	落ち着きのなさ	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Schizophrenia	統合失調症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Suicidal ideation	自殺念慮	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Abnormal behaviour	異常行動	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Nervous system disorders	神経系障害	5 (12.2)	3 (3.5)	5 (12.8)	11 (13.1)
Akathisia	アカシジア	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Bradykinesia	運動緩慢	1 (2.4)	0 (0.0)	0 (0.0)	1 (1.2)
Disturbance in attention	注意力障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Drooling	よだれ	1 (2.4)	0 (0.0)	1 (2.6)	0 (0.0)
Dysarthria	構語障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dyskinesia	ジスキネジア	1 (2.4)	1 (1.2)	0 (0.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Movement disorder	運動障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Parkinsonism	パーキンソニズム	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Somnolence	傾眠	2 (4.9)	0 (0.0)	1 (2.6)	4 (4.8)
Tremor	振戦	0 (0.0)	1 (1.2)	1 (2.6)	2 (2.4)

MedDRA Version 23.0.

表 2.7.4.7－67　減量に至った有害事象（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Cardiac disorders	心臓障害	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Palpitations	動悸	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	2 (4.9)	1 (1.2)	6 (15.4)	5 (6.0)
Dysphagia	嚥下障害	1 (2.4)	0 (0.0)	1 (2.6)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (2.4)	1 (1.2)	5 (12.8)	5 (6.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal stiffness	筋骨格硬直	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Renal and urinary disorders	腎および尿路障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dysuria	排尿困難	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	1 (2.4)	2 (2.4)	6 (15.4)	3 (3.6)
Asthenia	無力症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Decreased activity	活動性低下	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort	不快感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Fatigue	疲労	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Feeling abnormal	異常感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Gait disturbance	歩行障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Malaise	倦怠感	0 (0.0)	1 (1.2)	3 (7.7)	1 (1.2)
Thirst	口渇	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)
Contusion	挫傷	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Sedation complication	鎮静合併症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

MedDRA Version 23.0.

5.3.5.3－5 Table 3.1.3 より引用

表 2.7.4.7－68　減量に至った副作用（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Any System Organ Class		8 (19.5)	7 (8.2)	18 (46.2)	20 (23.8)
Metabolism and nutrition disorders	代謝および栄養障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Decreased appetite	食欲減退	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	1 (1.2)	3 (7.7)	3 (3.6)
Anxiety	不安	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Flat affect	感情の平板化	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Insomnia	不眠症	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Restlessness	落ち着きのなさ	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Schizophrenia	統合失調症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Suicidal ideation	自殺念慮	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Abnormal behaviour	異常行動	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Nervous system disorders	神経系障害	5 (12.2)	3 (3.5)	5 (12.8)	11 (13.1)
Akathisia	アカシジア	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Bradykinesia	運動緩慢	1 (2.4)	0 (0.0)	0 (0.0)	1 (1.2)
Disturbance in attention	注意力障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Drooling	よだれ	1 (2.4)	0 (0.0)	1 (2.6)	0 (0.0)
Dysarthria	構語障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dyskinesia	ジスキネジア	1 (2.4)	1 (1.2)	0 (0.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Movement disorder	運動障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Parkinsonism	パーキンソニズム	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Somnolence	傾眠	2 (4.9)	0 (0.0)	1 (2.6)	4 (4.8)
Tremor	振戦	0 (0.0)	1 (1.2)	1 (2.6)	2 (2.4)

MedDRA Version 23.0.

表 2.7.4.7－68　減量に至った副作用（P-40 mg 群/40-40 mg 群/P-80 mg 群/80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Placebo - 40 mg (N=41) n(%)	40 mg - 40 mg (N=85) n(%)	Placebo - 80 mg (N=39) n(%)	80 mg - 80 mg (N=84) n(%)
Cardiac disorders	心臓障害	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Palpitations	動悸	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	2 (4.9)	1 (1.2)	6 (15.4)	5 (6.0)
Dysphagia	嚥下障害	1 (2.4)	0 (0.0)	1 (2.6)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (2.4)	1 (1.2)	5 (12.8)	5 (6.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal stiffness	筋骨格硬直	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Renal and urinary disorders	腎および尿路障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Dysuria	排尿困難	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	1 (2.4)	2 (2.4)	6 (15.4)	3 (3.6)
Asthenia	無力症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Decreased activity	活動性低下	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort	不快感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Fatigue	疲労	0 (0.0)	1 (1.2)	1 (2.6)	0 (0.0)
Feeling abnormal	異常感	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Gait disturbance	歩行障害	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Malaise	倦怠感	0 (0.0)	1 (1.2)	3 (7.7)	1 (1.2)
Thirst	口渇	0 (0.0)	0 (0.0)	1 (2.6)	0 (0.0)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)
Contusion	挫傷	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Sedation complication	鎮静合併症	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

MedDRA Version 23.0.

5.3.5.3－5 Table 3.1.4 より引用

表 2.7.4.7－69　発現時期別の減量に至った有害事象の内訳（P-40 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

Placebo - MT-5199 40 mg		Timing of Onset						
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 2 (N=41) n(%)	Post Week 2 to Week 4 (N=37) n(%)	Post Week 4 to Week 6 (N=37) n(%)	Post Week 6 to Week 12 (N=36) n(%)	Post Week 12 to Week 24 (N=33) n(%)	Post Week 24 to Week 36 (N=32) n(%)	Post Week 36 to Week 48 (N=29) n(%)
Any System Organ Class		1 (2.4)	2 (5.4)	1 (2.7)	2 (5.6)	0 (0.0)	2 (6.3)	0 (0.0)
Nervous system disorders	神経系障害	0 (0.0)	1 (2.7)	1 (2.7)	1 (2.8)	0 (0.0)	2 (6.3)	0 (0.0)
Bradykinesia	運動緩慢	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)
Drooling	よだれ	0 (0.0)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dyskinesia	ジスキネジア	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)
Somnolence	傾眠	0 (0.0)	0 (0.0)	1 (2.7)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)
Gastrointestinal disorders	胃腸障害	1 (2.4)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dysphagia	嚥下障害	0 (0.0)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal and connective tissue disorders	筋骨格系および結合組織障害	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal stiffness	筋骨格硬直	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)
Decreased activity	活動性低下	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.3 より引用（一部改変）

表 2.7.4.7－70　発現時期別の減量に至った有害事象の内訳（40-40 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

MT-5199 40 mg - MT-5199 40 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=67) n(%)	Post Week 12 to Week 24 (N=60) n(%)	Post Week 24 to Week 36 (N=51) n(%)	Post Week 36 to Week 48 (N=44) n(%)
Any System Organ Class		1 (1.2)	2 (3.0)	5 (8.3)	1 (2.0)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	0 (0.0)	2 (3.3)	1 (2.0)	0 (0.0)
Bruxism	歯ぎしり	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Suicidal ideation	自殺念慮	0 (0.0)	0 (0.0)	1 (1.7)	1 (2.0)	0 (0.0)
Nervous system disorders	神経系障害	0 (0.0)	1 (1.5)	2 (3.3)	0 (0.0)	0 (0.0)
Dyskinesia	ジスキネジア	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)
Parkinsonism	パーキンソニズム	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Tremor	振戦	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Cardiac disorders	心臓障害	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Palpitations	動悸	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	0 (0.0)	1 (1.5)	1 (1.7)	0 (0.0)	0 (0.0)
Fatigue	疲労	0 (0.0)	0 (0.0)	1 (1.7)	0 (0.0)	0 (0.0)
Malaise	倦怠感	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.3 より引用（一部改変）

表 2.7.4.7－71　発現時期別の減量に至った有害事象の内訳（P-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

Placebo - MT-5199 80 mg		Timing of Onset						
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 2 (N=39) n(%)	Post Week 2 to Week 4 (N=35) n(%)	Post Week 4 to Week 6 (N=30) n(%)	Post Week 6 to Week 12 (N=29) n(%)	Post Week 12 to Week 24 (N=25) n(%)	Post Week 24 to Week 36 (N=21) n(%)	Post Week 36 to Week 48 (N=18) n(%)
Any System Organ Class		10 (25.6)	3 (8.6)	1 (3.3)	2 (6.9)	2 (8.0)	1 (4.8)	0 (0.0)
Metabolism and nutrition disorders	代謝および栄養障害	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	食欲減退	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Psychiatric disorders	精神障害	3 (7.7)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Anxiety	不安	2 (5.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flat affect	感情の平板化	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Insomnia	不眠症	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nervous system disorders	神経系障害	2 (5.1)	1 (2.9)	1 (3.3)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)
Disturbance in attention	注意力障害	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Drooling	よだれ	0 (0.0)	0 (0.0)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Movement disorder	運動障害	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Parkinsonism	パーキンソニズム	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Somnolence	傾眠	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tremor	振戦	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	2 (5.1)	1 (2.9)	0 (0.0)	1 (3.4)	1 (4.0)	1 (4.8)	0 (0.0)
Dysphagia	嚥下障害	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (2.6)	1 (2.9)	0 (0.0)	1 (3.4)	1 (4.0)	1 (4.8)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	3 (7.7)	2 (5.7)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	疲労	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gait disturbance	歩行障害	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Malaise	倦怠感	1 (2.6)	1 (2.9)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)
Thirst	口渇	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.3 より引用（一部改変）

表 2.7.4.7－72　発現時期別の減量に至った有害事象の内訳（80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）

MT-5199 80 mg - MT-5199 80 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=56) n(%)	Post Week 12 to Week 24 (N=49) n(%)	Post Week 24 to Week 36 (N=40) n(%)	Post Week 36 to Week 48 (N=36) n(%)
Any System Organ Class		10 (11.9)	9 (16.1)	3 (6.1)	0 (0.0)	0 (0.0)
Psychiatric disorders	精神障害	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)
Restlessness	落ち着きのなさ	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Schizophrenia	統合失調症	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Abnormal behaviour	異常行動	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Nervous system disorders	神経系障害	6 (7.1)	3 (5.4)	2 (4.1)	0 (0.0)	0 (0.0)
Akathisia	アカシジア	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Bradykinesia	運動緩慢	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Dysarthria	構語障害	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Somnolence	傾眠	4 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tremor	振戦	1 (1.2)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	胃腸障害	4 (4.8)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Salivary hypersecretion	流涎過多	4 (4.8)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Renal and urinary disorders	腎および尿路障害	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Dysuria	排尿困難	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	一般　全身障害および投与部位の状態	2 (2.4)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	無力症	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort	不快感	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Feeling abnormal	異常感	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Malaise	倦怠感	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

表 2.7.4.7－72　発現時期別の減量に至った有害事象の内訳（80-80 mg 群）：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

MT-5199 80 mg - MT-5199 80 mg		Timing of Onset				
System Organ Class Preferred Term (MedDRA)	System Organ Class Preferred Term (MedDRA) in Japanese	Day 1 to Week 6 (N=84) n(%)	Post Week 6 to Week 12 (N=56) n(%)	Post Week 12 to Week 24 (N=49) n(%)	Post Week 24 to Week 36 (N=40) n(%)	Post Week 36 to Week 48 (N=36) n(%)
Injury, poisoning and procedural complications	傷害、中毒および処置合併症	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)
Contusion	挫傷	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Sedation complication	鎮静合併症	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)

MedDRA Version 23.0.
For subjects with placebo treatment at DB period, Day 1 is defined the week6 visit.

5.3.5.3－5 Table 3.2.2.3 より引用（一部改変）

表 2.7.4.7－73　減量に至った有害事象の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
Any Adverse Event Leading to Dose Reduction	n (%)	0	2(1.8)	5(4.5)	0	7(2.8)	4(2.2)
胃腸障害	n (%)	0	0	1(0.9)	0	1(0.4)	0
流涎過多	n (%)	0	0	1(0.9)	0	1(0.4)	0
全身障害および投与局所様態	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
疲労	n (%)	0	1(0.9)	0	0	1(0.4)	0
歩行障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
易刺激性	n (%)	0	0	0	0	0	1(0.6)
臨床検査	n (%)	0	0	0	0	0	1(0.6)
γ－グルタミルトランスフェラーゼ増加	n (%)	0	0	0	0	0	1(0.6)
神経系障害	n (%)	0	2(1.8)	3(2.7)	0	5(2.0)	2(1.1)
傾眠	n (%)	0	2(1.8)	1(0.9)	0	3(1.2)	1(0.6)
アカシジア	n (%)	0	0	1(0.9)	0	1(0.4)	0
振戦	n (%)	0	0	1(0.9)	0	1(0.4)	0
遅発性ジスキネジー	n (%)	0	0	0	0	0	1(0.6)
精神障害	n (%)	0	1(0.9)	2(1.8)	0	3(1.2)	1(0.6)
不安	n (%)	0	0	1(0.9)	0	1(0.4)	0
パニック発作	n (%)	0	0	1(0.9)	0	1(0.4)	0
精神運動制止遅滞	n (%)	0	1(0.9)	0	0	1(0.4)	0
躁病	n (%)	0	0	0	0	0	1(0.6)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.

5.3.5.3－2 Table 1.2.10.1 より引用（一部改変）

表 2.7.4.7－74　減量に至った有害事象の内訳：MT-5199 長期投与期間（海外試験_120-Day Safety Update）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Any Adverse Event Leading to Dose Reduction	n (%)	10(5.0)	19(8.3)	1(0.5)	29(6.7)
胃腸障害	n (%)	1(0.5)	4(1.7)	0	5(1.2)
流涎過多	n (%)	0	3(1.3)	0	3(0.7)
嚥下障害	n (%)	1(0.5)	1(0.4)	0	2(0.5)
口内乾燥	n (%)	1(0.5)	0	0	1(0.2)
全身障害および投与局所様態	n (%)	1(0.5)	3(1.3)	0	4(0.9)
無力症	n (%)	0	2(0.9)	0	2(0.5)
疲労	n (%)	1(0.5)	0	0	1(0.2)
非心臓性胸痛	n (%)	0	1(0.4)	0	1(0.2)
感染症および寄生虫症	n (%)	0	1(0.4)	0	1(0.2)
鼻炎	n (%)	0	1(0.4)	0	1(0.2)
臨床検査	n (%)	1(0.5)	1(0.4)	0	2(0.5)
血中ブドウ糖減少	n (%)	0	1(0.4)	0	1(0.2)
体重減少	n (%)	1(0.5)	0	0	1(0.2)
代謝および栄養障害	n (%)	2(1.0)	0	0	2(0.5)
食欲不振	n (%)	1(0.5)	0	0	1(0.2)
食欲減退	n (%)	1(0.5)	0	0	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
Subject 1304-367-3006 (Dizziness) is included in the '80 mg Only' column since they discontinued the study before taking the planned reduced dose.

表 2.7.4.7－74　減量に至った有害事象の内訳：MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

MedDRA System Organ Class Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
筋骨格系および結合組織障害	n (%)	0	1(0.4)	0	1(0.2)
筋固縮	n (%)	0	1(0.4)	0	1(0.2)
神経系障害	n (%)	8(4.0)	9(3.9)	1(0.5)	17(4.0)
傾眠	n (%)	4(2.0)	3(1.3)	0	7(1.6)
振戦	n (%)	1(0.5)	2(0.9)	0	3(0.7)
ジスキネジー	n (%)	1(0.5)	1(0.4)	0	2(0.5)
鎮静	n (%)	1(0.5)	1(0.4)	0	2(0.5)
アカシジア	n (%)	1(0.5)	0	0	1(0.2)
浮動性めまい	n (%)	0	1(0.4)	1(0.5)	1(0.2)
嗜眠	n (%)	0	1(0.4)	0	1(0.2)
精神障害	n (%)	2(1.0)	2(0.9)	0	4(0.9)
不安	n (%)	0	2(0.9)	0	2(0.5)
抑うつ気分	n (%)	1(0.5)	0	0	1(0.2)
パニック発作	n (%)	1(0.5)	0	0	1(0.2)
落ち着きのなさ	n (%)	0	1(0.4)	0	1(0.2)
腎および尿路障害	n (%)	0	1(0.4)	0	1(0.2)
失禁	n (%)	0	1(0.4)	0	1(0.2)

[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event in a given System Organ Class, that subject is counted once for the class. If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
Subject 1304-367-3006 (Dizziness) is included in the '80 mg Only' column since they discontinued the study before taking the planned reduced dose.

5.3.5.3－3 Table 1.2.10.2 より引用（一部改変）

表 2.7.4.7－75　80 mg 群の減量有無別での主要な人口統計学的特性及びベースライン疾患特性：MT-5199 長期投与期間（MT-5199-J02 試験）

		MT-5199				
		40 mg	80 mg	80 mg (no dose reduction)	80 mg (with dose reduction)	All MT-5199
	Statistics	(N=126)	(N=123)	(N=84)	(N=39)	(N=249)
Age (years)	n	126	123	84	39	249
	Mean	58.8	58.9	59.1	58.5	58.9
	SD	13.8	13.6	13.8	13.2	13.6
	Median	59.0	60.0	60.5	60.0	60.0
	(Min, Max)	(21, 85)	(32, 84)	(33, 84)	(32, 84)	(21, 85)
<65	n(%)	76 (60.3)	75 (61.0)	49 (58.3)	26 (66.7)	151 (60.6)
>=65	n(%)	50 (39.7)	48 (39.0)	35 (41.7)	13 (33.3)	98 (39.4)
65 to <75	n(%)	34 (27.0)	33 (26.8)	24 (28.6)	9 (23.1)	67 (26.9)
>=75	n(%)	16 (12.7)	15 (12.2)	11 (13.1)	4 (10.3)	31 (12.4)
Gender						
Male	n(%)	59 (46.8)	68 (55.3)	48 (57.1)	20 (51.3)	127 (51.0)
Female	n(%)	67 (53.2)	55 (44.7)	36 (42.9)	19 (48.7)	122 (49.0)
Race						
Japanese	n(%)	126 (100.0)	123 (100.0)	84 (100.0)	39 (100.0)	249 (100.0)
Non-Japanese	n(%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity						
Hispanic or Latino	n(%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not Hispanic or Latino	n(%)	126 (100.0)	123 (100.0)	84 (100.0)	39 (100.0)	249 (100.0)
Body Mass Index (kg/m2)	n	126	123	84	39	249
	Mean	23.45	23.90	24.05	23.56	23.67
	SD	3.81	4.20	4.56	3.31	4.00
	Median	23.30	23.80	23.60	24.00	23.40
	(Min, Max)	(16.8, 34.0)	(16.4, 35.2)	(16.4, 35.2)	(17.5, 30.2)	(16.4, 35.2)
<18.5	n(%)	11 (8.7)	11 (8.9)	9 (10.7)	2 (5.1)	22 (8.8)
18.5 to <25	n(%)	72 (57.1)	66 (53.7)	40 (47.6)	26 (66.7)	138 (55.4)
25 to <30	n(%)	36 (28.6)	37 (30.1)	27 (32.1)	10 (25.6)	73 (29.3)
>=30	n(%)	7 (5.6)	9 (7.3)	8 (9.5)	1 (2.6)	16 (6.4)
CYP2D6 Phenotype Classification						
Ultra-rapid Metabolizer (UM)	n(%)	3 (2.4)	1 (0.8)	0 (0.0)	1 (2.6)	4 (1.6)
Extensive Metabolizer (EM)	n(%)	85 (67.5)	83 (67.5)	58 (69.0)	25 (64.1)	168 (67.5)
Intermediate Metabolizer (IM)	n(%)	34 (27.0)	32 (26.0)	20 (23.8)	12 (30.8)	66 (26.5)
Poor Metabolizer (PM)	n(%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not Reported	n(%)	4 (3.2)	7 (5.7)	6 (7.1)	1 (2.6)	11 (4.4)
Hepatic Abnormality						
Yes	n(%)	17 (13.5)	23 (18.7)	17 (20.2)	6 (15.4)	40 (16.1)
No	n(%)	109 (86.5)	100 (81.3)	67 (79.8)	33 (84.6)	209 (83.9)

Hepatic abnormality is defined as baseline GGT, ALT, or AST > ULN.

表 2.7.4.7－75　80 mg 群の減量有無別での主要な人口統計学的特性及びベースライン疾患特性：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

		MT-5199				
		40 mg	80 mg	80 mg (no dose reduction)	80 mg (with dose reduction)	All MT-5199
	Statistics	(N=126)	(N=123)	(N=84)	(N=39)	(N=249)
Age at Tardive Dyskinesia Diagnosis (years)	n	126	123	84	39	249
	Mean	55.7	55.0	55.5	53.9	55.4
	SD	13.9	14.3	14.5	14.0	14.1
	Median	55.5	56.0	56.0	54.0	56.0
	(Min, Max)	(20, 82)	(22, 83)	(22, 83)	(26, 75)	(20, 83)
Duration of Tardive Dyskinesia (years)						
<2	n(%)	64 (50.8)	51 (41.5)	32 (38.1)	19 (48.7)	115 (46.2)
>=2	n(%)	62 (49.2)	72 (58.5)	52 (61.9)	20 (51.3)	134 (53.8)
Disease Category						
Schizophrenia/Schizoaffective Disorder	n(%)	82 (65.1)	79 (64.2)	50 (59.5)	29 (74.4)	161 (64.7)
Bipolar Disorder/Depressive Disorder	n(%)	44 (34.9)	44 (35.8)	34 (40.5)	10 (25.6)	88 (35.3)
Age at Schizophrenia/Schizoaffective Disorder Diagnosis (years)	n	82	79	50	29	161
	Mean	41.1	38.3	39.1	36.7	39.7
	SD	15.7	15.9	17.2	13.6	15.9
	Median	39.5	34.0	34.0	35.0	36.0
	(Min, Max)	(16, 76)	(14, 75)	(14, 75)	(15, 66)	(14, 76)
Age at Bipolar Disorder/Depressive Disorder Diagnosis (years)	n	44	44	34	10	88
	Mean	44.0	48.4	47.6	51.0	46.2
	SD	15.0	13.5	14.0	11.9	14.4
	Median	42.5	49.0	48.5	51.0	48.5
	(Min, Max)	(16, 79)	(19, 76)	(19, 76)	(30, 71)	(16, 79)
Use of Antipsychotic Medication at Baseline						
Yes	n(%)	92 (73.0)	97 (78.9)	62 (73.8)	35 (89.7)	189 (75.9)
No	n(%)	34 (27.0)	26 (21.1)	22 (26.2)	4 (10.3)	60 (24.1)
Number of Antipsychotic Medication						
1	n(%)	62 (49.2)	66 (53.7)	40 (47.6)	26 (66.7)	128 (51.4)
2	n(%)	23 (18.3)	31 (25.2)	22 (26.2)	9 (23.1)	54 (21.7)
>=3	n(%)	7 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	7 (2.8)
Atypical vs Typical Antipsychotic Medication						
Atypical only	n(%)	72 (57.1)	79 (64.2)	48 (57.1)	31 (79.5)	151 (60.6)
Typical or both Typical and Atypical	n(%)	20 (15.9)	18 (14.6)	14 (16.7)	4 (10.3)	38 (15.3)
Dose Equivalent to 100mg of chlorpromazine at Baseline						
< 600 mg	n(%)	67 (53.2)	72 (58.5)	48 (57.1)	24 (61.5)	139 (55.8)
>= 600 mg	n(%)	25 (19.8)	25 (20.3)	14 (16.7)	11 (28.2)	50 (20.1)

表 2.7.4.7－75　80 mg 群の減量有無別での主要な人口統計学的特性及びベースライン疾患特性：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

		MT-5199				
		40 mg	80 mg	80 mg (no dose reduction)	80 mg (with dose reduction)	All MT-5199
	Statistics	(N=126)	(N=123)	(N=84)	(N=39)	(N=249)
Use of Anticholinergic Medication at Baseline						
Yes	n(%)	57 (45.2)	50 (40.7)	31 (36.9)	19 (48.7)	107 (43.0)
No	n(%)	69 (54.8)	73 (59.3)	53 (63.1)	20 (51.3)	142 (57.0)
Suicidality During Lifetime						
Yes	n(%)	50 (39.7)	51 (41.5)	38 (45.2)	13 (33.3)	101 (40.6)
No	n(%)	76 (60.3)	72 (58.5)	46 (54.8)	26 (66.7)	148 (59.4)
Suicidality Within 3 Months Prior to Screening						
Yes	n(%)	13 (10.3)	6 (4.9)	6 (7.1)	0 (0.0)	19 (7.6)
No	n(%)	113 (89.7)	117 (95.1)	78 (92.9)	39 (100.0)	230 (92.4)
Baseline AIMS Dyskinesia Total Score (Central Assessment)	n	126	123	84	39	249
	Mean	7.9	7.6	7.9	6.8	7.7
	SD	4.1	4.2	4.2	3.9	4.1
	Median	7.5	8.0	8.0	7.0	8.0
	(Min, Max)	(0, 20)	(0, 20)	(0, 20)	(0, 15)	(0, 20)

5.3.5.3－5 Table 1.2.2.1.1.2, Table 1.2.2.1.2.2 より引用（一部改変）

表 2.7.4.7－76　注目すべき有害事象の定義：MT-5199-J02 試験

注目すべき有害事象	定義
傾眠関連有害事象	MedDRA 基本語が「鎮静」,「傾眠」,「疲労」,「無力症」,「嗜眠」,「倦怠感」,「過眠症」,「鎮静合併症」又は「活動性低下」に該当する有害事象
過敏症関連有害事象	「アナフィラキシー／アナフィラキシー様ショック状態（ＳＭＱ）[狭域]」,「アナフィラキシー反応（ＳＭＱ）」,「過敏症（ＳＭＱ）」,「血管浮腫（ＳＭＱ）」,「好酸球増加および全身症状を伴う薬物反応症候群（ＳＭＱ）」又は「重症皮膚副作用（ＳＭＱ）」で抽出される有害事象
パーキンソニズム関連有害事象	「パーキンソン様事象（ＳＭＱ）」で抽出される有害事象，MedDRA 基本語が「流涎過多」に該当する有害事象
うつ病及び自殺関連有害事象	「うつ病（自殺／自傷を除く）（ＳＭＱ）」又は「自殺／自傷（ＳＭＱ）」で抽出される有害事象
心血管系及び QT 間隔延長関連有害事象	「トルサード　ド　ポアント／ＱＴ延長（ＳＭＱ）」で抽出される有害事象，MedDRA 基本語が「心不全」,「胸痛」,「心筋梗塞」,「死亡」又は「心筋虚血」に該当する有害事象
高プロラクチン血症関連有害事象	MedDRA 基本語が「血中プロラクチン増加」,「乳汁漏出症」又は「不規則月経」に該当する有害事象
錯乱関連有害事象	MedDRA 基本語が「錯乱状態」,「精神状態変化」又は「脳症」に該当する有害事象
アカシジア関連有害事象	「アカシジア（ＳＭＱ）」で抽出される有害事象
不安	MedDRA 基本語が「不安」に該当する有害事象
基礎疾患の悪化に関連する有害事象	MedDRA 基本語が「統合失調症」,「統合失調感情障害」,「うつ病」,「抑うつ気分」,「抑うつ症状」,「大うつ病」,「自殺念慮」,「自殺企図」,「自殺行為」,「故意の自傷行為」,「躁病」,「軽躁」,「双極性障害」,「双極１型障害」,「妄想症」,「精神病性障害」,「気分動揺」,「心的外傷後ストレス障害」,「敵意」，又は「易刺激性」に該当する有害事象
嚥下障害関連有害事象	MedDRA 基本語が「嚥下障害」又は「食道食物嵌入」に該当する有害事象
認知機能低下関連有害事象	MedDRA 基本語が「注意力障害」又は「認知障害」に該当する有害事象
肝障害関連有害事象	「悪性肝臓腫瘍（ＳＭＱ）」,「悪性度不明の肝臓腫瘍（ＳＭＱ）」,「肝臓に関連する凝固および出血障害（ＳＭＱ）」,「肝臓に起因する胆汁うっ滞および黄疸（ＳＭＱ）」,「肝臓関連臨床検査、徴候および症状（ＳＭＱ）」,「肝不全、肝線維症、肝硬変およびその他の肝細胞障害（ＳＭＱ）」,「非感染性肝炎（ＳＭＱ）」又は「良性肝新生物（嚢胞およびポリープを含む）（ＳＭＱ）」で抽出される有害事象
悪性症候群	MedDRA 基本語が「悪性高熱」,「悪性症候群」又は「セロトニン症候群」に該当する有害事象
低血圧関連有害事象	MedDRA 基本語が「血圧低下」,「浮動性めまい」,「体位性めまい」,「転倒」,「低血圧」,「起立性低血圧」,「起立不耐性」,「失神寸前の状態」又は「失神」に該当する有害事象

表 2.7.4.7－77　注目すべき副作用の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Any AESI		23 (27.1)	42 (50.0)	65 (38.5)	4 (4.8)
Somnolence	傾眠関連有害事象	14 (16.5)	22 (26.2)	36 (21.3)	1 (1.2)
Somnolence	傾眠	9 (10.6)	20 (23.8)	29 (17.2)	1 (1.2)
Malaise	倦怠感	5 (5.9)	3 (3.6)	8 (4.7)	0 (0.0)
Fatigue	疲労	0 (0.0)	2 (2.4)	2 (1.2)	0 (0.0)
Asthenia	無力症	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Sedation complication	鎮静合併症	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Hypersensitivity	過敏症関連有害事象	2 (2.4)	3 (3.6)	5 (3.0)	1 (1.2)
Blister	水疱	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Eczema	湿疹	1 (1.2)	0 (0.0)	1 (0.6)	1 (1.2)
Rash	発疹	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Rash erythematous	紅斑性皮疹	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Urticaria	蕁麻疹	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Parkinsonism	パーキンソニズム関連有害事象	3 (3.5)	17 (20.2)	20 (11.8)	1 (1.2)
Salivary hypersecretion	流涎過多	2 (2.4)	8 (9.5)	10 (5.9)	1 (1.2)
Tremor	振戦	0 (0.0)	5 (6.0)	5 (3.0)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	2 (2.4)	2 (1.2)	0 (0.0)
Parkinsonism	パーキンソニズム	1 (1.2)	1 (1.2)	2 (1.2)	0 (0.0)
Drooling	よだれ	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Reduced facial expression	表情減少	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Depression or Suicidality	うつ病及び自殺関連有害事象	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Depression	うつ病	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Suicide attempt	自殺企図	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－77　注目すべき副作用の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Akathisia	アカシジア関連有害事象	4 (4.7)	7 (8.3)	11 (6.5)	1 (1.2)
Akathisia	アカシジア	4 (4.7)	4 (4.8)	8 (4.7)	1 (1.2)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	2 (2.4)	2 (1.2)	0 (0.0)
Restlessness	落ち着きのなさ	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	3 (3.5)	1 (1.2)	4 (2.4)	0 (0.0)
Schizophrenia	統合失調症	2 (2.4)	0 (0.0)	2 (1.2)	0 (0.0)
Depression	うつ病	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Hypomania	軽躁	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Suicide attempt	自殺企図	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Dysphagia	嚥下障害関連有害事象	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Dysphagia	嚥下障害	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Hepatotoxicity	肝障害関連有害事象	1 (1.2)	1 (1.2)	2 (1.2)	0 (0.0)
Gamma-glutamyltransferase increased	γ－グルタミルトランスフェラーゼ増加	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Hepatic function abnormal	肝機能異常	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Hypotension	低血圧関連有害事象	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.13.1 より引用

表 2.7.4.7－78　注目すべき副作用の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Any AESI		52 (41.3)	86 (69.9)	49 (58.3)	138 (55.4)
Somnolence	傾眠関連有害事象	24 (19.0)	37 (30.1)	20 (23.8)	61 (24.5)
Somnolence	傾眠	16 (12.7)	26 (21.1)	17 (20.2)	42 (16.9)
Malaise	倦怠感	9 (7.1)	9 (7.3)	4 (4.8)	18 (7.2)
Fatigue	疲労	1 (0.8)	4 (3.3)	3 (3.6)	5 (2.0)
Asthenia	無力症	0 (0.0)	2 (1.6)	1 (1.2)	2 (0.8)
Sedation complication	鎮静合併症	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Decreased activity	活動性低下	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Sedation	鎮静	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Hypersensitivity	過敏症関連有害事象	3 (2.4)	5 (4.1)	4 (4.8)	8 (3.2)
Rash	発疹	1 (0.8)	2 (1.6)	2 (2.4)	3 (1.2)
Blister	水疱	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Eczema	湿疹	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Rash erythematous	紅斑性皮疹	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Urticaria	蕁麻疹	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Toxic skin eruption	中毒性皮疹	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－78　注目すべき副作用の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Parkinsonism	パーキンソニズム関連有害事象	17 (13.5)	44 (35.8)	20 (23.8)	61 (24.5)
Salivary hypersecretion	流涎過多	6 (4.8)	18 (14.6)	7 (8.3)	24 (9.6)
Tremor	振戦	4 (3.2)	14 (11.4)	8 (9.5)	18 (7.2)
Parkinsonism	パーキンソニズム	4 (3.2)	2 (1.6)	1 (1.2)	6 (2.4)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	4 (3.3)	2 (2.4)	5 (2.0)
Drooling	よだれ	1 (0.8)	3 (2.4)	2 (2.4)	4 (1.6)
Bradykinesia	運動緩慢	1 (0.8)	2 (1.6)	0 (0.0)	3 (1.2)
Gait disturbance	歩行障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Muscle rigidity	筋固縮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Musculoskeletal stiffness	筋骨格硬直	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Reduced facial expression	表情減少	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Propulsive gait	突進性歩行	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Depression or Suicidality	うつ病及び自殺関連有害事象	4 (3.2)	6 (4.9)	5 (6.0)	10 (4.0)
Depression	うつ病	3 (2.4)	3 (2.4)	3 (3.6)	6 (2.4)
Middle insomnia	中期不眠症	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Suicide attempt	自殺企図	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Major depression	大うつ病	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Cardiac events	心血管系及びQT間隔延長関連有害事象	2 (1.6)	0 (0.0)	0 (0.0)	2 (0.8)
Death	死亡	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Loss of consciousness	意識消失	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－78　注目すべき副作用の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Hyperprolactinemia	高プロラクチン血症関連有害事象	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Galactorrhoea	乳汁漏出症	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Menstruation irregular	不規則月経	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Akathisia	アカシジア関連有害事象	9 (7.1)	16 (13.0)	9 (10.7)	25 (10.0)
Akathisia	アカシジア	7 (5.6)	10 (8.1)	7 (8.3)	17 (6.8)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	4 (3.3)	2 (2.4)	5 (2.0)
Restlessness	落ち着きのなさ	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Anxiety	不安	1 (0.8)	2 (1.6)	1 (1.2)	3 (1.2)
Anxiety	不安	1 (0.8)	2 (1.6)	1 (1.2)	3 (1.2)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	6 (4.8)	8 (6.5)	5 (6.0)	14 (5.6)
Depression	うつ病	3 (2.4)	3 (2.4)	3 (3.6)	6 (2.4)
Schizophrenia	統合失調症	2 (1.6)	3 (2.4)	0 (0.0)	5 (2.0)
Hypomania	軽躁	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Suicide attempt	自殺企図	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Bipolar disorder	双極性障害	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Major depression	大うつ病	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Dysphagia	嚥下障害関連有害事象	2 (1.6)	3 (2.4)	1 (1.2)	5 (2.0)
Dysphagia	嚥下障害	2 (1.6)	3 (2.4)	1 (1.2)	5 (2.0)
Hepatotoxicity	肝障害関連有害事象	3 (2.4)	1 (0.8)	1 (1.2)	4 (1.6)
Liver function test increased	肝機能検査値上昇	2 (1.6)	0 (0.0)	0 (0.0)	2 (0.8)
Gamma-glutamyltransferase increased	γ－グルタミルトランスフェラーゼ増加	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Hepatic function abnormal	肝機能異常	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－78　注目すべき副作用の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Hypotension	低血圧関連有害事象	3 (2.4)	5 (4.1)	4 (4.8)	8 (3.2)
Dizziness	浮動性めまい	3 (2.4)	4 (3.3)	3 (3.6)	7 (2.8)
Fall	転倒	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Hypotension	低血圧	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Cognitive disorder	認知機能低下関連有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Cognitive disorder	認知障害	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.13.2 より引用

表 2.7.4.7－79　注目すべき重篤な有害事象の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Any AESI		2 (2.4)	0 (0.0)	2 (1.2)	1 (1.2)
Depression or Suicidality	うつ病及び自殺関連有害事象	1 (1.2)	0 (0.0)	1 (0.6)	1 (1.2)
Suicidal ideation	自殺念慮	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	2 (2.4)	0 (0.0)	2 (1.2)	1 (1.2)
Schizophrenia	統合失調症	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Suicidal ideation	自殺念慮	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.14.1 より引用

表 2.7.4.7－80　注目すべき重篤な有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Any AESI		11 (8.7)	7 (5.7)	5 (6.0)	18 (7.2)
Somnolence	傾眠関連有害事象	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Fatigue	疲労	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Somnolence	傾眠	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Hypersensitivity	過敏症関連有害事象	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Rash	発疹	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Parkinsonism	パーキンソニズム関連有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Depression or Suicidality	うつ病及び自殺関連有害事象	2 (1.6)	3 (2.4)	2 (2.4)	5 (2.0)
Depression	うつ病	0 (0.0)	2 (1.6)	2 (2.4)	2 (0.8)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Intentional overdose	企図的過量投与	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Suicide attempt	自殺企図	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Cardiac events	心血管系及びQT間隔延長関連有害事象	2 (1.6)	1 (0.8)	1 (1.2)	3 (1.2)
Death	死亡	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Myocardial ischaemia	心筋虚血	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Akathisia	アカシジア関連有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－80　注目すべき重篤な有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	7 (5.6)	3 (2.4)	2 (2.4)	10 (4.0)
Schizophrenia	統合失調症	5 (4.0)	1 (0.8)	0 (0.0)	6 (2.4)
Depression	うつ病	0 (0.0)	2 (1.6)	2 (2.4)	2 (0.8)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Suicide attempt	自殺企図	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Cognitive disorder	認知機能低下関連有害事象	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.14.2 より引用

表 2.7.4.7－81　注目すべき投与中止に至った有害事象の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Any AESI		5 (5.9)	11 (13.1)	16 (9.5)	2 (2.4)
Somnolence	傾眠関連有害事象	2 (2.4)	2 (2.4)	4 (2.4)	0 (0.0)
Malaise	倦怠感	2 (2.4)	1 (1.2)	3 (1.8)	0 (0.0)
Somnolence	傾眠	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Hypersensitivity	過敏症関連有害事象	1 (1.2)	1 (1.2)	2 (1.2)	1 (1.2)
Rash	発疹	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Rash erythematous	紅斑性皮疹	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Eczema	湿疹	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Parkinsonism	パーキンソニズム関連有害事象	0 (0.0)	3 (3.6)	3 (1.8)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Salivary hypersecretion	流涎過多	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Tremor	振戦	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Depression or Suicidality	うつ病及び自殺関連有害事象	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Depression	うつ病	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Akathisia	アカシジア関連有害事象	1 (1.2)	4 (4.8)	5 (3.0)	0 (0.0)
Akathisia	アカシジア	1 (1.2)	3 (3.6)	4 (2.4)	0 (0.0)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Anxiety	不安	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Anxiety	不安	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	1 (1.2)	1 (1.2)	2 (1.2)	1 (1.2)
Hypomania	軽躁	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Schizophrenia	統合失調症	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
Depression	うつ病	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Suicide attempt	自殺企図	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

AESI: adverse event of special interest, MedDRA Version 23.0.

表 2.7.4.7－81　注目すべき投与中止に至った有害事象の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Hypotension	低血圧関連有害事象	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Dizziness	浮動性めまい	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)

AESI: adverse event of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.15.1 より引用

表 2.7.4.7－82　注目すべき投与中止に至った有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Any AESI		20 (15.9)	24 (19.5)	19 (22.6)	44 (17.7)
Somnolence	傾眠関連有害事象	2 (1.6)	4 (3.3)	2 (2.4)	6 (2.4)
Malaise	倦怠感	2 (1.6)	2 (1.6)	1 (1.2)	4 (1.6)
Somnolence	傾眠	0 (0.0)	2 (1.6)	1 (1.2)	2 (0.8)
Hypersensitivity	過敏症関連有害事象	1 (0.8)	3 (2.4)	3 (3.6)	4 (1.6)
Rash	発疹	0 (0.0)	2 (1.6)	2 (2.4)	2 (0.8)
Rash erythematous	紅斑性皮疹	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Toxic skin eruption	中毒性皮疹	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Parkinsonism	パーキンソニズム関連有害事象	2 (1.6)	7 (5.7)	4 (4.8)	9 (3.6)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Tremor	振戦	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Bradykinesia	運動緩慢	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Gait disturbance	歩行障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Parkinsonism	パーキンソニズム	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Salivary hypersecretion	流涎過多	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Depression or Suicidality	うつ病及び自殺関連有害事象	6 (4.8)	4 (3.3)	3 (3.6)	10 (4.0)
Suicidal ideation	自殺念慮	3 (2.4)	0 (0.0)	0 (0.0)	3 (1.2)
Suicide attempt	自殺企図	2 (1.6)	1 (0.8)	1 (1.2)	3 (1.2)
Depression	うつ病	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Intentional overdose	企図的過量投与	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Middle insomnia	中期不眠症	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Major depression	大うつ病	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－82　注目すべき投与中止に至った有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Cardiac events	心血管系及びQT間隔延長関連有害事象	2 (1.6)	1 (0.8)	1 (1.2)	3 (1.2)
Death	死亡	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Myocardial ischaemia	心筋虚血	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Akathisia	アカシジア関連有害事象	3 (2.4)	5 (4.1)	4 (4.8)	8 (3.2)
Akathisia	アカシジア	2 (1.6)	3 (2.4)	3 (3.6)	5 (2.0)
Extrapyramidal disorder	錐体外路障害	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Anxiety	不安	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Anxiety	不安	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	9 (7.1)	4 (3.3)	4 (4.8)	13 (5.2)
Schizophrenia	統合失調症	5 (4.0)	0 (0.0)	0 (0.0)	5 (2.0)
Suicidal ideation	自殺念慮	3 (2.4)	0 (0.0)	0 (0.0)	3 (1.2)
Suicide attempt	自殺企図	2 (1.6)	1 (0.8)	1 (1.2)	3 (1.2)
Depression	うつ病	1 (0.8)	1 (0.8)	1 (1.2)	2 (0.8)
Hypomania	軽躁	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Major depression	大うつ病	0 (0.0)	1 (0.8)	1 (1.2)	1 (0.4)
Dysphagia	嚥下障害関連有害事象	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Dysphagia	嚥下障害	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Hypotension	低血圧関連有害事象	0 (0.0)	2 (1.6)	2 (2.4)	2 (0.8)
Dizziness	浮動性めまい	0 (0.0)	2 (1.6)	2 (2.4)	2 (0.8)
Cognitive disorder	認知機能低下関連有害事象	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.15.2 より引用

表 2.7.4.7－83　注目すべき減量に至った有害事象の内訳：プラセボ対照二重盲検期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=85) n(%)	MT-5199 80 mg (N=84) n(%)	All MT-5199 (N=169) n(%)	Placebo (N=84) n(%)
Any AESI		1 (1.2)	8 (9.5)	9 (5.3)	0 (0.0)
Somnolence	傾眠関連有害事象	0 (0.0)	4 (4.8)	4 (2.4)	0 (0.0)
Somnolence	傾眠	0 (0.0)	4 (4.8)	4 (2.4)	0 (0.0)
Asthenia	無力症	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)
Parkinsonism	パーキンソニズム関連有害事象	1 (1.2)	5 (6.0)	6 (3.6)	0 (0.0)
Salivary hypersecretion	流涎過多	1 (1.2)	4 (4.8)	5 (3.0)	0 (0.0)
Tremor	振戦	0 (0.0)	1 (1.2)	1 (0.6)	0 (0.0)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.16.1 より引用

表 2.7.4.7－84　注目すべき減量に至った有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Any AESI		12 (9.5)	34 (27.6)	0 (0.0)	46 (18.5)
Somnolence	傾眠関連有害事象	4 (3.2)	11 (8.9)	0 (0.0)	15 (6.0)
Somnolence	傾眠	2 (1.6)	5 (4.1)	0 (0.0)	7 (2.8)
Malaise	倦怠感	1 (0.8)	4 (3.3)	0 (0.0)	5 (2.0)
Fatigue	疲労	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Asthenia	無力症	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Decreased activity	活動性低下	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Sedation complication	鎮静合併症	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Parkinsonism	パーキンソニズム関連有害事象	7 (5.6)	19 (15.4)	0 (0.0)	26 (10.4)
Salivary hypersecretion	流涎過多	2 (1.6)	10 (8.1)	0 (0.0)	12 (4.8)
Tremor	振戦	1 (0.8)	3 (2.4)	0 (0.0)	4 (1.6)
Bradykinesia	運動緩慢	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Drooling	よだれ	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Parkinsonism	パーキンソニズム	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Gait disturbance	歩行障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Musculoskeletal stiffness	筋骨格硬直	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Depression or Suicidality	うつ病及び自殺関連有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

表 2.7.4.7－84　注目すべき減量に至った有害事象の内訳：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

AESI Preferred Term (MedDRA)	AESI Preferred Term (MedDRA) in Japanese	MT-5199 40 mg (N=126) n(%)	MT-5199 80 mg (N=123) n(%)	MT-5199 80 mg (no dose reduction) (N=84) n(%)	All MT-5199 (N=249) n(%)
Akathisia	アカシジア関連有害事象	0 (0.0)	4 (3.3)	0 (0.0)	4 (1.6)
Akathisia	アカシジア	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Extrapyramidal disorder	錐体外路障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Movement disorder	運動障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Restlessness	落ち着きのなさ	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Anxiety	不安	0 (0.0)	2 (1.6)	0 (0.0)	2 (0.8)
Anxiety	不安	0 (0.0)	2 (1.6)	0 (0.0)	2 (0.8)
Worsening of Underlying Psychiatric Condition	基礎疾患の悪化に関連する有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Schizophrenia	統合失調症	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Suicidal ideation	自殺念慮	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
Dysphagia	嚥下障害関連有害事象	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Dysphagia	嚥下障害	1 (0.8)	1 (0.8)	0 (0.0)	2 (0.8)
Hypotension	低血圧関連有害事象	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Dizziness	浮動性めまい	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Cognitive disorder	認知機能低下関連有害事象	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)
Disturbance in attention	注意力障害	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.4)

AESI: adverse events of special interest, MedDRA Version 23.0.

5.3.5.1－1 Table 14.3.1.2.16.2 より引用

表 2.7.4.7－85　注目すべき有害事象（MedDRA SMQに基づいて抽出された有害事象）の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

SMQ Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
Any Adverse Event from Selected MedDRA SMQs	n (%)	1(20.0)	12(10.9)	15(13.4)	2(7.4)	30(11.8)	10(5.6)
アカシジア関連有害事象	n (%)	0	4(3.6)	3(2.7)	0	7(2.8)	1(0.6)
アカシジア	n (%)	0	3(2.7)	3(2.7)	0	6(2.4)	1(0.6)
落ち着きのなさ	n (%)	0	1(0.9)	0	0	1(0.4)	0
うつ病及び自殺関連有害事象	n (%)	1(20.0)	8(7.3)	4(3.6)	0	13(5.1)	6(3.4)
自殺念慮	n (%)	0	4(3.6)	1(0.9)	0	5(2.0)	4(2.2)
うつ病	n (%)	0	0	2(1.8)	0	2(0.8)	2(1.1)
抑うつ気分	n (%)	1(20.0)	0	0	0	1(0.4)	0
抑うつ症状	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
注意力障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
睡眠の質低下	n (%)	0	1(0.9)	0	0	1(0.4)	0
精神運動制止遅滞	n (%)	0	1(0.9)	0	0	1(0.4)	0
自殺企図	n (%)	0	0	1(0.9)	0	1(0.4)	0
パーキンソニズム関連有害事象	n (%)	0	2(1.8)	4(3.6)	1(3.7)	7(2.8)	1(0.6)
歩行障害	n (%)	0	2(1.8)	0	1(3.7)	3(1.2)	0
よだれ	n (%)	0	0	2(1.8)	0	2(0.8)	0
振戦	n (%)	0	0	2(1.8)	0	2(0.8)	0
筋骨格硬直	n (%)	0	0	0	0	0	1(0.6)
肝障害関連有害事象	n (%)	1(20.0)	0	3(2.7)	0	4(1.6)	2(1.1)
γ－グルタミルトランスフェラーゼ増加	n (%)	0	0	2(1.8)	0	2(0.8)	1(0.6)
肝酵素上昇	n (%)	1(20.0)	0	0	0	1(0.4)	1(0.6)
急性肝炎	n (%)	0	0	1(0.9)	0	1(0.4)	0

SMQ = Standardised MedDRA Query.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表 2.7.4.7－85　注目すべき有害事象（MedDRA SMQに基づいて抽出された有害事象）の内訳：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

SMQ Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	 40 mg (N=110)	 80 mg (N=112)	 100 mg (N=27)	All NBI-98854 (N=254)	 Placebo (N=178)
黄疸	n (%)	0	0	1(0.9)	0	1(0.4)	0
血中ビリルビン増加	n (%)	0	0	0	0	0	1(0.6)
心血管系及びQT間隔延長関連有害事象	n (%)	0	0	1(0.9)	1(3.7)	2(0.8)	0
突然死	n (%)	0	0	1(0.9)	0	1(0.4)	0
失神	n (%)	0	0	0	1(3.7)	1(0.4)	0

SMQ = Standardised MedDRA Query.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

5.3.5.3－2 Table 1.2.13.2.2より引用（一部改変）

表 2.7.4.7－86　注目すべき有害事象（MedDRA SMQに基づいて抽出された有害事象）の内訳：MT-5199長期投与期間（海外試験_ISS）

SMQ Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=197)	 80 mg (N=230)	 80 mg Only[b] (N=214)	All NBI-98854 (N=427)
Any Adverse Event from Selected MedDRA SMQs	n (%)	40(20.3)	36(15.7)	30(14.0)	76(17.8)
アカシジア関連有害事象	n (%)	8(4.1)	5(2.2)	3(1.4)	13(3.0)
アカシジア	n (%)	7(3.6)	1(0.4)	1(0.5)	8(1.9)
落ち着きのなさ	n (%)	1(0.5)	2(0.9)	0	3(0.7)
錐体外路障害	n (%)	0	2(0.9)	2(0.9)	2(0.5)
うつ病及び自殺関連有害事象	n (%)	20(10.2)	19(8.3)	18(8.4)	39(9.1)
自殺念慮	n (%)	9(4.6)	10(4.3)	10(4.7)	19(4.4)
うつ病	n (%)	9(4.6)	5(2.2)	4(1.9)	14(3.3)
抑うつ気分	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
抑うつ症状	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
精神運動制止遅滞	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
自殺企図	n (%)	0	2(0.9)	2(0.9)	2(0.5)
アルコール症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
注意力障害	n (%)	0	1(0.4)	1(0.5)	1(0.2)
気分動揺	n (%)	0	1(0.4)	0	1(0.2)
自殺行為	n (%)	0	1(0.4)	1(0.5)	1(0.2)
パーキンソニズム関連有害事象	n (%)	8(4.1)	11(4.8)	7(3.3)	19(4.4)
振戦	n (%)	4(2.0)	3(1.3)	1(0.5)	7(1.6)
歩行障害	n (%)	3(1.5)	1(0.4)	0	4(0.9)
よだれ	n (%)	0	3(1.3)	3(1.4)	3(0.7)
錐体外路障害	n (%)	0	2(0.9)	2(0.9)	2(0.5)
パーキンソニズム	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)

SMQ = Standardised MedDRA Query.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表 2.7.4.7－86　注目すべき有害事象（MedDRA SMQに基づいて抽出された有害事象）の内訳：MT-5199長期投与期間（海外試験_ISS）（続き）

SMQ Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=197)	 80 mg (N=230)	 80 mg Only[b] (N=214)	All NBI-98854 (N=427)
歯車様固縮	n (%)	0	1(0.4)	1(0.5)	1(0.2)
筋固縮	n (%)	0	1(0.4)	0	1(0.2)
肝障害関連有害事象	n (%)	4(2.0)	6(2.6)	6(2.8)	10(2.3)
γ－グルタミルトランスフェラーゼ増加	n (%)	2(1.0)	3(1.3)	3(1.4)	5(1.2)
アラニン・アミノトランスフェラーゼ増加	n (%)	1(0.5)	0	0	1(0.2)
アスパラギン酸アミノトランスフェラーゼ増加	n (%)	1(0.5)	0	0	1(0.2)
肝酵素上昇	n (%)	1(0.5)	0	0	1(0.2)
肝不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性肝炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
低アルブミン血症	n (%)	0	1(0.4)	1(0.5)	1(0.2)
黄疸	n (%)	0	1(0.4)	1(0.5)	1(0.2)
心血管系及びQT間隔延長関連有害事象	n (%)	4(2.0)	4(1.7)	3(1.4)	8(1.9)
失神	n (%)	4(2.0)	2(0.9)	1(0.5)	6(1.4)
心電図ＱＴ延長	n (%)	0	1(0.4)	1(0.5)	1(0.2)
突然死	n (%)	0	1(0.4)	1(0.5)	1(0.2)

SMQ = Standardised MedDRA Query.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

5.3.5.3－2 Table 1.2.13.3.2より引用（一部改変）

表2.7.4.7－87　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：プラセボ対照二重盲検期間（海外試験_ISS）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Any Adverse Event of Special Interest	n (%)	1(20.0)	28(25.5)	23(20.5)	3(11.1)	55(21.7)	24(13.5)
アカシジア関連有害事象	n (%)	0	3(2.7)	3(2.7)	0	6(2.4)	1(0.6)
アカシジア	n (%)	0	3(2.7)	3(2.7)	0	6(2.4)	1(0.6)
不安	n (%)	0	1(0.9)	2(1.8)	0	3(1.2)	0
不安	n (%)	0	1(0.9)	2(1.8)	0	3(1.2)	0
心血管系及びQT間隔延長関連有害事象	n (%)	0	1(0.9)	1(0.9)	1(3.7)	3(1.2)	1(0.6)
胸痛	n (%)	0	1(0.9)	0	0	1(0.4)	0
突然死	n (%)	0	0	1(0.9)	0	1(0.4)	0
失神	n (%)	0	0	0	1(3.7)	1(0.4)	0
心筋梗塞	n (%)	0	0	0	0	0	1(0.6)
うつ病及び自殺関連有害事象	n (%)	1(20.0)	5(4.5)	4(3.6)	0	10(3.9)	6(3.4)
自殺念慮	n (%)	0	4(3.6)	1(0.9)	0	5(2.0)	4(2.2)
うつ病	n (%)	0	0	2(1.8)	0	2(0.8)	2(1.1)
抑うつ気分	n (%)	1(20.0)	0	0	0	1(0.4)	0
抑うつ症状	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
自殺企図	n (%)	0	0	1(0.9)	0	1(0.4)	0
嚥下障害関連有害事象	n (%)	0	2(1.8)	0	0	2(0.8)	0
嚥下障害	n (%)	0	2(1.8)	0	0	2(0.8)	0
傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）	n (%)	0	5(4.5)	3(2.7)	2(7.4)	10(3.9)	3(1.7)
疲労	n (%)	0	5(4.5)	3(2.7)	2(7.4)	10(3.9)	3(1.7)
肝障害関連有害事象	n (%)	0	0	1(0.9)	0	1(0.4)	0

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表2.7.4.7－87　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
急性肝炎	n (%)	0	0	1(0.9)	0	1(0.4)	0
低血圧関連有害事象	n (%)	0	4(3.6)	2(1.8)	1(3.7)	7(2.8)	4(2.2)
転倒・転落	n (%)	0	2(1.8)	1(0.9)	0	3(1.2)	0
浮動性めまい	n (%)	0	2(1.8)	0	0	2(0.8)	4(2.2)
低血圧	n (%)	0	0	1(0.9)	0	1(0.4)	0
失神	n (%)	0	0	0	1(3.7)	1(0.4)	0
パーキンソニズム関連有害事象	n (%)	0	0	2(1.8)	0	2(0.8)	0
振戦	n (%)	0	0	2(1.8)	0	2(0.8)	0
傾眠関連有害事象（傾眠又は鎮静）	n (%)	0	10(9.1)	6(5.4)	1(3.7)	17(6.7)	5(2.8)
傾眠	n (%)	0	9(8.2)	4(3.6)	1(3.7)	14(5.5)	4(2.2)
鎮静	n (%)	0	1(0.9)	2(1.8)	0	3(1.2)	1(0.6)
基礎疾患の悪化に関連する有害事象	n (%)	1(20.0)	10(9.1)	6(5.4)	0	17(6.7)	13(7.3)
自殺念慮	n (%)	0	4(3.6)	1(0.9)	0	5(2.0)	4(2.2)
うつ病	n (%)	0	0	2(1.8)	0	2(0.8)	2(1.1)
双極１型障害	n (%)	0	1(0.9)	0	0	1(0.4)	0
抑うつ気分	n (%)	1(20.0)	0	0	0	1(0.4)	0
抑うつ症状	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
敵意	n (%)	0	1(0.9)	0	0	1(0.4)	0
軽躁	n (%)	0	1(0.9)	0	0	1(0.4)	0
易刺激性	n (%)	0	1(0.9)	0	0	1(0.4)	2(1.1)
妄想症	n (%)	0	1(0.9)	0	0	1(0.4)	0
精神病性障害	n (%)	0	0	1(0.9)	0	1(0.4)	2(1.1)
統合失調感情障害	n (%)	0	0	1(0.9)	0	1(0.4)	1(0.6)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表2.7.4.7－87　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
統合失調症	n (%)	0	1(0.9)	0	0	1(0.4)	1(0.6)
自殺企図	n (%)	0	0	1(0.9)	0	1(0.4)	0
躁病	n (%)	0	0	0	0	0	1(0.6)
統合失調症、妄想型	n (%)	0	0	0	0	0	1(0.6)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

5.3.5.3－2 Table 1.2.13.2.1より引用（一部改変）

表2.7.4.7－88　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Any Adverse Event of Special Interest	n (%)	71(35.5)	80(34.8)	61(29.0)	151(35.1)
アカシジア関連有害事象	n (%)	8(4.0)	2(0.9)	1(0.5)	10(2.3)
アカシジア	n (%)	8(4.0)	2(0.9)	1(0.5)	10(2.3)
不安	n (%)	7(3.5)	8(3.5)	4(1.9)	15(3.5)
不安	n (%)	7(3.5)	8(3.5)	4(1.9)	15(3.5)
心血管系及びQT間隔延長関連有害事象	n (%)	6(3.0)	7(3.0)	6(2.9)	13(3.0)
失神	n (%)	4(2.0)	2(0.9)	1(0.5)	6(1.4)
胸痛	n (%)	3(1.5)	2(0.9)	2(1.0)	5(1.2)
心不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
心電図ＱＴ延長	n (%)	0	1(0.4)	1(0.5)	1(0.2)
突然死	n (%)	0	1(0.4)	1(0.5)	1(0.2)
うつ病及び自殺関連有害事象	n (%)	20(10.0)	19(8.3)	18(8.6)	39(9.1)
自殺念慮	n (%)	9(4.5)	11(4.8)	11(5.2)	20(4.7)
うつ病	n (%)	10(5.0)	5(2.2)	4(1.9)	15(3.5)
抑うつ気分	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
抑うつ症状	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
自殺企図	n (%)	0	2(0.9)	2(1.0)	2(0.5)
感情的苦悩	n (%)	0	1(0.4)	1(0.5)	1(0.2)
自殺行為	n (%)	0	1(0.4)	1(0.5)	1(0.2)
嚥下障害関連有害事象	n (%)	3(1.5)	3(1.3)	1(0.5)	6(1.4)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表2.7.4.7－88 注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
嚥下障害	n (%)	3(1.5)	3(1.3)	1(0.5)	6(1.4)
食道食物嵌入	n (%)	1(0.5)	0	0	1(0.2)
傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）	n (%)	14(7.0)	14(6.1)	9(4.3)	28(6.5)
疲労	n (%)	14(7.0)	8(3.5)	8(3.8)	22(5.1)
無力症	n (%)	1(0.5)	4(1.7)	0	5(1.2)
嗜眠	n (%)	0	1(0.4)	0	1(0.2)
倦怠感	n (%)	0	1(0.4)	1(0.5)	1(0.2)
肝障害関連有害事象	n (%)	0	2(0.9)	2(1.0)	2(0.5)
肝不全	n (%)	0	1(0.4)	1(0.5)	1(0.2)
急性肝炎	n (%)	0	1(0.4)	1(0.5)	1(0.2)
高プロラクチン血症関連有害事象	n (%)	3(1.5)	1(0.4)	0	4(0.9)
血中プロラクチン増加	n (%)	2(1.0)	1(0.4)	0	3(0.7)
乳汁漏出症	n (%)	1(0.5)	0	0	1(0.2)
低血圧関連有害事象	n (%)	15(7.5)	19(8.3)	17(8.1)	34(7.9)
浮動性めまい	n (%)	6(3.0)	12(5.2)	12(5.7)	18(4.2)
転倒・転落	n (%)	7(3.5)	7(3.0)	5(2.4)	14(3.3)
失神	n (%)	4(2.0)	2(0.9)	1(0.5)	6(1.4)
低血圧	n (%)	0	1(0.4)	1(0.5)	1(0.2)
起立性低血圧	n (%)	1(0.5)	0	0	1(0.2)
パーキンソニズム関連有害事象	n (%)	5(2.5)	8(3.5)	4(1.9)	13(3.0)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表2.7.4.7－88　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
振戦	n (%)	4(2.0)	6(2.6)	3(1.4)	10(2.3)
パーキンソニズム	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
歯車様固縮	n (%)	0	1(0.4)	1(0.5)	1(0.2)
筋固縮	n (%)	0	1(0.4)	0	1(0.2)
傾眠関連有害事象（傾眠又は鎮静）	n (%)	17(8.5)	16(7.0)	10(4.8)	33(7.7)
傾眠	n (%)	15(7.5)	12(5.2)	7(3.3)	27(6.3)
鎮静	n (%)	2(1.0)	4(1.7)	3(1.4)	6(1.4)
基礎疾患の悪化に関連する有害事象	n (%)	27(13.5)	27(11.7)	25(11.9)	54(12.6)
自殺念慮	n (%)	9(4.5)	11(4.8)	11(5.2)	20(4.7)
うつ病	n (%)	10(5.0)	5(2.2)	4(1.9)	15(3.5)
統合失調症	n (%)	4(2.0)	5(2.2)	5(2.4)	9(2.1)
易刺激性	n (%)	2(1.0)	2(0.9)	2(1.0)	4(0.9)
抑うつ気分	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
抑うつ症状	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
躁病	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
妄想症	n (%)	2(1.0)	0	0	2(0.5)
精神病性障害	n (%)	1(0.5)	1(0.4)	0	2(0.5)
統合失調感情障害	n (%)	1(0.5)	1(0.4)	1(0.5)	2(0.5)
自殺企図	n (%)	0	2(0.9)	2(1.0)	2(0.5)
双極1型障害	n (%)	1(0.5)	0	0	1(0.2)
敵意	n (%)	1(0.5)	0	0	1(0.2)
軽躁	n (%)	1(0.5)	0	0	1(0.2)
気分動揺	n (%)	0	1(0.4)	0	1(0.2)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

表2.7.4.7－88　注目すべき有害事象（Medical Reviewに基づいて抽出された有害事象）の内訳：
MT-5199長期投与期間（海外試験_120-Day Safety Update）（続き）

AESI Preferred Term	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	 80 mg (N=230)	 80 mg Only[b] (N=210)	All NBI-98854 (N=430)
外傷後ストレス障害	n (%)	1(0.5)	0	0	1(0.2)
自殺行為	n (%)	0	1(0.4)	1(0.5)	1(0.2)
暴力関連症状	n (%)	0	1(0.4)	1(0.5)	1(0.2)

AESI = Adverse Event of Special Interest.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: If a subject experienced more than 1 event within a given preferred term, that subject is counted only once for that term.
傾眠関連有害事象を傾眠関連有害事象（傾眠又は鎮静）と傾眠関連有害事象（疲労，無力症，嗜眠又は倦怠感）に分けて集計した

5.3.5.3－3 Table 1.2.13.3.1より引用（一部改変）

表 2.7.4.7－89　PCS 基準：国内外臨床試験

Category	Laboratory Parameter	PCS Threshold
Hematology	White Blood Cell Count	≤2.8 × 1000/μL
	Absolute Neutrophil Count	<1.5 × 1000/μL
Liver Function	ALT	>3 × ULN (upper limit of normal)
	AST	>3 × ULN
	GGT	>3 × ULN
	Total Bilirubin	>1.5 × ULN
Kidney Function	Creatinine	>1.5 × Baseline value, or >1.5 × ULN
	BUN	>30 mg/dL (>10.71 mmol/L)
Other Chemistry	Creatine Kinase	>5 × ULN

ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; GGT=gamma-glutamyl transferase; ULN=upper limit of normal

	PCS – Low if:			PCS – High if:		
Variable Name	Observed Value is:	AND	Decrease from Baseline is:	Observed Value is:	AND	Increase from Baseline is:
Systolic Blood Pressure	<90 mmHg		≥20 mmHg	>180 mmHg		≥20 mmHg
Diastolic Blood Pressure	<50 mmHg		≥10 mmHg	>105 mmHg		≥10 mmHg
Heart Rate	<50 bpm		≥15 bpm	>120 bpm		≥15 bpm

PCS=potentially clinically significant

5.3.5.3－2 Table 18, 1.4.2.8 より引用

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Leukocytes (/uL)	Baseline	n	85	84	169	84				
		Mean	6430.6	6234.5	6333.1	6283.3				
		SD	1808.1	1903.0	1852.9	1894.0				
		Median	6400.0	5950.0	6100.0	5850.0				
		(Min, Max)	(3300, 12500)	(3000, 11100)	(3000, 12500)	(3000, 13000)				
	Week 2	n	82	78	160	84	82	78	160	84
		Mean	6372.0	6723.1	6543.1	6177.4	-34.1	494.9	223.8	-106.0
		SD	1808.4	2359.3	2095.9	1944.4	1264.8	1704.7	1514.1	1359.4
		Median	6300.0	6350.0	6300.0	5600.0	-150.0	300.0	100.0	-150.0
		(Min, Max)	(2600, 11900)	(2300, 16300)	(2300, 16300)	(2600, 11300)	(-2800, 2800)	(-2400, 9800)	(-2800, 9800)	(-5400, 3800)
	Week 4	n	77	70	147	80	77	70	147	80
		Mean	6201.3	6525.7	6355.8	6222.5	-235.1	362.9	49.7	-56.3
		SD	2133.7	2081.1	2107.9	1904.4	1295.4	1273.5	1315.2	1408.0
		Median	5500.0	5900.0	5900.0	5900.0	-400.0	400.0	0.0	-200.0
		(Min, Max)	(3100, 15900)	(3200, 12800)	(3100, 15900)	(2900, 12200)	(-3100, 4500)	(-3200, 3500)	(-3200, 4500)	(-4800, 4700)
	Week 6	n	69	60	129	79	69	60	129	79
		Mean	6143.5	6325.0	6227.9	6208.9	-378.3	105.0	-153.5	-67.1
		SD	1816.5	2631.3	2225.4	1868.4	1207.9	1695.9	1469.5	1595.7
		Median	5700.0	5900.0	5800.0	5800.0	-500.0	-200.0	-300.0	-100.0
		(Min, Max)	(3700, 12100)	(2700, 18400)	(2700, 18400)	(3500, 12700)	(-3200, 3500)	(-4300, 7300)	(-4300, 7300)	(-5600, 6700)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Neutrophils/Leukocytes (%)	Baseline	n	84	84	168	84				
		Mean	61.56	61.65	61.61	60.65				
		SD	9.65	9.10	9.35	9.90				
		Median	61.50	61.95	61.80	60.55				
		(Min, Max)	(35.0, 84.5)	(39.0, 79.1)	(35.0, 84.5)	(39.7, 84.1)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	64.20	66.41	65.27	60.48	2.61	4.24	3.41	-0.18
		SD	9.30	7.85	8.67	10.11	8.57	6.68	7.72	6.84
		Median	64.85	67.00	66.00	60.10	1.80	3.40	2.30	0.00
		(Min, Max)	(43.5, 83.5)	(45.2, 83.5)	(43.5, 83.5)	(35.9, 83.7)	(-19.1, 23.7)	(-8.9, 24.7)	(-19.1, 24.7)	(-21.1, 14.8)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	65.64	67.51	66.53	60.84	3.91	5.49	4.67	0.10
		SD	8.84	9.09	8.98	10.24	8.18	8.34	8.27	7.81
		Median	65.50	69.10	66.70	61.45	3.20	5.15	4.00	0.40
		(Min, Max)	(49.0, 91.0)	(44.6, 83.7)	(44.6, 91.0)	(39.5, 82.0)	(-14.0, 27.3)	(-10.6, 27.2)	(-14.0, 27.3)	(-22.5, 20.1)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	64.48	66.09	65.23	60.90	2.79	4.85	3.75	0.08
		SD	9.12	9.77	9.42	10.84	7.74	8.60	8.19	7.89
		Median	65.20	66.80	65.80	61.60	2.35	5.20	3.70	-0.20
		(Min, Max)	(28.2, 83.5)	(40.6, 87.5)	(28.2, 87.5)	(31.4, 89.0)	(-13.7, 25.2)	(-14.5, 30.6)	(-14.5, 30.6)	(-21.5, 24.4)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Neutrophils (/uL)	Baseline	n	84	84	168	84				
		Mean	4042.0	3895.0	3968.5	3836.8				
		SD	1471.6	1483.6	1475.0	1432.2				
		Median	3880.0	3772.5	3792.0	3599.0				
		(Min, Max)	(1260, 8875)	(1476, 8203)	(1260, 8875)	(1513, 10205)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	4167.9	4522.5	4340.8	3758.7	139.5	600.5	365.6	-57.9
		SD	1573.2	1930.8	1760.1	1492.8	1123.2	1423.4	1296.0	1187.7
		Median	3922.5	4116.5	3979.5	3417.0	-44.0	431.5	278.0	-126.0
		(Min, Max)	(1339, 8400)	(1580, 13611)	(1339, 13611)	(1328, 8370)	(-2189, 3003)	(-1422, 8859)	(-2189, 8859)	(-4403, 2764)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	4168.6	4459.0	4306.9	3845.5	118.0	581.4	340.1	0.4
		SD	1888.4	1701.8	1801.7	1523.3	1342.0	1176.3	1282.1	1322.3
		Median	3657.0	4209.5	3933.0	3533.0	20.5	634.0	250.0	-79.0
		(Min, Max)	(1680, 11130)	(1670, 9920)	(1670, 11130)	(1267, 9102)	(-2867, 5350)	(-2119, 3892)	(-2867, 5350)	(-4303, 5140)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	4030.0	4265.3	4139.4	3843.7	-76.6	389.4	141.8	-5.2
		SD	1555.1	2201.4	1879.4	1538.1	1171.8	1478.1	1339.4	1476.4
		Median	3625.0	3897.5	3650.0	3465.0	-110.5	179.0	47.0	-43.0
		(Min, Max)	(1213, 8792)	(1415, 14904)	(1213, 14904)	(1439, 9879)	(-2455, 4066)	(-2552, 6701)	(-2552, 6701)	(-4568, 7037)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Lymphocytes/Leukocytes (%)	Baseline	n	84	84	168	84				
		Mean	28.74	29.12	28.93	30.12				
		SD	8.30	8.30	8.28	8.57				
		Median	28.90	28.10	28.10	30.25				
		(Min, Max)	(11.5, 52.3)	(12.5, 51.0)	(11.5, 52.3)	(10.7, 49.8)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	25.86	24.11	25.01	30.21	-2.88	-4.48	-3.66	0.11
		SD	8.15	7.20	7.73	8.57	6.93	6.47	6.73	6.00
		Median	25.00	22.90	24.00	30.40	-2.50	-2.95	-2.60	-0.20
		(Min, Max)	(10.5, 49.0)	(8.0, 46.1)	(8.0, 49.0)	(12.0, 53.4)	(-21.2, 11.0)	(-28.2, 8.1)	(-28.2, 11.0)	(-13.1, 16.9)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	24.29	22.58	23.47	29.66	-4.30	-6.34	-5.28	-0.51
		SD	7.55	7.56	7.58	8.66	7.04	6.85	7.00	6.60
		Median	23.10	21.50	22.60	28.60	-4.10	-6.45	-5.15	-0.50
		(Min, Max)	(6.0, 41.0)	(7.9, 47.6)	(6.0, 47.6)	(14.5, 51.1)	(-26.5, 12.0)	(-29.2, 5.9)	(-29.2, 12.0)	(-18.5, 19.2)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	25.97	24.34	25.21	29.58	-2.83	-5.32	-4.00	-0.49
		SD	8.51	8.48	8.51	9.01	6.40	7.02	6.79	6.56
		Median	24.20	23.40	23.50	28.20	-2.55	-6.00	-3.80	-0.50
		(Min, Max)	(10.5, 59.5)	(7.5, 49.3)	(7.5, 59.5)	(7.0, 55.0)	(-22.8, 12.2)	(-26.3, 10.9)	(-26.3, 12.2)	(-21.7, 15.0)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Lymphocytes (/uL)	Baseline	n	84	84	168	84				
		Mean	1812.1	1776.7	1794.4	1866.1				
		SD	638.2	638.9	636.9	750.0				
		Median	1703.0	1717.5	1710.0	1727.5				
		(Min, Max)	(736, 4446)	(575, 3822)	(575, 4446)	(556, 5065)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	1592.4	1579.5	1586.1	1837.2	-210.1	-162.7	-186.8	-15.9
		SD	555.1	653.5	603.2	770.6	458.3	465.5	461.0	366.6
		Median	1456.5	1468.5	1457.5	1660.0	-161.0	-145.0	-161.0	-44.0
		(Min, Max)	(773, 3572)	(442, 4979)	(442, 4979)	(572, 4743)	(-2130, 1288)	(-1491, 1485)	(-2130, 1485)	(-1045, 1341)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	1437.9	1439.2	1438.5	1808.9	-356.7	-300.1	-329.5	-57.4
		SD	505.2	613.9	557.6	674.7	433.2	452.1	441.8	356.9
		Median	1320.0	1419.0	1386.0	1689.5	-291.5	-270.5	-281.0	-42.0
		(Min, Max)	(498, 3498)	(442, 4611)	(442, 4611)	(664, 4209)	(-2302, 517)	(-1810, 1117)	(-2302, 1117)	(-1117, 952)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	1541.9	1483.9	1514.9	1795.5	-288.4	-310.1	-298.5	-62.7
		SD	547.2	764.0	655.0	710.3	423.8	539.7	479.8	324.7
		Median	1386.0	1429.0	1418.0	1670.0	-211.5	-264.0	-238.0	-47.0
		(Min, Max)	(775, 3739)	(600, 6015)	(600, 6015)	(552, 5194)	(-2143, 676)	(-1585, 2521)	(-2143, 2521)	(-870, 790)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Monocytes/Leukocytes (%)	Baseline	n	84	84	168	84				
		Mean	6.36	6.36	6.36	6.24				
		SD	2.00	1.78	1.89	1.72				
		Median	6.15	6.35	6.30	6.20				
		(Min, Max)	(2.3, 12.0)	(1.7, 10.8)	(1.7, 12.0)	(2.4, 10.3)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	6.79	6.56	6.68	6.19	0.40	0.20	0.31	-0.03
		SD	2.11	1.69	1.92	1.89	2.05	1.53	1.81	1.23
		Median	6.70	6.65	6.70	6.30	0.30	0.10	0.20	-0.10
		(Min, Max)	(2.1, 12.0)	(2.6, 10.2)	(2.1, 12.0)	(1.4, 10.9)	(-3.3, 7.7)	(-3.4, 4.1)	(-3.4, 7.7)	(-3.2, 2.7)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	6.80	6.55	6.68	6.33	0.41	0.23	0.32	0.09
		SD	2.43	1.95	2.21	1.87	2.43	2.22	2.32	1.42
		Median	7.00	6.50	6.90	6.00	0.20	0.40	0.25	0.00
		(Min, Max)	(2.0, 12.8)	(3.0, 12.2)	(2.0, 12.8)	(2.5, 11.4)	(-5.9, 7.2)	(-4.2, 6.8)	(-5.9, 7.2)	(-2.6, 3.5)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	6.55	6.32	6.44	6.47	0.18	0.14	0.16	0.23
		SD	1.97	1.92	1.94	1.94	2.08	1.88	1.98	1.50
		Median	6.70	6.00	6.40	6.40	0.30	0.00	0.15	0.30
		(Min, Max)	(2.0, 12.4)	(1.9, 10.6)	(1.9, 12.4)	(2.5, 11.6)	(-4.7, 5.0)	(-5.0, 6.0)	(-5.0, 6.0)	(-2.9, 6.4)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Monocytes (/uL)	Baseline	n	84	84	168	84				
		Mean	401.8	387.1	394.4	388.2				
		SD	154.9	140.2	147.5	154.4				
		Median	365.0	378.0	370.0	352.5				
		(Min, Max)	(180, 1158)	(106, 838)	(106, 1158)	(113, 928)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	419.8	434.1	426.8	367.2	18.0	46.2	31.8	-16.8
		SD	139.9	176.8	158.6	135.0	135.3	137.6	136.7	102.6
		Median	423.0	410.5	414.5	361.0	28.0	40.0	37.0	-19.0
		(Min, Max)	(138, 904)	(170, 1141)	(138, 1141)	(108, 784)	(-254, 392)	(-273, 718)	(-273, 718)	(-395, 254)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	400.2	420.0	409.7	384.4	-3.1	39.2	17.2	-3.8
		SD	151.3	175.6	163.1	140.1	136.4	168.2	153.4	107.7
		Median	371.0	401.5	371.0	359.0	-8.0	37.0	21.0	-8.0
		(Min, Max)	(121, 954)	(173, 1088)	(121, 1088)	(141, 854)	(-522, 293)	(-308, 913)	(-522, 913)	(-390, 276)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	392.2	390.3	391.3	391.1	-15.3	15.4	-0.9	3.3
		SD	152.1	193.0	171.7	146.0	136.9	143.0	140.1	125.5
		Median	362.0	345.0	350.0	356.0	10.0	-1.0	4.5	10.0
		(Min, Max)	(139, 968)	(131, 1104)	(131, 1104)	(168, 936)	(-484, 342)	(-252, 505)	(-484, 505)	(-522, 504)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Eosinophils/Leukocytes (%)	Baseline	n	84	84	168	84				
		Mean	3.01	2.51	2.76	2.65				
		SD	2.47	1.79	2.17	3.20				
		Median	2.60	2.05	2.35	1.70				
		(Min, Max)	(0.0, 15.5)	(0.0, 8.7)	(0.0, 15.5)	(0.0, 19.0)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	2.75	2.55	2.65	2.79	-0.22	0.01	-0.11	0.10
		SD	2.18	2.04	2.11	3.31	1.52	1.50	1.51	1.14
		Median	2.00	2.00	2.00	1.90	0.00	-0.10	0.00	0.10
		(Min, Max)	(0.0, 11.4)	(0.0, 12.8)	(0.0, 12.8)	(0.0, 19.5)	(-6.4, 4.0)	(-4.9, 4.7)	(-6.4, 4.7)	(-3.4, 3.5)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	2.94	3.03	2.98	2.79	-0.03	0.63	0.29	0.28
		SD	2.30	2.78	2.53	3.14	1.50	2.63	2.13	1.23
		Median	2.40	2.35	2.40	2.00	0.00	0.00	0.00	0.30
		(Min, Max)	(0.0, 13.5)	(0.0, 18.4)	(0.0, 18.4)	(0.0, 22.0)	(-3.6, 4.0)	(-2.8, 15.3)	(-3.6, 15.3)	(-4.0, 6.0)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	2.64	2.87	2.75	2.75	-0.16	0.30	0.06	0.22
		SD	1.97	2.38	2.17	3.26	1.64	2.54	2.11	1.64
		Median	2.10	2.20	2.10	1.90	-0.05	-0.10	-0.10	0.10
		(Min, Max)	(0.0, 9.7)	(0.0, 13.0)	(0.0, 13.0)	(0.0, 24.5)	(-4.1, 4.7)	(-5.7, 11.5)	(-5.7, 11.5)	(-4.8, 8.5)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Eosinophils (/uL)	Baseline	n	84	84	168	84				
		Mean	191.4	153.7	172.6	170.7				
		SD	162.2	115.4	141.6	259.4				
		Median	151.5	139.5	144.0	105.0				
		(Min, Max)	(0, 853)	(0, 713)	(0, 853)	(0, 1712)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	166.4	163.3	164.9	175.3	-20.9	8.1	-6.6	2.5
		SD	121.0	134.7	127.4	238.7	85.1	95.3	91.1	102.3
		Median	135.5	125.0	132.0	107.0	-6.0	3.5	0.0	2.0
		(Min, Max)	(0, 600)	(0, 883)	(0, 883)	(0, 1710)	(-443, 150)	(-244, 304)	(-443, 304)	(-678, 180)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	174.6	187.4	180.7	162.1	-13.9	42.8	13.3	4.2
		SD	136.3	180.1	158.2	177.8	99.0	157.5	133.0	75.4
		Median	137.0	150.5	145.0	108.0	-4.0	15.5	-1.0	9.0
		(Min, Max)	(0, 675)	(0, 1141)	(0, 1141)	(0, 1298)	(-271, 220)	(-190, 977)	(-271, 977)	(-414, 228)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	158.6	162.1	160.2	160.6	-24.3	7.8	-9.3	1.0
		SD	121.7	133.4	126.8	174.0	117.1	138.0	127.8	97.2
		Median	130.0	141.5	133.0	117.0	-13.0	-12.5	-13.0	6.0
		(Min, Max)	(0, 601)	(0, 741)	(0, 741)	(0, 1250)	(-516, 302)	(-303, 655)	(-516, 655)	(-462, 383)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Basophils/Leukocytes (%)	Baseline	n	84	84	168	84				
		Mean	0.33	0.36	0.34	0.34				
		SD	0.27	0.26	0.27	0.25				
		Median	0.30	0.30	0.30	0.30				
		(Min, Max)	(0.0, 1.0)	(0.0, 1.2)	(0.0, 1.2)	(0.0, 1.4)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	0.40	0.37	0.39	0.33	0.09	0.03	0.06	-0.01
		SD	0.33	0.27	0.30	0.24	0.41	0.31	0.36	0.34
		Median	0.40	0.35	0.40	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.5)	(0.0, 1.1)	(0.0, 1.5)	(0.0, 1.1)	(-0.7, 1.2)	(-0.8, 0.9)	(-0.8, 1.2)	(-1.0, 0.8)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	0.34	0.33	0.34	0.38	0.01	-0.01	0.00	0.04
		SD	0.36	0.27	0.32	0.25	0.43	0.36	0.40	0.36
		Median	0.30	0.30	0.30	0.40	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 2.4)	(0.0, 1.0)	(0.0, 2.4)	(0.0, 1.4)	(-1.0, 1.9)	(-1.2, 0.9)	(-1.2, 1.9)	(-1.0, 1.4)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	0.36	0.38	0.37	0.30	0.01	0.03	0.02	-0.04
		SD	0.28	0.33	0.30	0.24	0.32	0.36	0.34	0.34
		Median	0.40	0.30	0.40	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.0)	(0.0, 1.6)	(0.0, 1.6)	(0.0, 1.0)	(-0.9, 0.7)	(-0.5, 1.2)	(-0.9, 1.2)	(-1.4, 0.8)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Basophils (/uL)	Baseline	n	84	84	168	84				
		Mean	20.7	22.3	21.5	21.6				
		SD	19.8	19.4	19.6	19.0				
		Median	18.0	18.5	18.0	19.0				
		(Min, Max)	(0, 86)	(0, 95)	(0, 95)	(0, 91)				
	Week 2	n	82	78	160	83	81	78	159	83
		Mean	25.7	23.8	24.7	19.7	5.6	2.6	4.1	-2.1
		SD	23.1	19.4	21.3	15.2	28.0	20.3	24.5	23.9
		Median	20.5	22.0	21.0	18.0	1.0	1.5	1.0	0.0
		(Min, Max)	(0, 113)	(0, 95)	(0, 113)	(0, 68)	(-56, 90)	(-59, 74)	(-59, 90)	(-91, 40)
	Week 4	n	77	70	147	80	76	70	146	80
		Mean	20.0	20.3	20.2	22.0	-0.9	-0.3	-0.6	0.5
		SD	20.7	19.4	20.0	14.6	25.2	25.3	25.2	24.5
		Median	15.0	18.0	16.0	21.0	-1.5	0.0	-0.5	2.0
		(Min, Max)	(0, 106)	(0, 106)	(0, 106)	(0, 69)	(-70, 75)	(-91, 88)	(-91, 88)	(-91, 69)
	Week 6	n	69	60	129	79	68	60	128	79
		Mean	20.9	23.6	22.2	18.2	-1.3	2.5	0.5	-3.3
		SD	16.8	23.6	20.2	16.7	21.1	24.1	22.5	22.8
		Median	17.0	18.5	18.0	16.0	0.0	0.0	0.0	0.0
		(Min, Max)	(0, 65)	(0, 92)	(0, 92)	(0, 93)	(-61, 47)	(-56, 88)	(-61, 88)	(-86, 56)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Erythrocytes (10^4/uL)	Baseline	n	85	84	169	84				
		Mean	438.1	445.2	441.6	436.1				
		SD	45.8	49.0	47.4	51.6				
		Median	442.0	451.0	448.0	430.5				
		(Min, Max)	(335, 547)	(308, 548)	(308, 548)	(336, 592)				
	Week 2	n	82	78	160	84	82	78	160	84
		Mean	434.6	446.0	440.2	437.8	-3.2	1.2	-1.1	1.7
		SD	42.5	51.9	47.5	50.1	22.8	20.2	21.6	20.4
		Median	442.5	449.0	445.0	431.5	1.0	1.0	1.0	1.0
		(Min, Max)	(328, 513)	(318, 570)	(318, 570)	(336, 573)	(-75, 65)	(-42, 53)	(-75, 65)	(-35, 62)
	Week 4	n	77	70	147	80	77	70	147	80
		Mean	432.8	442.4	437.3	432.0	-5.8	-0.9	-3.5	-3.3
		SD	38.3	48.2	43.4	46.2	24.0	21.1	22.7	19.5
		Median	440.0	447.0	443.0	427.5	-7.0	-1.0	-3.0	-3.5
		(Min, Max)	(346, 511)	(347, 557)	(346, 557)	(342, 589)	(-77, 40)	(-56, 76)	(-77, 76)	(-47, 34)
	Week 6	n	69	60	129	79	69	60	129	79
		Mean	439.3	447.5	443.1	432.4	-1.2	-0.2	-0.8	-2.7
		SD	41.3	46.9	44.0	47.4	24.8	23.2	24.0	23.2
		Median	445.0	448.0	447.0	424.0	-6.0	1.0	-2.0	-4.0
		(Min, Max)	(337, 536)	(351, 553)	(337, 553)	(337, 572)	(-65, 61)	(-49, 98)	(-65, 98)	(-78, 61)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Hemoglobin (g/dL)	Baseline	n	85	84	169	84				
		Mean	13.44	13.66	13.55	13.43				
		SD	1.38	1.49	1.44	1.49				
		Median	13.50	13.60	13.60	13.40				
		(Min, Max)	(10.2, 16.5)	(10.3, 16.7)	(10.2, 16.7)	(10.4, 19.3)				
	Week 2	n	82	78	160	84	82	78	160	84
		Mean	13.36	13.64	13.50	13.49	-0.07	0.02	-0.03	0.06
		SD	1.35	1.56	1.45	1.43	0.67	0.60	0.63	0.61
		Median	13.40	13.60	13.50	13.45	0.00	-0.05	0.00	0.00
		(Min, Max)	(10.3, 15.7)	(10.1, 17.1)	(10.1, 17.1)	(10.6, 18.8)	(-1.7, 2.1)	(-1.2, 1.7)	(-1.7, 2.1)	(-1.1, 1.8)
	Week 4	n	77	70	147	80	77	70	147	80
		Mean	13.29	13.53	13.41	13.33	-0.17	-0.05	-0.12	-0.11
		SD	1.36	1.45	1.41	1.39	0.67	0.67	0.67	0.55
		Median	13.40	13.55	13.50	13.15	-0.20	-0.10	-0.10	-0.10
		(Min, Max)	(9.8, 16.1)	(10.8, 16.5)	(9.8, 16.5)	(10.5, 19.0)	(-2.2, 1.3)	(-1.7, 2.3)	(-2.2, 2.3)	(-1.4, 1.2)
	Week 6	n	69	60	129	79	69	60	129	79
		Mean	13.37	13.72	13.53	13.37	-0.07	-0.01	-0.04	-0.08
		SD	1.41	1.44	1.43	1.47	0.69	0.73	0.71	0.67
		Median	13.40	13.60	13.50	13.30	-0.10	-0.10	-0.10	0.00
		(Min, Max)	(9.8, 16.6)	(10.8, 16.6)	(9.8, 16.6)	(10.4, 18.9)	(-1.5, 1.9)	(-1.4, 2.9)	(-1.5, 2.9)	(-1.7, 1.7)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Hematocrit (%)	Baseline	n	85	84	169	84				
		Mean	40.11	40.65	40.38	40.06				
		SD	3.95	4.27	4.11	4.29				
		Median	39.60	40.65	40.40	39.85				
		(Min, Max)	(32.3, 48.9)	(29.5, 50.0)	(29.5, 50.0)	(31.3, 57.1)				
	Week 2	n	82	78	160	84	82	78	160	84
		Mean	39.78	40.68	40.22	40.24	-0.26	0.10	-0.09	0.19
		SD	3.79	4.55	4.19	4.19	2.10	1.86	1.99	1.92
		Median	39.75	40.55	40.10	39.95	0.00	0.00	0.00	0.05
		(Min, Max)	(31.9, 46.8)	(30.5, 51.6)	(30.5, 51.6)	(31.5, 55.8)	(-6.2, 6.8)	(-3.9, 5.0)	(-6.2, 6.8)	(-3.7, 5.8)
	Week 4	n	77	70	147	80	77	70	147	80
		Mean	39.61	40.37	39.97	39.80	-0.53	-0.11	-0.33	-0.27
		SD	3.74	4.15	3.94	3.96	2.19	1.98	2.10	1.75
		Median	39.80	40.85	40.40	39.70	-0.50	-0.15	-0.30	-0.40
		(Min, Max)	(31.0, 48.0)	(32.3, 50.3)	(31.0, 50.3)	(31.9, 56.3)	(-7.3, 4.3)	(-5.1, 6.9)	(-7.3, 6.9)	(-4.0, 4.3)
	Week 6	n	69	60	129	79	69	60	129	79
		Mean	40.00	40.95	40.44	39.82	-0.14	0.02	-0.06	-0.24
		SD	4.00	4.02	4.02	4.15	2.25	2.18	2.21	2.04
		Median	40.20	40.60	40.40	39.70	-0.70	0.15	-0.20	-0.20
		(Min, Max)	(31.0, 50.7)	(33.1, 49.0)	(31.0, 50.7)	(31.3, 55.2)	(-5.9, 5.5)	(-4.2, 9.3)	(-5.9, 9.3)	(-5.8, 5.2)

表 2.7.4.7－90　各評価時点での臨床検査値及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Platelets (10^4/uL)	Baseline	n	84	83	167	84				
		Mean	24.53	24.45	24.49	24.90				
		SD	6.60	6.29	6.43	5.27				
		Median	23.00	23.70	23.60	25.40				
		(Min, Max)	(14.1, 46.3)	(11.9, 42.1)	(11.9, 46.3)	(14.6, 37.8)				
	Week 2	n	80	78	158	83	79	77	156	83
		Mean	24.21	24.28	24.25	25.18	-0.25	-0.38	-0.32	0.20
		SD	6.72	6.04	6.37	5.87	2.65	3.27	2.96	2.91
		Median	22.75	24.25	23.45	24.40	-0.10	0.00	-0.10	0.10
		(Min, Max)	(12.2, 49.4)	(12.1, 41.0)	(12.1, 49.4)	(16.3, 42.7)	(-10.9, 7.9)	(-10.3, 8.4)	(-10.9, 8.4)	(-10.4, 6.8)
	Week 4	n	77	68	145	79	76	68	144	79
		Mean	24.18	25.34	24.72	24.40	-0.11	0.55	0.20	-0.44
		SD	6.61	6.18	6.42	5.76	3.11	4.39	3.77	2.46
		Median	23.00	25.05	24.00	23.60	0.35	0.55	0.40	-0.20
		(Min, Max)	(11.5, 43.3)	(10.3, 44.0)	(10.3, 44.0)	(15.4, 40.6)	(-14.3, 6.4)	(-8.0, 18.7)	(-14.3, 18.7)	(-8.5, 6.2)
	Week 6	n	69	59	128	79	68	58	126	79
		Mean	25.02	25.11	25.06	24.86	0.61	0.45	0.54	0.00
		SD	6.82	6.02	6.44	5.87	3.37	3.48	3.41	3.18
		Median	23.30	24.20	23.65	24.30	0.70	0.60	0.60	-0.20
		(Min, Max)	(12.8, 45.1)	(12.0, 44.3)	(12.0, 45.1)	(14.5, 43.1)	(-8.4, 11.5)	(-7.8, 13.1)	(-8.4, 13.1)	(-9.4, 6.9)

5.3.5.1－1 Table 14.3.2.1.1 より引用

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Leukocytes (/uL)	Baseline	n	126	123	84	249				
		Mean	6384.9	6244.7	6256.0	6315.7				
		SD	1788.0	1924.4	1921.4	1854.2				
		Median	6100.0	6100.0	5950.0	6100.0				
		(Min, Max)	(3300, 12500)	(3000, 13000)	(3000, 13000)	(3000, 13000)				
	Week 2	n	82	78	59	160	82	78	59	160
		Mean	6372.0	6723.1	6654.2	6543.1	-34.1	494.9	527.1	223.8
		SD	1808.4	2359.3	2506.7	2095.9	1264.8	1704.7	1838.7	1514.1
		Median	6300.0	6350.0	6200.0	6300.0	-150.0	300.0	200.0	100.0
		(Min, Max)	(2600, 11900)	(2300, 16300)	(2300, 16300)	(2300, 16300)	(-2800, 2800)	(-2400, 9800)	(-1900, 9800)	(-2800, 9800)
	Week 4	n	77	70	50	147	77	70	50	147
		Mean	6201.3	6525.7	6496.0	6355.8	-235.1	362.9	450.0	49.7
		SD	2133.7	2081.1	2252.6	2107.9	1295.4	1273.5	1231.1	1315.2
		Median	5500.0	5900.0	5900.0	5900.0	-400.0	400.0	400.0	0.0
		(Min, Max)	(3100, 15900)	(3200, 12800)	(3200, 12800)	(3100, 15900)	(-3100, 4500)	(-3200, 3500)	(-1800, 3500)	(-3200, 4500)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	6143.5	6325.0	6397.5	6227.9	-378.3	105.0	295.0	-153.5
		SD	1816.5	2631.3	2996.1	2225.4	1207.9	1695.9	1747.5	1469.5
		Median	5700.0	5900.0	5550.0	5800.0	-500.0	-200.0	-200.0	-300.0
		(Min, Max)	(3700, 12100)	(2700, 18400)	(2700, 18400)	(2700, 18400)	(-3200, 3500)	(-4300, 7300)	(-2300, 7300)	(-4300, 7300)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	5985.7	6398.9	6465.5	6179.8	-525.7	77.4	107.3	-242.4
		SD	1728.4	2020.5	2056.6	1877.8	1287.1	1466.8	1361.1	1403.7
		Median	5700.0	6200.0	6200.0	5800.0	-500.0	0.0	0.0	-250.0
		(Min, Max)	(2700, 12100)	(2900, 12400)	(3200, 12400)	(2700, 12400)	(-4900, 2800)	(-3800, 3700)	(-3400, 3700)	(-4900, 3700)
	Week 12	n	99	81	47	180	99	81	47	180
		Mean	6120.2	6367.9	6438.3	6231.7	-343.4	-51.9	-6.4	-212.2
		SD	1877.2	2024.1	2134.5	1943.1	1852.5	1369.6	1451.7	1654.8
		Median	5800.0	6200.0	6300.0	5900.0	-400.0	-100.0	-100.0	-200.0
		(Min, Max)	(2600, 13700)	(2900, 12100)	(2900, 12100)	(2600, 13700)	(-5200, 7900)	(-3900, 3200)	(-3900, 3200)	(-5200, 7900)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Leukocytes (/uL)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	6121.3	6623.3	6720.9	6340.7	-383.0	172.6	246.5	-140.1
		SD	1681.1	2229.6	2145.4	1949.8	1648.1	1741.1	1655.5	1706.8
		Median	6000.0	6300.0	6500.0	6000.0	-350.0	100.0	300.0	-100.0
		(Min, Max)	(3000, 12400)	(2800, 13800)	(3500, 13800)	(2800, 13800)	(-5800, 5900)	(-5400, 4400)	(-5400, 2800)	(-5800, 5900)
	Week 20	n	92	67	39	159	92	67	39	159
		Mean	6241.3	6549.3	6502.6	6371.1	-296.7	113.4	20.5	-123.9
		SD	2052.7	2407.3	2443.3	2207.0	1866.3	1984.5	2132.1	1921.6
		Median	5800.0	6300.0	6200.0	5900.0	-450.0	0.0	-400.0	-300.0
		(Min, Max)	(3600, 15800)	(3200, 13100)	(3200, 13100)	(3200, 15800)	(-6100, 8400)	(-5700, 6400)	(-5700, 6400)	(-6100, 8400)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	6098.8	6581.5	6502.6	6306.6	-384.9	80.0	20.5	-184.8
		SD	1873.2	2245.8	2008.9	2048.8	1550.3	1572.6	1566.1	1571.8
		Median	5750.0	6400.0	6500.0	5900.0	-300.0	0.0	-100.0	-200.0
		(Min, Max)	(3600, 12900)	(3000, 12900)	(3000, 11400)	(3000, 12900)	(-6100, 3800)	(-3200, 4800)	(-3200, 3800)	(-6100, 4800)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	6120.0	6518.0	6448.6	6286.3	-371.8	6.6	-86.5	-213.7
		SD	1876.2	2281.6	2496.6	2057.2	1898.6	1323.4	1210.6	1687.6
		Median	5700.0	6300.0	6200.0	5950.0	-400.0	100.0	-200.0	-300.0
		(Min, Max)	(3400, 14800)	(2800, 13400)	(3400, 13400)	(2800, 14800)	(-6200, 8400)	(-2900, 4300)	(-2700, 2100)	(-6200, 8400)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	6270.7	6463.8	6348.6	6350.7	-181.7	-106.9	-302.9	-150.7
		SD	2027.7	2197.3	1872.3	2094.0	1916.6	1666.5	1531.7	1811.3
		Median	5900.0	6100.0	6000.0	5950.0	-100.0	100.0	-100.0	0.0
		(Min, Max)	(3500, 14200)	(2900, 14600)	(3300, 11600)	(2900, 14600)	(-6200, 7700)	(-3900, 5100)	(-3500, 3500)	(-6200, 7700)
	Week 36	n	77	55	33	132	77	55	33	132
		Mean	6096.1	6845.5	6724.2	6408.3	-348.1	369.1	148.5	-49.2
		SD	1688.8	2222.9	2346.9	1956.8	1708.2	1484.8	1547.0	1651.6
		Median	5800.0	6400.0	6300.0	6100.0	-300.0	100.0	0.0	-100.0
		(Min, Max)	(3300, 12700)	(2800, 14600)	(3100, 14600)	(2800, 14600)	(-5200, 4400)	(-2900, 4300)	(-2900, 4300)	(-5200, 4400)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Leukocytes (/uL)	Week 40	n	71	54	32	125	71	54	32	125
		Mean	6043.7	6733.3	6625.0	6341.6	-245.1	70.4	-268.8	-108.8
		SD	1587.7	2171.7	2082.2	1885.9	1450.8	1396.7	1170.7	1430.6
		Median	5800.0	6300.0	5950.0	6000.0	-200.0	50.0	-250.0	-100.0
		(Min, Max)	(3300, 11500)	(3300, 13100)	(3800, 12700)	(3300, 13100)	(-5700, 4300)	(-2800, 5800)	(-2800, 1600)	(-5700, 5800)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	6120.9	6733.3	6869.0	6385.6	-191.0	3.9	-165.5	-106.8
		SD	1498.3	2165.1	2314.9	1833.7	1547.8	1635.7	1716.2	1582.5
		Median	5700.0	6300.0	6300.0	6000.0	-100.0	-300.0	-500.0	-200.0
		(Min, Max)	(3300, 10100)	(2900, 12600)	(3800, 12600)	(2900, 12600)	(-6400, 3800)	(-4400, 4600)	(-4400, 4300)	(-6400, 4600)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	5898.5	6614.0	6875.9	6204.3	-413.4	-104.0	-158.6	-281.2
		SD	1594.7	2166.2	2082.7	1885.6	1381.8	1310.5	1347.1	1354.8
		Median	5600.0	5950.0	6100.0	5800.0	-400.0	-200.0	-400.0	-400.0
		(Min, Max)	(3400, 13700)	(3200, 13700)	(3600, 12500)	(3200, 13700)	(-6600, 3300)	(-3600, 3100)	(-3600, 3100)	(-6600, 3300)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	6001.5	6573.5	6642.9	6245.2	-293.9	-177.6	-460.7	-244.3
		SD	1613.1	2163.6	2230.7	1880.2	1636.1	1533.0	1530.3	1587.2
		Median	5850.0	6200.0	6150.0	5900.0	-250.0	-400.0	-600.0	-300.0
		(Min, Max)	(3700, 10400)	(2900, 12200)	(2900, 12200)	(2900, 12200)	(-6900, 3100)	(-3700, 3200)	(-3700, 3000)	(-6900, 3200)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils/Leukocytes (%)	Baseline	n	125	123	84	248				
		Mean	61.09	61.58	61.62	61.33				
		SD	9.62	9.42	8.82	9.51				
		Median	60.60	61.80	61.80	61.35				
		(Min, Max)	(35.0, 84.5)	(39.0, 79.1)	(39.0, 79.1)	(35.0, 84.5)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	64.20	66.41	65.84	65.27	2.61	4.24	3.90	3.41
		SD	9.30	7.85	8.12	8.67	8.57	6.68	6.83	7.72
		Median	64.85	67.00	66.00	66.00	1.80	3.40	2.10	2.30
		(Min, Max)	(43.5, 83.5)	(45.2, 83.5)	(45.2, 83.5)	(43.5, 83.5)	(-19.1, 23.7)	(-8.9, 24.7)	(-8.9, 24.7)	(-19.1, 24.7)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	65.64	67.51	67.41	66.53	3.91	5.49	5.39	4.67
		SD	8.84	9.09	8.76	8.98	8.18	8.34	8.62	8.27
		Median	65.50	69.10	68.90	66.70	3.20	5.15	4.80	4.00
		(Min, Max)	(49.0, 91.0)	(44.6, 83.7)	(45.5, 83.7)	(44.6, 91.0)	(-14.0, 27.3)	(-10.6, 27.2)	(-10.6, 27.2)	(-14.0, 27.3)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	64.48	66.09	66.10	65.23	2.79	4.85	5.24	3.75
		SD	9.12	9.77	9.25	9.42	7.74	8.60	8.94	8.19
		Median	65.20	66.80	66.50	65.80	2.35	5.20	5.00	3.70
		(Min, Max)	(28.2, 83.5)	(40.6, 87.5)	(40.6, 84.0)	(28.2, 87.5)	(-13.7, 25.2)	(-14.5, 30.6)	(-11.9, 30.6)	(-14.5, 30.6)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	62.59	65.98	66.01	64.18	1.44	4.42	4.33	2.85
		SD	8.17	9.57	8.96	8.99	8.47	7.87	8.10	8.31
		Median	63.00	66.50	66.00	64.75	1.25	4.70	4.60	3.00
		(Min, Max)	(36.0, 80.0)	(42.4, 83.5)	(44.2, 83.0)	(36.0, 83.5)	(-28.0, 24.1)	(-12.1, 27.0)	(-12.1, 27.0)	(-28.0, 27.0)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	64.26	66.19	66.11	65.13	2.81	4.10	4.24	3.39
		SD	8.87	10.67	10.72	9.74	7.71	7.72	8.38	7.72
		Median	63.80	67.50	66.10	66.05	3.00	4.40	4.30	3.30
		(Min, Max)	(38.0, 89.0)	(42.5, 86.2)	(44.3, 86.2)	(38.0, 89.0)	(-19.7, 23.1)	(-11.5, 20.5)	(-11.5, 20.5)	(-19.7, 23.1)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils/Leukocytes (%)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	64.55	66.82	67.37	65.54	3.30	5.40	5.81	4.22
		SD	9.81	11.08	9.80	10.41	9.56	8.73	9.05	9.24
		Median	63.30	68.00	68.00	64.80	1.80	4.60	3.00	3.15
		(Min, Max)	(36.2, 89.5)	(37.4, 86.4)	(41.1, 86.0)	(36.2, 89.5)	(-17.2, 36.1)	(-14.5, 39.1)	(-6.2, 39.1)	(-17.2, 39.1)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	64.20	65.56	65.83	64.77	2.74	4.14	4.32	3.34
		SD	10.34	10.72	10.57	10.49	8.20	9.33	9.87	8.70
		Median	63.50	65.20	66.40	64.50	2.95	4.00	2.40	3.10
		(Min, Max)	(38.9, 90.0)	(32.9, 85.7)	(32.9, 81.6)	(32.9, 90.0)	(-16.0, 24.9)	(-13.2, 39.3)	(-9.0, 39.3)	(-16.0, 39.3)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	63.88	66.49	67.01	65.00	2.68	5.26	5.50	3.80
		SD	9.37	10.06	9.43	9.73	8.26	8.87	9.59	8.59
		Median	63.50	67.20	66.00	64.90	4.00	4.20	3.90	4.15
		(Min, Max)	(40.3, 87.0)	(42.2, 92.0)	(47.9, 87.2)	(40.3, 92.0)	(-18.0, 26.4)	(-13.2, 43.0)	(-9.2, 43.0)	(-18.0, 43.0)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	63.98	65.82	66.10	64.75	2.51	4.43	4.44	3.32
		SD	10.10	9.41	9.63	9.83	8.97	7.60	7.56	8.44
		Median	64.50	66.90	66.90	65.15	1.90	4.50	4.50	2.70
		(Min, Max)	(41.0, 84.0)	(43.8, 86.0)	(46.8, 86.0)	(41.0, 86.0)	(-19.2, 31.0)	(-10.5, 25.1)	(-10.5, 25.1)	(-19.2, 31.0)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	65.00	65.26	65.57	65.11	3.73	3.56	3.93	3.66
		SD	9.17	10.70	10.23	9.80	9.52	7.93	8.01	8.86
		Median	65.40	67.55	67.50	66.10	3.70	2.70	2.00	3.30
		(Min, Max)	(34.0, 90.0)	(35.1, 82.5)	(35.1, 82.5)	(34.0, 90.0)	(-22.0, 25.8)	(-12.4, 24.4)	(-8.2, 20.9)	(-22.0, 25.8)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	63.72	67.43	67.67	65.27	2.06	5.82	6.49	3.64
		SD	9.26	9.65	10.48	9.56	8.97	8.68	8.99	9.01
		Median	63.80	66.60	66.60	65.55	1.35	4.50	4.60	3.50
		(Min, Max)	(34.2, 82.6)	(45.8, 91.5)	(45.9, 91.5)	(34.2, 91.5)	(-26.4, 24.9)	(-15.1, 31.8)	(-11.5, 31.8)	(-26.4, 31.8)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils/Leukocytes (%)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	63.98	65.45	64.77	64.62	3.00	3.59	3.15	3.25
		SD	9.15	9.48	9.75	9.28	8.29	8.08	8.58	8.17
		Median	64.70	64.75	63.40	64.70	3.20	3.65	2.25	3.50
		(Min, Max)	(44.0, 85.0)	(43.7, 88.5)	(44.1, 84.5)	(43.7, 88.5)	(-16.0, 25.8)	(-13.4, 26.3)	(-12.0, 26.3)	(-16.0, 26.3)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	65.17	66.65	66.86	65.82	3.53	4.62	4.97	4.01
		SD	8.98	8.95	9.14	8.96	7.34	6.67	7.05	7.05
		Median	66.05	66.70	66.00	66.10	3.20	4.00	4.00	3.70
		(Min, Max)	(47.2, 85.5)	(47.6, 86.5)	(47.8, 83.0)	(47.2, 86.5)	(-14.8, 19.4)	(-11.8, 18.6)	(-11.8, 18.6)	(-14.8, 19.4)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	63.93	64.93	66.90	64.35	2.71	3.19	5.01	2.91
		SD	10.13	10.38	10.16	10.21	7.10	9.60	9.76	8.23
		Median	63.90	66.45	68.90	64.70	3.05	4.25	5.10	3.30
		(Min, Max)	(37.8, 88.6)	(41.2, 84.5)	(43.8, 84.5)	(37.8, 88.6)	(-14.8, 19.4)	(-22.0, 39.4)	(-8.2, 39.4)	(-22.0, 39.4)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	63.44	63.35	63.92	63.40	2.37	1.72	2.22	2.09
		SD	9.76	9.05	8.65	9.42	6.63	7.56	7.09	7.02
		Median	63.30	62.00	64.80	62.10	2.70	3.00	2.75	2.75
		(Min, Max)	(41.9, 90.0)	(44.5, 82.2)	(44.5, 78.8)	(41.9, 90.0)	(-15.8, 20.1)	(-16.4, 16.7)	(-15.1, 16.7)	(-16.4, 20.1)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils (/uL)	Baseline	n	125	123	84	248				
		Mean	3964.6	3892.2	3914.2	3928.7				
		SD	1418.3	1504.3	1558.6	1459.1				
		Median	3721.0	3726.0	3640.0	3723.5				
		(Min, Max)	(1260, 8875)	(1476, 10205)	(1476, 10205)	(1260, 10205)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	4167.9	4522.5	4451.1	4340.8	139.5	600.5	593.7	365.6
		SD	1573.2	1930.8	2072.8	1760.1	1123.2	1423.4	1561.1	1296.0
		Median	3922.5	4116.5	3912.0	3979.5	-44.0	431.5	375.0	278.0
		(Min, Max)	(1339, 8400)	(1580, 13611)	(1580, 13611)	(1339, 13611)	(-2189, 3003)	(-1422, 8859)	(-1422, 8859)	(-2189, 8859)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	4168.6	4459.0	4450.1	4306.9	118.0	581.4	631.4	340.1
		SD	1888.4	1701.8	1844.7	1801.7	1342.0	1176.3	1199.7	1282.1
		Median	3657.0	4209.5	4180.5	3933.0	20.5	634.0	562.5	250.0
		(Min, Max)	(1680, 11130)	(1670, 9920)	(1670, 9920)	(1670, 11130)	(-2867, 5350)	(-2119, 3892)	(-1682, 3892)	(-2867, 5350)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	4030.0	4265.3	4312.7	4139.4	-76.6	389.4	511.3	141.8
		SD	1555.1	2201.4	2459.1	1879.4	1171.8	1478.1	1534.3	1339.4
		Median	3625.0	3897.5	3657.0	3650.0	-110.5	179.0	179.0	47.0
		(Min, Max)	(1213, 8792)	(1415, 14904)	(1415, 14904)	(1213, 14904)	(-2455, 4066)	(-2552, 6701)	(-2111, 6701)	(-2552, 6701)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	3790.7	4293.2	4327.9	4026.7	-249.2	349.2	333.6	33.3
		SD	1382.2	1703.9	1713.0	1558.1	1233.4	1280.5	1205.3	1287.9
		Median	3488.0	4028.0	3912.0	3703.5	-127.0	314.0	314.0	82.0
		(Min, Max)	(1551, 9075)	(1526, 9821)	(1613, 9821)	(1526, 9821)	(-4105, 2858)	(-2541, 3305)	(-2285, 3305)	(-4105, 3305)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	3982.8	4265.3	4339.2	4109.9	-94.9	232.6	272.4	53.3
		SD	1547.8	1671.6	1852.8	1606.3	1467.9	1136.8	1214.8	1334.8
		Median	3782.0	4040.0	4002.0	3850.5	-101.0	366.0	137.0	50.0
		(Min, Max)	(1560, 10146)	(1404, 9913)	(1404, 9913)	(1404, 10146)	(-4109, 5862)	(-3486, 3150)	(-3486, 3150)	(-4109, 5862)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils (/uL)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	4001.4	4526.4	4596.3	4230.9	-39.1	517.9	528.6	205.8
		SD	1490.9	1922.6	1798.9	1707.8	1568.1	1516.4	1486.4	1565.7
		Median	3722.0	4379.0	4542.0	3847.0	-110.0	392.0	408.0	96.0
		(Min, Max)	(1717, 11098)	(1197, 10419)	(1831, 10419)	(1197, 11098)	(-4341, 6814)	(-3996, 4011)	(-3996, 3322)	(-4341, 6814)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	4086.7	4395.9	4383.6	4217.8	14.8	383.3	296.1	172.1
		SD	1827.6	2062.9	2118.2	1930.6	1684.8	1792.5	1914.9	1735.6
		Median	3719.0	4258.0	4258.0	3724.0	-70.0	70.0	35.0	40.0
		(Min, Max)	(1517, 14220)	(1672, 10415)	(1672, 10415)	(1517, 14220)	(-4518, 8515)	(-4723, 5145)	(-4723, 5145)	(-4723, 8515)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	3954.0	4466.5	4430.2	4174.6	-67.7	423.5	342.7	145.2
		SD	1533.4	1936.1	1700.0	1731.0	1435.9	1477.2	1415.2	1469.5
		Median	3677.0	4115.0	4040.0	3856.0	-4.0	245.0	189.0	144.0
		(Min, Max)	(1771, 8664)	(1611, 11132)	(1611, 8075)	(1611, 11132)	(-4081, 4421)	(-2378, 5526)	(-2378, 5051)	(-4081, 5526)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	3976.2	4384.2	4372.8	4146.7	-77.7	332.5	249.8	94.9
		SD	1620.9	1969.9	2144.8	1780.0	1704.0	1105.2	964.0	1491.2
		Median	3613.0	4114.0	4071.0	3735.0	-15.0	211.0	133.0	63.0
		(Min, Max)	(1394, 12432)	(1624, 11524)	(1747, 11524)	(1394, 12432)	(-4708, 8163)	(-2170, 4138)	(-2170, 2128)	(-4708, 8163)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	4136.1	4313.7	4226.6	4209.7	126.6	197.1	21.4	156.0
		SD	1756.3	1904.8	1586.7	1814.7	1855.4	1566.9	1439.7	1735.2
		Median	3577.0	4218.0	4154.0	3802.0	181.0	187.0	18.0	181.0
		(Min, Max)	(2059, 12060)	(1455, 11753)	(1455, 8108)	(1455, 12060)	(-4001, 8401)	(-2985, 5245)	(-2985, 3715)	(-4001, 8401)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	3917.3	4719.6	4698.1	4251.6	-115.7	669.0	578.3	213.7
		SD	1347.8	2019.4	2292.8	1700.7	1560.7	1485.4	1613.4	1572.6
		Median	3684.0	4385.0	4302.0	3875.5	-79.0	425.0	290.0	203.0
		(Min, Max)	(1710, 7874)	(1758, 13359)	(1758, 13359)	(1710, 13359)	(-3823, 4113)	(-2529, 5212)	(-2529, 5212)	(-3823, 5212)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Neutrophils (/uL)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	3896.7	4497.0	4377.7	4156.0	20.5	303.4	14.3	143.7
		SD	1264.0	1950.0	1879.4	1617.5	1299.8	1349.4	1165.0	1323.7
		Median	3765.0	4142.5	3977.5	3914.0	64.5	328.0	194.0	180.5
		(Min, Max)	(1742, 8775)	(2112, 11594)	(2170, 10097)	(1742, 11594)	(-4334, 4750)	(-2372, 5988)	(-2372, 3099)	(-4334, 5988)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	4030.7	4567.8	4712.3	4264.8	73.5	319.1	234.5	181.5
		SD	1244.2	1844.4	2065.3	1550.9	1238.6	1393.6	1491.4	1308.9
		Median	3890.5	4464.0	4525.0	3988.0	98.0	77.0	80.0	78.5
		(Min, Max)	(2030, 8535)	(1978, 10269)	(2262, 10269)	(1978, 10269)	(-4604, 2646)	(-3351, 4277)	(-3351, 4277)	(-4604, 4277)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	3784.6	4344.4	4698.5	4023.8	-131.5	122.9	220.7	-21.8
		SD	1170.4	1735.6	1850.1	1459.1	1134.7	1299.6	1360.5	1209.7
		Median	3557.0	3948.5	4045.0	3724.0	-238.0	195.5	191.0	-17.5
		(Min, Max)	(1758, 6955)	(1910, 9000)	(1992, 9000)	(1758, 9000)	(-4699, 2217)	(-3362, 4382)	(-3362, 4382)	(-4699, 4382)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	3852.8	4241.3	4334.8	4018.3	-35.9	3.5	-180.5	-19.0
		SD	1318.5	1697.3	1785.4	1497.2	1308.7	1342.8	1383.0	1317.7
		Median	3583.0	3906.0	3994.0	3764.0	44.0	151.0	-87.5	83.0
		(Min, Max)	(1872, 8089)	(1412, 8723)	(1412, 8723)	(1412, 8723)	(-4753, 3020)	(-3211, 3562)	(-3211, 3562)	(-4753, 3562)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes/Leukocytes (%)	Baseline	n	125	123	84	248				
		Mean	29.28	29.39	28.90	29.33				
		SD	8.39	8.49	8.03	8.42				
		Median	29.50	28.80	28.90	29.10				
		(Min, Max)	(10.7, 52.3)	(12.5, 51.0)	(12.5, 51.0)	(10.7, 52.3)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	25.86	24.11	24.31	25.01	-2.88	-4.48	-4.12	-3.66
		SD	8.15	7.20	7.43	7.73	6.93	6.47	6.59	6.73
		Median	25.00	22.90	23.30	24.00	-2.50	-2.95	-2.30	-2.60
		(Min, Max)	(10.5, 49.0)	(8.0, 46.1)	(8.0, 46.1)	(8.0, 49.0)	(-21.2, 11.0)	(-28.2, 8.1)	(-28.2, 8.1)	(-28.2, 11.0)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	24.29	22.58	22.33	23.47	-4.30	-6.34	-6.20	-5.28
		SD	7.55	7.56	6.93	7.58	7.04	6.85	6.64	7.00
		Median	23.10	21.50	21.60	22.60	-4.10	-6.45	-6.05	-5.15
		(Min, Max)	(6.0, 41.0)	(7.9, 47.6)	(7.9, 43.5)	(6.0, 47.6)	(-26.5, 12.0)	(-29.2, 5.9)	(-24.3, 5.9)	(-29.2, 12.0)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	25.97	24.34	24.27	25.21	-2.83	-5.32	-5.28	-4.00
		SD	8.51	8.48	7.82	8.51	6.40	7.02	7.30	6.79
		Median	24.20	23.40	23.40	23.50	-2.55	-6.00	-5.70	-3.80
		(Min, Max)	(10.5, 59.5)	(7.5, 49.3)	(11.8, 49.3)	(7.5, 59.5)	(-22.8, 12.2)	(-26.3, 10.9)	(-26.3, 10.9)	(-26.3, 12.2)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	27.27	24.72	24.15	26.07	-2.11	-5.03	-5.09	-3.49
		SD	6.96	8.42	7.86	7.76	7.34	6.55	6.47	7.11
		Median	27.00	24.00	23.90	25.70	-2.20	-4.80	-5.00	-3.40
		(Min, Max)	(13.5, 48.5)	(8.5, 47.2)	(8.5, 46.1)	(8.5, 48.5)	(-23.2, 23.7)	(-24.7, 8.0)	(-24.7, 8.0)	(-24.7, 23.7)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	26.03	24.21	23.69	25.21	-3.12	-5.25	-5.67	-4.08
		SD	7.67	9.22	8.45	8.43	6.98	6.06	6.18	6.64
		Median	25.70	23.20	22.30	24.45	-3.15	-5.60	-6.30	-4.30
		(Min, Max)	(6.5, 48.0)	(10.2, 49.6)	(10.2, 45.8)	(6.5, 49.6)	(-20.7, 18.4)	(-18.7, 7.7)	(-18.7, 7.4)	(-20.7, 18.4)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes/Leukocytes (%)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	26.03	24.27	23.33	25.26	-3.29	-5.80	-6.34	-4.39
		SD	8.55	9.76	8.60	9.12	7.67	7.48	7.57	7.67
		Median	25.40	23.40	23.00	25.00	-3.40	-4.70	-4.00	-3.90
		(Min, Max)	(6.0, 50.0)	(5.5, 52.3)	(5.5, 46.2)	(5.5, 52.3)	(-32.1, 16.2)	(-36.2, 11.2)	(-36.2, 5.0)	(-36.2, 16.2)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	26.48	25.07	24.21	25.89	-2.61	-4.99	-5.50	-3.63
		SD	8.62	9.61	9.42	9.05	7.15	7.90	8.06	7.55
		Median	26.60	24.00	21.90	25.35	-2.40	-5.00	-5.10	-3.40
		(Min, Max)	(7.0, 50.7)	(9.3, 53.7)	(9.3, 53.7)	(7.0, 53.7)	(-21.8, 16.4)	(-35.3, 11.4)	(-35.3, 6.3)	(-35.3, 16.4)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	26.55	24.25	23.56	25.56	-2.82	-5.92	-6.15	-4.16
		SD	8.54	9.09	8.36	8.82	6.84	7.46	7.89	7.26
		Median	26.15	23.60	23.30	25.00	-3.60	-6.10	-5.80	-4.40
		(Min, Max)	(8.0, 50.2)	(4.5, 50.3)	(7.7, 41.6)	(4.5, 50.3)	(-22.9, 17.9)	(-36.6, 10.4)	(-36.6, 6.0)	(-36.6, 17.9)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	26.70	25.05	24.64	26.01	-2.42	-4.99	-4.94	-3.50
		SD	8.90	8.45	8.13	8.72	8.02	6.59	6.71	7.53
		Median	26.10	24.50	25.00	25.20	-2.50	-5.50	-5.50	-3.80
		(Min, Max)	(9.5, 51.6)	(9.4, 48.6)	(9.4, 40.7)	(9.4, 51.6)	(-28.7, 24.9)	(-23.9, 12.0)	(-23.9, 12.0)	(-28.7, 24.9)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	25.98	25.30	24.58	25.70	-3.40	-4.50	-4.97	-3.86
		SD	8.08	9.85	9.28	8.83	7.99	7.06	7.28	7.61
		Median	25.65	23.90	24.00	24.90	-3.70	-4.15	-4.40	-3.70
		(Min, Max)	(6.5, 51.5)	(8.3, 53.4)	(8.3, 53.4)	(6.5, 53.4)	(-22.7, 21.8)	(-24.7, 11.2)	(-24.7, 8.1)	(-24.7, 21.8)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	26.74	23.52	23.00	25.40	-2.15	-6.27	-6.89	-3.88
		SD	8.06	8.08	8.34	8.19	7.69	7.09	7.04	7.69
		Median	27.10	23.60	23.00	25.00	-2.05	-5.70	-6.00	-4.50
		(Min, Max)	(10.4, 54.1)	(6.0, 44.9)	(6.0, 42.2)	(6.0, 54.1)	(-20.2, 23.3)	(-26.3, 10.6)	(-26.3, 6.3)	(-26.3, 23.3)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes/Leukocytes (%)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	26.45	25.62	25.73	26.09	-2.95	-4.04	-3.93	-3.43
		SD	7.50	8.26	8.43	7.82	6.31	6.97	7.45	6.60
		Median	26.20	26.10	26.00	26.20	-3.35	-3.85	-3.85	-3.45
		(Min, Max)	(8.5, 46.4)	(7.5, 46.1)	(10.0, 45.4)	(7.5, 46.4)	(-19.7, 9.6)	(-23.3, 11.4)	(-23.3, 8.0)	(-23.3, 11.4)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	25.24	24.58	24.24	24.95	-3.66	-5.05	-5.39	-4.28
		SD	6.90	7.49	7.69	7.14	6.06	6.37	6.49	6.21
		Median	25.20	22.90	22.90	24.40	-3.70	-4.50	-4.50	-4.20
		(Min, Max)	(11.0, 42.4)	(8.5, 39.7)	(10.0, 39.7)	(8.5, 42.4)	(-18.2, 13.5)	(-19.2, 6.7)	(-19.2, 6.7)	(-19.2, 13.5)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	26.69	26.09	24.26	26.44	-2.62	-3.75	-5.36	-3.11
		SD	8.05	9.05	8.65	8.46	5.74	8.66	8.77	7.13
		Median	27.50	25.80	24.80	25.90	-2.70	-3.90	-4.00	-3.25
		(Min, Max)	(8.6, 50.6)	(9.5, 49.0)	(9.5, 44.2)	(8.6, 50.6)	(-14.7, 13.1)	(-39.5, 21.0)	(-39.5, 7.9)	(-39.5, 21.0)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	27.12	27.55	26.80	27.30	-2.33	-2.34	-2.90	-2.33
		SD	7.90	7.90	7.57	7.87	5.92	6.72	5.90	6.24
		Median	27.35	28.80	25.95	27.70	-2.00	-3.10	-3.05	-2.60
		(Min, Max)	(7.0, 43.4)	(12.6, 43.0)	(12.6, 41.5)	(7.0, 43.4)	(-14.2, 15.0)	(-14.4, 14.5)	(-14.4, 7.8)	(-14.4, 15.0)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes (/uL)	Baseline	n	125	123	84	248				
		Mean	1836.7	1798.2	1765.0	1817.6				
		SD	673.8	679.1	608.0	675.3				
		Median	1710.0	1714.0	1712.0	1712.0				
		(Min, Max)	(556, 5065)	(575, 3886)	(575, 3494)	(556, 5065)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	1592.4	1579.5	1568.8	1586.1	-210.1	-162.7	-127.4	-186.8
		SD	555.1	653.5	683.1	603.2	458.3	465.5	465.3	461.0
		Median	1456.5	1468.5	1430.0	1457.5	-161.0	-145.0	-112.0	-161.0
		(Min, Max)	(773, 3572)	(442, 4979)	(442, 4979)	(442, 4979)	(-2130, 1288)	(-1491, 1485)	(-1478, 1485)	(-2130, 1485)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	1437.9	1439.2	1408.2	1438.5	-356.7	-300.1	-267.1	-329.5
		SD	505.2	613.9	625.0	557.6	433.2	452.1	444.0	441.8
		Median	1320.0	1419.0	1350.5	1386.0	-291.5	-270.5	-209.0	-281.0
		(Min, Max)	(498, 3498)	(442, 4611)	(442, 4611)	(442, 4611)	(-2302, 517)	(-1810, 1117)	(-1810, 1117)	(-2302, 1117)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	1541.9	1483.9	1505.2	1514.9	-288.4	-310.1	-236.0	-298.5
		SD	547.2	764.0	860.3	655.0	423.8	539.7	568.6	479.8
		Median	1386.0	1429.0	1429.0	1418.0	-211.5	-264.0	-246.5	-238.0
		(Min, Max)	(775, 3739)	(600, 6015)	(603, 6015)	(600, 6015)	(-2143, 676)	(-1585, 2521)	(-1197, 2521)	(-2143, 2521)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	1603.6	1537.4	1534.7	1572.5	-269.2	-298.8	-267.2	-283.2
		SD	548.9	644.1	703.8	594.9	407.7	471.5	464.0	438.1
		Median	1537.0	1490.0	1490.0	1523.5	-252.0	-276.0	-247.0	-256.0
		(Min, Max)	(734, 3604)	(501, 5071)	(501, 5071)	(501, 5071)	(-1570, 817)	(-1867, 1577)	(-1279, 1577)	(-1867, 1577)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	1552.9	1514.1	1489.6	1535.5	-307.3	-335.9	-339.7	-320.2
		SD	572.5	752.3	743.6	657.8	435.9	488.0	523.2	459.1
		Median	1439.0	1368.0	1338.0	1414.0	-270.0	-324.0	-345.0	-296.0
		(Min, Max)	(498, 3836)	(469, 5267)	(469, 5267)	(469, 5267)	(-1572, 883)	(-1962, 1773)	(-1307, 1773)	(-1962, 1773)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes (/uL)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	1563.7	1535.0	1536.0	1551.1	-311.7	-363.2	-320.9	-334.3
		SD	656.4	676.6	698.9	663.4	417.3	463.0	447.2	437.4
		Median	1459.5	1521.0	1521.0	1462.0	-263.0	-279.0	-249.0	-264.5
		(Min, Max)	(444, 4485)	(358, 3681)	(358, 3681)	(358, 4485)	(-1824, 745)	(-1962, 882)	(-1361, 882)	(-1962, 882)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	1609.8	1567.1	1510.8	1591.7	-255.1	-312.7	-334.8	-279.7
		SD	677.7	668.6	635.3	672.1	393.0	464.4	483.7	424.5
		Median	1422.0	1453.0	1404.0	1441.5	-210.5	-300.0	-355.0	-261.0
		(Min, Max)	(420, 4788)	(335, 3329)	(335, 3329)	(335, 4788)	(-1743, 719)	(-1734, 964)	(-1463, 964)	(-1743, 964)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	1574.4	1526.8	1491.6	1553.9	-296.0	-378.7	-354.1	-331.9
		SD	618.7	626.2	599.1	620.3	358.3	438.5	459.8	395.8
		Median	1476.0	1464.0	1450.0	1473.0	-284.0	-383.0	-383.0	-308.5
		(Min, Max)	(567, 4255)	(416, 3270)	(416, 3102)	(416, 4255)	(-1453, 808)	(-1352, 576)	(-1350, 576)	(-1453, 808)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	1586.2	1575.2	1533.2	1581.6	-277.6	-334.0	-326.2	-301.3
		SD	582.2	609.6	622.1	591.7	451.5	491.9	506.4	468.1
		Median	1500.0	1558.0	1513.0	1533.5	-232.5	-242.0	-363.0	-242.0
		(Min, Max)	(448, 3560)	(320, 3294)	(320, 3294)	(320, 3560)	(-2217, 721)	(-1574, 790)	(-1574, 790)	(-2217, 790)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	1579.6	1556.0	1524.4	1569.8	-284.8	-346.9	-355.8	-310.7
		SD	574.6	561.6	587.8	567.3	446.6	457.7	425.7	450.7
		Median	1561.5	1600.0	1595.0	1584.0	-290.0	-211.0	-253.0	-251.0
		(Min, Max)	(508, 3458)	(292, 3151)	(292, 3151)	(292, 3458)	(-1997, 619)	(-2061, 390)	(-1506, 390)	(-2061, 619)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	1612.3	1537.8	1448.0	1581.3	-221.9	-335.4	-439.4	-269.5
		SD	629.8	595.5	523.0	614.5	406.6	420.0	403.8	414.5
		Median	1512.0	1470.0	1470.0	1489.5	-236.0	-227.0	-312.0	-233.0
		(Min, Max)	(494, 4064)	(605, 3690)	(605, 3138)	(494, 4064)	(-1264, 1214)	(-1474, 586)	(-1474, 297)	(-1474, 1214)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Lymphocytes (/uL)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	1586.9	1660.7	1645.1	1618.8	-247.0	-247.8	-302.2	-247.4
		SD	601.3	605.8	571.3	601.9	399.3	491.7	529.2	440.0
		Median	1370.0	1539.5	1484.5	1427.0	-319.5	-231.0	-244.0	-238.5
		(Min, Max)	(527, 3564)	(420, 3660)	(420, 2850)	(420, 3660)	(-1501, 753)	(-1771, 738)	(-1771, 738)	(-1771, 753)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	1527.8	1599.2	1579.0	1558.9	-284.0	-323.7	-397.7	-301.5
		SD	520.2	614.6	553.5	561.9	398.5	526.9	570.5	457.7
		Median	1462.0	1462.0	1462.0	1462.0	-273.0	-340.0	-376.0	-308.5
		(Min, Max)	(572, 3023)	(638, 3399)	(770, 3399)	(572, 3399)	(-2042, 386)	(-1568, 1287)	(-1568, 1287)	(-2042, 1287)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	1573.5	1680.1	1596.3	1619.1	-262.1	-253.2	-380.3	-258.3
		SD	733.9	727.6	571.2	730.0	364.3	475.6	474.0	414.0
		Median	1448.0	1547.0	1555.0	1513.0	-259.5	-221.0	-380.0	-242.5
		(Min, Max)	(404, 5891)	(518, 3956)	(518, 2652)	(404, 5891)	(-1150, 826)	(-1504, 1191)	(-1504, 389)	(-1504, 1191)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	1599.5	1753.4	1722.2	1665.0	-240.8	-190.9	-275.2	-219.4
		SD	592.7	616.5	582.3	605.1	398.0	450.5	432.9	420.2
		Median	1489.5	1764.0	1618.5	1561.0	-160.0	-170.0	-304.0	-160.0
		(Min, Max)	(455, 3541)	(554, 3511)	(554, 2890)	(455, 3541)	(-1524, 758)	(-1207, 1181)	(-1207, 549)	(-1524, 1181)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes/Leukocytes (%)	Baseline	n	125	123	84	248				
		Mean	6.32	6.33	6.58	6.32				
		SD	1.92	1.78	1.75	1.85				
		Median	6.20	6.30	6.50	6.25				
		(Min, Max)	(2.3, 12.0)	(1.7, 10.8)	(1.7, 10.8)	(1.7, 12.0)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	6.79	6.56	6.81	6.68	0.40	0.20	0.18	0.31
		SD	2.11	1.69	1.63	1.92	2.05	1.53	1.39	1.81
		Median	6.70	6.65	7.00	6.70	0.30	0.10	0.10	0.20
		(Min, Max)	(2.1, 12.0)	(2.6, 10.2)	(3.3, 10.2)	(2.1, 12.0)	(-3.3, 7.7)	(-3.4, 4.1)	(-3.4, 4.1)	(-3.4, 7.7)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	6.80	6.55	6.80	6.68	0.41	0.23	0.19	0.32
		SD	2.43	1.95	1.96	2.21	2.43	2.22	2.26	2.32
		Median	7.00	6.50	7.00	6.90	0.20	0.40	0.35	0.25
		(Min, Max)	(2.0, 12.8)	(3.0, 12.2)	(3.0, 12.2)	(2.0, 12.8)	(-5.9, 7.2)	(-4.2, 6.8)	(-4.2, 6.8)	(-5.9, 7.2)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	6.55	6.32	6.44	6.44	0.18	0.14	-0.03	0.16
		SD	1.97	1.92	1.83	1.94	2.08	1.88	1.76	1.98
		Median	6.70	6.00	6.25	6.40	0.30	0.00	-0.15	0.15
		(Min, Max)	(2.0, 12.4)	(1.9, 10.6)	(2.5, 10.6)	(1.9, 12.4)	(-4.7, 5.0)	(-5.0, 6.0)	(-3.3, 6.0)	(-5.0, 6.0)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	6.91	6.45	6.68	6.69	0.62	0.32	0.33	0.48
		SD	2.10	2.10	1.99	2.11	1.76	2.12	2.12	1.94
		Median	6.60	6.20	6.50	6.40	0.55	0.60	0.80	0.60
		(Min, Max)	(1.4, 14.0)	(2.0, 12.2)	(2.0, 12.2)	(1.4, 14.0)	(-3.8, 4.9)	(-5.0, 5.3)	(-4.2, 5.3)	(-5.0, 5.3)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	6.51	6.53	6.78	6.52	0.24	0.60	0.63	0.40
		SD	2.09	2.15	2.51	2.11	1.83	2.19	2.42	2.00
		Median	6.20	6.10	6.20	6.15	0.35	0.50	0.40	0.40
		(Min, Max)	(3.0, 13.0)	(0.3, 12.7)	(0.3, 12.7)	(0.3, 13.0)	(-6.2, 5.8)	(-5.2, 7.1)	(-5.2, 7.1)	(-6.2, 7.1)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes/Leukocytes (%)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	6.47	6.01	6.07	6.27	0.21	0.01	-0.02	0.12
		SD	1.80	2.02	2.12	1.91	1.88	2.33	2.38	2.09
		Median	6.15	6.00	6.00	6.00	0.10	0.00	-0.20	0.05
		(Min, Max)	(2.9, 11.4)	(0.7, 12.4)	(0.7, 12.4)	(0.7, 12.4)	(-6.7, 4.6)	(-6.3, 4.9)	(-6.3, 4.4)	(-6.7, 4.9)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	6.45	6.63	6.99	6.53	0.22	0.66	0.97	0.40
		SD	2.13	2.09	2.09	2.11	1.94	1.97	1.79	1.96
		Median	6.50	6.50	6.90	6.50	0.45	0.80	1.00	0.60
		(Min, Max)	(1.5, 11.7)	(1.8, 12.3)	(3.0, 12.3)	(1.5, 12.3)	(-6.9, 4.4)	(-6.0, 5.0)	(-2.5, 5.0)	(-6.9, 5.0)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	6.58	6.48	6.43	6.54	0.31	0.49	0.42	0.39
		SD	1.89	2.01	1.91	1.94	1.92	2.14	2.20	2.01
		Median	6.60	6.30	6.40	6.60	0.50	0.40	0.40	0.45
		(Min, Max)	(2.4, 12.4)	(1.2, 13.5)	(1.2, 10.3)	(1.2, 13.5)	(-4.5, 5.2)	(-5.2, 5.2)	(-5.2, 4.9)	(-5.2, 5.2)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	6.58	6.31	6.31	6.47	0.33	0.38	0.35	0.35
		SD	1.96	1.72	1.87	1.86	1.82	1.92	1.89	1.85
		Median	6.30	6.00	6.00	6.10	0.45	0.50	0.30	0.50
		(Min, Max)	(2.2, 11.2)	(2.0, 10.7)	(2.0, 10.7)	(2.0, 11.2)	(-3.9, 5.9)	(-4.0, 5.9)	(-4.0, 5.9)	(-4.0, 5.9)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	6.46	6.52	6.74	6.49	0.27	0.59	0.80	0.40
		SD	1.94	1.55	1.59	1.79	1.78	1.50	1.56	1.67
		Median	6.50	6.65	7.00	6.50	0.40	0.40	0.50	0.40
		(Min, Max)	(1.5, 13.0)	(2.0, 12.1)	(4.0, 12.1)	(1.5, 13.0)	(-4.9, 3.8)	(-3.3, 4.0)	(-3.0, 3.8)	(-4.9, 4.0)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	6.51	6.67	6.62	6.58	0.27	0.65	0.55	0.43
		SD	1.98	1.79	1.88	1.90	1.64	1.85	1.89	1.74
		Median	6.20	7.00	6.70	6.35	0.30	0.90	0.90	0.40
		(Min, Max)	(3.0, 12.1)	(2.5, 10.3)	(2.5, 10.3)	(2.5, 12.1)	(-5.3, 3.7)	(-4.0, 4.5)	(-4.0, 4.5)	(-5.3, 4.5)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes/Leukocytes (%)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	6.40	6.19	6.56	6.31	0.09	0.21	0.56	0.14
		SD	1.98	1.72	1.67	1.87	1.68	2.05	1.91	1.85
		Median	6.20	6.00	6.55	6.10	0.20	0.60	0.85	0.35
		(Min, Max)	(2.1, 12.0)	(3.0, 10.0)	(3.0, 9.7)	(2.1, 12.0)	(-4.2, 3.5)	(-5.0, 5.1)	(-5.0, 5.1)	(-5.0, 5.1)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	6.51	6.16	6.29	6.36	0.35	0.24	0.40	0.31
		SD	2.03	1.68	1.64	1.88	1.57	1.84	1.62	1.69
		Median	6.35	6.10	6.30	6.30	0.30	0.60	0.90	0.30
		(Min, Max)	(2.7, 11.5)	(2.7, 10.5)	(3.1, 10.5)	(2.7, 11.5)	(-3.7, 4.5)	(-4.0, 3.4)	(-3.0, 3.3)	(-4.0, 4.5)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	6.43	6.30	6.25	6.38	0.24	0.33	0.35	0.28
		SD	2.23	1.75	1.70	2.03	1.75	2.03	2.07	1.87
		Median	6.20	6.20	6.30	6.20	0.20	0.80	0.70	0.55
		(Min, Max)	(1.7, 11.4)	(2.7, 10.4)	(2.7, 9.5)	(1.7, 11.4)	(-4.9, 4.8)	(-5.3, 4.5)	(-5.3, 4.5)	(-5.3, 4.8)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	6.35	6.31	6.41	6.33	0.16	0.30	0.44	0.22
		SD	2.08	1.60	1.55	1.88	1.48	1.82	1.64	1.63
		Median	6.10	6.50	6.85	6.40	0.10	0.30	0.00	0.10
		(Min, Max)	(2.5, 14.0)	(2.4, 9.9)	(2.4, 8.5)	(2.4, 14.0)	(-3.0, 4.5)	(-4.0, 4.0)	(-2.2, 4.0)	(-4.0, 4.5)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes (/uL)	Baseline	n	125	123	84	248				
		Mean	396.2	388.5	401.9	392.4				
		SD	148.9	151.3	138.9	149.8				
		Median	360.0	369.0	389.0	365.0				
		(Min, Max)	(180, 1158)	(106, 928)	(113, 780)	(106, 1158)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	419.8	434.1	444.1	426.8	18.0	46.2	49.5	31.8
		SD	139.9	176.8	180.1	158.6	135.3	137.6	138.4	136.7
		Median	423.0	410.5	421.0	414.5	28.0	40.0	37.0	37.0
		(Min, Max)	(138, 904)	(170, 1141)	(170, 1141)	(138, 1141)	(-254, 392)	(-273, 718)	(-154, 718)	(-273, 718)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	400.2	420.0	432.3	409.7	-3.1	39.2	45.4	17.2
		SD	151.3	175.6	183.4	163.1	136.4	168.2	173.6	153.4
		Median	371.0	401.5	422.5	371.0	-8.0	37.0	40.0	21.0
		(Min, Max)	(121, 954)	(173, 1088)	(173, 1088)	(121, 1088)	(-522, 293)	(-308, 913)	(-258, 913)	(-522, 913)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	392.2	390.3	401.9	391.3	-15.3	15.4	22.4	-0.9
		SD	152.1	193.0	199.5	171.7	136.9	143.0	148.0	140.1
		Median	362.0	345.0	348.0	350.0	10.0	-1.0	-11.0	4.5
		(Min, Max)	(139, 968)	(131, 1104)	(139, 1104)	(131, 1104)	(-484, 342)	(-252, 505)	(-252, 505)	(-484, 505)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	402.8	398.9	419.5	401.0	0.2	16.3	23.1	7.8
		SD	144.6	162.4	159.2	152.9	122.6	151.1	170.5	136.7
		Median	384.0	360.0	378.0	370.0	6.0	34.0	41.0	16.0
		(Min, Max)	(120, 896)	(170, 944)	(174, 855)	(120, 944)	(-416, 316)	(-321, 553)	(-311, 553)	(-416, 553)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	391.4	401.8	411.7	396.1	-11.2	23.8	23.3	4.6
		SD	160.1	162.8	160.5	160.9	150.6	154.9	174.6	153.1
		Median	374.0	371.0	384.0	372.0	-22.5	21.0	58.0	4.0
		(Min, Max)	(132, 1118)	(35, 980)	(35, 781)	(35, 1118)	(-441, 681)	(-680, 414)	(-680, 414)	(-680, 681)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes (/uL)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	382.5	382.0	394.0	382.3	-20.0	-3.2	8.1	-12.6
		SD	110.4	153.3	152.5	130.4	131.5	177.1	174.0	153.0
		Median	372.0	369.0	380.0	371.0	-13.0	1.0	0.0	-3.0
		(Min, Max)	(186, 774)	(53, 854)	(53, 828)	(53, 854)	(-391, 248)	(-706, 381)	(-662, 381)	(-706, 381)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	389.3	421.7	441.3	403.1	-12.9	38.8	58.7	9.2
		SD	151.0	179.6	173.0	164.0	177.1	144.4	142.4	165.4
		Median	368.0	408.0	423.0	371.5	-5.0	45.0	65.0	10.0
		(Min, Max)	(116, 968)	(96, 1044)	(96, 953)	(96, 1044)	(-759, 763)	(-365, 367)	(-365, 367)	(-759, 763)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	392.1	422.6	407.7	405.2	-8.6	34.1	25.2	9.9
		SD	144.3	226.4	161.6	184.1	145.1	190.5	179.4	167.1
		Median	368.5	377.0	377.0	374.0	13.0	17.0	19.0	15.5
		(Min, Max)	(106, 1029)	(118, 1742)	(118, 798)	(106, 1742)	(-435, 450)	(-597, 904)	(-597, 419)	(-597, 904)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	396.8	394.0	382.4	395.7	-4.8	9.7	-0.4	1.3
		SD	151.9	124.6	123.6	140.7	165.5	152.5	154.8	159.8
		Median	378.0	378.0	364.0	378.0	-7.0	37.0	27.0	6.0
		(Min, Max)	(147, 828)	(119, 720)	(162, 720)	(119, 828)	(-474, 436)	(-447, 383)	(-447, 383)	(-474, 436)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	398.3	417.4	419.9	406.2	4.2	29.3	29.5	14.6
		SD	170.5	173.5	138.2	171.4	142.9	128.3	127.2	137.1
		Median	374.0	358.0	378.0	367.5	-6.0	30.0	32.0	10.0
		(Min, Max)	(176, 1062)	(160, 1026)	(195, 789)	(160, 1062)	(-420, 423)	(-346, 459)	(-346, 233)	(-420, 459)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	387.3	447.1	432.4	412.2	-6.2	58.9	39.9	21.1
		SD	123.9	174.4	161.6	149.4	136.5	138.3	141.1	140.5
		Median	378.0	392.0	374.0	380.5	-10.0	49.0	35.0	22.0
		(Min, Max)	(109, 645)	(138, 1107)	(138, 792)	(109, 1107)	(-401, 383)	(-344, 397)	(-344, 309)	(-401, 397)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Monocytes (/uL)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	376.9	405.0	426.7	389.0	-8.9	7.9	19.0	-1.6
		SD	122.7	141.7	148.7	131.4	127.9	150.9	155.7	138.1
		Median	350.0	374.5	399.0	360.0	-4.0	17.0	34.5	-2.5
		(Min, Max)	(141, 723)	(147, 855)	(147, 855)	(141, 855)	(-428, 282)	(-430, 491)	(-430, 491)	(-430, 491)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	392.3	401.6	419.0	396.3	10.9	3.9	9.3	7.8
		SD	140.8	142.3	147.5	140.9	124.3	152.3	162.5	136.7
		Median	371.0	377.0	400.0	372.0	23.0	23.0	24.0	23.0
		(Min, Max)	(143, 884)	(170, 791)	(182, 770)	(143, 884)	(-390, 390)	(-448, 323)	(-448, 323)	(-448, 390)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	374.0	415.4	418.8	391.7	-8.8	14.6	9.1	1.3
		SD	157.2	197.9	163.7	176.1	116.3	158.8	169.3	136.1
		Median	343.0	360.0	372.0	354.0	-8.5	24.5	25.0	9.5
		(Min, Max)	(80, 1082)	(165, 1233)	(208, 1000)	(80, 1233)	(-442, 354)	(-528, 401)	(-528, 401)	(-528, 401)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	372.8	407.1	414.2	387.4	-9.5	2.3	-2.9	-4.4
		SD	138.1	155.9	145.1	146.3	138.1	126.2	125.3	132.7
		Median	345.0	374.0	391.5	353.0	-23.0	0.0	-2.0	-7.0
		(Min, Max)	(163, 854)	(157, 928)	(157, 763)	(157, 928)	(-594, 296)	(-296, 274)	(-227, 274)	(-594, 296)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils/Leukocytes (%)	Baseline	n	125	123	84	248				
		Mean	2.98	2.36	2.55	2.68				
		SD	2.71	1.87	1.91	2.35				
		Median	2.50	2.00	2.00	2.10				
		(Min, Max)	(0.0, 16.0)	(0.0, 9.0)	(0.0, 9.0)	(0.0, 16.0)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	2.75	2.55	2.65	2.65	-0.22	0.01	0.01	-0.11
		SD	2.18	2.04	1.70	2.11	1.52	1.50	1.50	1.51
		Median	2.00	2.00	2.10	2.00	0.00	-0.10	0.00	0.00
		(Min, Max)	(0.0, 11.4)	(0.0, 12.8)	(0.0, 7.8)	(0.0, 12.8)	(-6.4, 4.0)	(-4.9, 4.7)	(-4.9, 4.7)	(-6.4, 4.7)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	2.94	3.03	3.10	2.98	-0.03	0.63	0.61	0.29
		SD	2.30	2.78	2.88	2.53	1.50	2.63	2.92	2.13
		Median	2.40	2.35	2.35	2.40	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 13.5)	(0.0, 18.4)	(0.0, 18.4)	(0.0, 18.4)	(-3.6, 4.0)	(-2.8, 15.3)	(-2.8, 15.3)	(-3.6, 15.3)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	2.64	2.87	2.81	2.75	-0.16	0.30	0.05	0.06
		SD	1.97	2.38	1.94	2.17	1.64	2.54	2.42	2.11
		Median	2.10	2.20	2.20	2.10	-0.05	-0.10	-0.10	-0.10
		(Min, Max)	(0.0, 9.7)	(0.0, 13.0)	(0.0, 8.7)	(0.0, 13.0)	(-4.1, 4.7)	(-5.7, 11.5)	(-5.7, 7.0)	(-5.7, 11.5)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	2.86	2.50	2.77	2.69	0.03	0.26	0.36	0.14
		SD	2.39	2.53	2.64	2.45	1.55	2.09	2.44	1.82
		Median	2.50	1.70	1.80	2.10	0.20	0.00	-0.20	0.00
		(Min, Max)	(0.0, 17.1)	(0.0, 14.5)	(0.2, 14.5)	(0.0, 17.1)	(-4.8, 5.3)	(-3.3, 10.7)	(-3.3, 10.7)	(-4.8, 10.7)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	2.83	2.69	3.03	2.77	0.04	0.50	0.74	0.25
		SD	2.58	3.17	3.75	2.85	1.75	2.62	3.19	2.19
		Median	2.00	1.90	2.00	2.00	-0.10	0.00	0.10	-0.10
		(Min, Max)	(0.3, 13.0)	(0.1, 18.5)	(0.1, 18.5)	(0.1, 18.5)	(-3.9, 10.6)	(-3.8, 13.7)	(-3.8, 13.7)	(-3.9, 13.7)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils/Leukocytes (%)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	2.62	2.56	2.89	2.60	-0.21	0.37	0.51	0.05
		SD	2.17	3.24	3.60	2.68	2.09	2.72	3.36	2.40
		Median	1.95	1.70	2.00	1.90	0.00	0.00	0.20	0.00
		(Min, Max)	(0.0, 13.8)	(0.0, 21.5)	(0.0, 21.5)	(0.0, 21.5)	(-8.7, 5.9)	(-4.1, 16.7)	(-4.1, 16.7)	(-8.7, 16.7)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	2.54	2.41	2.65	2.48	-0.33	0.18	0.20	-0.11
		SD	2.21	2.74	3.12	2.44	1.90	2.41	3.06	2.14
		Median	2.20	1.80	1.90	2.00	0.00	0.00	-0.10	0.00
		(Min, Max)	(0.0, 14.8)	(0.0, 19.1)	(0.2, 19.1)	(0.0, 19.1)	(-9.2, 4.6)	(-5.4, 14.3)	(-5.4, 14.3)	(-9.2, 14.3)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	2.63	2.46	2.68	2.56	-0.18	0.17	0.24	-0.03
		SD	2.61	2.32	2.54	2.48	2.39	2.09	2.51	2.26
		Median	2.05	2.00	2.40	2.00	-0.20	0.00	0.00	-0.15
		(Min, Max)	(0.0, 17.5)	(0.0, 12.2)	(0.0, 12.2)	(0.0, 17.5)	(-6.4, 14.5)	(-4.5, 7.4)	(-4.5, 7.4)	(-6.4, 14.5)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	2.37	2.52	2.66	2.43	-0.42	0.19	0.16	-0.16
		SD	1.84	2.01	2.32	1.91	1.92	2.08	2.39	2.00
		Median	2.00	2.00	1.90	2.00	0.00	0.00	-0.10	0.00
		(Min, Max)	(0.0, 9.9)	(0.0, 10.5)	(0.0, 10.5)	(0.0, 10.5)	(-8.1, 3.5)	(-6.9, 5.8)	(-6.9, 5.8)	(-8.1, 5.8)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	2.18	2.60	2.77	2.36	-0.62	0.32	0.22	-0.23
		SD	1.57	2.03	2.10	1.78	2.19	1.95	2.33	2.14
		Median	1.85	2.20	2.30	2.00	-0.20	0.15	0.00	-0.10
		(Min, Max)	(0.0, 7.5)	(0.0, 9.9)	(0.0, 9.9)	(0.0, 9.9)	(-10.6, 4.2)	(-6.0, 6.4)	(-6.0, 6.4)	(-10.6, 6.4)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	2.66	2.10	2.38	2.42	-0.21	-0.19	-0.16	-0.20
		SD	2.36	2.44	3.03	2.40	1.79	2.53	3.18	2.12
		Median	2.00	1.40	1.30	1.85	0.00	-0.20	-0.40	-0.10
		(Min, Max)	(0.0, 13.5)	(0.0, 16.1)	(0.0, 16.1)	(0.0, 16.1)	(-9.1, 4.0)	(-8.5, 11.3)	(-8.5, 11.3)	(-9.1, 11.3)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils/Leukocytes (%)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	2.81	2.41	2.62	2.64	-0.13	0.20	0.20	0.01
		SD	3.07	1.72	1.72	2.57	2.07	1.64	1.66	1.89
		Median	2.00	2.00	2.15	2.00	0.05	0.10	0.10	0.10
		(Min, Max)	(0.0, 22.5)	(0.0, 6.5)	(0.0, 6.5)	(0.0, 22.5)	(-10.0, 6.5)	(-4.5, 4.0)	(-4.5, 4.0)	(-10.0, 6.5)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	2.75	2.32	2.29	2.56	-0.23	0.19	0.00	-0.04
		SD	2.36	1.94	1.67	2.19	1.86	1.42	1.64	1.69
		Median	2.30	1.80	1.80	2.10	0.00	0.10	0.10	0.00
		(Min, Max)	(0.0, 14.4)	(0.0, 10.5)	(0.0, 5.7)	(0.0, 14.4)	(-8.6, 3.3)	(-4.1, 3.1)	(-4.1, 3.1)	(-8.6, 3.3)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	2.56	2.30	2.18	2.45	-0.38	0.14	-0.11	-0.16
		SD	2.39	1.80	1.36	2.15	1.70	1.60	1.76	1.67
		Median	2.20	2.00	2.00	2.10	-0.15	0.00	-0.10	0.00
		(Min, Max)	(0.0, 15.7)	(0.0, 10.7)	(0.0, 4.8)	(0.0, 15.7)	(-7.1, 2.6)	(-5.7, 4.2)	(-5.7, 4.2)	(-7.1, 4.2)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	2.65	2.42	2.48	2.55	-0.29	0.24	0.15	-0.06
		SD	2.36	2.35	2.07	2.35	1.65	1.82	2.15	1.74
		Median	2.15	2.00	1.90	2.00	-0.20	0.20	0.10	-0.05
		(Min, Max)	(0.2, 15.0)	(0.0, 13.5)	(0.0, 8.2)	(0.0, 15.0)	(-8.5, 4.0)	(-4.0, 5.5)	(-4.0, 5.5)	(-8.5, 5.5)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils (/uL)	Baseline	n	125	123	84	248				
		Mean	191.1	144.1	152.5	167.8				
		SD	205.1	116.8	109.3	168.5				
		Median	141.0	113.0	134.0	128.0				
		(Min, Max)	(0, 1712)	(0, 713)	(0, 469)	(0, 1712)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	166.4	163.3	165.7	164.9	-20.9	8.1	7.9	-6.6
		SD	121.0	134.7	108.3	127.4	85.1	95.3	94.3	91.1
		Median	135.5	125.0	126.0	132.0	-6.0	3.5	10.0	0.0
		(Min, Max)	(0, 600)	(0, 883)	(0, 468)	(0, 883)	(-443, 150)	(-244, 304)	(-244, 304)	(-443, 304)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	174.6	187.4	183.5	180.7	-13.9	42.8	38.2	13.3
		SD	136.3	180.1	169.9	158.2	99.0	157.5	170.6	133.0
		Median	137.0	150.5	152.5	145.0	-4.0	15.5	15.5	-1.0
		(Min, Max)	(0, 675)	(0, 1141)	(0, 1141)	(0, 1141)	(-271, 220)	(-190, 977)	(-190, 977)	(-271, 977)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	158.6	162.1	154.1	160.2	-24.3	7.8	-5.8	-9.3
		SD	121.7	133.4	92.1	126.8	117.1	138.0	126.9	127.8
		Median	130.0	141.5	133.0	133.0	-13.0	-12.5	-7.0	-13.0
		(Min, Max)	(0, 601)	(0, 741)	(0, 391)	(0, 741)	(-516, 302)	(-303, 655)	(-303, 385)	(-516, 655)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	166.4	149.1	159.8	158.3	-21.3	11.0	15.1	-6.0
		SD	141.3	149.9	134.6	145.3	123.0	119.3	133.8	122.0
		Median	138.0	118.0	125.0	124.5	1.5	1.0	-7.0	1.0
		(Min, Max)	(0, 992)	(0, 980)	(8, 841)	(0, 992)	(-720, 256)	(-268, 666)	(-268, 666)	(-720, 666)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	171.1	164.3	174.5	168.0	-13.8	26.7	35.4	4.5
		SD	163.6	183.0	196.4	172.2	162.5	152.5	181.2	158.9
		Median	122.0	126.0	126.0	126.0	-13.5	2.0	7.0	-5.0
		(Min, Max)	(17, 949)	(3, 1115)	(7, 1115)	(3, 1115)	(-997, 817)	(-274, 940)	(-274, 940)	(-997, 940)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils (/uL)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	153.8	159.0	173.0	156.1	-34.4	20.3	29.1	-10.3
		SD	126.1	189.1	182.7	156.3	161.3	157.5	188.5	161.5
		Median	114.5	116.0	129.0	115.0	-11.0	0.0	0.0	-4.0
		(Min, Max)	(0, 676)	(0, 1087)	(0, 989)	(0, 1087)	(-1036, 344)	(-259, 840)	(-259, 840)	(-1036, 840)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	146.8	144.4	147.5	145.8	-45.0	4.2	0.9	-24.0
		SD	117.5	151.9	123.1	132.7	167.2	115.4	131.3	148.9
		Median	125.0	108.0	120.0	119.0	-5.0	-10.0	-13.0	-5.0
		(Min, Max)	(0, 681)	(0, 979)	(13, 649)	(0, 979)	(-1031, 228)	(-249, 500)	(-249, 500)	(-1031, 500)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	156.8	146.6	154.4	152.4	-27.8	2.7	7.8	-14.6
		SD	157.2	135.1	121.2	147.7	195.2	117.4	131.6	166.2
		Median	119.5	110.0	135.0	119.0	-14.0	7.0	-6.0	-10.0
		(Min, Max)	(0, 1015)	(0, 799)	(0, 524)	(0, 1015)	(-1252, 847)	(-316, 303)	(-241, 303)	(-1252, 847)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	139.8	146.9	143.0	142.8	-44.7	0.4	-7.5	-25.8
		SD	105.1	106.6	105.5	105.4	175.6	122.9	128.8	156.7
		Median	114.0	125.0	125.0	120.0	-3.5	8.0	7.0	4.0
		(Min, Max)	(0, 446)	(0, 492)	(0, 472)	(0, 492)	(-1266, 156)	(-325, 267)	(-325, 267)	(-1266, 267)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	134.7	157.2	157.6	144.0	-48.9	13.6	2.1	-22.8
		SD	95.5	126.6	97.1	109.6	195.1	99.9	105.1	164.7
		Median	115.0	120.5	135.0	117.0	-9.0	7.0	0.0	-2.0
		(Min, Max)	(0, 443)	(0, 725)	(0, 426)	(0, 725)	(-1410, 174)	(-204, 330)	(-204, 205)	(-1410, 330)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	158.7	123.3	125.3	144.0	-29.4	-22.0	-31.2	-26.3
		SD	140.9	108.6	118.2	129.2	161.8	124.8	151.3	146.9
		Median	126.0	95.0	88.0	107.0	-2.0	-12.0	-14.0	-5.0
		(Min, Max)	(0, 743)	(0, 499)	(0, 499)	(0, 743)	(-969, 217)	(-427, 350)	(-427, 350)	(-969, 350)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Eosinophils (/uL)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	162.3	151.3	155.7	157.5	-24.9	7.1	0.7	-11.0
		SD	162.1	108.1	95.6	140.9	136.1	104.2	98.4	123.8
		Median	112.0	121.0	141.0	120.0	-2.5	1.5	-15.0	-1.5
		(Min, Max)	(0, 1125)	(0, 435)	(0, 395)	(0, 1125)	(-639, 196)	(-323, 246)	(-207, 246)	(-639, 246)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	167.3	147.4	139.6	158.6	-26.0	6.7	-10.2	-11.6
		SD	133.2	134.4	93.5	133.5	175.7	84.6	92.9	143.4
		Median	132.0	110.0	121.0	123.0	-6.0	5.0	5.0	-2.5
		(Min, Max)	(0, 619)	(0, 809)	(0, 359)	(0, 809)	(-1093, 305)	(-231, 188)	(-231, 154)	(-1093, 305)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	143.6	150.3	136.3	146.5	-46.5	7.6	-13.5	-23.2
		SD	118.3	143.8	76.4	129.3	158.3	101.8	100.8	139.0
		Median	116.0	136.5	146.0	128.0	-18.0	7.0	-11.0	-6.5
		(Min, Max)	(0, 644)	(0, 942)	(0, 274)	(0, 942)	(-1068, 114)	(-281, 295)	(-281, 160)	(-1068, 295)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	151.1	147.1	145.3	149.4	-39.5	2.8	-7.7	-21.4
		SD	117.5	138.0	110.9	126.1	173.1	98.5	125.1	146.7
		Median	123.0	123.0	117.5	123.0	1.0	1.0	-9.0	1.0
		(Min, Max)	(12, 570)	(0, 824)	(0, 451)	(0, 824)	(-1142, 194)	(-199, 284)	(-199, 284)	(-1142, 284)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils/Leukocytes (%)	Baseline	n	125	123	84	248				
		Mean	0.34	0.35	0.36	0.34				
		SD	0.27	0.25	0.24	0.26				
		Median	0.30	0.30	0.40	0.30				
		(Min, Max)	(0.0, 1.4)	(0.0, 1.2)	(0.0, 1.2)	(0.0, 1.4)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	0.40	0.37	0.39	0.39	0.09	0.03	0.03	0.06
		SD	0.33	0.27	0.27	0.30	0.41	0.31	0.32	0.36
		Median	0.40	0.35	0.40	0.40	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.5)	(0.0, 1.1)	(0.0, 1.1)	(0.0, 1.5)	(-0.7, 1.2)	(-0.8, 0.9)	(-0.8, 0.9)	(-0.8, 1.2)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	0.34	0.33	0.36	0.34	0.01	-0.01	0.02	0.00
		SD	0.36	0.27	0.28	0.32	0.43	0.36	0.35	0.40
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 2.4)	(0.0, 1.0)	(0.0, 1.0)	(0.0, 2.4)	(-1.0, 1.9)	(-1.2, 0.9)	(-1.2, 0.9)	(-1.2, 1.9)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	0.36	0.38	0.38	0.37	0.01	0.03	0.02	0.02
		SD	0.28	0.33	0.31	0.30	0.32	0.36	0.32	0.34
		Median	0.40	0.30	0.35	0.40	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.0)	(0.0, 1.6)	(0.0, 1.6)	(0.0, 1.6)	(-0.9, 0.7)	(-0.5, 1.2)	(-0.5, 1.2)	(-0.9, 1.2)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	0.37	0.36	0.40	0.37	0.03	0.03	0.07	0.03
		SD	0.29	0.32	0.36	0.31	0.41	0.40	0.43	0.40
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.6)	(0.0, 1.8)	(0.0, 1.8)	(0.0, 1.8)	(-1.0, 1.2)	(-1.1, 1.4)	(-1.1, 1.4)	(-1.1, 1.4)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	0.37	0.38	0.39	0.37	0.02	0.05	0.06	0.03
		SD	0.28	0.26	0.27	0.27	0.39	0.40	0.39	0.39
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.3)	(0.0, 1.0)	(0.0, 1.0)	(0.0, 1.3)	(-1.4, 1.0)	(-1.1, 1.0)	(-1.1, 1.0)	(-1.4, 1.0)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils/Leukocytes (%)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	0.34	0.34	0.35	0.34	-0.01	0.02	0.03	0.01
		SD	0.25	0.27	0.27	0.25	0.33	0.35	0.37	0.34
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.3)	(0.0, 1.0)	(0.0, 1.0)	(0.0, 1.3)	(-1.1, 1.1)	(-1.2, 0.8)	(-1.2, 0.8)	(-1.2, 1.1)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	0.33	0.33	0.33	0.33	-0.02	0.01	0.01	-0.01
		SD	0.20	0.25	0.26	0.22	0.33	0.30	0.28	0.31
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 0.8)	(0.0, 1.0)	(0.0, 0.9)	(0.0, 1.0)	(-1.4, 0.5)	(-0.7, 1.0)	(-0.7, 0.6)	(-1.4, 1.0)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	0.37	0.32	0.31	0.34	0.01	0.00	-0.01	0.01
		SD	0.29	0.27	0.20	0.28	0.35	0.32	0.29	0.34
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.5)	(0.0, 1.5)	(0.0, 0.9)	(0.0, 1.5)	(-1.0, 1.1)	(-1.0, 0.8)	(-1.0, 0.5)	(-1.0, 1.1)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	0.37	0.30	0.29	0.34	0.00	-0.01	-0.01	0.00
		SD	0.30	0.25	0.27	0.28	0.39	0.34	0.35	0.37
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.2)	(0.0, 1.1)	(0.0, 1.1)	(0.0, 1.2)	(-1.0, 1.1)	(-1.1, 1.0)	(-1.1, 1.0)	(-1.1, 1.1)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	0.37	0.33	0.34	0.35	0.03	0.03	0.03	0.03
		SD	0.29	0.25	0.25	0.27	0.40	0.32	0.32	0.37
		Median	0.30	0.30	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.4)	(0.0, 1.0)	(0.0, 1.0)	(0.0, 1.4)	(-1.1, 1.4)	(-0.8, 1.0)	(-0.8, 1.0)	(-1.1, 1.4)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	0.36	0.29	0.33	0.33	0.03	-0.01	0.02	0.01
		SD	0.33	0.28	0.29	0.31	0.41	0.33	0.31	0.38
		Median	0.30	0.20	0.30	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 1.9)	(0.0, 1.2)	(0.0, 1.2)	(0.0, 1.9)	(-1.0, 1.4)	(-1.1, 0.7)	(-0.6, 0.6)	(-1.1, 1.4)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils/Leukocytes (%)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	0.36	0.33	0.33	0.34	0.00	0.04	0.03	0.02
		SD	0.24	0.30	0.24	0.27	0.35	0.37	0.32	0.36
		Median	0.30	0.30	0.30	0.30	0.00	0.05	0.05	0.00
		(Min, Max)	(0.0, 1.0)	(0.0, 1.5)	(0.0, 1.0)	(0.0, 1.5)	(-1.0, 1.0)	(-1.1, 1.0)	(-1.0, 0.7)	(-1.1, 1.0)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	0.33	0.29	0.32	0.31	0.00	0.00	0.02	0.00
		SD	0.20	0.23	0.22	0.22	0.30	0.31	0.31	0.30
		Median	0.30	0.30	0.40	0.30	0.00	0.00	0.00	0.00
		(Min, Max)	(0.0, 0.8)	(0.0, 1.0)	(0.0, 0.8)	(0.0, 1.0)	(-1.0, 0.8)	(-0.6, 0.8)	(-0.6, 0.8)	(-1.0, 0.8)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	0.39	0.38	0.41	0.39	0.05	0.09	0.11	0.07
		SD	0.25	0.29	0.33	0.27	0.36	0.37	0.39	0.36
		Median	0.40	0.30	0.30	0.40	0.00	0.10	0.20	0.05
		(Min, Max)	(0.0, 1.4)	(0.0, 1.4)	(0.0, 1.4)	(0.0, 1.4)	(-1.0, 1.2)	(-0.9, 1.1)	(-0.9, 1.1)	(-1.0, 1.2)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	0.44	0.37	0.40	0.41	0.10	0.07	0.10	0.09
		SD	0.34	0.26	0.28	0.31	0.36	0.36	0.33	0.36
		Median	0.40	0.30	0.40	0.30	0.00	0.00	0.10	0.00
		(Min, Max)	(0.0, 2.0)	(0.0, 1.0)	(0.0, 1.0)	(0.0, 2.0)	(-0.8, 1.7)	(-1.0, 1.0)	(-0.5, 1.0)	(-1.0, 1.7)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils (/uL)	Baseline	n	125	123	84	248				
		Mean	21.1	21.9	22.5	21.5				
		SD	19.9	19.1	17.8	19.5				
		Median	18.0	19.0	20.0	18.0				
		(Min, Max)	(0, 86)	(0, 95)	(0, 95)	(0, 95)				
	Week 2	n	82	78	59	160	81	78	59	159
		Mean	25.7	23.8	24.5	24.7	5.6	2.6	3.3	4.1
		SD	23.1	19.4	19.0	21.3	28.0	20.3	20.6	24.5
		Median	20.5	22.0	23.0	21.0	1.0	1.5	3.0	1.0
		(Min, Max)	(0, 113)	(0, 95)	(0, 95)	(0, 113)	(-56, 90)	(-59, 74)	(-59, 74)	(-59, 90)
	Week 4	n	77	70	50	147	76	70	50	146
		Mean	20.0	20.3	22.3	20.2	-0.9	-0.3	2.2	-0.6
		SD	20.7	19.4	20.3	20.0	25.2	25.3	23.9	25.2
		Median	15.0	18.0	19.0	16.0	-1.5	0.0	0.0	-0.5
		(Min, Max)	(0, 106)	(0, 106)	(0, 106)	(0, 106)	(-70, 75)	(-91, 88)	(-84, 88)	(-91, 88)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	20.9	23.6	23.7	22.2	-1.3	2.5	3.0	0.5
		SD	16.8	23.6	23.0	20.2	21.1	24.1	20.9	22.5
		Median	17.0	18.5	18.0	18.0	0.0	0.0	0.0	0.0
		(Min, Max)	(0, 65)	(0, 92)	(0, 92)	(0, 92)	(-61, 47)	(-56, 88)	(-24, 67)	(-61, 88)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	22.4	20.7	23.9	21.6	0.3	-0.3	2.9	0.0
		SD	22.0	17.8	19.7	20.1	31.4	25.2	26.4	28.6
		Median	17.0	17.0	21.0	17.0	0.0	0.0	3.0	0.0
		(Min, Max)	(0, 127)	(0, 74)	(0, 74)	(0, 127)	(-86, 127)	(-84, 56)	(-84, 56)	(-86, 127)
	Week 12	n	99	81	47	180	98	81	47	179
		Mean	22.1	22.6	23.5	22.3	-0.4	1.0	2.2	0.2
		SD	17.8	17.0	17.8	17.4	25.6	28.3	28.4	26.8
		Median	19.0	19.0	19.0	19.0	-1.0	1.0	-1.0	0.0
		(Min, Max)	(0, 82)	(0, 91)	(0, 91)	(0, 91)	(-77, 67)	(-91, 91)	(-77, 91)	(-91, 91)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils (/uL)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	20.0	21.2	22.0	20.5	-2.3	0.8	1.9	-1.0
		SD	16.1	17.1	16.6	16.5	23.0	23.3	23.5	23.1
		Median	19.0	19.0	21.0	19.0	0.0	0.0	2.0	0.0
		(Min, Max)	(0, 78)	(0, 76)	(0, 64)	(0, 78)	(-86, 66)	(-84, 43)	(-84, 43)	(-86, 66)
	Week 20	n	91	67	39	158	90	67	39	157
		Mean	19.2	20.3	19.4	19.7	-3.0	-0.2	-0.5	-1.8
		SD	13.1	18.6	16.9	15.6	23.5	20.5	17.4	22.2
		Median	19.0	16.0	18.0	18.0	1.5	-1.0	0.0	0.0
		(Min, Max)	(0, 67)	(0, 75)	(0, 66)	(0, 75)	(-86, 37)	(-59, 75)	(-59, 43)	(-86, 75)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	21.7	19.3	18.9	20.7	-1.2	-1.4	-0.9	-1.3
		SD	19.3	19.8	13.7	19.5	23.9	22.5	21.0	23.2
		Median	18.0	18.0	18.0	18.0	0.0	-1.0	-1.0	0.0
		(Min, Max)	(0, 99)	(0, 128)	(0, 57)	(0, 128)	(-86, 57)	(-72, 47)	(-72, 47)	(-86, 57)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	21.1	17.9	17.4	19.8	-2.4	-2.1	-2.2	-2.3
		SD	16.9	17.0	18.8	16.9	27.6	25.2	25.8	26.5
		Median	20.0	15.0	14.0	17.5	-1.0	0.0	0.0	0.0
		(Min, Max)	(0, 65)	(0, 79)	(0, 79)	(0, 79)	(-86, 62)	(-90, 79)	(-77, 79)	(-90, 79)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	22.2	19.7	20.3	21.2	0.4	0.0	0.0	0.2
		SD	19.9	15.5	14.5	18.2	28.3	19.3	18.0	24.8
		Median	19.5	18.5	21.0	19.0	0.0	0.5	2.0	0.0
		(Min, Max)	(0, 105)	(0, 65)	(0, 50)	(0, 105)	(-82, 105)	(-48, 50)	(-48, 50)	(-82, 105)
	Week 36	n	77	55	33	132	76	55	33	131
		Mean	20.8	17.8	20.6	19.6	-0.4	-1.4	0.8	-0.8
		SD	18.2	19.7	21.1	18.8	27.0	23.8	21.3	25.7
		Median	17.0	13.0	17.0	17.0	0.5	0.0	2.0	0.0
		(Min, Max)	(0, 101)	(0, 89)	(0, 89)	(0, 101)	(-86, 64)	(-90, 45)	(-65, 43)	(-90, 64)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Basophils (/uL)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	21.1	19.8	20.3	20.5	-1.0	0.0	-0.4	-0.6
		SD	15.5	18.4	16.3	16.7	24.7	26.8	24.9	25.5
		Median	18.0	18.5	19.5	18.0	0.0	4.0	4.0	0.0
		(Min, Max)	(0, 81)	(0, 75)	(0, 68)	(0, 81)	(-72, 59)	(-90, 64)	(-71, 55)	(-90, 64)
	Week 44	n	66	51	29	117	65	51	29	116
		Mean	20.0	17.7	19.2	19.0	-0.5	-2.0	-1.4	-1.1
		SD	13.3	15.5	14.7	14.3	21.1	19.9	20.5	20.5
		Median	20.0	15.0	16.0	17.0	2.0	0.0	-3.0	0.0
		(Min, Max)	(0, 50)	(0, 60)	(0, 55)	(0, 60)	(-86, 41)	(-46, 55)	(-41, 55)	(-86, 55)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	22.9	24.1	26.3	23.4	2.0	4.3	5.6	3.0
		SD	16.3	20.0	21.9	17.9	23.1	25.4	23.6	24.0
		Median	22.0	20.5	21.0	21.0	1.5	5.0	9.0	2.0
		(Min, Max)	(0, 88)	(0, 85)	(0, 85)	(0, 88)	(-72, 75)	(-72, 81)	(-61, 62)	(-72, 81)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	25.5	24.9	26.8	25.2	4.1	4.9	5.7	4.4
		SD	19.9	21.5	21.5	20.5	20.9	25.2	19.9	22.8
		Median	20.5	20.0	25.0	20.0	2.0	3.0	3.5	2.0
		(Min, Max)	(0, 100)	(0, 95)	(0, 93)	(0, 100)	(-55, 86)	(-84, 95)	(-30, 75)	(-84, 95)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Erythrocytes (10^4/uL)	Baseline	n	126	123	84	249				
		Mean	436.8	442.4	445.8	439.6				
		SD	46.8	51.2	52.4	49.0				
		Median	434.0	448.0	451.0	445.0				
		(Min, Max)	(335, 570)	(308, 592)	(308, 592)	(308, 592)				
	Week 2	n	82	78	59	160	82	78	59	160
		Mean	434.6	446.0	448.9	440.2	-3.2	1.2	1.9	-1.1
		SD	42.5	51.9	51.4	47.5	22.8	20.2	20.7	21.6
		Median	442.5	449.0	451.0	445.0	1.0	1.0	1.0	1.0
		(Min, Max)	(328, 513)	(318, 570)	(318, 539)	(318, 570)	(-75, 65)	(-42, 53)	(-42, 53)	(-75, 65)
	Week 4	n	77	70	50	147	77	70	50	147
		Mean	432.8	442.4	445.7	437.3	-5.8	-0.9	-0.2	-3.5
		SD	38.3	48.2	49.0	43.4	24.0	21.1	22.6	22.7
		Median	440.0	447.0	448.5	443.0	-7.0	-1.0	-1.5	-3.0
		(Min, Max)	(346, 511)	(347, 557)	(347, 557)	(346, 557)	(-77, 40)	(-56, 76)	(-56, 76)	(-77, 76)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	439.3	447.5	457.5	443.1	-1.2	-0.2	4.3	-0.8
		SD	41.3	46.9	44.0	44.0	24.8	23.2	24.9	24.0
		Median	445.0	448.0	459.0	447.0	-6.0	1.0	3.5	-2.0
		(Min, Max)	(337, 536)	(351, 553)	(354, 553)	(337, 553)	(-65, 61)	(-49, 98)	(-49, 98)	(-65, 98)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	430.9	442.0	449.1	436.1	-7.2	-0.6	1.3	-4.1
		SD	44.5	50.7	53.5	47.7	26.5	20.9	20.7	24.2
		Median	431.0	436.0	441.0	432.0	-5.0	-2.0	1.0	-3.5
		(Min, Max)	(347, 567)	(344, 568)	(356, 568)	(344, 568)	(-103, 49)	(-45, 58)	(-36, 44)	(-103, 58)
	Week 12	n	99	81	47	180	99	81	47	180
		Mean	432.5	440.7	449.4	436.2	-4.7	-1.4	2.4	-3.2
		SD	48.0	49.2	50.1	48.6	27.9	22.9	20.9	25.7
		Median	437.0	446.0	449.0	440.0	-6.0	-2.0	-1.0	-3.0
		(Min, Max)	(338, 583)	(335, 551)	(351, 551)	(335, 583)	(-102, 71)	(-67, 45)	(-46, 45)	(-102, 71)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Erythrocytes (10^4/uL)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	434.7	444.9	453.1	439.1	-2.5	1.2	4.2	-0.9
		SD	45.2	53.8	56.0	49.2	24.7	31.1	34.6	27.7
		Median	430.0	443.0	449.0	437.0	-2.0	1.0	3.0	-1.0
		(Min, Max)	(348, 546)	(327, 606)	(327, 606)	(327, 606)	(-72, 68)	(-82, 127)	(-82, 127)	(-82, 127)
	Week 20	n	92	67	39	159	92	67	39	159
		Mean	434.4	439.8	448.1	436.7	-3.7	-2.2	0.8	-3.1
		SD	46.0	48.0	46.7	46.8	26.0	24.7	23.4	25.4
		Median	432.0	440.0	446.0	436.0	-1.0	-3.0	0.0	-2.0
		(Min, Max)	(339, 559)	(344, 545)	(354, 539)	(339, 559)	(-63, 58)	(-49, 57)	(-39, 51)	(-63, 58)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	434.5	442.8	452.1	438.0	-4.0	-1.0	4.7	-2.7
		SD	47.0	47.4	45.2	47.2	27.4	27.3	27.5	27.3
		Median	433.5	440.0	449.0	439.0	-3.5	-3.0	5.0	-3.0
		(Min, Max)	(338, 568)	(337, 560)	(338, 560)	(337, 568)	(-75, 73)	(-56, 62)	(-53, 62)	(-75, 73)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	438.9	445.3	451.0	441.6	0.1	-1.6	1.3	-0.6
		SD	45.8	53.1	54.6	48.9	28.6	29.1	29.5	28.7
		Median	437.0	447.0	453.0	444.5	-1.0	-1.0	-1.0	-1.0
		(Min, Max)	(344, 571)	(295, 554)	(295, 554)	(295, 571)	(-86, 69)	(-84, 57)	(-84, 57)	(-86, 69)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	442.3	447.2	453.5	444.4	3.0	-2.0	0.7	1.0
		SD	48.0	50.9	52.3	49.1	26.3	26.3	26.9	26.3
		Median	448.0	446.5	454.0	447.5	1.0	-3.0	-3.0	-1.5
		(Min, Max)	(347, 550)	(325, 554)	(325, 554)	(325, 554)	(-49, 75)	(-56, 51)	(-56, 48)	(-56, 75)
	Week 36	n	77	55	33	132	77	55	33	132
		Mean	444.5	442.6	448.4	443.7	4.2	-3.6	-1.8	0.9
		SD	49.5	47.5	48.0	48.5	30.9	27.6	27.1	29.7
		Median	448.0	444.0	448.0	446.0	5.0	0.0	2.0	3.0
		(Min, Max)	(346, 546)	(338, 550)	(338, 537)	(338, 550)	(-53, 111)	(-71, 75)	(-71, 75)	(-71, 111)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Erythrocytes (10^4/uL)	Week 40	n	71	54	32	125	71	54	32	125
		Mean	444.4	446.9	458.1	445.5	2.9	-3.5	0.6	0.1
		SD	49.3	46.6	44.1	48.0	29.8	26.4	25.3	28.4
		Median	449.0	455.0	464.5	454.0	1.0	-5.5	1.5	-2.0
		(Min, Max)	(346, 544)	(344, 542)	(354, 542)	(344, 544)	(-71, 75)	(-73, 50)	(-73, 47)	(-73, 75)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	445.0	446.9	455.8	445.8	2.7	-2.4	-0.5	0.5
		SD	50.7	46.5	45.0	48.7	30.4	30.1	32.0	30.2
		Median	447.0	450.0	461.0	448.0	-2.0	2.0	5.0	-0.5
		(Min, Max)	(347, 542)	(343, 546)	(345, 534)	(343, 546)	(-64, 77)	(-99, 38)	(-99, 38)	(-99, 77)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	443.2	449.5	457.0	445.9	0.9	0.2	0.6	0.6
		SD	50.2	51.9	50.2	50.8	30.6	30.5	32.4	30.5
		Median	453.0	450.0	464.0	450.0	2.0	2.5	2.0	2.0
		(Min, Max)	(346, 557)	(326, 563)	(326, 538)	(326, 563)	(-74, 71)	(-73, 83)	(-73, 83)	(-74, 83)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	445.3	447.2	453.7	446.1	2.2	-2.1	-2.9	0.4
		SD	54.5	47.3	45.0	51.3	30.5	26.0	29.2	28.6
		Median	449.0	449.0	457.0	449.0	-1.0	-3.0	-2.5	-1.0
		(Min, Max)	(331, 567)	(336, 555)	(338, 527)	(331, 567)	(-79, 81)	(-78, 50)	(-78, 50)	(-79, 81)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hemoglobin (g/dL)	Baseline	n	126	123	84	249				
		Mean	13.45	13.59	13.67	13.52				
		SD	1.37	1.55	1.60	1.46				
		Median	13.40	13.60	13.60	13.50				
		(Min, Max)	(10.2, 17.0)	(10.3, 19.3)	(10.3, 19.3)	(10.2, 19.3)				
	Week 2	n	82	78	59	160	82	78	59	160
		Mean	13.36	13.64	13.67	13.50	-0.07	0.02	0.03	-0.03
		SD	1.35	1.56	1.58	1.45	0.67	0.60	0.61	0.63
		Median	13.40	13.60	13.70	13.50	0.00	-0.05	0.00	0.00
		(Min, Max)	(10.3, 15.7)	(10.1, 17.1)	(10.1, 16.6)	(10.1, 17.1)	(-1.7, 2.1)	(-1.2, 1.7)	(-1.2, 1.7)	(-1.7, 2.1)
	Week 4	n	77	70	50	147	77	70	50	147
		Mean	13.29	13.53	13.56	13.41	-0.17	-0.05	-0.04	-0.12
		SD	1.36	1.45	1.53	1.41	0.67	0.67	0.68	0.67
		Median	13.40	13.55	13.60	13.50	-0.20	-0.10	-0.10	-0.10
		(Min, Max)	(9.8, 16.1)	(10.8, 16.5)	(10.8, 16.3)	(9.8, 16.5)	(-2.2, 1.3)	(-1.7, 2.3)	(-1.5, 2.3)	(-2.2, 2.3)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	13.37	13.72	13.93	13.53	-0.07	-0.01	0.11	-0.04
		SD	1.41	1.44	1.41	1.43	0.69	0.73	0.80	0.71
		Median	13.40	13.60	14.05	13.50	-0.10	-0.10	0.10	-0.10
		(Min, Max)	(9.8, 16.6)	(10.8, 16.6)	(10.8, 16.6)	(9.8, 16.6)	(-1.5, 1.9)	(-1.4, 2.9)	(-1.4, 2.9)	(-1.5, 2.9)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	13.20	13.53	13.70	13.36	-0.25	-0.03	0.02	-0.15
		SD	1.41	1.54	1.62	1.48	0.73	0.67	0.68	0.71
		Median	13.10	13.40	13.50	13.30	-0.20	-0.10	0.00	-0.10
		(Min, Max)	(9.7, 16.7)	(10.4, 18.7)	(10.9, 18.7)	(9.7, 18.7)	(-2.4, 1.8)	(-1.4, 1.8)	(-1.3, 1.8)	(-2.4, 1.8)
	Week 12	n	99	81	47	180	99	81	47	180
		Mean	13.23	13.45	13.61	13.33	-0.21	-0.12	0.00	-0.17
		SD	1.42	1.42	1.43	1.42	0.74	0.70	0.62	0.72
		Median	13.10	13.40	13.60	13.20	-0.20	-0.20	-0.10	-0.20
		(Min, Max)	(10.3, 17.2)	(11.0, 16.5)	(11.1, 16.4)	(10.3, 17.2)	(-2.2, 2.1)	(-1.7, 1.8)	(-1.4, 1.8)	(-2.2, 2.1)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hemoglobin (g/dL)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	13.25	13.58	13.72	13.39	-0.19	-0.02	0.10	-0.12
		SD	1.43	1.54	1.65	1.49	0.73	0.86	0.93	0.79
		Median	13.15	13.50	13.60	13.30	-0.25	-0.10	0.00	-0.20
		(Min, Max)	(9.5, 17.1)	(10.9, 18.0)	(11.0, 18.0)	(9.5, 18.0)	(-2.6, 2.1)	(-2.1, 3.3)	(-2.1, 3.3)	(-2.6, 3.3)
	Week 20	n	92	67	39	159	92	67	39	159
		Mean	13.24	13.41	13.57	13.31	-0.22	-0.14	0.00	-0.19
		SD	1.37	1.39	1.37	1.38	0.75	0.72	0.66	0.74
		Median	13.25	13.10	13.60	13.20	-0.20	-0.10	0.10	-0.10
		(Min, Max)	(10.1, 16.9)	(11.0, 16.9)	(11.0, 16.9)	(10.1, 16.9)	(-1.9, 1.8)	(-1.4, 1.4)	(-1.4, 1.3)	(-1.9, 1.8)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	13.27	13.48	13.67	13.36	-0.20	-0.12	0.10	-0.16
		SD	1.44	1.38	1.38	1.41	0.80	0.81	0.77	0.80
		Median	13.30	13.40	13.50	13.30	-0.20	-0.30	0.00	-0.30
		(Min, Max)	(9.4, 16.9)	(10.8, 17.2)	(10.8, 17.2)	(9.4, 17.2)	(-2.2, 2.4)	(-1.7, 1.7)	(-1.0, 1.7)	(-2.2, 2.4)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	13.34	13.56	13.65	13.43	-0.14	-0.12	-0.01	-0.13
		SD	1.39	1.52	1.60	1.44	0.87	0.83	0.81	0.85
		Median	13.30	13.60	13.70	13.40	-0.20	-0.10	0.00	-0.10
		(Min, Max)	(9.6, 16.7)	(10.0, 17.6)	(10.0, 17.6)	(9.6, 17.6)	(-2.7, 2.3)	(-2.5, 1.6)	(-2.5, 1.6)	(-2.7, 2.3)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	13.46	13.59	13.72	13.52	-0.04	-0.16	-0.04	-0.09
		SD	1.46	1.46	1.58	1.46	0.81	0.82	0.79	0.81
		Median	13.65	13.45	13.80	13.60	-0.10	-0.20	-0.10	-0.10
		(Min, Max)	(9.9, 17.2)	(10.8, 17.1)	(10.8, 17.1)	(9.9, 17.2)	(-1.5, 2.6)	(-1.8, 1.5)	(-1.6, 1.5)	(-1.8, 2.6)
	Week 36	n	77	55	33	132	77	55	33	132
		Mean	13.50	13.40	13.49	13.46	-0.03	-0.24	-0.17	-0.12
		SD	1.47	1.40	1.46	1.44	0.93	0.83	0.81	0.89
		Median	13.50	13.40	13.80	13.50	0.00	0.00	0.00	0.00
		(Min, Max)	(10.3, 17.1)	(11.0, 16.9)	(11.0, 16.7)	(10.3, 17.1)	(-1.9, 3.1)	(-2.0, 1.5)	(-2.0, 1.3)	(-2.0, 3.1)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hemoglobin (g/dL)	Week 40	n	71	54	32	125	71	54	32	125
		Mean	13.54	13.48	13.68	13.51	-0.08	-0.27	-0.16	-0.16
		SD	1.44	1.42	1.46	1.42	0.87	0.85	0.88	0.86
		Median	13.60	13.50	13.70	13.50	-0.10	-0.40	-0.20	-0.20
		(Min, Max)	(10.3, 16.9)	(10.2, 16.6)	(10.2, 16.5)	(10.2, 16.9)	(-2.0, 2.8)	(-2.8, 1.7)	(-2.8, 1.7)	(-2.8, 2.8)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	13.55	13.51	13.72	13.54	-0.06	-0.21	-0.09	-0.12
		SD	1.46	1.33	1.42	1.40	0.88	0.87	0.96	0.87
		Median	13.50	13.70	13.90	13.60	-0.10	-0.20	0.20	-0.20
		(Min, Max)	(10.5, 16.9)	(10.4, 16.5)	(10.4, 16.3)	(10.4, 16.9)	(-1.9, 2.6)	(-3.0, 1.2)	(-3.0, 1.2)	(-3.0, 2.6)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	13.56	13.56	13.74	13.56	-0.05	-0.16	-0.07	-0.10
		SD	1.46	1.50	1.51	1.47	0.88	0.96	1.02	0.91
		Median	13.80	13.75	13.90	13.80	0.00	-0.15	-0.20	-0.10
		(Min, Max)	(10.7, 16.9)	(10.0, 17.0)	(10.0, 16.4)	(10.0, 17.0)	(-2.2, 2.6)	(-2.1, 2.0)	(-2.1, 2.0)	(-2.2, 2.6)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	13.60	13.48	13.63	13.55	-0.04	-0.22	-0.16	-0.12
		SD	1.54	1.44	1.49	1.49	0.90	0.88	0.96	0.89
		Median	13.70	13.80	13.95	13.70	-0.10	-0.30	-0.25	-0.20
		(Min, Max)	(10.0, 17.3)	(11.0, 17.3)	(11.0, 17.3)	(10.0, 17.3)	(-2.9, 1.9)	(-2.6, 1.6)	(-2.6, 1.6)	(-2.9, 1.9)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hematocrit (%)	Baseline	n	126	123	84	249				
		Mean	40.10	40.46	40.69	40.28				
		SD	3.92	4.47	4.64	4.19				
		Median	39.60	40.50	40.75	40.00				
		(Min, Max)	(32.3, 50.4)	(29.5, 57.1)	(29.5, 57.1)	(29.5, 57.1)				
	Week 2	n	82	78	59	160	82	78	59	160
		Mean	39.78	40.68	40.78	40.22	-0.26	0.10	0.15	-0.09
		SD	3.79	4.55	4.62	4.19	2.10	1.86	1.91	1.99
		Median	39.75	40.55	40.30	40.10	0.00	0.00	0.00	0.00
		(Min, Max)	(31.9, 46.8)	(30.5, 51.6)	(30.5, 49.4)	(30.5, 51.6)	(-6.2, 6.8)	(-3.9, 5.0)	(-3.9, 5.0)	(-6.2, 6.8)
	Week 4	n	77	70	50	147	77	70	50	147
		Mean	39.61	40.37	40.46	39.97	-0.53	-0.11	-0.08	-0.33
		SD	3.74	4.15	4.30	3.94	2.19	1.98	2.12	2.10
		Median	39.80	40.85	40.85	40.40	-0.50	-0.15	-0.10	-0.30
		(Min, Max)	(31.0, 48.0)	(32.3, 50.3)	(32.3, 47.4)	(31.0, 50.3)	(-7.3, 4.3)	(-5.1, 6.9)	(-5.1, 6.9)	(-7.3, 6.9)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	40.00	40.95	41.60	40.44	-0.14	0.02	0.37	-0.06
		SD	4.00	4.02	3.94	4.02	2.25	2.18	2.38	2.21
		Median	40.20	40.60	42.00	40.40	-0.70	0.15	0.20	-0.20
		(Min, Max)	(31.0, 50.7)	(33.1, 49.0)	(33.2, 49.0)	(31.0, 50.7)	(-5.9, 5.5)	(-4.2, 9.3)	(-4.2, 9.3)	(-5.9, 9.3)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	39.43	40.42	40.92	39.90	-0.67	-0.05	0.07	-0.38
		SD	4.03	4.31	4.53	4.18	2.31	1.93	1.92	2.16
		Median	39.20	40.00	40.50	39.55	-0.30	0.00	0.30	-0.20
		(Min, Max)	(30.0, 50.4)	(32.1, 54.3)	(32.9, 54.3)	(30.0, 54.3)	(-6.6, 4.3)	(-4.1, 4.6)	(-3.7, 4.6)	(-6.6, 4.6)
	Week 12	n	99	81	47	180	99	81	47	180
		Mean	39.58	40.33	40.87	39.92	-0.49	-0.15	0.14	-0.34
		SD	4.13	4.11	4.19	4.12	2.46	2.15	1.89	2.32
		Median	39.10	40.20	40.70	39.75	-0.60	-0.20	-0.20	-0.50
		(Min, Max)	(31.9, 51.4)	(33.3, 50.4)	(33.8, 50.4)	(31.9, 51.4)	(-7.7, 7.6)	(-5.2, 5.6)	(-4.2, 5.0)	(-7.7, 7.6)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hematocrit (%)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	39.76	40.66	41.12	40.15	-0.33	0.09	0.35	-0.15
		SD	4.04	4.56	4.86	4.29	2.36	2.63	2.85	2.49
		Median	39.15	40.20	40.80	39.80	-0.35	-0.20	0.00	-0.20
		(Min, Max)	(30.7, 49.6)	(32.7, 54.3)	(32.7, 54.3)	(30.7, 54.3)	(-6.7, 7.5)	(-6.5, 10.7)	(-6.5, 10.7)	(-6.7, 10.7)
	Week 20	n	92	67	39	159	92	67	39	159
		Mean	39.67	40.15	40.68	39.87	-0.49	-0.28	0.08	-0.41
		SD	3.83	3.97	3.89	3.88	2.38	2.12	1.90	2.27
		Median	39.30	39.70	40.70	39.60	-0.30	-0.10	0.20	-0.30
		(Min, Max)	(32.8, 49.2)	(33.3, 50.2)	(34.0, 50.2)	(32.8, 50.2)	(-6.1, 5.8)	(-4.4, 4.8)	(-3.7, 3.7)	(-6.1, 5.8)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	39.78	40.43	41.12	40.06	-0.41	-0.14	0.52	-0.30
		SD	4.08	4.09	4.04	4.09	2.52	2.36	2.27	2.45
		Median	39.70	40.20	40.80	39.80	-0.30	-0.40	-0.10	-0.40
		(Min, Max)	(30.3, 50.1)	(33.1, 51.9)	(33.5, 51.9)	(30.3, 51.9)	(-6.7, 7.5)	(-5.5, 5.1)	(-3.6, 5.1)	(-6.7, 7.5)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	40.14	40.69	41.02	40.37	-0.06	-0.14	0.18	-0.09
		SD	4.01	4.55	4.67	4.24	2.64	2.51	2.47	2.58
		Median	39.80	40.40	41.50	40.25	0.00	-0.20	-0.20	-0.20
		(Min, Max)	(30.6, 50.3)	(29.9, 52.4)	(29.9, 52.4)	(29.9, 52.4)	(-8.1, 6.1)	(-7.2, 5.3)	(-7.2, 5.3)	(-8.1, 6.1)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	40.40	40.87	41.21	40.60	0.17	-0.15	0.08	0.04
		SD	4.29	4.50	4.69	4.37	2.54	2.29	2.27	2.43
		Median	40.60	40.60	41.30	40.60	-0.10	0.00	0.00	-0.10
		(Min, Max)	(30.9, 52.2)	(32.0, 51.4)	(32.0, 51.4)	(30.9, 52.2)	(-4.7, 7.8)	(-4.8, 4.4)	(-4.6, 4.0)	(-4.8, 7.8)
	Week 36	n	77	55	33	132	77	55	33	132
		Mean	40.52	40.48	40.70	40.51	0.23	-0.25	-0.14	0.03
		SD	4.29	4.12	4.12	4.20	2.84	2.41	2.31	2.67
		Median	40.40	40.40	41.20	40.40	0.20	-0.10	0.10	0.20
		(Min, Max)	(32.1, 50.1)	(33.6, 51.6)	(33.6, 50.2)	(32.1, 51.6)	(-5.3, 11.0)	(-6.0, 5.2)	(-6.0, 5.2)	(-6.0, 11.0)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Hematocrit (%)	Week 40	n	71	54	32	125	71	54	32	125
		Mean	40.67	40.80	41.50	40.72	0.16	-0.26	0.10	-0.02
		SD	4.14	4.38	4.33	4.23	2.66	2.44	2.48	2.56
		Median	40.40	40.45	41.70	40.40	0.20	-0.50	-0.15	-0.20
		(Min, Max)	(31.4, 50.9)	(30.5, 51.1)	(30.5, 50.6)	(30.5, 51.1)	(-4.3, 7.2)	(-7.8, 5.2)	(-7.8, 5.2)	(-7.8, 7.2)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	40.72	40.71	41.29	40.71	0.21	-0.27	0.00	0.00
		SD	4.30	3.88	3.92	4.11	2.69	2.56	2.81	2.63
		Median	40.70	41.00	42.00	40.95	-0.10	-0.30	0.50	-0.15
		(Min, Max)	(31.6, 50.7)	(31.9, 49.7)	(31.9, 49.1)	(31.6, 50.7)	(-5.4, 7.6)	(-8.8, 4.1)	(-8.8, 4.1)	(-8.8, 7.6)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	40.61	40.97	41.42	40.76	0.10	-0.02	0.12	0.05
		SD	4.29	4.39	4.27	4.32	2.69	2.89	3.08	2.77
		Median	40.80	41.35	41.90	41.10	-0.10	0.20	0.20	0.10
		(Min, Max)	(32.8, 50.8)	(30.1, 52.1)	(30.1, 49.1)	(30.1, 52.1)	(-6.1, 6.7)	(-7.1, 7.0)	(-7.1, 7.0)	(-7.1, 7.0)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	40.82	40.73	41.15	40.78	0.24	-0.22	-0.08	0.05
		SD	4.64	4.13	4.11	4.41	2.75	2.49	2.60	2.64
		Median	41.15	40.90	42.05	41.10	0.20	-0.60	-0.50	0.00
		(Min, Max)	(30.6, 51.0)	(33.1, 51.4)	(33.3, 51.4)	(30.6, 51.4)	(-8.0, 6.2)	(-6.6, 4.7)	(-6.6, 4.7)	(-8.0, 6.2)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Platelets (10^4/uL)	Baseline	n	125	122	83	247				
		Mean	24.38	24.78	24.67	24.58				
		SD	6.08	6.06	6.32	6.06				
		Median	24.10	24.25	24.10	24.10				
		(Min, Max)	(14.1, 46.3)	(11.9, 42.1)	(11.9, 42.1)	(11.9, 46.3)				
	Week 2	n	80	78	59	158	79	77	58	156
		Mean	24.21	24.28	23.96	24.25	-0.25	-0.38	-0.39	-0.32
		SD	6.72	6.04	5.94	6.37	2.65	3.27	3.14	2.96
		Median	22.75	24.25	23.80	23.45	-0.10	0.00	0.15	-0.10
		(Min, Max)	(12.2, 49.4)	(12.1, 41.0)	(12.1, 40.2)	(12.1, 49.4)	(-10.9, 7.9)	(-10.3, 8.4)	(-10.3, 8.4)	(-10.9, 8.4)
	Week 4	n	77	68	49	145	76	68	49	144
		Mean	24.18	25.34	24.55	24.72	-0.11	0.55	0.12	0.20
		SD	6.61	6.18	5.85	6.42	3.11	4.39	3.79	3.77
		Median	23.00	25.05	24.30	24.00	0.35	0.55	0.20	0.40
		(Min, Max)	(11.5, 43.3)	(10.3, 44.0)	(10.3, 36.8)	(10.3, 44.0)	(-14.3, 6.4)	(-8.0, 18.7)	(-7.3, 13.0)	(-14.3, 18.7)
	Week 6	n	69	59	40	128	68	58	39	126
		Mean	25.02	25.11	24.49	25.06	0.61	0.45	0.12	0.54
		SD	6.82	6.02	5.65	6.44	3.37	3.48	3.61	3.41
		Median	23.30	24.20	24.00	23.65	0.70	0.60	0.00	0.60
		(Min, Max)	(12.8, 45.1)	(12.0, 44.3)	(12.0, 35.9)	(12.0, 45.1)	(-8.4, 11.5)	(-7.8, 13.1)	(-7.8, 13.1)	(-8.4, 13.1)
	Week 8	n	104	93	55	197	103	92	54	195
		Mean	23.94	24.96	24.60	24.42	-0.40	-0.33	-0.78	-0.37
		SD	6.19	5.94	5.76	6.08	2.80	3.83	4.12	3.32
		Median	23.10	24.60	25.10	23.80	-0.30	-0.15	-0.40	-0.20
		(Min, Max)	(12.3, 41.5)	(11.7, 41.1)	(11.7, 38.7)	(11.7, 41.5)	(-8.4, 9.5)	(-12.4, 12.5)	(-12.4, 12.5)	(-12.4, 12.5)
	Week 12	n	97	80	47	177	96	79	46	175
		Mean	23.85	25.45	25.30	24.57	-0.10	-0.15	-0.37	-0.13
		SD	5.98	6.39	6.32	6.20	2.91	3.47	3.53	3.16
		Median	23.10	24.85	25.40	24.20	-0.15	-0.30	-0.55	-0.20
		(Min, Max)	(11.8, 42.1)	(11.9, 42.3)	(11.9, 42.0)	(11.8, 42.3)	(-7.9, 7.9)	(-9.0, 8.2)	(-9.0, 8.2)	(-9.0, 8.2)

表 2.7.4.7－91 各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Platelets (10^4/uL)	Week 16	n	92	71	42	163	91	70	41	161
		Mean	24.45	25.70	25.95	25.00	0.47	0.06	0.04	0.29
		SD	6.55	6.35	6.33	6.48	3.98	3.49	3.55	3.77
		Median	23.90	24.80	25.20	24.40	0.50	-0.20	-0.20	0.30
		(Min, Max)	(12.2, 49.4)	(12.5, 43.8)	(12.5, 39.9)	(12.2, 49.4)	(-11.4, 19.5)	(-9.7, 8.0)	(-9.7, 8.0)	(-11.4, 19.5)
	Week 20	n	92	65	39	157	91	64	38	155
		Mean	24.38	25.70	26.14	24.92	0.26	-0.25	-0.43	0.05
		SD	6.44	6.24	6.50	6.37	3.53	3.92	4.58	3.69
		Median	23.75	25.00	25.00	24.10	0.10	0.20	0.40	0.20
		(Min, Max)	(11.7, 44.2)	(12.4, 44.4)	(12.4, 44.4)	(11.7, 44.4)	(-9.7, 14.3)	(-12.0, 8.5)	(-12.0, 8.5)	(-12.0, 14.3)
	Week 24	n	85	65	39	150	84	64	38	148
		Mean	24.32	25.88	26.10	25.00	0.32	-0.22	-0.58	0.09
		SD	7.23	5.37	5.68	6.51	5.37	4.57	4.84	5.03
		Median	23.20	25.40	24.90	23.85	0.00	0.00	-0.30	0.00
		(Min, Max)	(12.4, 56.7)	(16.0, 38.7)	(16.0, 38.7)	(12.4, 56.7)	(-11.8, 30.8)	(-13.6, 15.5)	(-13.6, 10.7)	(-13.6, 30.8)
	Week 28	n	83	58	35	141	82	57	34	139
		Mean	24.40	25.63	25.24	24.91	0.35	-0.55	-1.37	-0.02
		SD	6.76	6.00	6.13	6.47	4.54	4.52	4.45	4.54
		Median	23.60	24.60	23.90	23.70	0.35	0.00	-0.60	0.20
		(Min, Max)	(11.3, 54.3)	(12.2, 40.4)	(12.2, 39.4)	(11.3, 54.3)	(-13.9, 17.4)	(-11.2, 15.3)	(-11.2, 8.5)	(-13.9, 17.4)
	Week 32	n	80	58	35	138	79	57	34	136
		Mean	24.21	26.47	26.47	25.16	0.18	0.18	-0.20	0.18
		SD	5.95	6.45	6.62	6.24	3.60	4.77	5.22	4.12
		Median	23.20	25.10	25.20	24.35	0.50	0.00	-0.60	0.40
		(Min, Max)	(10.7, 44.7)	(12.9, 44.5)	(12.9, 44.5)	(10.7, 44.7)	(-9.7, 8.3)	(-9.3, 15.3)	(-9.3, 15.3)	(-9.7, 15.3)
	Week 36	n	77	54	33	131	76	53	32	129
		Mean	23.76	26.64	26.32	24.95	0.06	0.40	-0.18	0.20
		SD	5.32	6.36	6.49	5.92	3.95	4.86	5.24	4.33
		Median	23.50	25.60	25.80	24.50	-0.20	-0.20	-0.40	-0.20
		(Min, Max)	(11.0, 46.1)	(13.3, 42.3)	(13.3, 42.3)	(11.0, 46.1)	(-10.3, 17.3)	(-11.2, 16.5)	(-11.2, 16.5)	(-11.2, 17.3)

表 2.7.4.7－91　各評価時点での臨床検査値及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Platelets (10^4/uL)	Week 40	n	70	54	32	124	69	53	31	122
		Mean	23.23	26.92	26.89	24.84	0.10	0.36	-0.21	0.21
		SD	4.68	6.75	6.72	5.94	3.18	4.74	4.01	3.92
		Median	22.40	25.40	25.20	24.15	0.10	0.40	0.50	0.30
		(Min, Max)	(12.8, 34.2)	(15.0, 47.0)	(15.0, 41.8)	(12.8, 47.0)	(-7.6, 6.2)	(-7.9, 22.2)	(-7.9, 9.4)	(-7.9, 22.2)
	Week 44	n	66	51	29	117	65	50	28	115
		Mean	23.09	27.16	27.07	24.86	0.24	0.43	-0.39	0.32
		SD	4.87	6.70	6.60	6.06	2.99	4.43	3.55	3.67
		Median	22.35	26.10	26.10	24.00	-0.30	-0.20	-0.55	-0.30
		(Min, Max)	(13.0, 35.8)	(13.4, 43.4)	(13.4, 39.8)	(13.0, 43.4)	(-7.7, 7.9)	(-6.5, 18.6)	(-6.3, 9.3)	(-7.7, 18.6)
	Week 48	n	65	50	29	115	64	49	28	113
		Mean	23.58	26.45	27.09	24.83	0.48	-0.18	-0.43	0.19
		SD	5.60	6.04	6.80	5.94	3.86	3.83	4.55	3.85
		Median	22.80	25.20	25.30	24.10	-0.05	-0.20	-0.70	-0.10
		(Min, Max)	(11.8, 44.8)	(15.2, 42.7)	(15.2, 42.7)	(11.8, 44.8)	(-8.3, 16.8)	(-8.0, 8.2)	(-8.0, 8.2)	(-8.3, 16.8)
	Week 52	n	65	48	28	113	64	47	27	111
		Mean	23.38	26.46	26.74	24.69	0.47	-0.19	-0.69	0.19
		SD	4.96	6.26	6.77	5.73	3.12	4.12	4.39	3.57
		Median	23.10	25.45	25.25	24.50	0.50	-0.20	-0.70	0.20
		(Min, Max)	(13.5, 35.4)	(14.7, 43.2)	(14.7, 42.9)	(13.5, 43.2)	(-7.5, 10.5)	(-9.6, 10.0)	(-9.6, 10.0)	(-9.6, 10.5)

5.3.5.1－1 Table 14.3.2.2.1 より引用

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）

Category: Hematology

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Absolute Neutrophil Count <1.5 × 1000/uL	Week 2	n/N (%)	0/5	2/97 (2.1)	0/105	0/25	2/232 (0.9)	3/167 (1.8)
	Week 4	n/N (%)	0/4	1/71 (1.4)	1/99 (1.0)	0/0	2/174 (1.1)	2/111 (1.8)
	Week 6	n/N (%)	0/4	1/92 (1.1)	0/95	2/21 (9.5)	3/212 (1.4)	3/156 (1.9)
	Worst Post-Baseline Decrease	n/N (%)	0/5	2/103 (1.9)	1/110 (0.9)	2/25 (8.0)	5/243 (2.1)	6/171 (3.5)
	Last on Treatment	n/N (%)	0/5	1/103 (1.0)	1/110 (0.9)	2/25 (8.0)	4/243 (1.6)	3/171 (1.8)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Hematology

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
White Blood Cell Count <=2.8 × 1000/uL	Week 2	n/N (%)	0/5	0/97	0/105	0/25	0/232	2/167 (1.2)
	Week 4	n/N (%)	0/4	0/71	1/99 (1.0)	0/0	1/174 (0.6)	1/111 (0.9)
	Week 6	n/N (%)	0/4	0/92	0/95	0/21	0/212	1/156 (0.6)
	Worst Post-Baseline Decrease	n/N (%)	0/5	0/103	1/110 (0.9)	0/25	1/243 (0.4)	4/171 (2.3)
	Last on Treatment	n/N (%)	0/5	0/103	0/110	0/25	0/243	1/171 (0.6)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
ALT >3 x ULN	Week 2	n/N (%)	0/5	0/104	0/108	0/25	0/242	0/170
	Week 4	n/N (%)	0/4	0/72	0/105	0/0	0/181	0/115
	Week 6	n/N (%)	0/4	0/96	1/101 (1.0)	0/21	1/222 (0.5)	1/158 (0.6)
	Worst Post-Baseline Increase	n/N (%)	0/5	0/104	1/110 (0.9)	0/25	1/244 (0.4)	1/171 (0.6)
	Last on Treatment	n/N (%)	0/5	0/104	1/110 (0.9)	0/25	1/244 (0.4)	1/171 (0.6)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
AST >3 x ULN	Week 2	n/N (%)	0/5	0/104	0/108	0/25	0/242	0/170
	Week 4	n/N (%)	0/4	0/72	1/105 (1.0)	0/0	1/181 (0.6)	0/115
	Week 6	n/N (%)	0/4	0/96	1/101 (1.0)	0/21	1/222 (0.5)	1/158 (0.6)
	Worst Post-Baseline Increase	n/N (%)	0/5	0/104	2/110 (1.8)	0/25	2/244 (0.8)	1/171 (0.6)
	Last on Treatment	n/N (%)	0/5	0/104	1/110 (0.9)	0/25	1/244 (0.4)	1/171 (0.6)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Total Bilirubin >1.5 x ULN	Week 2	n/N (%)	0/5	0/104	0/108	0/25	0/242	0/170
	Week 4	n/N (%)	0/4	0/72	0/105	0/0	0/181	0/115
	Week 6	n/N (%)	0/4	0/96	0/101	0/21	0/222	0/158
	Worst Post-Baseline Increase	n/N (%)	0/5	0/104	0/110	0/25	0/244	0/171
	Last on Treatment	n/N (%)	0/5	0/104	0/110	0/25	0/244	0/171

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
GGT >3 x ULN	Week 2	n/N (%)	0/5	0/104	1/108 (0.9)	1/25 (4.0)	2/242 (0.8)	1/170 (0.6)
	Week 4	n/N (%)	0/4	0/72	3/105 (2.9)	0/0	3/181 (1.7)	1/115 (0.9)
	Week 6	n/N (%)	0/4	0/96	4/101 (4.0)	0/21	4/222 (1.8)	1/158 (0.6)
	Worst Post-Baseline Increase	n/N (%)	0/5	0/104	5/110 (4.5)	1/25 (4.0)	6/244 (2.5)	1/171 (0.6)
	Last on Treatment	n/N (%)	0/5	0/104	4/110 (3.6)	0/25	4/244 (1.6)	1/171 (0.6)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Kidney Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
BUN >30 mg/dL (>10.71 mmol/L)	Week 2	n/N (%)	0/5	1/104 (1.0)	0/108	0/25	1/242 (0.4)	3/170 (1.8)
	Week 4	n/N (%)	0/4	0/72	0/105	0/0	0/181	2/115 (1.7)
	Week 6	n/N (%)	0/4	0/96	1/101 (1.0)	1/21 (4.8)	2/222 (0.9)	1/158 (0.6)
	Worst Post-Baseline Increase	n/N (%)	0/5	1/104 (1.0)	1/110 (0.9)	1/25 (4.0)	3/244 (1.2)	4/171 (2.3)
	Last on Treatment	n/N (%)	0/5	0/104	1/110 (0.9)	1/25 (4.0)	2/244 (0.8)	1/171 (0.6)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Kidney Function

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Creatinine >1.5 x Baseline value, or >1.5 x ULN	Week 2	n/N (%)	0/5	1/104 (1.0)	1/108 (0.9)	0/25	2/242 (0.8)	1/170 (0.6)
	Week 4	n/N (%)	0/4	1/72 (1.4)	1/105 (1.0)	0/0	2/181 (1.1)	0/115
	Week 6	n/N (%)	0/4	1/96 (1.0)	2/101 (2.0)	0/21	3/222 (1.4)	0/158
	Worst Post-Baseline Increase	n/N (%)	0/5	2/104 (1.9)	3/110 (2.7)	0/25	5/244 (2.0)	1/171 (0.6)
	Last on Treatment	n/N (%)	0/5	1/104 (1.0)	2/110 (1.8)	0/25	3/244 (1.2)	0/171

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－92　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Category: Other Chemistry

Parameter (PCS Threshold)	Visit	Statistic [b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Creatine Kinase >5 x ULN	Week 2	n/N (%)	0/5	0/104	0/108	0/25	0/242	0/170
	Week 4	n/N (%)	0/4	0/72	1/105 (1.0)	0/0	1/181 (0.6)	0/115
	Week 6	n/N (%)	0/4	0/96	0/101	0/21	0/222	0/158
	Worst Post-Baseline Increase	n/N (%)	0/5	0/104	1/110 (0.9)	0/25	1/244 (0.4)	0/171
	Last on Treatment	n/N (%)	0/5	0/104	0/110	0/25	0/244	0/171

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

5.3.5.3－2 Table 1.4.3.1より引用

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）

Category: Hematology

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Absolute Neutrophil Count <1.5 × 1000/uL	Week 2	n/N (%)	2/107 (1.9)	0/71	0/66	2/178 (1.1)
	Week 4	n/N (%)	3/99 (3.0)	3/179 (1.7)	3/163 (1.8)	6/278 (2.2)
	Week 6	n/N (%)	3/98 (3.1)	0/62	0/58	3/160 (1.9)
	Week 12	n/N (%)	0/130	2/188 (1.1)	2/171 (1.2)	2/318 (0.6)
	Week 24	n/N (%)	1/91 (1.1)	0/151	0/142	1/242 (0.4)
	Week 36	n/N (%)	1/73 (1.4)	0/120	0/113	1/193 (0.5)
	Week 48	n/N (%)	1/67 (1.5)	0/85	0/81	1/152 (0.7)
	Week 52	n/N (%)	3/66 (4.5)	0/81	0/77	3/147 (2.0)
	Worst Post-Baseline Decrease	n/N (%)	9/183 (4.9)	6/223 (2.7)	6/203 (3.0)	15/406 (3.7)
	Last on Treatment	n/N (%)	2/183 (1.1)	0/223	0/203	2/406 (0.5)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase; ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Hematology

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
White Blood Cell Count <=2.8 x 1000/uL	Week 2	n/N (%)	0/107	0/71	0/66	0/178
	Week 4	n/N (%)	1/99 (1.0)	2/179 (1.1)	2/163 (1.2)	3/278 (1.1)
	Week 6	n/N (%)	0/98	0/62	0/58	0/160
	Week 12	n/N (%)	0/130	0/188	0/171	0/318
	Week 24	n/N (%)	0/91	0/151	0/142	0/242
	Week 36	n/N (%)	0/73	0/120	0/113	0/193
	Week 48	n/N (%)	0/67	0/85	0/81	0/152
	Week 52	n/N (%)	0/66	0/81	0/77	0/147
	Worst Post-Baseline Decrease	n/N (%)	2/183 (1.1)	2/223 (0.9)	2/203 (1.0)	4/406 (1.0)
	Last on Treatment	n/N (%)	0/183	0/223	0/203	0/406

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
ALT >3 x ULN	Week 2	n/N (%)	0/113	0/72	0/67	0/185
	Week 4	n/N (%)	0/100	0/185	0/169	0/285
	Week 6	n/N (%)	0/101	1/66 (1.5)	1/61 (1.6)	1/167 (0.6)
	Week 12	n/N (%)	0/139	0/196	0/178	0/335
	Week 24	n/N (%)	0/93	0/156	0/146	0/249
	Week 36	n/N (%)	0/73	0/120	0/113	0/193
	Week 48	n/N (%)	0/67	0/87	0/83	0/154
	Week 52	n/N (%)	0/67	0/83	0/79	0/150
	Worst Post-Baseline Increase	n/N (%)	0/183	1/223 (0.4)	1/203 (0.5)	1/406 (0.2)
	Last on Treatment	n/N (%)	0/183	1/223 (0.4)	1/203 (0.5)	1/406 (0.2)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
AST >3 x ULN	Week 2	n/N (%)	0/113	0/72	0/67	0/185
	Week 4	n/N (%)	0/100	1/185 (0.5)	1/169 (0.6)	1/285 (0.4)
	Week 6	n/N (%)	0/101	1/66 (1.5)	1/61 (1.6)	1/167 (0.6)
	Week 12	n/N (%)	0/139	0/196	0/178	0/335
	Week 24	n/N (%)	0/93	0/156	0/146	0/249
	Week 36	n/N (%)	0/73	0/120	0/113	0/193
	Week 48	n/N (%)	0/67	0/87	0/83	0/154
	Week 52	n/N (%)	0/67	0/83	0/79	0/150
	Worst Post-Baseline Increase	n/N (%)	1/183 (0.5)	2/223 (0.9)	2/203 (1.0)	3/406 (0.7)
	Last on Treatment	n/N (%)	0/183	1/223 (0.4)	1/203 (0.5)	1/406 (0.2)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Total Bilirubin >1.5 x ULN	Week 2	n/N (%)	0/113	0/72	0/67	0/185
	Week 4	n/N (%)	0/100	0/185	0/169	0/285
	Week 6	n/N (%)	0/101	0/66	0/61	0/167
	Week 12	n/N (%)	0/139	0/196	0/178	0/335
	Week 24	n/N (%)	1/93 (1.1)	0/156	0/146	1/249 (0.4)
	Week 36	n/N (%)	0/73	0/120	0/113	0/193
	Week 48	n/N (%)	0/67	0/87	0/83	0/154
	Week 52	n/N (%)	0/67	0/83	0/79	0/150
	Worst Post-Baseline Increase	n/N (%)	1/183 (0.5)	0/223	0/203	1/406 (0.2)
	Last on Treatment	n/N (%)	0/183	0/223	0/203	0/406

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Liver Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
GGT >3 x ULN	Week 2	n/N (%)	0/113	1/72 (1.4)	1/67 (1.5)	1/185 (0.5)
	Week 4	n/N (%)	1/100 (1.0)	5/185 (2.7)	5/169 (3.0)	6/285 (2.1)
	Week 6	n/N (%)	0/101	3/66 (4.5)	3/61 (4.9)	3/167 (1.8)
	Week 12	n/N (%)	0/139	3/196 (1.5)	3/178 (1.7)	3/335 (0.9)
	Week 24	n/N (%)	0/93	3/156 (1.9)	3/146 (2.1)	3/249 (1.2)
	Week 36	n/N (%)	0/73	3/120 (2.5)	3/113 (2.7)	3/193 (1.6)
	Week 48	n/N (%)	0/67	2/87 (2.3)	2/83 (2.4)	2/154 (1.3)
	Week 52	n/N (%)	1/67 (1.5)	2/83 (2.4)	2/79 (2.5)	3/150 (2.0)
	Worst Post-Baseline Increase	n/N (%)	3/183 (1.6)	11/223 (4.9)	11/203 (5.4)	14/406 (3.4)
	Last on Treatment	n/N (%)	2/183 (1.1)	3/223 (1.3)	3/203 (1.5)	5/406 (1.2)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Kidney Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
BUN >30 mg/dL (>10.71 mmol/L)	Week 2	n/N (%)	1/113 (0.9)	0/72	0/67	1/185 (0.5)
	Week 4	n/N (%)	0/100	0/185	0/169	0/285
	Week 6	n/N (%)	1/101 (1.0)	1/66 (1.5)	0/61	2/167 (1.2)
	Week 12	n/N (%)	1/139 (0.7)	2/196 (1.0)	1/178 (0.6)	3/335 (0.9)
	Week 24	n/N (%)	1/93 (1.1)	2/156 (1.3)	1/146 (0.7)	3/249 (1.2)
	Week 36	n/N (%)	0/73	3/120 (2.5)	3/113 (2.7)	3/193 (1.6)
	Week 48	n/N (%)	1/67 (1.5)	0/87	0/83	1/154 (0.6)
	Week 52	n/N (%)	1/67 (1.5)	0/83	0/79	1/150 (0.7)
	Worst Post-Baseline Increase	n/N (%)	3/183 (1.6)	11/223 (4.9)	8/203 (3.9)	14/406 (3.4)
	Last on Treatment	n/N (%)	1/183 (0.5)	4/223 (1.8)	3/203 (1.5)	5/406 (1.2)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Kidney Function

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Creatinine >1.5 x Baseline value, or >1.5 x ULN	Week 2	n/N (%)	1/113 (0.9)	1/72 (1.4)	1/67 (1.5)	2/185 (1.1)
	Week 4	n/N (%)	1/100 (1.0)	0/185	0/169	1/285 (0.4)
	Week 6	n/N (%)	1/101 (1.0)	1/66 (1.5)	0/61	2/167 (1.2)
	Week 12	n/N (%)	2/139 (1.4)	0/196	0/178	2/335 (0.6)
	Week 24	n/N (%)	1/93 (1.1)	4/156 (2.6)	4/146 (2.7)	5/249 (2.0)
	Week 36	n/N (%)	1/73 (1.4)	1/120 (0.8)	1/113 (0.9)	2/193 (1.0)
	Week 48	n/N (%)	1/67 (1.5)	0/87	0/83	1/154 (0.6)
	Week 52	n/N (%)	1/67 (1.5)	1/83 (1.2)	1/79 (1.3)	2/150 (1.3)
	Worst Post-Baseline Increase	n/N (%)	9/183 (4.9)	11/223 (4.9)	10/203 (4.9)	20/406 (4.9)
	Last on Treatment	n/N (%)	2/183 (1.1)	0/223	0/203	2/406 (0.5)

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

表 2.7.4.7－93　臨床的に重要な変動を認めた被験者の割合（臨床検査値）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Category: Other Chemistry

Parameter (PCS Threshold)	Visit	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Creatine Kinase >5 x ULN	Week 2	n/N (%)	0/113	0/72	0/67	0/185
	Week 4	n/N (%)	0/100	1/185 (0.5)	1/169 (0.6)	1/285 (0.4)
	Week 6	n/N (%)	0/101	0/66	0/61	0/167
	Week 12	n/N (%)	0/139	2/196 (1.0)	2/178 (1.1)	2/335 (0.6)
	Week 24	n/N (%)	0/93	0/156	0/146	0/249
	Week 36	n/N (%)	0/73	0/120	0/113	0/193
	Week 48	n/N (%)	0/67	0/87	0/83	0/154
	Week 52	n/N (%)	0/67	0/83	0/79	0/150
	Worst Post-Baseline Increase	n/N (%)	1/183 (0.5)	4/223 (1.8)	4/203 (2.0)	5/406 (1.2)
	Last on Treatment	n/N (%)	0/183	0/223	0/203	0/406

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; BUN = Blood Urea Nitrogen; GGT = Gamma-Glutamyl Transferase;
ULN = Upper Limit of Normal.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] n= number of subjects with a PCS value, N= number of subjects with a post baseline measurement.

5.3.5.3－3 Table 1.4.3.2 より引用

表 2.7.4.7－94　各評価時点でのバイタルサイン及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Systolic Blood Pressure (mmHg)	Baseline	n	84	84	168	84				
		Mean	122.1	123.7	122.9	125.6				
		SD	15.6	18.4	17.0	17.2				
		Median	122.0	123.5	123.0	123.0				
		(Min, Max)	(87, 159)	(89, 192)	(87, 192)	(90, 188)				
	Week 2	n	82	79	161	84	81	79	160	84
		Mean	124.1	120.0	122.1	124.6	1.4	-3.3	-0.9	-1.0
		SD	17.0	16.4	16.8	16.4	16.0	12.5	14.6	14.6
		Median	121.0	120.0	120.0	124.5	0.0	-2.0	0.0	0.0
		(Min, Max)	(95, 164)	(86, 162)	(86, 164)	(88, 171)	(-32, 45)	(-42, 20)	(-42, 45)	(-37, 39)
	Week 4	n	77	71	148	80	76	71	147	80
		Mean	125.9	121.8	123.9	122.1	2.6	-0.8	1.0	-2.6
		SD	18.4	18.8	18.7	16.6	15.9	15.5	15.8	15.5
		Median	128.0	120.0	122.5	122.0	2.5	-1.0	1.0	-3.0
		(Min, Max)	(80, 181)	(91, 173)	(80, 181)	(86, 168)	(-30, 61)	(-35, 50)	(-35, 61)	(-44, 34)
	Week 6	n	69	60	129	80	68	60	128	80
		Mean	122.3	121.0	121.7	122.9	-1.1	-2.8	-1.9	-1.9
		SD	18.6	17.5	18.0	15.4	16.8	14.3	15.7	15.3
		Median	120.0	120.0	120.0	122.0	0.0	-2.5	0.0	-1.0
		(Min, Max)	(81, 167)	(92, 183)	(81, 183)	(92, 175)	(-34, 46)	(-52, 28)	(-52, 46)	(-42, 47)

表 2.7.4.7－94　各評価時点でのバイタルサイン及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Diastolic Blood Pressure (mmHg)	Baseline	n	84	84	168	84				
		Mean	77.4	77.1	77.3	78.5				
		SD	10.8	12.4	11.6	11.9				
		Median	78.0	77.0	78.0	78.0				
		(Min, Max)	(54, 99)	(47, 115)	(47, 115)	(48, 114)				
	Week 2	n	82	79	161	84	81	79	160	84
		Mean	75.7	74.1	74.9	77.3	-2.2	-2.9	-2.5	-1.2
		SD	12.6	11.5	12.1	11.8	9.6	9.6	9.5	9.0
		Median	76.0	74.0	75.0	76.5	-3.0	-4.0	-3.0	-1.5
		(Min, Max)	(49, 110)	(50, 100)	(49, 110)	(50, 115)	(-27, 25)	(-26, 34)	(-27, 34)	(-23, 30)
	Week 4	n	77	71	148	80	76	71	147	80
		Mean	76.9	75.1	76.0	77.4	-1.1	-1.8	-1.4	-0.9
		SD	13.8	11.6	12.8	10.5	9.7	11.1	10.4	9.7
		Median	78.0	77.0	77.0	77.0	-1.5	-1.0	-1.0	-1.0
		(Min, Max)	(41, 105)	(51, 102)	(41, 105)	(56, 103)	(-25, 20)	(-39, 31)	(-39, 31)	(-26, 31)
	Week 6	n	69	60	129	80	68	60	128	80
		Mean	75.3	75.6	75.4	76.8	-3.0	-1.8	-2.4	-1.4
		SD	11.8	10.7	11.3	12.1	8.7	8.4	8.6	10.4
		Median	75.0	74.5	75.0	76.5	-3.5	-3.0	-3.5	-2.0
		(Min, Max)	(44, 101)	(56, 103)	(44, 103)	(56, 112)	(-20, 24)	(-18, 22)	(-20, 24)	(-24, 35)

表 2.7.4.7－94　各評価時点でのバイタルサイン及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Pulse Rate (beats/min)	Baseline	n	84	84	168	84				
		Mean	81.5	80.2	80.8	81.2				
		SD	15.9	14.7	15.3	15.8				
		Median	78.5	79.0	79.0	79.0				
		(Min, Max)	(51, 143)	(45, 116)	(45, 143)	(57, 132)				
	Week 2	n	82	79	161	84	81	79	160	84
		Mean	77.3	74.3	75.8	80.3	-3.2	-6.1	-4.6	-0.9
		SD	13.2	10.7	12.1	14.7	11.9	13.4	12.7	12.4
		Median	75.5	75.0	75.0	80.5	-3.0	-4.0	-4.0	0.0
		(Min, Max)	(40, 109)	(57, 103)	(40, 109)	(50, 128)	(-41, 22)	(-36, 27)	(-41, 27)	(-39, 32)
	Week 4	n	77	71	148	80	76	71	147	80
		Mean	78.6	76.4	77.6	79.8	-2.6	-4.6	-3.5	-1.1
		SD	14.1	12.6	13.4	14.8	12.7	13.9	13.3	13.6
		Median	79.0	74.0	77.0	78.0	-1.0	-5.0	-2.0	0.0
		(Min, Max)	(42, 114)	(54, 116)	(42, 116)	(51, 125)	(-51, 38)	(-41, 24)	(-51, 38)	(-54, 35)
	Week 6	n	69	60	129	80	68	60	128	80
		Mean	78.6	78.6	78.6	77.6	-2.8	-3.1	-3.0	-3.2
		SD	13.7	15.8	14.6	13.5	12.4	17.0	14.7	11.8
		Median	77.0	77.0	77.0	78.0	-2.0	-2.5	-2.0	-1.0
		(Min, Max)	(44, 109)	(51, 145)	(44, 145)	(52, 126)	(-47, 23)	(-35, 76)	(-47, 76)	(-48, 23)

表 2.7.4.7－94　各評価時点でのバイタルサイン及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Temperature (C)	Baseline	n	84	84	168	84				
		Mean	36.34	36.33	36.34	36.33				
		SD	0.41	0.48	0.45	0.50				
		Median	36.50	36.35	36.45	36.40				
		(Min, Max)	(35.1, 37.0)	(35.2, 37.7)	(35.1, 37.7)	(34.0, 37.3)				
	Week 2	n	82	79	161	84	81	79	160	84
		Mean	36.35	36.37	36.36	36.36	0.02	0.03	0.02	0.03
		SD	0.38	0.46	0.42	0.50	0.45	0.53	0.49	0.44
		Median	36.40	36.40	36.40	36.40	0.00	0.00	0.00	0.00
		(Min, Max)	(35.1, 37.0)	(35.4, 37.5)	(35.1, 37.5)	(34.5, 37.6)	(-1.2, 1.2)	(-1.3, 1.3)	(-1.3, 1.3)	(-1.2, 1.2)
	Week 4	n	77	71	148	80	76	71	147	80
		Mean	36.37	36.35	36.36	36.27	0.03	-0.01	0.01	-0.06
		SD	0.42	0.47	0.44	0.47	0.51	0.50	0.50	0.44
		Median	36.40	36.40	36.40	36.40	0.00	0.00	0.00	0.00
		(Min, Max)	(35.5, 37.4)	(35.0, 37.4)	(35.0, 37.4)	(35.1, 37.7)	(-1.0, 1.7)	(-1.0, 1.7)	(-1.0, 1.7)	(-1.3, 1.2)
	Week 6	n	69	60	129	80	68	60	128	80
		Mean	36.32	36.39	36.35	36.27	-0.04	-0.03	-0.03	-0.06
		SD	0.43	0.38	0.41	0.53	0.46	0.47	0.46	0.50
		Median	36.40	36.40	36.40	36.35	-0.10	-0.10	-0.10	-0.10
		(Min, Max)	(34.9, 37.2)	(35.5, 37.2)	(34.9, 37.2)	(34.5, 37.4)	(-1.3, 1.2)	(-1.1, 1.0)	(-1.3, 1.2)	(-1.1, 1.3)

表 2.7.4.7－94　各評価時点でのバイタルサイン及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Weight (kg)	Baseline	n	84	84	168	84				
		Mean	61.46	63.96	62.71	60.47				
		SD	13.11	14.24	13.71	12.98				
		Median	61.30	62.90	61.60	58.00				
		(Min, Max)	(34.8, 94.7)	(35.6, 107.8)	(34.8, 107.8)	(37.5, 95.1)				
	Week 2	n	82	79	161	84	81	79	160	84
		Mean	61.58	63.66	62.60	60.52	0.22	0.18	0.20	0.05
		SD	13.12	14.36	13.74	13.13	1.24	1.31	1.27	0.99
		Median	61.95	62.50	62.20	58.05	0.10	0.00	0.10	0.10
		(Min, Max)	(35.0, 95.0)	(35.5, 108.4)	(35.0, 108.4)	(38.7, 97.6)	(-2.6, 5.0)	(-4.9, 3.5)	(-4.9, 5.0)	(-2.7, 3.1)
	Week 4	n	77	71	148	80	76	71	147	80
		Mean	62.06	63.72	62.86	60.40	0.51	0.35	0.43	0.05
		SD	13.44	14.24	13.81	12.92	1.65	1.81	1.72	1.27
		Median	62.10	62.50	62.40	58.00	0.20	0.40	0.40	-0.10
		(Min, Max)	(36.6, 95.7)	(36.1, 108.2)	(36.1, 108.2)	(37.9, 96.4)	(-2.4, 6.4)	(-6.1, 4.6)	(-6.1, 6.4)	(-3.8, 4.7)
	Week 6	n	69	60	129	80	68	60	128	80
		Mean	62.42	64.68	63.47	60.26	0.35	0.29	0.32	-0.08
		SD	13.99	14.17	14.07	12.95	1.67	2.21	1.93	1.35
		Median	62.40	63.40	63.00	58.20	0.25	0.20	0.20	-0.10
		(Min, Max)	(36.2, 96.6)	(36.7, 105.0)	(36.2, 105.0)	(37.3, 94.9)	(-3.7, 6.7)	(-6.1, 6.9)	(-6.1, 6.9)	(-5.5, 3.8)

5.3.5.1－1 Table 14.3.3.1.1 より引用

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Systolic Blood Pressure (mmHg)	Baseline	n	125	123	84	248				
		Mean	123.2	123.8	124.6	123.5				
		SD	16.1	17.9	18.4	17.0				
		Median	123.0	122.0	124.0	123.0				
		(Min, Max)	(87, 179)	(89, 192)	(89, 192)	(87, 192)				
	Week 2	n	82	79	59	161	81	79	59	160
		Mean	124.1	120.0	120.6	122.1	1.4	-3.3	-3.5	-0.9
		SD	17.0	16.4	17.2	16.8	16.0	12.5	13.8	14.6
		Median	121.0	120.0	119.0	120.0	0.0	-2.0	-1.0	0.0
		(Min, Max)	(95, 164)	(86, 162)	(89, 162)	(86, 164)	(-32, 45)	(-42, 20)	(-42, 20)	(-42, 45)
	Week 4	n	77	71	51	148	76	71	51	147
		Mean	125.9	121.8	124.1	123.9	2.6	-0.8	0.9	1.0
		SD	18.4	18.8	20.0	18.7	15.9	15.5	16.6	15.8
		Median	128.0	120.0	121.0	122.5	2.5	-1.0	0.0	1.0
		(Min, Max)	(80, 181)	(91, 173)	(92, 173)	(80, 181)	(-30, 61)	(-35, 50)	(-35, 50)	(-35, 61)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	122.3	121.0	120.6	121.7	-1.1	-2.8	-4.6	-1.9
		SD	18.6	17.5	19.0	18.0	16.8	14.3	15.2	15.7
		Median	120.0	120.0	119.5	120.0	0.0	-2.5	-4.5	0.0
		(Min, Max)	(81, 167)	(92, 183)	(92, 183)	(81, 183)	(-34, 46)	(-52, 28)	(-52, 24)	(-52, 46)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	122.0	120.1	120.9	121.1	-1.9	-3.2	-3.3	-2.5
		SD	17.7	17.4	17.0	17.6	14.5	18.5	19.1	16.5
		Median	120.0	118.0	123.0	120.0	-1.0	-3.0	-3.0	-1.0
		(Min, Max)	(82, 187)	(90, 176)	(90, 167)	(82, 187)	(-33, 45)	(-46, 45)	(-46, 45)	(-46, 45)
	Week 12	n	100	81	47	181	99	81	47	180
		Mean	122.1	118.6	118.9	120.5	-1.6	-5.5	-5.6	-3.4
		SD	16.5	17.0	17.4	16.8	14.8	16.9	18.0	15.8
		Median	120.0	117.0	120.0	120.0	-1.0	-4.0	-5.0	-2.0
		(Min, Max)	(76, 178)	(80, 168)	(88, 168)	(76, 178)	(-53, 48)	(-43, 30)	(-43, 30)	(-53, 48)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Systolic Blood Pressure (mmHg)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	123.0	119.1	120.5	121.3	-0.5	-5.5	-4.7	-2.7
		SD	15.0	16.4	16.6	15.7	14.1	13.8	14.1	14.1
		Median	122.5	119.0	120.0	120.0	0.0	-4.0	-2.0	-2.0
		(Min, Max)	(88, 180)	(81, 168)	(81, 168)	(81, 180)	(-56, 32)	(-45, 26)	(-45, 26)	(-56, 32)
	Week 20	n	92	67	39	159	91	67	39	158
		Mean	121.6	117.9	119.1	120.0	-1.9	-7.2	-7.3	-4.2
		SD	17.2	14.4	14.9	16.1	14.6	15.3	15.3	15.1
		Median	121.5	116.0	117.0	120.0	-1.0	-5.0	-6.0	-3.0
		(Min, Max)	(86, 176)	(93, 152)	(93, 152)	(86, 176)	(-41, 60)	(-51, 29)	(-42, 29)	(-51, 60)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	124.0	119.8	121.5	122.2	-0.4	-5.0	-4.8	-2.4
		SD	16.9	16.0	15.0	16.6	16.1	16.8	18.4	16.5
		Median	125.0	118.0	122.0	122.0	0.0	-4.0	-2.0	-2.0
		(Min, Max)	(84, 181)	(94, 169)	(98, 158)	(84, 181)	(-48, 58)	(-55, 26)	(-55, 26)	(-55, 58)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	124.0	116.7	116.9	120.9	-0.6	-8.8	-10.2	-4.1
		SD	15.0	12.9	13.1	14.6	15.8	17.4	16.2	16.9
		Median	124.0	115.0	115.0	121.5	-2.0	-9.0	-10.0	-6.0
		(Min, Max)	(96, 179)	(98, 152)	(98, 152)	(96, 179)	(-34, 41)	(-56, 31)	(-56, 23)	(-56, 41)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	120.5	118.1	118.4	119.5	-3.6	-7.6	-9.8	-5.2
		SD	16.1	12.7	13.5	14.8	15.7	17.0	18.2	16.3
		Median	121.0	116.5	120.0	120.0	-4.0	-7.5	-8.0	-5.0
		(Min, Max)	(87, 171)	(91, 149)	(91, 149)	(87, 171)	(-43, 46)	(-70, 23)	(-70, 23)	(-70, 46)
	Week 36	n	77	56	34	133	76	56	34	132
		Mean	122.5	117.0	118.2	120.2	-2.6	-8.8	-10.2	-5.2
		SD	16.2	14.6	16.2	15.7	14.6	17.3	19.2	16.0
		Median	121.0	114.5	116.5	119.0	-2.5	-7.5	-11.0	-4.0
		(Min, Max)	(89, 185)	(87, 156)	(87, 156)	(87, 185)	(-40, 36)	(-77, 18)	(-77, 18)	(-77, 36)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Systolic Blood Pressure (mmHg)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	123.0	118.9	118.8	121.2	-2.1	-7.0	-10.0	-4.3
		SD	17.7	15.6	15.1	16.9	16.3	19.0	21.2	17.6
		Median	120.0	116.5	118.5	119.0	-3.5	-4.0	-5.5	-3.5
		(Min, Max)	(93, 179)	(89, 172)	(89, 144)	(89, 179)	(-39, 29)	(-70, 22)	(-70, 22)	(-70, 29)
	Week 44	n	67	51	29	118	66	51	29	117
		Mean	121.5	118.2	118.2	120.0	-3.1	-8.1	-11.6	-5.3
		SD	14.4	15.7	16.2	15.0	14.6	21.2	20.4	17.9
		Median	120.0	117.0	116.0	119.5	-3.0	-6.0	-11.0	-4.0
		(Min, Max)	(93, 156)	(78, 154)	(78, 154)	(78, 156)	(-37, 43)	(-54, 25)	(-46, 25)	(-54, 43)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	122.4	117.2	117.2	120.2	-2.2	-9.3	-12.6	-5.3
		SD	16.2	19.0	19.7	17.6	15.2	18.9	18.6	17.2
		Median	122.0	115.5	117.0	119.0	-3.0	-9.0	-11.0	-4.5
		(Min, Max)	(95, 174)	(65, 164)	(65, 152)	(65, 174)	(-40, 48)	(-54, 42)	(-54, 16)	(-54, 48)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	123.3	117.4	118.4	120.8	-1.4	-9.3	-11.9	-4.8
		SD	14.1	17.2	18.5	15.7	14.2	19.4	20.0	17.0
		Median	123.0	118.0	119.0	121.0	-2.0	-4.0	-9.5	-2.5
		(Min, Max)	(85, 159)	(79, 153)	(79, 153)	(79, 159)	(-30, 44)	(-56, 20)	(-56, 20)	(-56, 44)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Diastolic Blood Pressure (mmHg)	Baseline	n	125	123	84	248				
		Mean	77.8	77.3	77.4	77.6				
		SD	11.5	11.9	11.8	11.7				
		Median	78.0	77.0	77.0	78.0				
		(Min, Max)	(48, 105)	(47, 115)	(47, 115)	(47, 115)				
	Week 2	n	82	79	59	161	81	79	59	160
		Mean	75.7	74.1	74.2	74.9	-2.2	-2.9	-2.4	-2.5
		SD	12.6	11.5	11.4	12.1	9.6	9.6	10.0	9.5
		Median	76.0	74.0	74.0	75.0	-3.0	-4.0	-3.0	-3.0
		(Min, Max)	(49, 110)	(50, 100)	(50, 100)	(49, 110)	(-27, 25)	(-26, 34)	(-26, 34)	(-27, 34)
	Week 4	n	77	71	51	148	76	71	51	147
		Mean	76.9	75.1	74.7	76.0	-1.1	-1.8	-1.6	-1.4
		SD	13.8	11.6	11.2	12.8	9.7	11.1	11.7	10.4
		Median	78.0	77.0	77.0	77.0	-1.5	-1.0	-1.0	-1.0
		(Min, Max)	(41, 105)	(51, 102)	(52, 100)	(41, 105)	(-25, 20)	(-39, 31)	(-39, 31)	(-39, 31)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	75.3	75.6	74.7	75.4	-3.0	-1.8	-2.2	-2.4
		SD	11.8	10.7	11.3	11.3	8.7	8.4	8.6	8.6
		Median	75.0	74.5	73.5	75.0	-3.5	-3.0	-3.0	-3.5
		(Min, Max)	(44, 101)	(56, 103)	(56, 103)	(44, 103)	(-20, 24)	(-18, 22)	(-18, 22)	(-20, 24)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	75.8	74.0	74.9	74.9	-2.5	-3.3	-2.3	-2.9
		SD	12.0	11.6	11.2	11.8	9.9	11.2	11.6	10.5
		Median	76.0	74.0	76.0	75.0	-2.0	-3.0	-2.0	-3.0
		(Min, Max)	(48, 103)	(47, 101)	(52, 101)	(47, 103)	(-27, 24)	(-34, 27)	(-34, 27)	(-34, 27)
	Week 12	n	100	81	47	181	99	81	47	180
		Mean	74.3	72.7	73.8	73.6	-3.9	-4.8	-2.9	-4.3
		SD	12.8	11.1	11.3	12.0	10.5	10.3	10.4	10.4
		Median	73.5	75.0	76.0	74.0	-5.0	-6.0	-4.0	-5.0
		(Min, Max)	(40, 111)	(46, 102)	(48, 102)	(40, 111)	(-35, 26)	(-27, 30)	(-27, 30)	(-35, 30)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Diastolic Blood Pressure (mmHg)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	76.7	73.4	74.6	75.2	-1.6	-4.1	-2.1	-2.7
		SD	11.3	12.0	11.7	11.7	10.0	10.3	10.4	10.2
		Median	78.0	73.0	75.0	76.0	-1.0	-4.0	-3.0	-3.0
		(Min, Max)	(46, 101)	(42, 100)	(42, 100)	(42, 101)	(-35, 22)	(-33, 37)	(-22, 37)	(-35, 37)
	Week 20	n	92	67	39	159	91	67	39	158
		Mean	75.3	74.1	73.2	74.8	-3.2	-3.3	-3.3	-3.2
		SD	12.0	9.6	9.3	11.0	10.8	9.1	8.0	10.1
		Median	75.0	73.0	72.0	74.0	-3.0	-3.0	-4.0	-3.0
		(Min, Max)	(51, 99)	(58, 97)	(58, 97)	(51, 99)	(-30, 21)	(-21, 16)	(-20, 16)	(-30, 21)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	75.7	73.5	73.9	74.7	-3.1	-4.1	-2.6	-3.5
		SD	11.5	10.5	9.5	11.1	10.5	12.7	12.9	11.5
		Median	76.0	74.0	74.0	75.0	-3.0	-5.0	-4.0	-4.0
		(Min, Max)	(49, 104)	(48, 96)	(56, 92)	(48, 104)	(-32, 21)	(-39, 36)	(-39, 36)	(-39, 36)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	77.2	71.6	72.2	74.8	-1.9	-6.7	-4.8	-3.9
		SD	11.4	10.5	9.2	11.3	10.8	11.2	9.6	11.2
		Median	78.0	73.0	73.0	75.0	-2.0	-7.0	-4.0	-4.0
		(Min, Max)	(53, 103)	(48, 92)	(56, 92)	(48, 103)	(-31, 28)	(-31, 18)	(-31, 14)	(-31, 28)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	76.1	74.6	75.1	75.5	-2.5	-3.9	-2.3	-3.1
		SD	11.7	11.9	12.4	11.8	11.3	12.1	13.0	11.6
		Median	76.0	74.5	78.0	76.0	-3.0	-4.0	-3.0	-3.0
		(Min, Max)	(49, 110)	(50, 105)	(52, 105)	(49, 110)	(-34, 25)	(-28, 41)	(-28, 41)	(-34, 41)
	Week 36	n	77	56	34	133	76	56	34	132
		Mean	76.8	74.4	73.0	75.8	-2.0	-3.8	-4.7	-2.7
		SD	13.0	11.5	12.4	12.4	11.3	11.5	11.6	11.4
		Median	77.0	76.5	74.0	77.0	-3.5	-4.0	-6.0	-4.0
		(Min, Max)	(42, 118)	(47, 96)	(47, 96)	(42, 118)	(-27, 31)	(-28, 38)	(-28, 38)	(-28, 38)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Diastolic Blood Pressure (mmHg)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	76.4	74.1	74.8	75.4	-2.3	-4.5	-3.5	-3.2
		SD	12.1	11.2	10.4	11.7	9.3	11.1	10.5	10.1
		Median	77.0	75.5	76.0	77.0	-3.0	-4.0	-4.0	-4.0
		(Min, Max)	(38, 107)	(48, 98)	(50, 97)	(38, 107)	(-24, 21)	(-38, 34)	(-24, 34)	(-38, 34)
	Week 44	n	67	51	29	118	66	51	29	117
		Mean	77.9	72.2	73.1	75.4	-0.4	-6.6	-5.6	-3.1
		SD	11.9	13.2	12.5	12.8	12.1	13.3	11.9	13.0
		Median	77.0	72.0	75.0	75.0	-2.0	-7.0	-6.0	-4.0
		(Min, Max)	(53, 116)	(43, 100)	(43, 93)	(43, 116)	(-28, 31)	(-36, 28)	(-35, 19)	(-36, 31)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	77.1	72.9	72.8	75.3	-1.4	-6.0	-5.9	-3.4
		SD	11.7	14.1	12.9	12.9	11.3	12.6	13.5	12.1
		Median	76.0	73.5	75.0	75.0	-2.5	-7.5	-6.0	-4.0
		(Min, Max)	(55, 104)	(46, 135)	(46, 96)	(46, 135)	(-21, 34)	(-28, 45)	(-28, 45)	(-28, 45)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	77.3	75.1	75.8	76.3	-1.4	-4.5	-4.0	-2.8
		SD	9.5	12.0	12.5	10.6	10.4	10.5	11.6	10.5
		Median	78.5	77.0	81.0	78.0	-3.0	-5.0	-4.0	-4.0
		(Min, Max)	(58, 100)	(50, 98)	(50, 98)	(50, 100)	(-24, 34)	(-31, 20)	(-31, 20)	(-31, 34)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Pulse Rate (beats/min)	Baseline	n	125	123	84	248				
		Mean	80.6	81.1	81.6	80.8				
		SD	15.0	15.7	16.1	15.3				
		Median	78.0	79.0	79.0	79.0				
		(Min, Max)	(51, 143)	(45, 132)	(45, 132)	(45, 143)				
	Week 2	n	82	79	59	161	81	79	59	160
		Mean	77.3	74.3	74.2	75.8	-3.2	-6.1	-5.8	-4.6
		SD	13.2	10.7	10.9	12.1	11.9	13.4	13.8	12.7
		Median	75.5	75.0	75.0	75.0	-3.0	-4.0	-4.0	-4.0
		(Min, Max)	(40, 109)	(57, 103)	(58, 103)	(40, 109)	(-41, 22)	(-36, 27)	(-36, 27)	(-41, 27)
	Week 4	n	77	71	51	148	76	71	51	147
		Mean	78.6	76.4	75.4	77.6	-2.6	-4.6	-5.3	-3.5
		SD	14.1	12.6	12.7	13.4	12.7	13.9	14.8	13.3
		Median	79.0	74.0	73.0	77.0	-1.0	-5.0	-6.0	-2.0
		(Min, Max)	(42, 114)	(54, 116)	(54, 116)	(42, 116)	(-51, 38)	(-41, 24)	(-41, 24)	(-51, 38)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	78.6	78.6	76.8	78.6	-2.8	-3.1	-5.1	-3.0
		SD	13.7	15.8	16.8	14.6	12.4	17.0	19.0	14.7
		Median	77.0	77.0	74.5	77.0	-2.0	-2.5	-4.0	-2.0
		(Min, Max)	(44, 109)	(51, 145)	(51, 145)	(44, 145)	(-47, 23)	(-35, 76)	(-35, 76)	(-47, 76)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	76.3	77.5	76.7	76.9	-4.1	-5.5	-8.5	-4.8
		SD	12.3	13.2	12.2	12.7	11.9	14.3	15.8	13.1
		Median	76.0	79.0	78.0	77.0	-2.0	-4.0	-7.0	-3.0
		(Min, Max)	(41, 106)	(51, 117)	(53, 117)	(41, 117)	(-47, 26)	(-48, 29)	(-48, 29)	(-48, 29)
	Week 12	n	100	81	47	181	99	81	47	180
		Mean	77.6	76.9	74.9	77.3	-2.7	-5.5	-8.2	-4.0
		SD	14.1	14.2	14.0	14.1	11.5	14.8	15.2	13.1
		Median	76.5	75.0	74.0	76.0	-1.0	-3.0	-4.0	-2.0
		(Min, Max)	(45, 119)	(51, 113)	(51, 113)	(45, 119)	(-53, 17)	(-38, 45)	(-38, 28)	(-53, 45)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Pulse Rate (beats/min)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	77.1	76.7	76.3	76.9	-3.5	-5.9	-6.9	-4.5
		SD	13.6	13.8	13.8	13.7	13.1	13.5	14.7	13.3
		Median	76.0	75.0	75.0	76.0	-2.0	-6.0	-6.0	-4.5
		(Min, Max)	(42, 119)	(54, 113)	(54, 106)	(42, 119)	(-55, 22)	(-31, 36)	(-31, 36)	(-55, 36)
	Week 20	n	92	67	39	159	91	67	39	158
		Mean	76.0	76.3	74.6	76.1	-5.3	-6.7	-9.2	-5.9
		SD	12.1	12.3	11.7	12.2	14.0	12.0	12.4	13.2
		Median	75.0	76.0	74.0	76.0	-4.0	-6.0	-11.0	-4.0
		(Min, Max)	(43, 109)	(50, 102)	(50, 100)	(43, 109)	(-43, 35)	(-35, 21)	(-35, 17)	(-43, 35)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	76.3	79.3	77.5	77.6	-4.0	-4.3	-6.3	-4.1
		SD	13.6	14.8	15.7	14.2	14.9	13.9	14.0	14.4
		Median	74.5	77.0	74.0	75.0	-2.0	-5.0	-8.0	-3.0
		(Min, Max)	(41, 109)	(54, 115)	(54, 115)	(41, 115)	(-58, 30)	(-48, 29)	(-48, 24)	(-58, 30)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	75.8	77.4	75.7	76.5	-4.6	-6.8	-8.6	-5.5
		SD	12.1	11.9	13.1	12.0	13.5	13.0	13.6	13.3
		Median	74.0	76.0	74.0	76.0	-2.5	-7.0	-8.0	-4.0
		(Min, Max)	(44, 111)	(48, 100)	(48, 100)	(44, 111)	(-52, 22)	(-49, 14)	(-49, 14)	(-52, 22)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	77.7	80.3	78.8	78.8	-2.7	-4.5	-6.1	-3.5
		SD	13.3	13.1	14.0	13.2	15.1	13.1	14.4	14.3
		Median	76.0	79.5	77.0	77.0	-3.0	-2.5	-5.0	-3.0
		(Min, Max)	(42, 119)	(56, 108)	(56, 103)	(42, 119)	(-57, 29)	(-44, 29)	(-44, 29)	(-57, 29)
	Week 36	n	77	56	34	133	76	56	34	132
		Mean	76.1	78.2	78.0	77.0	-4.2	-6.4	-7.4	-5.1
		SD	13.7	15.2	17.9	14.4	16.7	15.3	17.0	16.1
		Median	74.0	78.5	77.5	76.0	-4.5	-6.0	-5.5	-5.5
		(Min, Max)	(50, 123)	(50, 133)	(50, 133)	(50, 133)	(-43, 59)	(-48, 43)	(-48, 43)	(-48, 59)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Pulse Rate (beats/min)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	77.2	80.3	79.7	78.5	-3.5	-5.0	-6.9	-4.2
		SD	11.9	12.7	13.2	12.3	13.7	13.8	14.8	13.7
		Median	78.0	82.0	80.0	80.0	-3.5	-3.0	-8.5	-3.0
		(Min, Max)	(51, 115)	(54, 108)	(56, 108)	(51, 115)	(-46, 23)	(-33, 30)	(-33, 30)	(-46, 30)
	Week 44	n	67	51	29	118	66	51	29	117
		Mean	77.2	78.3	77.5	77.6	-3.0	-7.2	-9.5	-4.8
		SD	13.6	14.1	15.0	13.8	13.8	13.1	12.0	13.6
		Median	79.0	80.0	80.0	80.0	-4.0	-7.0	-8.0	-5.0
		(Min, Max)	(50, 129)	(37, 105)	(37, 105)	(37, 129)	(-53, 30)	(-32, 14)	(-32, 12)	(-53, 30)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	75.5	79.4	78.0	77.2	-4.8	-6.1	-9.1	-5.4
		SD	12.5	11.0	10.9	12.0	13.1	14.9	17.1	13.9
		Median	73.0	80.0	78.0	77.0	-4.0	-5.0	-11.0	-4.0
		(Min, Max)	(51, 113)	(55, 102)	(55, 99)	(51, 113)	(-51, 28)	(-37, 37)	(-37, 37)	(-51, 37)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	80.0	82.4	79.5	81.0	-1.0	-3.3	-7.9	-2.0
		SD	14.3	14.0	14.2	14.2	12.7	12.3	11.7	12.5
		Median	80.0	82.0	80.0	80.0	1.0	-4.0	-6.5	-1.5
		(Min, Max)	(49, 113)	(54, 115)	(54, 108)	(49, 115)	(-45, 29)	(-41, 31)	(-41, 18)	(-45, 31)

表 2.7.4.7－95 各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Temperature (C)	Baseline	n	125	123	84	248				
		Mean	36.34	36.33	36.31	36.33				
		SD	0.47	0.47	0.47	0.47				
		Median	36.50	36.40	36.30	36.40				
		(Min, Max)	(34.0, 37.3)	(35.0, 37.7)	(35.2, 37.7)	(34.0, 37.7)				
	Week 2	n	82	79	59	161	81	79	59	160
		Mean	36.35	36.37	36.38	36.36	0.02	0.03	0.07	0.02
		SD	0.38	0.46	0.45	0.42	0.45	0.53	0.49	0.49
		Median	36.40	36.40	36.40	36.40	0.00	0.00	0.00	0.00
		(Min, Max)	(35.1, 37.0)	(35.4, 37.5)	(35.4, 37.2)	(35.1, 37.5)	(-1.2, 1.2)	(-1.3, 1.3)	(-1.3, 1.3)	(-1.3, 1.3)
	Week 4	n	77	71	51	148	76	71	51	147
		Mean	36.37	36.35	36.32	36.36	0.03	-0.01	-0.02	0.01
		SD	0.42	0.47	0.52	0.44	0.51	0.50	0.51	0.50
		Median	36.40	36.40	36.40	36.40	0.00	0.00	0.10	0.00
		(Min, Max)	(35.5, 37.4)	(35.0, 37.4)	(35.0, 37.4)	(35.0, 37.4)	(-1.0, 1.7)	(-1.0, 1.7)	(-1.0, 1.7)	(-1.0, 1.7)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	36.32	36.39	36.42	36.35	-0.04	-0.03	-0.01	-0.03
		SD	0.43	0.38	0.38	0.41	0.46	0.47	0.49	0.46
		Median	36.40	36.40	36.50	36.40	-0.10	-0.10	-0.05	-0.10
		(Min, Max)	(34.9, 37.2)	(35.5, 37.2)	(35.8, 37.2)	(34.9, 37.2)	(-1.3, 1.2)	(-1.1, 1.0)	(-1.1, 1.0)	(-1.3, 1.2)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	36.31	36.30	36.21	36.31	-0.01	-0.10	-0.20	-0.05
		SD	0.48	0.51	0.55	0.49	0.46	0.52	0.54	0.49
		Median	36.40	36.40	36.30	36.40	0.00	-0.10	-0.10	-0.10
		(Min, Max)	(34.1, 37.2)	(34.2, 37.5)	(34.2, 37.5)	(34.1, 37.5)	(-1.1, 1.5)	(-2.7, 1.2)	(-2.7, 0.8)	(-2.7, 1.5)
	Week 12	n	100	81	47	181	99	81	47	180
		Mean	36.34	36.39	36.30	36.36	0.01	-0.02	-0.16	0.00
		SD	0.46	0.50	0.53	0.48	0.48	0.52	0.52	0.50
		Median	36.40	36.40	36.40	36.40	0.00	0.00	-0.30	0.00
		(Min, Max)	(35.0, 37.4)	(35.1, 37.8)	(35.1, 37.3)	(35.0, 37.8)	(-1.7, 1.1)	(-1.7, 1.4)	(-1.7, 0.8)	(-1.7, 1.4)

表 2.7.4.7－95 各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Temperature (C)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	36.31	36.36	36.33	36.33	-0.02	-0.03	-0.09	-0.02
		SD	0.45	0.43	0.41	0.44	0.50	0.50	0.47	0.50
		Median	36.30	36.40	36.40	36.40	0.00	0.00	-0.10	0.00
		(Min, Max)	(34.7, 37.1)	(35.2, 37.6)	(35.2, 36.9)	(34.7, 37.6)	(-1.5, 1.3)	(-1.1, 1.1)	(-1.1, 0.9)	(-1.5, 1.3)
	Week 20	n	92	67	39	159	91	67	39	158
		Mean	36.37	36.40	36.38	36.38	0.04	0.01	-0.03	0.03
		SD	0.45	0.36	0.37	0.42	0.51	0.53	0.51	0.52
		Median	36.40	36.40	36.40	36.40	0.00	0.10	0.10	0.05
		(Min, Max)	(35.0, 37.5)	(35.3, 37.2)	(35.3, 37.2)	(35.0, 37.5)	(-1.4, 1.2)	(-1.0, 1.5)	(-1.0, 1.3)	(-1.4, 1.5)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	36.33	36.41	36.33	36.37	0.04	0.00	-0.08	0.02
		SD	0.47	0.47	0.45	0.47	0.50	0.58	0.50	0.53
		Median	36.40	36.50	36.40	36.40	0.00	0.10	-0.10	0.10
		(Min, Max)	(35.0, 37.1)	(35.3, 37.7)	(35.3, 37.2)	(35.0, 37.7)	(-1.7, 1.1)	(-1.5, 2.0)	(-1.5, 0.8)	(-1.7, 2.0)
	Week 28	n	85	61	37	146	84	61	37	145
		Mean	36.31	36.40	36.33	36.35	0.00	0.02	-0.06	0.01
		SD	0.42	0.42	0.40	0.42	0.56	0.47	0.42	0.53
		Median	36.30	36.40	36.30	36.40	0.00	0.10	-0.10	0.00
		(Min, Max)	(35.1, 37.3)	(35.0, 37.0)	(35.4, 37.0)	(35.0, 37.3)	(-1.2, 1.4)	(-1.2, 1.1)	(-1.2, 0.8)	(-1.2, 1.4)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	36.40	36.41	36.36	36.40	0.11	-0.02	-0.08	0.05
		SD	0.43	0.33	0.34	0.39	0.53	0.47	0.43	0.51
		Median	36.40	36.40	36.40	36.40	0.10	0.00	-0.10	0.00
		(Min, Max)	(34.7, 37.3)	(35.4, 37.0)	(35.4, 37.0)	(34.7, 37.3)	(-1.0, 1.4)	(-1.2, 1.1)	(-0.8, 0.9)	(-1.2, 1.4)
	Week 36	n	77	56	34	133	76	56	34	132
		Mean	36.37	36.38	36.42	36.37	0.08	-0.08	-0.04	0.01
		SD	0.33	0.54	0.54	0.42	0.52	0.53	0.56	0.53
		Median	36.40	36.40	36.40	36.40	0.00	-0.10	-0.05	0.00
		(Min, Max)	(35.6, 37.2)	(35.0, 37.7)	(35.1, 37.7)	(35.0, 37.7)	(-0.8, 1.6)	(-1.4, 1.1)	(-1.4, 1.1)	(-1.4, 1.6)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Temperature (C)	Week 40	n	71	54	32	125	70	54	32	124
		Mean	36.36	36.45	36.38	36.40	0.10	-0.01	-0.08	0.05
		SD	0.45	0.41	0.43	0.43	0.60	0.47	0.45	0.55
		Median	36.40	36.40	36.40	36.40	0.10	0.00	-0.10	0.00
		(Min, Max)	(35.5, 38.5)	(35.4, 37.6)	(35.4, 37.6)	(35.4, 38.5)	(-1.1, 2.7)	(-1.1, 1.3)	(-1.1, 0.8)	(-1.1, 2.7)
	Week 44	n	67	51	29	118	66	51	29	117
		Mean	36.40	36.42	36.41	36.41	0.15	-0.04	-0.06	0.07
		SD	0.40	0.38	0.44	0.39	0.54	0.42	0.45	0.50
		Median	36.40	36.40	36.50	36.40	0.10	0.00	-0.10	0.10
		(Min, Max)	(35.1, 37.4)	(35.7, 37.5)	(35.7, 37.5)	(35.1, 37.5)	(-0.9, 1.5)	(-1.1, 0.6)	(-1.1, 0.6)	(-1.1, 1.5)
	Week 48	n	67	50	29	117	66	50	29	116
		Mean	36.26	36.48	36.46	36.35	0.02	0.01	0.00	0.01
		SD	0.50	0.34	0.36	0.45	0.53	0.47	0.50	0.50
		Median	36.40	36.50	36.40	36.50	0.00	-0.05	-0.10	0.00
		(Min, Max)	(34.9, 37.1)	(35.8, 37.3)	(35.8, 37.3)	(34.9, 37.3)	(-1.7, 1.0)	(-1.0, 1.1)	(-0.7, 1.1)	(-1.7, 1.1)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	36.36	36.51	36.49	36.42	0.11	0.04	0.04	0.08
		SD	0.38	0.37	0.43	0.38	0.53	0.41	0.41	0.48
		Median	36.40	36.60	36.60	36.50	0.10	0.00	0.05	0.10
		(Min, Max)	(35.2, 37.2)	(35.4, 37.1)	(35.4, 37.0)	(35.2, 37.2)	(-1.1, 1.5)	(-0.9, 0.9)	(-0.9, 0.7)	(-1.1, 1.5)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Weight (kg)	Baseline	n	125	123	84	248				
		Mean	61.41	62.50	63.56	61.95				
		SD	12.98	14.02	14.78	13.49				
		Median	60.90	61.00	62.30	60.95				
		(Min, Max)	(34.8, 94.7)	(35.6, 107.8)	(35.6, 107.8)	(34.8, 107.8)				
	Week 2	n	82	79	59	161	81	79	59	160
		Mean	61.58	63.66	62.83	62.60	0.22	0.18	0.08	0.20
		SD	13.12	14.36	15.01	13.74	1.24	1.31	1.33	1.27
		Median	61.95	62.50	62.50	62.20	0.10	0.00	0.00	0.10
		(Min, Max)	(35.0, 95.0)	(35.5, 108.4)	(35.5, 108.4)	(35.0, 108.4)	(-2.6, 5.0)	(-4.9, 3.5)	(-4.9, 2.8)	(-4.9, 5.0)
	Week 4	n	77	71	51	148	76	71	51	147
		Mean	62.06	63.72	62.84	62.86	0.51	0.35	0.35	0.43
		SD	13.44	14.24	14.88	13.81	1.65	1.81	2.05	1.72
		Median	62.10	62.50	61.50	62.40	0.20	0.40	0.40	0.40
		(Min, Max)	(36.6, 95.7)	(36.1, 108.2)	(36.1, 108.2)	(36.1, 108.2)	(-2.4, 6.4)	(-6.1, 4.6)	(-6.1, 4.6)	(-6.1, 6.4)
	Week 6	n	69	60	40	129	68	60	40	128
		Mean	62.42	64.68	63.94	63.47	0.35	0.29	0.15	0.32
		SD	13.99	14.17	15.14	14.07	1.67	2.21	2.41	1.93
		Median	62.40	63.40	63.40	63.00	0.25	0.20	-0.05	0.20
		(Min, Max)	(36.2, 96.6)	(36.7, 105.0)	(36.7, 105.0)	(36.2, 105.0)	(-3.7, 6.7)	(-6.1, 6.9)	(-6.1, 6.9)	(-6.1, 6.9)
	Week 8	n	105	93	55	198	104	93	55	197
		Mean	61.80	62.69	64.19	62.22	0.30	0.04	0.07	0.18
		SD	13.48	14.16	15.40	13.78	2.02	2.19	2.45	2.10
		Median	59.70	61.70	62.80	61.25	0.25	-0.10	-0.20	0.20
		(Min, Max)	(36.0, 96.4)	(36.8, 104.0)	(37.4, 104.0)	(36.0, 104.0)	(-4.2, 7.7)	(-6.2, 5.8)	(-6.2, 5.8)	(-6.2, 7.7)
	Week 12	n	100	81	47	181	99	81	47	180
		Mean	61.89	62.21	63.28	62.03	0.51	0.22	0.26	0.38
		SD	13.20	14.37	15.84	13.69	2.78	2.65	2.99	2.72
		Median	60.85	61.20	62.50	61.20	0.50	0.00	0.00	0.30
		(Min, Max)	(37.6, 96.4)	(37.1, 106.0)	(37.1, 106.0)	(37.1, 106.0)	(-7.7, 8.1)	(-9.7, 6.9)	(-9.7, 6.3)	(-9.7, 8.1)

表 2.7.4.7－95 各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Weight (kg)	Week 16	n	94	73	43	167	93	73	43	166
		Mean	61.98	62.23	63.60	62.09	0.54	0.20	0.33	0.39
		SD	12.97	14.52	15.83	13.63	3.38	3.26	3.52	3.32
		Median	60.35	61.40	64.00	61.20	0.70	0.20	0.20	0.60
		(Min, Max)	(38.8, 97.9)	(36.2, 100.0)	(36.2, 100.0)	(36.2, 100.0)	(-10.8, 9.1)	(-8.9, 8.2)	(-8.9, 8.2)	(-10.8, 9.1)
	Week 20	n	92	67	39	159	91	67	39	158
		Mean	62.28	62.34	63.46	62.31	0.67	0.62	1.05	0.65
		SD	12.97	14.15	15.20	13.44	3.78	3.94	4.28	3.84
		Median	61.55	63.00	63.30	62.00	0.90	0.10	0.30	0.70
		(Min, Max)	(37.6, 96.5)	(37.6, 98.8)	(37.6, 98.8)	(37.6, 98.8)	(-10.9, 11.6)	(-11.5, 10.6)	(-11.5, 10.6)	(-11.5, 11.6)
	Week 24	n	86	65	39	151	85	65	39	150
		Mean	62.48	62.72	63.23	62.58	0.77	0.34	0.81	0.59
		SD	13.13	13.70	14.97	13.34	4.16	4.71	4.91	4.40
		Median	61.50	61.80	63.40	61.70	0.80	0.00	0.40	0.45
		(Min, Max)	(39.8, 98.2)	(37.9, 96.6)	(37.9, 96.6)	(37.9, 98.2)	(-14.0, 13.5)	(-12.0, 11.7)	(-9.9, 11.7)	(-14.0, 13.5)
	Week 28	n	84	61	37	145	83	61	37	144
		Mean	62.26	63.20	64.11	62.65	0.64	-0.03	0.74	0.35
		SD	12.88	13.44	14.25	13.08	4.73	5.12	5.32	4.89
		Median	61.50	63.40	63.90	62.80	1.00	-0.50	-0.50	0.15
		(Min, Max)	(39.8, 94.8)	(37.9, 96.8)	(37.9, 96.8)	(37.9, 96.8)	(-17.9, 12.2)	(-13.5, 12.2)	(-10.1, 12.2)	(-17.9, 12.2)
	Week 32	n	82	58	35	140	81	58	35	139
		Mean	62.01	63.51	64.60	62.63	0.59	0.32	1.08	0.48
		SD	13.30	13.84	14.77	13.50	5.16	5.47	5.93	5.27
		Median	60.50	64.35	66.80	62.60	0.80	0.40	1.90	0.60
		(Min, Max)	(34.6, 89.8)	(37.5, 99.1)	(37.5, 99.1)	(34.6, 99.1)	(-17.8, 14.8)	(-13.4, 13.3)	(-11.0, 13.3)	(-17.8, 14.8)
	Week 36	n	76	56	34	132	75	56	34	131
		Mean	62.66	63.00	63.96	62.80	0.55	-0.09	0.51	0.28
		SD	12.39	13.99	14.83	13.04	5.56	6.37	7.02	5.91
		Median	62.85	63.50	65.25	62.85	0.80	-0.40	-0.05	0.50
		(Min, Max)	(38.0, 87.9)	(33.4, 97.2)	(33.4, 97.2)	(33.4, 97.2)	(-21.6, 15.3)	(-17.0, 13.9)	(-16.6, 13.9)	(-21.6, 15.3)

表 2.7.4.7－95　各評価時点でのバイタルサイン及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Weight (kg)	Week 40	n	71	53	31	124	70	53	31	123
		Mean	62.38	63.93	65.72	63.04	0.79	-0.18	0.49	0.37
		SD	12.72	13.29	13.94	12.93	5.22	6.47	6.90	5.79
		Median	62.80	65.00	67.30	63.70	0.45	0.10	1.40	0.40
		(Min, Max)	(37.4, 88.8)	(35.0, 95.7)	(35.0, 95.7)	(35.0, 95.7)	(-11.7, 16.2)	(-21.0, 13.8)	(-13.5, 13.8)	(-21.0, 16.2)
	Week 44	n	67	50	29	117	66	50	29	116
		Mean	62.19	63.57	64.81	62.78	0.78	-0.16	0.38	0.37
		SD	12.93	13.11	14.13	12.97	4.95	6.32	6.87	5.58
		Median	62.80	63.90	65.30	62.90	0.55	-0.35	1.10	0.45
		(Min, Max)	(33.0, 87.5)	(35.9, 95.0)	(35.9, 95.0)	(33.0, 95.0)	(-11.1, 14.9)	(-22.2, 14.8)	(-15.0, 14.8)	(-22.2, 14.9)
	Week 48	n	66	50	29	116	65	50	29	115
		Mean	62.39	63.40	64.53	62.83	0.80	-0.33	0.10	0.31
		SD	12.84	12.90	13.81	12.82	5.22	6.71	6.96	5.92
		Median	63.20	63.05	64.60	63.20	0.20	-0.20	0.60	0.00
		(Min, Max)	(35.4, 88.9)	(35.4, 92.7)	(35.4, 92.7)	(35.4, 92.7)	(-11.0, 16.3)	(-26.0, 12.7)	(-14.4, 12.7)	(-26.0, 16.3)
	Week 52	n	66	49	28	115	65	49	28	114
		Mean	61.85	62.51	63.63	62.13	0.17	-1.55	-1.39	-0.57
		SD	12.59	12.87	13.92	12.66	4.75	6.07	5.62	5.40
		Median	61.80	62.20	63.55	62.00	0.00	-1.00	-1.20	-0.75
		(Min, Max)	(37.9, 86.5)	(36.1, 93.8)	(36.1, 93.8)	(36.1, 93.8)	(-10.9, 11.2)	(-27.7, 11.9)	(-13.5, 11.9)	(-27.7, 11.9)

5.3.5.1－1 Table 14.3.3.2.1 より引用

表 2.7.4.7－96　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：プラセボ対照二重盲検期間（海外試験_ISS）

Visit: Week 6

Parameter	PCS Category	PCS Criteria	Statistic[b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Systolic Blood Pressure (mmHg)	Low	<90 mmHg and Decrease from BL >=20 mmHg	n/N (%)	0/4	0/96	1/101 (1.0)	0/20	1/221 (0.5)	0/159
	High	>180 mmHg and Increase from BL >=20 mmHg	n/N (%)	0/4	0/96	1/101 (1.0)	0/20	1/221 (0.5)	1/159 (0.6)
Diastolic Blood Pressure (mmHg)	Low	<50 mmHg and Decrease from BL >=10 mmHg	n/N (%)	0/4	0/96	0/101	0/20	0/221	0/159
	High	>105 mmHg and Increase from BL >=10 mmHg	n/N (%)	0/4	1/96 (1.0)	0/101	1/20 (5.0)	2/221 (0.9)	1/159 (0.6)
Heart Rate (bpm)	Low	<50 bpm and Decrease from BL >=15 bpm	n/N (%)	0/4	0/96	1/101 (1.0)	0/20	1/221 (0.5)	1/159 (0.6)
	High	>120 bpm and Increase from BL >=15 bpm	n/N (%)	0/4	0/96	0/101	0/20	0/221	1/159 (0.6)
Orthostatic Systolic Blood Pressure (mmHg)	Low	Decrease of >=20 mmHg	n/N (%)	0/4	3/96 (3.1)	2/101 (2.0)	0/20	5/221 (2.3)	6/159 (3.8)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] N= number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－96 臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：プラセボ対照二重盲検期間（海外試験_ISS）（続き）

Visit: Week 6

Parameter	PCS Category	PCS Criteria	Statistic[b]	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Orthostatic Systolic Blood Pressure (mmHg)	High	Increase of >=20 mmHg	n/N (%)	0/4	2/96 (2.1)	0/101	0/20	2/221 (0.9)	1/159 (0.6)
Orthostatic Diastolic Blood Pressure (mmHg)	Low	Decrease of >=10 mmHg	n/N (%)	1/4 (25.0)	3/96 (3.1)	3/101 (3.0)	0/20	7/221 (3.2)	6/159 (3.8)
	High	Increase of >=10 mmHg	n/N (%)	0/4	14/96 (14.6)	13/101 (12.9)	6/20 (30.0)	33/221 (14.9)	14/159 (8.8)
Orthostatic Heart Rate (bpm)	Low	Decrease of >=15 bpm	n/N (%)	0/4	1/96 (1.0)	0/101	0/20	1/221 (0.5)	0/159
	High	Increase of >=15 bpm	n/N (%)	0/4	9/96 (9.4)	16/101 (15.8)	2/20 (10.0)	27/221 (12.2)	17/159 (10.7)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
[b] N= number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

5.3.5.3－2 Table 1.4.7.1より引用

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）

Visit: Week 8

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Systolic Blood Pressure (mmHg)	Low	<90 mmHg and Decrease from BL >=20 mmHg	n/N (%)	1/159 (0.6)	0/206	0/186	1/365 (0.3)
	High	>180 mmHg and Increase from BL >=20 mmHg	n/N (%)	0/159	0/206	0/186	0/365
Diastolic Blood Pressure (mmHg)	Low	<50 mmHg and Decrease from BL >=10 mmHg	n/N (%)	0/159	0/206	0/186	0/365
	High	>105 mmHg and Increase from BL >=10 mmHg	n/N (%)	1/159 (0.6)	1/206 (0.5)	1/186 (0.5)	2/365 (0.5)
Heart Rate (bpm)	Low	<50 bpm and Decrease from BL >=15 bpm	n/N (%)	1/159 (0.6)	1/206 (0.5)	1/186 (0.5)	2/365 (0.5)
	High	>120 bpm and Increase from BL >=15 bpm	n/N (%)	0/159	0/206	0/186	0/365

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 8

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Orthostatic Systolic Blood Pressure (mmHg)	Low	Decrease of >=20 mmHg	n/N (%)	7/158 (4.4)	7/206 (3.4)	4/186 (2.2)	14/364 (3.8)
	High	Increase of >=20 mmHg	n/N (%)	2/158 (1.3)	2/206 (1.0)	2/186 (1.1)	4/364 (1.1)
Orthostatic Diastolic Blood Pressure (mmHg)	Low	Decrease of >=10 mmHg	n/N (%)	9/158 (5.7)	9/206 (4.4)	8/186 (4.3)	18/364 (4.9)
	High	Increase of >=10 mmHg	n/N (%)	16/158 (10.1)	14/206 (6.8)	13/186 (7.0)	30/364 (8.2)
Orthostatic Heart Rate (bpm)	Low	Decrease of >=15 bpm	n/N (%)	0/158	1/206 (0.5)	1/186 (0.5)	1/364 (0.3)
	High	Increase of >=15 bpm	n/N (%)	20/158 (12.7)	15/206 (7.3)	14/186 (7.5)	35/364 (9.6)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 12

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Systolic Blood Pressure (mmHg)	Low	<90 mmHg and Decrease from BL >=20 mmHg	n/N (%)	0/141	0/197	0/179	0/338
	High	>180 mmHg and Increase from BL >=20 mmHg	n/N (%)	0/141	0/197	0/179	0/338
Diastolic Blood Pressure (mmHg)	Low	<50 mmHg and Decrease from BL >=10 mmHg	n/N (%)	0/141	0/197	0/179	0/338
	High	>105 mmHg and Increase from BL >=10 mmHg	n/N (%)	0/141	0/197	0/179	0/338
Heart Rate (bpm)	Low	<50 bpm and Decrease from BL >=15 bpm	n/N (%)	1/141 (0.7)	1/197 (0.5)	1/179 (0.6)	2/338 (0.6)
	High	>120 bpm and Increase from BL >=15 bpm	n/N (%)	0/141	0/197	0/179	0/338

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 12

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Orthostatic Systolic Blood Pressure (mmHg)	Low	Decrease of >=20 mmHg	n/N (%)	9/141 (6.4)	7/197 (3.6)	5/179 (2.8)	16/338 (4.7)
	High	Increase of >=20 mmHg	n/N (%)	1/141 (0.7)	9/197 (4.6)	7/179 (3.9)	10/338 (3.0)
Orthostatic Diastolic Blood Pressure (mmHg)	Low	Decrease of >=10 mmHg	n/N (%)	7/141 (5.0)	9/197 (4.6)	7/179 (3.9)	16/338 (4.7)
	High	Increase of >=10 mmHg	n/N (%)	16/141 (11.3)	26/197 (13.2)	22/179 (12.3)	42/338 (12.4)
Orthostatic Heart Rate (bpm)	Low	Decrease of >=15 bpm	n/N (%)	0/141	2/197 (1.0)	2/179 (1.1)	2/338 (0.6)
	High	Increase of >=15 bpm	n/N (%)	16/141 (11.3)	20/197 (10.2)	18/179 (10.1)	36/338 (10.7)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 48

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Systolic Blood Pressure (mmHg)	Low	<90 mmHg and Decrease from BL >=20 mmHg	n/N (%)	1/68 (1.5)	0/88	0/84	1/156 (0.6)
	High	>180 mmHg and Increase from BL >=20 mmHg	n/N (%)	0/68	0/88	0/84	0/156
Diastolic Blood Pressure (mmHg)	Low	<50 mmHg and Decrease from BL >=10 mmHg	n/N (%)	0/68	1/88 (1.1)	1/84 (1.2)	1/156 (0.6)
	High	>105 mmHg and Increase from BL >=10 mmHg	n/N (%)	1/68 (1.5)	1/88 (1.1)	1/84 (1.2)	2/156 (1.3)
Heart Rate (bpm)	Low	<50 bpm and Decrease from BL >=15 bpm	n/N (%)	0/68	0/88	0/84	0/156
	High	>120 bpm and Increase from BL >=15 bpm	n/N (%)	0/68	0/88	0/84	0/156

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 48

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Orthostatic Systolic Blood Pressure (mmHg)	Low	Decrease of >=20 mmHg	n/N (%)	4/68 (5.9)	5/88 (5.7)	5/84 (6.0)	9/156 (5.8)
	High	Increase of >=20 mmHg	n/N (%)	2/68 (2.9)	0/88	0/84	2/156 (1.3)
Orthostatic Diastolic Blood Pressure (mmHg)	Low	Decrease of >=10 mmHg	n/N (%)	4/68 (5.9)	4/88 (4.5)	4/84 (4.8)	8/156 (5.1)
	High	Increase of >=10 mmHg	n/N (%)	7/68 (10.3)	8/88 (9.1)	8/84 (9.5)	15/156 (9.6)
Orthostatic Heart Rate (bpm)	Low	Decrease of >=15 bpm	n/N (%)	0/68	0/88	0/84	0/156
	High	Increase of >=15 bpm	n/N (%)	13/68 (19.1)	10/88 (11.4)	10/84 (11.9)	23/156 (14.7)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 52

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Systolic Blood Pressure (mmHg)	Low	<90 mmHg and Decrease from BL >=20 mmHg	n/N (%)	1/67 (1.5)	1/83 (1.2)	1/79 (1.3)	2/150 (1.3)
	High	>180 mmHg and Increase from BL >=20 mmHg	n/N (%)	0/67	0/83	0/79	0/150
Diastolic Blood Pressure (mmHg)	Low	<50 mmHg and Decrease from BL >=10 mmHg	n/N (%)	0/67	0/83	0/79	0/150
	High	>105 mmHg and Increase from BL >=10 mmHg	n/N (%)	0/67	0/83	0/79	0/150
Heart Rate (bpm)	Low	<50 bpm and Decrease from BL >=15 bpm	n/N (%)	0/67	0/83	0/79	0/150
	High	>120 bpm and Increase from BL >=15 bpm	n/N (%)	0/67	0/83	0/79	0/150

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

表 2.7.4.7－97　臨床的に重要な変動を認めた被験者の割合（バイタルサイン）：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Visit: Week 52

Parameter	PCS Category	PCS Criteria	Statistic[c]	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Orthostatic Systolic Blood Pressure (mmHg)	Low	Decrease of >=20 mmHg	n/N (%)	2/67 (3.0)	5/82 (6.1)	5/78 (6.4)	7/149 (4.7)
	High	Increase of >=20 mmHg	n/N (%)	1/67 (1.5)	0/82	0/78	1/149 (0.7)
Orthostatic Diastolic Blood Pressure (mmHg)	Low	Decrease of >=10 mmHg	n/N (%)	1/67 (1.5)	2/82 (2.4)	2/78 (2.6)	3/149 (2.0)
	High	Increase of >=10 mmHg	n/N (%)	3/67 (4.5)	10/82 (12.2)	10/78 (12.8)	13/149 (8.7)
Orthostatic Heart Rate (bpm)	Low	Decrease of >=15 bpm	n/N (%)	0/67	0/82	0/78	0/149
	High	Increase of >=15 bpm	n/N (%)	13/67 (19.4)	9/82 (11.0)	8/78 (10.3)	22/149 (14.8)

BL= Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
[c] N=number of subjects with a post baseline measurement, n= number of subjects with a PCS value.

5.3.5.3－3 Table 1.4.7.2 より引用

表 2.7.4.7－98　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
QT (msec)	Baseline	n	85	84	169	84				
		Mean	384.8	384.9	384.9	383.3				
		SD	30.8	30.7	30.7	30.9				
		Median	384.0	379.0	382.0	386.5				
		(Min, Max)	(304, 484)	(326, 492)	(304, 492)	(300, 445)				
	Week 2	n	82	79	161	84	82	79	161	84
		Mean	394.2	399.9	397.0	385.3	8.4	16.3	12.3	1.9
		SD	31.0	30.4	30.8	32.4	23.4	24.6	24.3	18.4
		Median	396.5	395.0	396.0	386.0	10.0	18.0	13.0	2.0
		(Min, Max)	(325, 503)	(348, 488)	(325, 503)	(298, 458)	(-84, 67)	(-37, 98)	(-84, 98)	(-34, 82)
	Week 4	n	77	71	148	80	77	71	148	80
		Mean	390.1	394.4	392.2	386.2	4.8	11.7	8.1	1.9
		SD	34.1	30.4	32.3	33.3	25.0	23.9	24.6	21.6
		Median	392.0	392.0	392.0	390.0	6.0	10.0	8.0	0.0
		(Min, Max)	(326, 498)	(310, 460)	(310, 498)	(309, 454)	(-59, 84)	(-36, 84)	(-59, 84)	(-41, 86)
	Week 6	n	69	60	129	80	69	60	129	80
		Mean	390.2	393.8	391.9	387.0	4.3	14.0	8.8	2.7
		SD	30.7	32.8	31.6	34.5	26.7	26.6	27.0	22.4
		Median	388.0	396.0	390.0	389.5	2.0	13.0	6.0	2.0
		(Min, Max)	(326, 503)	(282, 475)	(282, 503)	(302, 480)	(-102, 67)	(-64, 80)	(-102, 80)	(-46, 86)

表 2.7.4.7－98 各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
QRS (msec)	Baseline	n	85	84	169	84				
		Mean	95.7	95.2	95.5	94.3				
		SD	14.0	15.4	14.7	13.2				
		Median	94.0	93.5	94.0	93.0				
		(Min, Max)	(69, 148)	(66, 148)	(66, 148)	(61, 150)				
	Week 2	n	82	79	161	84	82	79	161	84
		Mean	95.0	94.9	94.9	94.6	-0.2	0.0	-0.1	0.3
		SD	13.0	15.3	14.2	13.9	5.7	7.0	6.3	6.5
		Median	94.0	94.0	94.0	94.0	0.0	0.0	0.0	0.0
		(Min, Max)	(72, 150)	(55, 146)	(55, 150)	(59, 144)	(-14, 18)	(-33, 14)	(-33, 18)	(-23, 20)
	Week 4	n	77	71	148	80	77	71	148	80
		Mean	94.0	94.4	94.2	93.9	-0.7	0.4	-0.2	-0.3
		SD	12.4	14.6	13.4	14.1	5.4	5.6	5.5	6.7
		Median	93.0	93.0	93.0	93.5	0.0	0.0	0.0	0.0
		(Min, Max)	(68, 132)	(64, 150)	(64, 150)	(61, 147)	(-22, 12)	(-18, 14)	(-22, 14)	(-40, 14)
	Week 6	n	69	60	129	80	69	60	129	80
		Mean	95.1	96.4	95.7	94.6	-0.3	1.7	0.6	0.4
		SD	12.3	16.5	14.4	13.4	4.9	5.5	5.3	4.4
		Median	92.0	94.0	94.0	93.0	0.0	2.0	0.0	0.0
		(Min, Max)	(70, 134)	(68, 162)	(68, 162)	(62, 148)	(-14, 16)	(-14, 16)	(-14, 16)	(-10, 13)

表 2.7.4.7－98　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
PR (msec)	Baseline	n	83	84	167	84				
		Mean	163.3	162.8	163.1	165.0				
		SD	24.2	29.6	27.0	26.8				
		Median	162.0	159.5	160.0	161.0				
		(Min, Max)	(118, 244)	(114, 306)	(114, 306)	(116, 253)				
	Week 2	n	81	79	160	83	80	79	159	83
		Mean	161.7	164.7	163.2	164.9	-1.5	2.2	0.4	-0.3
		SD	24.1	29.8	27.0	25.9	17.0	13.3	15.4	10.1
		Median	160.0	162.0	160.0	162.0	-2.0	0.0	-1.0	0.0
		(Min, Max)	(117, 220)	(108, 314)	(108, 314)	(120, 247)	(-94, 60)	(-28, 54)	(-94, 60)	(-36, 24)
	Week 4	n	76	71	147	80	75	71	146	80
		Mean	161.8	160.2	161.0	167.1	-0.7	1.3	0.3	1.7
		SD	23.8	23.6	23.6	27.9	16.3	11.9	14.3	14.4
		Median	159.5	156.0	158.0	166.5	0.0	1.0	1.0	0.0
		(Min, Max)	(116, 234)	(114, 228)	(114, 234)	(116, 226)	(-100, 28)	(-38, 26)	(-100, 28)	(-30, 76)
	Week 6	n	68	60	128	80	67	60	127	80
		Mean	159.8	161.8	160.7	168.0	-0.2	2.9	1.3	2.6
		SD	22.9	25.4	24.0	28.4	17.2	16.8	17.0	17.9
		Median	160.0	155.5	158.0	166.0	2.0	2.0	2.0	2.0
		(Min, Max)	(118, 224)	(110, 240)	(110, 240)	(122, 286)	(-94, 40)	(-22, 80)	(-94, 80)	(-28, 140)

表 2.7.4.7－98　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
RR (msec)	Baseline	n	85	84	169	84				
		Mean	839.8	841.2	840.5	821.5				
		SD	164.4	154.6	159.1	143.8				
		Median	817.0	830.5	822.0	791.5				
		(Min, Max)	(472, 1367)	(557, 1395)	(472, 1395)	(470, 1204)				
	Week 2	n	82	79	161	84	82	79	161	84
		Mean	908.8	918.2	913.4	843.0	63.3	85.2	74.1	21.5
		SD	172.6	144.5	159.0	159.6	137.5	144.7	141.0	102.6
		Median	882.0	912.0	888.0	845.0	63.0	87.0	70.0	7.0
		(Min, Max)	(612, 1626)	(664, 1367)	(612, 1626)	(477, 1304)	(-175, 628)	(-211, 493)	(-211, 628)	(-209, 456)
	Week 4	n	77	71	148	80	77	71	148	80
		Mean	882.2	886.6	884.3	858.6	35.8	55.1	45.1	32.1
		SD	181.7	145.5	164.7	162.3	141.9	135.4	138.7	119.9
		Median	862.0	860.0	861.0	845.5	37.0	35.0	37.0	11.0
		(Min, Max)	(566, 1576)	(607, 1250)	(566, 1576)	(458, 1304)	(-321, 578)	(-267, 459)	(-321, 578)	(-253, 434)
	Week 6	n	69	60	129	80	69	60	129	80
		Mean	889.5	885.0	887.4	852.8	38.1	65.5	50.8	26.4
		SD	153.7	150.3	151.6	164.1	128.8	142.2	135.4	106.5
		Median	870.0	889.0	873.0	834.5	31.0	74.0	42.0	28.0
		(Min, Max)	(616, 1381)	(610, 1298)	(610, 1381)	(408, 1304)	(-228, 383)	(-326, 397)	(-326, 397)	(-238, 393)

表 2.7.4.7－98　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Heart Rate (beats/min)	Baseline	n	85	84	169	84				
		Mean	73.9	73.5	73.7	75.3				
		SD	14.3	12.9	13.6	14.2				
		Median	73.0	72.0	73.0	75.5				
		(Min, Max)	(44, 127)	(43, 107)	(43, 127)	(49, 128)				
	Week 2	n	82	79	161	84	82	79	161	84
		Mean	68.4	66.8	67.6	73.7	-4.9	-7.3	-6.1	-1.6
		SD	12.2	10.4	11.4	14.8	11.4	12.0	11.7	8.1
		Median	68.0	66.0	67.0	71.0	-5.5	-7.0	-6.0	-1.0
		(Min, Max)	(37, 98)	(43, 90)	(37, 98)	(46, 126)	(-35, 34)	(-39, 18)	(-39, 34)	(-34, 19)
	Week 4	n	77	71	148	80	77	71	148	80
		Mean	70.6	69.4	70.0	72.5	-2.9	-5.0	-3.9	-2.1
		SD	13.8	11.4	12.7	15.1	12.6	11.5	12.1	10.0
		Median	69.0	69.0	69.0	70.5	-3.0	-4.0	-3.0	-1.0
		(Min, Max)	(38, 106)	(48, 98)	(38, 106)	(46, 131)	(-50, 28)	(-38, 24)	(-50, 28)	(-33, 27)
	Week 6	n	69	60	129	80	69	60	129	80
		Mean	69.2	69.7	69.4	73.1	-3.7	-5.7	-4.7	-1.5
		SD	11.3	12.1	11.7	16.0	11.2	12.3	11.7	9.9
		Median	69.0	67.5	69.0	71.5	-3.0	-6.0	-4.0	-2.0
		(Min, Max)	(43, 97)	(46, 98)	(43, 98)	(46, 147)	(-48, 16)	(-32, 27)	(-48, 27)	(-31, 43)

表 2.7.4.7－98　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)	40 mg (N=85)	80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
QTcF (msec)	Baseline	n	85	84	169	84				
		Mean	409.5	409.1	409.3	410.6				
		SD	18.7	20.6	19.6	20.6				
		Median	410.0	409.0	409.0	411.5				
		(Min, Max)	(353, 454)	(363, 457)	(353, 457)	(355, 451)				
	Week 2	n	82	79	161	84	82	79	161	84
		Mean	408.4	412.4	410.4	409.3	-1.1	3.4	1.1	-1.4
		SD	20.1	20.4	20.2	19.1	15.4	16.7	16.1	12.0
		Median	410.5	410.0	410.0	411.5	-0.5	1.0	0.0	-1.0
		(Min, Max)	(357, 453)	(363, 455)	(357, 455)	(358, 448)	(-67, 41)	(-45, 50)	(-67, 50)	(-31, 28)
	Week 4	n	77	71	148	80	77	71	148	80
		Mean	408.5	411.6	410.0	407.8	-0.4	3.2	1.3	-2.9
		SD	21.6	19.7	20.7	21.3	14.8	15.3	15.1	13.1
		Median	409.0	411.0	409.5	409.5	0.0	3.0	0.0	-1.0
		(Min, Max)	(353, 459)	(366, 462)	(353, 462)	(354, 454)	(-40, 51)	(-45, 46)	(-45, 51)	(-39, 24)
	Week 6	n	69	60	129	80	69	60	129	80
		Mean	406.9	411.3	408.9	409.8	-1.8	3.9	0.9	-1.0
		SD	21.7	21.2	21.5	23.3	19.1	18.6	19.0	14.3
		Median	411.0	412.0	411.0	411.0	1.0	5.5	3.0	-0.5
		(Min, Max)	(341, 452)	(327, 456)	(327, 456)	(351, 474)	(-107, 23)	(-84, 47)	(-107, 47)	(-35, 44)

5.3.5.1－1 Table 14.3.4.1.1 より引用

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QT (msec)	Baseline	n	126	123	84	249				
		Mean	385.3	384.0	386.2	384.7				
		SD	30.0	30.7	31.6	30.3				
		Median	386.0	382.0	384.5	385.0				
		(Min, Max)	(304, 484)	(318, 492)	(318, 492)	(304, 492)				
	Week 2	n	82	79	59	161	82	79	59	161
		Mean	394.2	399.9	398.1	397.0	8.4	16.3	12.5	12.3
		SD	31.0	30.4	27.1	30.8	23.4	24.6	23.3	24.3
		Median	396.5	395.0	394.0	396.0	10.0	18.0	12.0	13.0
		(Min, Max)	(325, 503)	(348, 488)	(348, 460)	(325, 503)	(-84, 67)	(-37, 98)	(-37, 84)	(-84, 98)
	Week 4	n	77	71	51	148	77	71	51	148
		Mean	390.1	394.4	398.0	392.2	4.8	11.7	13.4	8.1
		SD	34.1	30.4	29.5	32.3	25.0	23.9	26.3	24.6
		Median	392.0	392.0	398.0	392.0	6.0	10.0	12.0	8.0
		(Min, Max)	(326, 498)	(310, 460)	(310, 460)	(310, 498)	(-59, 84)	(-36, 84)	(-36, 84)	(-59, 84)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	390.2	393.8	395.1	391.9	4.3	14.0	14.3	8.8
		SD	30.7	32.8	31.3	31.6	26.7	26.6	25.1	27.0
		Median	388.0	396.0	396.5	390.0	2.0	13.0	13.0	6.0
		(Min, Max)	(326, 503)	(282, 475)	(282, 442)	(282, 503)	(-102, 67)	(-64, 80)	(-64, 62)	(-102, 80)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	396.8	393.2	398.4	395.1	11.1	13.4	17.6	12.2
		SD	31.4	33.4	35.2	32.4	25.2	24.0	26.0	24.6
		Median	394.0	392.0	399.0	392.0	10.0	12.0	17.0	11.5
		(Min, Max)	(337, 491)	(307, 476)	(307, 476)	(307, 491)	(-48, 82)	(-34, 68)	(-34, 62)	(-48, 82)
	Week 12	n	100	80	47	180	100	80	47	180
		Mean	394.0	394.3	403.9	394.1	8.5	14.0	20.0	10.9
		SD	28.4	33.2	34.0	30.5	24.1	27.9	31.0	25.9
		Median	395.0	393.0	407.0	394.0	8.0	8.5	18.0	8.0
		(Min, Max)	(320, 468)	(308, 496)	(332, 496)	(308, 496)	(-50, 68)	(-51, 82)	(-51, 82)	(-51, 82)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QT (msec)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	393.6	392.5	395.1	393.1	8.8	11.4	11.5	10.0
		SD	31.9	32.6	36.3	32.1	27.8	26.4	32.0	27.2
		Median	393.0	395.0	396.0	394.0	8.5	14.0	14.0	9.0
		(Min, Max)	(320, 487)	(278, 464)	(278, 464)	(278, 487)	(-40, 98)	(-68, 70)	(-68, 70)	(-68, 98)
	Week 20	n	91	67	39	158	91	67	39	158
		Mean	394.4	393.5	400.8	394.0	9.3	11.8	16.6	10.3
		SD	31.4	30.6	29.4	31.0	25.8	26.8	28.4	26.2
		Median	392.0	394.0	408.0	392.0	6.0	10.0	23.0	8.0
		(Min, Max)	(320, 497)	(308, 458)	(308, 458)	(308, 497)	(-42, 90)	(-50, 72)	(-50, 70)	(-50, 90)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	392.9	390.9	398.3	392.0	6.7	9.7	14.1	8.0
		SD	30.2	31.7	34.6	30.8	28.1	26.4	29.3	27.3
		Median	388.5	388.0	404.0	388.0	5.0	8.0	16.0	6.0
		(Min, Max)	(322, 535)	(306, 464)	(306, 464)	(306, 535)	(-86, 99)	(-52, 76)	(-52, 76)	(-86, 99)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	392.6	391.8	399.4	392.3	6.6	11.6	15.3	8.7
		SD	28.1	31.4	32.8	29.4	26.2	25.8	28.4	26.1
		Median	390.0	389.0	402.0	389.5	6.0	11.0	18.0	8.0
		(Min, Max)	(336, 487)	(306, 454)	(306, 454)	(306, 487)	(-48, 68)	(-50, 78)	(-50, 78)	(-50, 78)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	394.3	389.5	397.2	392.3	8.0	10.3	14.0	9.0
		SD	27.9	32.6	34.2	29.9	27.0	25.0	25.7	26.1
		Median	390.0	383.0	396.0	389.0	8.0	11.0	12.0	9.0
		(Min, Max)	(346, 498)	(302, 458)	(302, 458)	(302, 498)	(-52, 72)	(-44, 68)	(-44, 68)	(-52, 72)
	Week 36	n	77	56	34	133	77	56	34	133
		Mean	396.0	391.6	397.9	394.1	10.0	12.3	16.1	11.0
		SD	29.1	32.6	36.2	30.6	30.3	26.7	31.1	28.8
		Median	391.0	388.0	397.0	390.0	10.0	13.5	21.5	12.0
		(Min, Max)	(333, 472)	(304, 462)	(304, 462)	(304, 472)	(-66, 89)	(-68, 68)	(-68, 68)	(-68, 89)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QT (msec)	Week 40	n	71	55	33	126	71	55	33	126
		Mean	393.0	392.0	400.2	392.5	7.2	13.6	19.7	10.0
		SD	27.8	33.1	34.0	30.1	31.0	24.5	26.7	28.4
		Median	390.0	384.0	390.0	388.0	6.0	8.0	18.0	8.0
		(Min, Max)	(336, 463)	(330, 468)	(348, 468)	(330, 468)	(-110, 84)	(-36, 74)	(-26, 74)	(-110, 84)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	393.4	389.5	394.4	391.7	7.3	11.6	14.6	9.2
		SD	28.7	30.8	33.2	29.5	28.1	19.4	21.4	24.7
		Median	392.0	388.0	404.0	390.0	6.0	10.0	14.0	8.5
		(Min, Max)	(346, 476)	(326, 466)	(341, 466)	(326, 476)	(-57, 72)	(-26, 58)	(-26, 58)	(-57, 72)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	395.7	394.6	401.9	395.2	9.6	16.6	22.0	12.6
		SD	30.1	31.8	35.1	30.7	27.7	25.3	30.2	26.8
		Median	390.0	389.0	408.0	390.0	5.0	15.0	32.0	9.0
		(Min, Max)	(349, 485)	(308, 491)	(308, 491)	(308, 491)	(-44, 76)	(-38, 64)	(-38, 64)	(-44, 76)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	386.9	378.9	382.8	383.5	1.1	1.1	3.2	1.1
		SD	30.0	29.4	29.7	29.9	27.0	18.8	18.9	23.8
		Median	379.0	374.0	379.0	378.0	-1.5	0.0	2.0	0.0
		(Min, Max)	(306, 478)	(324, 441)	(340, 441)	(306, 478)	(-50, 76)	(-43, 40)	(-32, 40)	(-50, 76)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QRS (msec)	Baseline	n	126	123	84	249				
		Mean	95.0	95.1	95.0	95.1				
		SD	12.9	15.7	15.9	14.3				
		Median	93.5	93.0	93.0	93.0				
		(Min, Max)	(69, 148)	(61, 150)	(66, 150)	(61, 150)				
	Week 2	n	82	79	59	161	82	79	59	161
		Mean	95.0	94.9	94.1	94.9	-0.2	0.0	-0.1	-0.1
		SD	13.0	15.3	15.2	14.2	5.7	7.0	7.1	6.3
		Median	94.0	94.0	94.0	94.0	0.0	0.0	0.0	0.0
		(Min, Max)	(72, 150)	(55, 146)	(55, 146)	(55, 150)	(-14, 18)	(-33, 14)	(-33, 12)	(-33, 18)
	Week 4	n	77	71	51	148	77	71	51	148
		Mean	94.0	94.4	93.7	94.2	-0.7	0.4	1.0	-0.2
		SD	12.4	14.6	14.9	13.4	5.4	5.6	5.7	5.5
		Median	93.0	93.0	93.0	93.0	0.0	0.0	0.0	0.0
		(Min, Max)	(68, 132)	(64, 150)	(64, 150)	(64, 150)	(-22, 12)	(-18, 14)	(-18, 14)	(-22, 14)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	95.1	96.4	94.9	95.7	-0.3	1.7	1.5	0.6
		SD	12.3	16.5	17.1	14.4	4.9	5.5	5.3	5.3
		Median	92.0	94.0	94.0	94.0	0.0	2.0	2.0	0.0
		(Min, Max)	(70, 134)	(68, 162)	(68, 162)	(68, 162)	(-14, 16)	(-14, 16)	(-14, 14)	(-14, 16)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	95.1	95.7	95.9	95.4	0.3	1.2	2.2	0.7
		SD	12.1	15.7	16.8	13.9	7.1	5.8	5.3	6.5
		Median	94.0	94.0	94.0	94.0	0.0	0.0	0.0	0.0
		(Min, Max)	(72, 142)	(63, 166)	(70, 166)	(63, 166)	(-28, 20)	(-16, 18)	(-8, 18)	(-28, 20)
	Week 12	n	100	80	47	180	100	80	47	180
		Mean	95.0	94.6	95.3	94.8	0.4	1.0	1.8	0.7
		SD	11.5	16.1	17.2	13.7	5.6	6.9	5.6	6.2
		Median	93.5	92.0	92.0	93.0	0.0	0.5	2.0	0.0
		(Min, Max)	(70, 134)	(63, 160)	(63, 160)	(63, 160)	(-20, 14)	(-18, 35)	(-12, 21)	(-20, 35)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QRS (msec)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	95.7	94.7	94.8	95.3	0.7	1.6	2.7	1.1
		SD	12.2	17.8	18.6	14.8	6.5	9.8	10.5	8.1
		Median	94.0	92.0	92.0	93.0	0.0	1.0	2.0	0.0
		(Min, Max)	(72, 142)	(63, 162)	(70, 162)	(63, 162)	(-20, 20)	(-18, 48)	(-12, 48)	(-20, 48)
	Week 20	n	91	67	39	158	91	67	39	158
		Mean	95.3	96.2	95.2	95.7	0.0	2.4	2.5	1.0
		SD	11.9	16.4	17.1	13.9	7.1	8.3	7.6	7.7
		Median	93.0	94.0	92.0	93.0	0.0	1.0	2.0	0.0
		(Min, Max)	(74, 138)	(66, 164)	(66, 164)	(66, 164)	(-18, 24)	(-12, 37)	(-12, 20)	(-18, 37)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	94.9	94.9	94.1	94.9	-0.4	0.7	1.4	0.1
		SD	11.6	16.5	15.5	13.9	6.1	6.9	6.8	6.5
		Median	94.0	92.0	92.0	94.0	0.0	0.0	1.0	0.0
		(Min, Max)	(74, 132)	(70, 156)	(70, 156)	(70, 156)	(-18, 13)	(-19, 20)	(-15, 20)	(-19, 20)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	94.9	94.4	94.1	94.7	-0.4	0.4	0.2	-0.1
		SD	11.5	13.8	15.0	12.4	6.7	5.2	5.1	6.1
		Median	94.0	93.0	94.0	94.0	0.0	0.0	0.0	0.0
		(Min, Max)	(74, 140)	(64, 152)	(64, 152)	(64, 152)	(-22, 18)	(-16, 14)	(-16, 12)	(-22, 18)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	95.6	94.2	94.4	95.0	0.2	0.2	1.0	0.2
		SD	11.7	14.6	15.1	12.9	5.6	4.9	4.0	5.3
		Median	95.5	94.0	94.0	94.0	0.0	0.0	0.0	0.0
		(Min, Max)	(76, 134)	(63, 156)	(72, 156)	(63, 156)	(-12, 16)	(-13, 13)	(-6, 10)	(-13, 16)
	Week 36	n	77	56	34	133	77	56	34	133
		Mean	96.1	94.3	94.6	95.3	0.5	0.5	1.3	0.5
		SD	14.3	13.9	15.1	14.1	8.0	4.8	4.5	6.8
		Median	96.0	92.0	92.0	94.0	0.0	2.0	2.0	1.0
		(Min, Max)	(72, 150)	(70, 152)	(70, 152)	(70, 152)	(-20, 38)	(-12, 11)	(-8, 11)	(-20, 38)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QRS (msec)	Week 40	n	71	55	33	126	71	55	33	126
		Mean	94.7	93.9	94.1	94.4	-0.7	0.3	0.9	-0.3
		SD	12.0	15.3	16.4	13.5	6.6	4.8	5.0	5.9
		Median	95.0	92.0	92.0	93.5	0.0	0.0	0.0	0.0
		(Min, Max)	(74, 142)	(70, 158)	(70, 158)	(70, 158)	(-20, 17)	(-10, 10)	(-10, 10)	(-20, 17)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	94.3	94.0	93.6	94.2	-0.8	0.0	-0.1	-0.5
		SD	10.1	14.0	14.5	11.9	6.3	5.7	5.5	6.1
		Median	94.0	92.0	92.0	92.0	0.0	0.0	-2.0	0.0
		(Min, Max)	(74, 126)	(70, 144)	(70, 144)	(70, 144)	(-18, 19)	(-13, 16)	(-10, 12)	(-18, 19)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	93.3	93.8	94.2	93.5	-1.8	0.3	0.6	-0.9
		SD	11.0	14.2	15.4	12.4	6.2	4.5	3.8	5.6
		Median	92.0	92.5	93.0	92.0	-1.0	0.0	0.0	0.0
		(Min, Max)	(73, 130)	(70, 146)	(70, 146)	(70, 146)	(-24, 14)	(-10, 11)	(-8, 9)	(-24, 14)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	93.3	93.1	92.5	93.2	-1.8	-0.3	-1.2	-1.2
		SD	10.7	14.4	15.7	12.4	6.0	5.6	6.1	5.9
		Median	94.0	91.0	90.0	93.0	-0.5	0.0	-0.5	0.0
		(Min, Max)	(74, 128)	(66, 144)	(66, 144)	(66, 144)	(-22, 7)	(-18, 17)	(-18, 17)	(-22, 17)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
PR (msec)	Baseline	n	124	123	84	247				
		Mean	165.2	162.5	166.8	163.8				
		SD	26.2	27.8	30.3	27.0				
		Median	162.0	158.0	165.5	160.0				
		(Min, Max)	(116, 253)	(114, 306)	(114, 306)	(114, 306)				
	Week 2	n	81	79	59	160	80	79	59	159
		Mean	161.7	164.7	168.3	163.2	-1.5	2.2	2.4	0.4
		SD	24.1	29.8	31.6	27.0	17.0	13.3	14.1	15.4
		Median	160.0	162.0	164.0	160.0	-2.0	0.0	0.0	-1.0
		(Min, Max)	(117, 220)	(108, 314)	(108, 314)	(108, 314)	(-94, 60)	(-28, 54)	(-28, 54)	(-94, 60)
	Week 4	n	76	71	51	147	75	71	51	146
		Mean	161.8	160.2	161.4	161.0	-0.7	1.3	-0.2	0.3
		SD	23.8	23.6	24.3	23.6	16.3	11.9	12.1	14.3
		Median	159.5	156.0	158.0	158.0	0.0	1.0	1.0	1.0
		(Min, Max)	(116, 234)	(114, 228)	(114, 228)	(114, 234)	(-100, 28)	(-38, 26)	(-38, 24)	(-100, 28)
	Week 6	n	68	60	40	128	67	60	40	127
		Mean	159.8	161.8	164.4	160.7	-0.2	2.9	2.1	1.3
		SD	22.9	25.4	25.5	24.0	17.2	16.8	18.7	17.0
		Median	160.0	155.5	163.5	158.0	2.0	2.0	1.0	2.0
		(Min, Max)	(118, 224)	(110, 240)	(110, 240)	(110, 240)	(-94, 40)	(-22, 80)	(-22, 80)	(-94, 80)
	Week 8	n	104	93	55	197	103	93	55	196
		Mean	161.5	163.3	167.5	162.3	-0.9	3.4	3.4	1.1
		SD	23.5	25.9	28.6	24.6	13.9	13.2	14.3	13.7
		Median	159.5	158.0	162.0	159.0	0.0	2.0	2.0	2.0
		(Min, Max)	(118, 240)	(108, 238)	(108, 238)	(108, 240)	(-88, 32)	(-32, 50)	(-30, 50)	(-88, 50)
	Week 12	n	99	80	47	179	98	80	47	178
		Mean	163.4	162.3	166.3	162.9	0.9	3.8	3.4	2.2
		SD	22.7	26.9	29.3	24.6	15.1	17.2	20.3	16.1
		Median	161.0	155.5	158.0	160.0	2.0	0.0	-1.0	2.0
		(Min, Max)	(114, 221)	(112, 242)	(112, 242)	(112, 242)	(-86, 50)	(-32, 76)	(-32, 76)	(-86, 76)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
PR (msec)	Week 16	n	93	73	43	166	92	73	43	165
		Mean	164.0	162.5	164.2	163.3	1.3	4.5	2.3	2.7
		SD	24.8	27.5	30.2	26.0	15.4	17.1	20.5	16.2
		Median	160.0	162.0	160.0	160.5	2.5	4.0	2.0	3.0
		(Min, Max)	(112, 234)	(84, 228)	(84, 228)	(84, 234)	(-86, 54)	(-46, 86)	(-46, 86)	(-86, 86)
	Week 20	n	90	67	39	157	89	67	39	156
		Mean	162.8	161.5	165.1	162.3	1.1	5.0	5.1	2.8
		SD	24.3	28.7	31.2	26.2	16.7	21.5	25.8	18.9
		Median	160.0	158.0	162.0	160.0	4.0	0.0	-1.0	2.0
		(Min, Max)	(112, 242)	(110, 254)	(110, 254)	(110, 254)	(-92, 42)	(-26, 124)	(-26, 124)	(-92, 124)
	Week 24	n	85	65	39	150	84	65	39	149
		Mean	163.6	160.9	165.2	162.4	2.3	4.5	5.2	3.3
		SD	23.2	27.0	29.7	24.8	15.8	18.0	21.3	16.7
		Median	160.0	157.0	162.0	159.0	2.5	1.0	2.0	2.0
		(Min, Max)	(120, 234)	(108, 232)	(108, 232)	(108, 234)	(-86, 54)	(-36, 76)	(-36, 76)	(-86, 76)
	Week 28	n	84	61	37	145	83	61	37	144
		Mean	160.9	159.0	162.4	160.1	-0.2	4.0	4.1	1.6
		SD	23.9	24.6	26.6	24.1	15.1	14.6	17.4	15.0
		Median	158.0	154.0	156.0	156.0	2.0	3.0	3.0	2.0
		(Min, Max)	(117, 238)	(123, 234)	(123, 234)	(117, 238)	(-90, 28)	(-36, 60)	(-36, 60)	(-90, 60)
	Week 32	n	81	58	35	139	81	58	35	139
		Mean	162.2	159.2	163.6	160.9	0.8	4.7	5.6	2.4
		SD	24.7	25.8	28.7	25.1	16.9	16.4	19.4	16.8
		Median	158.0	153.5	158.0	156.0	2.0	3.0	3.0	2.0
		(Min, Max)	(112, 230)	(122, 225)	(122, 225)	(112, 230)	(-90, 42)	(-26, 82)	(-26, 82)	(-90, 82)
	Week 36	n	76	56	34	132	76	56	34	132
		Mean	160.7	160.4	164.5	160.6	-1.2	5.5	5.8	1.7
		SD	23.8	25.7	29.3	24.5	19.2	15.8	19.4	18.1
		Median	158.5	157.0	161.0	158.0	2.5	4.0	3.5	4.0
		(Min, Max)	(113, 208)	(106, 230)	(106, 230)	(106, 230)	(-88, 40)	(-38, 76)	(-38, 76)	(-88, 76)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
PR (msec)	Week 40	n	70	55	33	125	70	55	33	125
		Mean	162.8	159.0	161.3	161.1	0.8	4.7	3.4	2.5
		SD	24.6	25.7	27.9	25.0	16.8	15.9	18.1	16.5
		Median	159.5	154.0	162.0	158.0	3.5	2.0	2.0	3.0
		(Min, Max)	(108, 216)	(110, 226)	(110, 226)	(108, 226)	(-86, 30)	(-26, 76)	(-26, 76)	(-86, 76)
	Week 44	n	66	51	29	117	66	51	29	117
		Mean	162.5	155.9	157.4	159.6	1.4	2.4	0.4	1.8
		SD	25.8	23.4	26.4	24.9	15.6	12.1	14.5	14.1
		Median	158.0	152.0	160.0	154.0	2.0	2.0	-2.0	2.0
		(Min, Max)	(110, 229)	(112, 218)	(112, 218)	(110, 229)	(-90, 26)	(-30, 50)	(-30, 50)	(-90, 50)
	Week 48	n	66	50	29	116	66	50	29	116
		Mean	161.6	158.0	160.6	160.1	0.5	4.7	3.6	2.3
		SD	23.6	27.1	31.1	25.1	15.7	15.8	19.5	15.8
		Median	159.0	156.0	157.0	157.0	2.0	3.5	2.0	3.0
		(Min, Max)	(110, 223)	(106, 254)	(106, 254)	(106, 254)	(-90, 32)	(-38, 58)	(-38, 58)	(-90, 58)
	Week 52	n	65	49	28	114	65	49	28	114
		Mean	162.0	156.7	160.4	159.7	0.6	3.6	3.7	1.9
		SD	23.6	21.3	23.6	22.7	14.2	14.5	17.3	14.4
		Median	162.0	150.0	156.5	156.5	0.0	3.0	-0.5	2.0
		(Min, Max)	(110, 230)	(126, 218)	(126, 218)	(110, 230)	(-64, 34)	(-40, 56)	(-40, 56)	(-64, 56)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
RR (msec)	Baseline	n	126	123	84	249				
		Mean	835.5	836.4	835.9	836.0				
		SD	153.6	152.8	158.2	152.9				
		Median	808.5	828.0	833.0	812.0				
		(Min, Max)	(472, 1367)	(510, 1395)	(510, 1395)	(472, 1395)				
	Week 2	n	82	79	59	161	82	79	59	161
		Mean	908.8	918.2	905.9	913.4	63.3	85.2	68.2	74.1
		SD	172.6	144.5	140.4	159.0	137.5	144.7	146.6	141.0
		Median	882.0	912.0	882.0	888.0	63.0	87.0	61.0	70.0
		(Min, Max)	(612, 1626)	(664, 1367)	(664, 1173)	(612, 1626)	(-175, 628)	(-211, 493)	(-211, 493)	(-211, 628)
	Week 4	n	77	71	51	148	77	71	51	148
		Mean	882.2	886.6	895.3	884.3	35.8	55.1	58.9	45.1
		SD	181.7	145.5	141.3	164.7	141.9	135.4	149.6	138.7
		Median	862.0	860.0	880.0	861.0	37.0	35.0	33.0	37.0
		(Min, Max)	(566, 1576)	(607, 1250)	(607, 1250)	(566, 1576)	(-321, 578)	(-267, 459)	(-267, 459)	(-321, 578)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	889.5	885.0	895.4	887.4	38.1	65.5	75.7	50.8
		SD	153.7	150.3	137.6	151.6	128.8	142.2	142.1	135.4
		Median	870.0	889.0	902.5	873.0	31.0	74.0	90.0	42.0
		(Min, Max)	(616, 1381)	(610, 1298)	(643, 1154)	(610, 1381)	(-228, 383)	(-326, 397)	(-326, 397)	(-326, 397)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	897.7	885.3	904.6	891.8	55.2	65.6	95.5	60.0
		SD	155.3	169.6	169.5	161.9	135.8	146.4	155.4	140.6
		Median	891.0	870.0	896.0	881.0	50.0	57.0	90.0	50.5
		(Min, Max)	(608, 1476)	(521, 1269)	(521, 1269)	(521, 1476)	(-451, 478)	(-268, 458)	(-268, 341)	(-451, 478)
	Week 12	n	100	80	47	180	100	80	47	180
		Mean	879.8	891.1	921.4	884.8	37.9	66.8	95.1	50.7
		SD	158.4	163.7	172.1	160.4	132.5	154.8	177.6	143.2
		Median	851.0	870.0	905.0	868.0	40.5	29.5	82.0	36.5
		(Min, Max)	(550, 1430)	(581, 1252)	(608, 1252)	(550, 1430)	(-267, 432)	(-217, 501)	(-217, 501)	(-267, 501)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
RR (msec)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	879.1	891.8	896.7	884.7	41.6	62.7	69.7	50.8
		SD	155.4	156.0	164.6	155.3	142.5	160.9	190.6	150.7
		Median	857.0	881.0	881.0	858.0	45.5	44.0	44.0	45.0
		(Min, Max)	(555, 1405)	(580, 1333)	(580, 1333)	(555, 1405)	(-412, 413)	(-607, 454)	(-607, 454)	(-607, 454)
	Week 20	n	91	67	39	158	91	67	39	158
		Mean	886.4	888.0	902.8	887.1	49.9	58.1	75.9	53.3
		SD	165.5	149.5	153.4	158.4	152.0	156.1	175.7	153.3
		Median	870.0	882.0	882.0	876.0	37.0	30.0	37.0	35.0
		(Min, Max)	(554, 1496)	(595, 1333)	(595, 1333)	(554, 1496)	(-408, 498)	(-236, 574)	(-236, 574)	(-408, 574)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	889.4	869.9	892.2	881.0	46.4	48.1	65.3	47.1
		SD	166.3	151.5	161.2	159.8	150.3	139.5	155.9	145.3
		Median	870.0	857.0	896.0	870.0	47.5	38.0	56.0	44.0
		(Min, Max)	(558, 1463)	(583, 1250)	(583, 1250)	(558, 1463)	(-294, 465)	(-310, 450)	(-310, 450)	(-310, 465)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	893.3	876.1	909.3	886.1	48.7	59.2	87.5	53.1
		SD	156.9	153.5	168.9	155.2	137.3	138.2	138.5	137.3
		Median	877.0	857.0	882.0	872.0	42.0	47.0	68.0	45.5
		(Min, Max)	(576, 1363)	(581, 1304)	(581, 1304)	(576, 1363)	(-255, 365)	(-303, 330)	(-167, 330)	(-303, 365)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	898.3	872.6	895.7	887.7	49.3	63.5	81.9	55.2
		SD	156.8	161.6	172.2	158.7	138.6	141.7	148.0	139.6
		Median	870.0	850.5	909.0	870.0	53.5	52.5	50.0	53.5
		(Min, Max)	(604, 1501)	(566, 1191)	(593, 1191)	(566, 1501)	(-231, 503)	(-267, 434)	(-164, 434)	(-267, 503)
	Week 36	n	77	56	34	133	77	56	34	133
		Mean	902.4	878.2	891.1	892.2	51.4	68.8	83.2	58.7
		SD	151.7	168.0	195.8	158.6	152.0	148.7	170.3	150.3
		Median	903.0	882.5	894.5	893.0	70.0	47.5	58.5	63.0
		(Min, Max)	(568, 1306)	(472, 1215)	(472, 1215)	(472, 1306)	(-400, 577)	(-251, 400)	(-251, 400)	(-400, 577)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
RR (msec)	Week 40	n	71	55	33	126	71	55	33	126
		Mean	899.9	864.7	881.7	884.5	48.6	63.8	88.0	55.3
		SD	143.9	157.6	174.9	150.5	157.7	133.2	145.7	147.2
		Median	864.0	847.0	857.0	858.0	60.0	35.0	100.0	42.5
		(Min, Max)	(674, 1333)	(606, 1231)	(606, 1231)	(606, 1333)	(-352, 428)	(-286, 338)	(-286, 338)	(-352, 428)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	903.7	855.6	865.1	882.9	49.1	55.7	74.0	51.9
		SD	161.4	148.7	168.1	157.2	133.9	124.1	115.1	129.3
		Median	870.0	845.0	866.0	859.5	52.0	48.0	63.0	48.5
		(Min, Max)	(637, 1358)	(627, 1141)	(627, 1141)	(627, 1358)	(-349, 319)	(-340, 356)	(-131, 356)	(-349, 356)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	901.1	889.2	913.5	896.0	46.5	89.1	122.4	64.7
		SD	154.5	146.7	156.7	150.7	139.8	150.7	170.2	145.5
		Median	845.0	865.0	938.0	860.0	42.0	69.0	127.0	45.0
		(Min, Max)	(577, 1294)	(619, 1310)	(643, 1310)	(577, 1310)	(-308, 336)	(-197, 400)	(-197, 400)	(-308, 400)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	865.5	802.0	811.0	838.4	11.5	3.5	23.1	8.1
		SD	155.3	140.4	153.8	151.8	142.8	92.5	92.4	123.4
		Median	844.5	759.0	762.5	811.0	13.0	-8.0	1.0	0.0
		(Min, Max)	(593, 1277)	(571, 1129)	(571, 1129)	(571, 1277)	(-368, 373)	(-174, 217)	(-131, 217)	(-368, 373)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Heart Rate (beats/min)	Baseline	n	126	123	84	249				
		Mean	74.0	74.0	74.2	74.0				
		SD	13.5	13.3	13.9	13.4				
		Median	74.0	72.0	72.0	74.0				
		(Min, Max)	(44, 127)	(43, 117)	(43, 117)	(43, 127)				
	Week 2	n	82	79	59	161	82	79	59	161
		Mean	68.4	66.8	67.6	67.6	-4.9	-7.3	-5.9	-6.1
		SD	12.2	10.4	10.5	11.4	11.4	12.0	12.0	11.7
		Median	68.0	66.0	68.0	67.0	-5.5	-7.0	-6.0	-6.0
		(Min, Max)	(37, 98)	(43, 90)	(51, 90)	(37, 98)	(-35, 34)	(-39, 18)	(-39, 18)	(-39, 34)
	Week 4	n	77	71	51	148	77	71	51	148
		Mean	70.6	69.4	68.5	70.0	-2.9	-5.0	-5.4	-3.9
		SD	13.8	11.4	10.9	12.7	12.6	11.5	12.6	12.1
		Median	69.0	69.0	68.0	69.0	-3.0	-4.0	-4.0	-3.0
		(Min, Max)	(38, 106)	(48, 98)	(48, 98)	(38, 106)	(-50, 28)	(-38, 24)	(-38, 24)	(-50, 28)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	69.2	69.7	68.5	69.4	-3.7	-5.7	-6.9	-4.7
		SD	11.3	12.1	10.8	11.7	11.2	12.3	11.5	11.7
		Median	69.0	67.5	66.5	69.0	-3.0	-6.0	-7.0	-4.0
		(Min, Max)	(43, 97)	(46, 98)	(52, 93)	(43, 98)	(-48, 16)	(-32, 27)	(-32, 27)	(-48, 27)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	68.6	70.2	68.6	69.4	-4.9	-5.4	-8.2	-5.1
		SD	11.1	14.1	13.9	12.6	11.1	13.2	13.9	12.1
		Median	67.0	69.0	67.0	68.0	-5.0	-4.0	-7.0	-5.0
		(Min, Max)	(41, 98)	(47, 115)	(47, 115)	(41, 115)	(-41, 22)	(-40, 24)	(-40, 24)	(-41, 24)
	Week 12	n	100	80	47	180	100	80	47	180
		Mean	70.2	69.5	67.3	69.9	-3.4	-5.4	-7.7	-4.3
		SD	12.4	12.9	12.6	12.6	11.4	12.5	13.6	11.9
		Median	70.5	69.0	66.0	69.0	-3.0	-3.0	-5.0	-3.0
		(Min, Max)	(42, 109)	(47, 103)	(47, 98)	(42, 109)	(-47, 20)	(-34, 22)	(-34, 21)	(-47, 22)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Heart Rate (beats/min)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	70.2	69.2	69.0	69.8	-3.8	-5.3	-6.0	-4.4
		SD	12.2	12.4	12.7	12.3	12.4	13.1	15.2	12.7
		Median	70.0	68.0	68.0	70.0	-3.5	-4.0	-5.0	-4.0
		(Min, Max)	(43, 108)	(45, 103)	(45, 103)	(43, 108)	(-42, 21)	(-34, 43)	(-34, 43)	(-42, 43)
	Week 20	n	91	67	39	158	91	67	39	158
		Mean	69.9	69.4	68.2	69.7	-4.3	-5.2	-7.0	-4.7
		SD	12.5	11.7	11.3	12.1	12.7	12.4	13.3	12.5
		Median	68.0	68.0	68.0	68.0	-3.0	-2.0	-3.0	-3.0
		(Min, Max)	(40, 108)	(45, 100)	(45, 100)	(40, 108)	(-44, 24)	(-34, 15)	(-34, 15)	(-44, 24)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	69.6	70.7	68.9	70.1	-4.0	-4.4	-6.2	-4.2
		SD	12.6	12.3	12.6	12.5	13.0	10.9	11.2	12.1
		Median	69.0	70.0	67.0	69.0	-4.0	-4.0	-4.0	-4.0
		(Min, Max)	(41, 107)	(48, 102)	(48, 102)	(41, 107)	(-49, 25)	(-28, 20)	(-28, 15)	(-49, 25)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	69.3	70.4	68.2	69.8	-4.1	-5.2	-7.5	-4.6
		SD	12.4	12.2	13.1	12.3	12.1	11.3	10.6	11.8
		Median	68.0	70.0	68.0	69.0	-3.0	-6.0	-6.0	-4.0
		(Min, Max)	(44, 105)	(46, 103)	(46, 103)	(44, 105)	(-55, 19)	(-25, 27)	(-25, 16)	(-55, 27)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	68.6	71.1	69.4	69.6	-4.4	-5.2	-6.9	-4.7
		SD	11.3	13.6	14.2	12.3	12.0	11.6	11.4	11.8
		Median	69.0	70.0	66.0	69.0	-4.0	-5.0	-6.0	-4.0
		(Min, Max)	(40, 99)	(50, 106)	(50, 101)	(40, 106)	(-53, 22)	(-34, 20)	(-34, 12)	(-53, 22)
	Week 36	n	77	56	34	133	77	56	34	133
		Mean	68.2	70.9	70.8	69.4	-4.6	-5.2	-6.0	-4.9
		SD	11.5	14.8	17.6	13.0	14.2	13.6	15.8	13.9
		Median	66.0	67.5	66.5	67.0	-5.0	-4.0	-5.5	-4.0
		(Min, Max)	(45, 105)	(49, 127)	(49, 127)	(45, 127)	(-52, 44)	(-29, 44)	(-29, 44)	(-52, 44)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Heart Rate (beats/min)	Week 40	n	71	55	33	126	71	55	33	126
		Mean	68.2	71.4	70.5	69.6	-4.8	-5.2	-7.3	-5.0
		SD	10.2	12.4	13.7	11.3	13.5	11.7	12.9	12.7
		Median	69.0	70.0	70.0	70.0	-5.0	-4.0	-10.0	-4.0
		(Min, Max)	(45, 89)	(49, 99)	(49, 99)	(45, 99)	(-49, 25)	(-36, 22)	(-36, 22)	(-49, 25)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	68.3	72.0	71.8	69.9	-4.5	-4.9	-6.5	-4.6
		SD	11.6	12.5	14.0	12.1	12.4	11.0	10.3	11.8
		Median	69.0	71.0	69.0	69.0	-4.0	-5.0	-5.0	-4.0
		(Min, Max)	(44, 94)	(53, 95)	(53, 95)	(44, 95)	(-41, 29)	(-29, 32)	(-29, 13)	(-41, 32)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	68.4	69.2	67.4	68.7	-4.4	-7.8	-10.9	-5.8
		SD	11.5	11.1	11.3	11.3	12.4	12.5	13.6	12.5
		Median	71.0	69.5	64.0	70.0	-4.0	-7.5	-14.0	-4.0
		(Min, Max)	(46, 104)	(46, 97)	(46, 93)	(46, 104)	(-52, 20)	(-34, 17)	(-34, 14)	(-52, 20)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	71.3	76.9	76.3	73.7	-1.5	-0.2	-2.4	-1.0
		SD	12.2	12.9	13.7	12.7	13.3	9.9	10.1	11.9
		Median	71.0	79.0	79.0	74.0	-1.0	0.0	-1.0	0.0
		(Min, Max)	(47, 101)	(53, 105)	(53, 105)	(47, 105)	(-56, 35)	(-20, 22)	(-20, 19)	(-56, 35)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QTcF (msec)	Baseline	n	126	123	84	249				
		Mean	410.5	409.0	411.5	409.8				
		SD	18.9	20.8	20.2	19.8				
		Median	410.0	409.0	411.5	410.0				
		(Min, Max)	(353, 454)	(355, 457)	(367, 457)	(353, 457)				
	Week 2	n	82	79	59	161	82	79	59	161
		Mean	408.4	412.4	412.5	410.4	-1.1	3.4	2.0	1.1
		SD	20.1	20.4	18.2	20.2	15.4	16.7	14.6	16.1
		Median	410.5	410.0	410.0	410.0	-0.5	1.0	1.0	0.0
		(Min, Max)	(357, 453)	(363, 455)	(376, 454)	(357, 455)	(-67, 41)	(-45, 50)	(-45, 35)	(-67, 50)
	Week 4	n	77	71	51	148	77	71	51	148
		Mean	408.5	411.6	413.9	410.0	-0.4	3.2	4.2	1.3
		SD	21.6	19.7	18.7	20.7	14.8	15.3	16.3	15.1
		Median	409.0	411.0	413.0	409.5	0.0	3.0	4.0	0.0
		(Min, Max)	(353, 459)	(366, 462)	(366, 462)	(353, 462)	(-40, 51)	(-45, 46)	(-45, 46)	(-45, 51)
	Week 6	n	69	60	40	129	69	60	40	129
		Mean	406.9	411.3	410.8	408.9	-1.8	3.9	2.3	0.9
		SD	21.7	21.2	21.8	21.5	19.1	18.6	19.7	19.0
		Median	411.0	412.0	411.5	411.0	1.0	5.5	6.5	3.0
		(Min, Max)	(341, 452)	(327, 456)	(327, 456)	(327, 456)	(-107, 23)	(-84, 47)	(-84, 47)	(-107, 47)
	Week 8	n	105	93	55	198	105	93	55	198
		Mean	412.4	411.2	413.3	411.8	2.6	3.8	3.0	3.1
		SD	17.7	23.1	22.0	20.4	15.0	18.5	18.1	16.7
		Median	410.0	411.0	412.0	411.0	3.0	4.0	4.0	3.0
		(Min, Max)	(370, 456)	(346, 476)	(346, 456)	(346, 476)	(-46, 51)	(-65, 66)	(-65, 52)	(-65, 66)
	Week 12	n	100	80	47	180	100	80	47	180
		Mean	412.6	411.2	416.5	412.0	2.9	4.1	5.7	3.4
		SD	17.5	23.0	20.5	20.1	16.4	16.0	17.2	16.2
		Median	412.5	408.5	414.0	412.0	4.0	2.0	7.0	3.0
		(Min, Max)	(364, 453)	(352, 469)	(378, 469)	(352, 469)	(-75, 42)	(-33, 60)	(-33, 60)	(-75, 60)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QTcF (msec)	Week 16	n	94	73	43	167	94	73	43	167
		Mean	412.2	409.0	410.8	410.8	2.5	1.8	0.3	2.2
		SD	20.3	22.8	23.4	21.4	14.3	17.7	20.2	15.8
		Median	414.0	412.0	412.0	413.0	3.0	2.0	2.0	2.0
		(Min, Max)	(345, 477)	(333, 458)	(333, 458)	(333, 477)	(-41, 39)	(-78, 39)	(-78, 39)	(-78, 39)
	Week 20	n	91	67	39	158	91	67	39	158
		Mean	411.9	410.6	415.9	411.4	1.7	2.7	4.6	2.1
		SD	17.8	21.2	19.3	19.3	13.7	17.4	19.5	15.4
		Median	411.0	413.0	415.0	412.0	2.0	1.0	6.0	2.0
		(Min, Max)	(373, 451)	(358, 453)	(366, 453)	(358, 453)	(-38, 33)	(-45, 53)	(-45, 53)	(-45, 53)
	Week 24	n	86	65	39	151	86	65	39	151
		Mean	410.1	410.8	414.9	410.4	-0.2	2.2	3.6	0.8
		SD	19.5	21.8	21.3	20.4	15.3	19.3	23.3	17.1
		Median	412.5	411.0	415.0	411.0	1.0	2.0	3.0	1.0
		(Min, Max)	(359, 471)	(353, 457)	(366, 457)	(353, 471)	(-79, 35)	(-60, 85)	(-60, 85)	(-79, 85)
	Week 28	n	85	61	37	146	85	61	37	146
		Mean	409.1	410.7	413.6	409.8	-0.7	2.5	1.6	0.6
		SD	18.9	20.0	18.2	19.3	14.0	17.7	17.2	15.7
		Median	406.0	412.0	414.0	411.0	1.0	2.0	3.0	1.0
		(Min, Max)	(358, 458)	(367, 451)	(367, 451)	(358, 458)	(-32, 36)	(-46, 40)	(-44, 37)	(-46, 40)
	Week 32	n	82	58	35	140	82	58	35	140
		Mean	410.0	409.0	413.5	409.6	0.6	0.6	1.3	0.6
		SD	18.7	19.0	17.5	18.7	15.7	12.6	13.6	14.4
		Median	409.0	412.5	416.0	410.0	-1.0	-0.5	5.0	-1.0
		(Min, Max)	(366, 474)	(357, 446)	(357, 446)	(357, 474)	(-49, 37)	(-54, 23)	(-54, 20)	(-54, 37)
	Week 36	n	77	56	34	133	77	56	34	133
		Mean	411.1	410.5	415.6	410.8	2.3	2.1	3.9	2.2
		SD	20.4	19.8	18.8	20.1	17.5	15.8	17.3	16.8
		Median	411.0	408.5	416.5	410.0	2.0	3.0	5.5	2.0
		(Min, Max)	(366, 477)	(375, 451)	(375, 451)	(366, 477)	(-38, 47)	(-36, 49)	(-36, 49)	(-38, 49)

表 2.7.4.7－99　各評価時点での心電図パラメータ及びベースラインからの変化量：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

			Absolute				Change from baseline			
			MT-5199				MT-5199			
Parameter (unit)	Analysis visit	Statistics	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)	40 mg (N=126)	80 mg (N=123)	80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
QTcF (msec)	Week 40	n	71	55	33	126	71	55	33	126
		Mean	408.0	412.7	418.9	410.1	-0.6	4.0	6.5	1.4
		SD	19.0	20.6	17.4	19.8	17.3	14.0	14.0	16.0
		Median	408.0	414.0	417.0	409.0	0.0	4.0	8.0	2.0
		(Min, Max)	(354, 454)	(360, 462)	(384, 462)	(354, 462)	(-63, 46)	(-30, 35)	(-30, 35)	(-63, 46)
	Week 44	n	67	51	29	118	67	51	29	118
		Mean	408.4	411.5	415.3	409.7	-0.1	3.1	3.1	1.3
		SD	20.4	18.8	17.3	19.7	18.8	12.8	12.5	16.5
		Median	412.0	410.0	415.0	411.0	1.0	4.0	3.0	2.5
		(Min, Max)	(356, 444)	(369, 450)	(382, 450)	(356, 450)	(-83, 53)	(-32, 39)	(-20, 26)	(-83, 53)
	Week 48	n	67	50	29	117	67	50	29	117
		Mean	411.0	411.3	414.9	411.1	2.5	2.8	2.7	2.6
		SD	20.8	21.0	19.8	20.8	15.8	14.3	15.5	15.1
		Median	413.0	412.5	415.0	413.0	1.0	4.0	5.0	3.0
		(Min, Max)	(356, 456)	(357, 449)	(357, 449)	(356, 456)	(-44, 36)	(-54, 35)	(-54, 25)	(-54, 36)
	Week 52	n	66	49	28	115	66	49	28	115
		Mean	407.3	409.1	411.9	408.1	-1.0	0.5	-0.6	-0.3
		SD	20.6	20.2	15.9	20.4	15.3	15.1	13.4	15.2
		Median	406.5	408.0	409.5	407.0	-2.0	-1.0	0.5	-2.0
		(Min, Max)	(349, 486)	(353, 445)	(389, 445)	(349, 486)	(-32, 47)	(-44, 45)	(-44, 21)	(-44, 47)

5.3.5.1－1 Table 14.3.4.2.1 より引用

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Baseline	Actual	n	5	110	112	27	254	177
		Mean(SD)	73.7(8.47)	73.3(13.03)	74.3(13.62)	73.8(11.98)	73.8(13.06)	75.3(13.12)
		SEM	3.79	1.24	1.29	2.31	0.82	0.99
		Median	72.0	72.5	73.7	71.7	72.8	72.7
		Min, Max	64, 83	45, 108	46, 102	54, 98	45, 108	50, 116
Week 2	Actual	n	5	103	108	25	241	170
		Mean(SD)	69.9(13.08)	70.9(11.63)	69.5(12.42)	70.1(12.30)	70.2(12.03)	75.6(12.76)
		SEM	5.85	1.15	1.20	2.46	0.77	0.98
		Median	67.7	72.0	68.0	71.3	70.3	74.0
		Min, Max	53, 85	45, 106	45, 101	51, 103	45, 106	50, 107
	Change	n	5	103	108	25	241	170
		Mean(SD)	-3.7(4.80)	-2.3(9.62)	-4.8(10.26)	-3.6(10.39)	-3.6(9.94)	0.3(9.94)
		SEM	2.15	0.95	0.99	2.08	0.64	0.76
		Median	-4.3	-1.7	-5.7	-2.3	-3.0	0.7
		Min, Max	-11, 2	-36, 17	-37, 42	-23, 16	-37, 42	-34, 31
Week 4	Actual	n	4	72	105	0	181	117
		Mean(SD)	73.7(3.90)	71.0(12.35)	70.9(12.47)		71.0(12.26)	74.7(10.48)
		SEM	1.95	1.46	1.22		0.91	0.97
		Median	74.3	72.2	71.3		71.3	74.7
		Min, Max	68, 78	46, 99	47, 107		46, 107	52, 101

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Week 4	Change	n	4	72	105	0	181	117
		Mean(SD)	-1.4(5.61)	-3.1(10.11)	-3.5(9.52)		-3.3(9.66)	-0.4(10.83)
		SEM	2.80	1.19	0.93		0.72	1.00
		Median	-1.8	-1.0	-3.3		-3.0	0.3
		Min, Max	-7, 5	-26, 20	-30, 29		-30, 29	-38, 25
Week 6	Actual	n	4	96	101	21	222	158
		Mean(SD)	72.1(10.76)	72.0(11.96)	71.1(11.93)	71.0(14.18)	71.5(12.08)	74.7(12.93)
		SEM	5.38	1.22	1.19	3.10	0.81	1.03
		Median	73.7	70.3	72.7	69.0	71.3	72.8
		Min, Max	58, 83	46, 110	43, 95	47, 100	43, 110	42, 105
	Change	n	4	96	101	21	222	158
		Mean(SD)	-3.0(9.41)	-1.8(11.88)	-3.4(10.62)	-4.1(13.51)	-2.7(11.41)	-0.5(10.24)
		SEM	4.70	1.21	1.06	2.95	0.77	0.81
		Median	-2.8	-0.8	-4.3	-4.0	-2.7	-0.7
		Min, Max	-14, 8	-33, 32	-31, 38	-38, 33	-38, 38	-30, 38

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Baseline	Actual	n	5	110	112	27	254	177
		Mean(SD)	148.1(16.32)	157.1(25.92)	153.7(24.01)	158.3(19.22)	155.5(24.27)	158.4(22.59)
		SEM	7.30	2.47	2.27	3.70	1.52	1.70
		Median	147.3	153.8	151.3	152.7	152.7	157.3
		Min, Max	127, 171	94, 301	93, 247	132, 206	93, 301	101, 236
Week 2	Actual	n	5	102	108	25	240	168
		Mean(SD)	143.9(11.31)	157.6(25.12)	156.6(25.12)	155.8(16.41)	156.6(24.13)	157.7(21.08)
		SEM	5.06	2.49	2.42	3.28	1.56	1.63
		Median	143.3	153.8	155.0	156.0	154.2	155.0
		Min, Max	127, 155	103, 293	87, 240	130, 197	87, 293	106, 219
	Change	n	5	102	108	25	240	168
		Mean(SD)	-4.2(6.70)	1.3(9.32)	2.1(13.36)	-1.7(6.28)	1.2(11.10)	-0.5(12.71)
		SEM	3.00	0.92	1.29	1.26	0.72	0.98
		Median	-2.0	1.0	1.3	-3.3	0.2	-0.3
		Min, Max	-16, 1	-30, 25	-48, 47	-19, 13	-48, 47	-53, 62
Week 4	Actual	n	4	71	105	0	180	117
		Mean(SD)	149.1(22.90)	156.9(22.46)	154.8(23.64)		155.5(23.08)	156.8(21.76)
		SEM	11.45	2.67	2.31		1.72	2.01
		Median	150.0	156.0	150.0		153.0	153.7
		Min, Max	121, 176	99, 214	85, 213		85, 214	102, 230

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100 各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Week 4	Change	n	4	71	105	0	180	117
		Mean(SD)	0.8(5.34)	2.6(9.67)	0.6(12.66)		1.4(11.45)	-0.4(12.63)
		SEM	2.67	1.15	1.24		0.85	1.17
		Median	2.7	2.0	0.0		1.3	0.3
		Min, Max	-7, 5	-29, 27	-50, 42		-50, 42	-66, 43
Week 6	Actual	n	4	95	101	21	221	156
		Mean(SD)	151.8(21.78)	158.0(24.64)	156.0(24.14)	154.0(23.30)	156.6(24.13)	157.5(22.33)
		SEM	10.89	2.53	2.40	5.08	1.62	1.79
		Median	153.3	155.0	153.0	155.0	154.0	154.8
		Min, Max	124, 176	111, 277	91, 228	111, 200	91, 277	85, 229
	Change	n	4	95	101	21	221	156
		Mean(SD)	3.5(5.06)	1.6(10.72)	2.2(14.25)	-4.8(8.61)	1.3(12.35)	-1.0(14.20)
		SEM	2.53	1.10	1.42	1.88	0.83	1.14
		Median	4.3	1.3	2.7	-3.7	2.0	-0.7
		Min, Max	-3, 9	-31, 30	-43, 47	-22, 14	-43, 47	-83, 54

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Baseline	Actual	n	5	110	112	27	254	177
		Mean(SD)	93.4(17.01)	90.0(10.63)	90.8(11.59)	90.3(10.57)	90.4(11.13)	92.2(15.80)
		SEM	7.61	1.01	1.10	2.03	0.70	1.19
		Median	88.7	88.3	90.0	91.3	90.0	89.0
		Min, Max	77, 122	67, 147	56, 124	71, 112	56, 147	68, 153
Week 2	Actual	n	5	103	108	25	241	170
		Mean(SD)	95.7(15.45)	89.8(11.92)	90.2(10.71)	90.1(14.03)	90.2(11.65)	93.1(16.81)
		SEM	6.91	1.17	1.03	2.81	0.75	1.29
		Median	96.7	88.3	90.7	90.0	89.3	90.0
		Min, Max	75, 117	66, 153	58, 119	58, 127	58, 153	63, 169
	Change	n	5	103	108	25	241	170
		Mean(SD)	2.3(5.22)	-0.2(6.28)	-0.5(6.43)	0.0(5.65)	-0.2(6.24)	0.6(7.00)
		SEM	2.34	0.62	0.62	1.13	0.40	0.54
		Median	4.0	0.0	0.0	0.0	0.0	-0.7
		Min, Max	-4, 8	-14, 43	-27, 17	-15, 15	-27, 43	-15, 50
Week 4	Actual	n	4	72	105	0	181	117
		Mean(SD)	94.3(18.22)	88.8(11.46)	89.7(11.13)		89.4(11.38)	92.0(16.28)
		SEM	9.11	1.35	1.09		0.85	1.50
		Median	89.0	88.0	89.3		88.7	90.3
		Min, Max	79, 120	54, 133	64, 127		54, 133	32, 145

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100 各評価時点での心電図パラメータ及びベースラインからの変化量：
プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Week 4	Change	n	4	72	105	0	181	117
		Mean(SD)	1.2(1.91)	-1.0(6.38)	-1.1(7.83)		-1.0(7.19)	0.6(9.02)
		SEM	0.96	0.75	0.76		0.53	0.83
		Median	1.3	-0.5	-0.7		-0.7	0.7
		Min, Max	-1, 3	-30, 16	-41, 17		-41, 17	-56, 45
Week 6	Actual	n	4	96	101	21	222	158
		Mean(SD)	93.7(18.13)	89.1(11.82)	90.0(11.63)	87.9(9.87)	89.5(11.63)	92.9(16.73)
		SEM	9.07	1.21	1.16	2.15	0.78	1.33
		Median	88.0	88.0	90.0	88.0	89.2	89.7
		Min, Max	79, 120	61, 157	59, 123	71, 102	59, 157	63, 161
	Change	n	4	96	101	21	222	158
		Mean(SD)	0.6(1.60)	-1.0(6.02)	-0.8(7.69)	-0.7(6.01)	-0.8(6.76)	0.1(6.80)
		SEM	0.80	0.61	0.77	1.31	0.45	0.54
		Median	1.0	0.0	-0.7	-0.3	-0.3	0.0
		Min, Max	-2, 2	-23, 16	-37, 23	-22, 8	-37, 23	-24, 45

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100 各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Baseline	Actual	n	5	110	112	27	254	177
		Mean(SD)	382.5(21.09)	390.7(34.94)	387.5(32.27)	373.9(28.91)	387.4(33.17)	384.5(31.94)
		SEM	9.43	3.33	3.05	5.56	2.08	2.40
		Median	368.3	386.7	386.7	367.3	385.3	382.7
		Min, Max	366, 411	307, 471	309, 467	311, 435	307, 471	304, 460
Week 2	Actual	n	5	103	108	25	241	170
		Mean(SD)	394.9(35.20)	394.5(31.37)	396.2(31.71)	383.4(32.88)	394.1(31.77)	383.7(34.05)
		SEM	15.74	3.09	3.05	6.58	2.05	2.61
		Median	379.3	389.0	398.2	379.7	392.7	382.3
		Min, Max	355, 441	329, 479	321, 459	288, 450	288, 479	300, 536
	Change	n	5	103	108	25	241	170
		Mean(SD)	12.3(19.06)	3.7(23.98)	8.8(24.92)	11.7(20.76)	7.0(24.07)	-0.9(23.05)
		SEM	8.53	2.36	2.40	4.15	1.55	1.77
		Median	10.0	5.3	7.8	13.3	7.3	-0.8
		Min, Max	-11, 42	-54, 66	-79, 70	-30, 65	-79, 70	-74, 77
Week 4	Actual	n	4	72	105	0	181	117
		Mean(SD)	392.6(12.10)	396.9(36.38)	392.6(30.86)		394.3(32.85)	385.9(28.04)
		SEM	6.05	4.29	3.01		2.44	2.59
		Median	389.3	393.8	390.0		392.0	384.0
		Min, Max	382, 410	321, 489	326, 482		321, 489	326, 478

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100 各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Week 4	Change	n	4	72	105	0	181	117
		Mean(SD)	6.5(12.79)	7.5(25.02)	6.0(23.13)		6.6(23.65)	2.0(25.17)
		SEM	6.40	2.95	2.26		1.76	2.33
		Median	7.3	5.3	6.0		6.0	0.0
		Min, Max	-7, 19	-56, 69	-57, 68		-57, 69	-65, 82
Week 6	Actual	n	4	96	101	21	222	158
		Mean(SD)	391.1(28.78)	393.1(32.76)	394.8(29.26)	382.2(28.91)	392.8(30.79)	386.8(32.78)
		SEM	14.39	3.34	2.91	6.31	2.07	2.61
		Median	381.7	390.7	390.3	376.7	389.2	385.8
		Min, Max	368, 433	307, 468	337, 499	325, 432	307, 499	321, 495
	Change	n	4	96	101	21	222	158
		Mean(SD)	5.0(15.46)	3.8(28.87)	8.1(24.29)	11.1(28.20)	6.5(26.59)	1.9(23.34)
		SEM	7.73	2.95	2.42	6.15	1.78	1.86
		Median	6.3	5.0	7.3	10.7	7.0	2.3
		Min, Max	-15, 22	-91, 61	-96, 87	-64, 61	-96, 87	-82, 96

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Baseline	Actual	n	5	110	112	27	254	177
		Mean(SD)	408.7(18.61)	414.5(20.63)	412.9(21.87)	401.8(24.47)	412.3(21.78)	412.0(20.34)
		SEM	8.32	1.97	2.07	4.71	1.37	1.53
		Median	407.0	414.8	411.2	399.7	411.0	412.3
		Min, Max	385, 437	342, 458	366, 465	347, 450	342, 465	365, 461
Week 2	Actual	n	5	103	108	25	241	170
		Mean(SD)	412.5(20.41)	414.4(18.89)	413.2(22.13)	401.6(23.86)	412.5(21.17)	411.5(22.24)
		SEM	9.13	1.86	2.13	4.77	1.36	1.71
		Median	418.3	414.7	416.0	398.7	414.0	411.5
		Min, Max	386, 438	370, 457	335, 466	345, 469	335, 469	364, 498
	Change	n	5	103	108	25	241	170
		Mean(SD)	3.8(9.84)	0.0(15.59)	0.3(15.16)	2.3(14.91)	0.5(15.17)	-0.6(14.79)
		SEM	4.40	1.54	1.46	2.98	0.98	1.13
		Median	1.3	0.0	0.3	2.0	0.3	0.0
		Min, Max	-10, 15	-56, 68	-68, 38	-24, 28	-68, 68	-73, 54
Week 4	Actual	n	4	72	105	0	181	117
		Mean(SD)	419.8(11.90)	416.7(20.59)	412.5(19.56)		414.3(19.89)	413.4(22.27)
		SEM	5.95	2.43	1.91		1.48	2.06
		Median	416.2	416.7	413.0		415.0	411.7
		Min, Max	410, 437	369, 465	365, 448		365, 465	363, 478

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

表 2.7.4.7－100　各評価時点での心電図パラメータ及びベースラインからの変化量：プラセボ対照二重盲検期間（海外試験__ISS）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] <40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
Week 4	Change	n	4	72	105	0	181	117
		Mean(SD)	5.0(4.38)	2.1(14.17)	0.1(14.63)		1.0(14.30)	2.5(15.20)
		SEM	2.19	1.67	1.43		1.06	1.40
		Median	5.5	-0.2	0.3		0.3	2.0
		Min, Max	0, 9	-41, 61	-51, 44		-51, 61	-34, 73
Week 6	Actual	n	4	96	101	21	222	158
		Mean(SD)	413.8(9.04)	414.8(20.21)	415.0(20.17)	401.0(13.56)	413.6(19.85)	413.7(22.30)
		SEM	4.52	2.06	2.01	2.96	1.33	1.77
		Median	409.8	412.7	413.3	399.0	410.7	411.8
		Min, Max	408, 427	366, 469	373, 469	381, 432	366, 469	368, 485
	Change	n	4	96	101	21	222	158
		Mean(SD)	-0.9(5.85)	1.1(16.60)	2.1(14.98)	3.7(16.29)	1.8(15.66)	1.2(13.92)
		SEM	2.93	1.69	1.49	3.55	1.05	1.11
		Median	1.8	2.2	2.0	0.7	1.8	0.2
		Min, Max	-10, 2	-48, 51	-37, 53	-26, 41	-48, 53	-34, 59

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.

5.3.5.3－2 Table 1.4.8.1より引用

表 2.7.4.7－101　QTcF 間隔のカテゴリカル解析結果：プラセボ対照二重盲検期間（海外試験__ISS）

			NBI-98854 Dose[a]					
Parameter	Category	Statistic	<40 mg (N=5)	40 mg (N=110)	80 mg (N=112)	100 mg (N=27)	All NBI-98854 (N=254)	Placebo (N=178)
QT	>450 msec	n (%)	0	10 (9.1)	7 (6.3)	0	17 (6.7)	7 (3.9)
	>480 msec	n (%)	0	2 (1.8)	2 (1.8)	0	4 (1.6)	2 (1.1)
	>500 msec	n (%)	0	0	0	0	0	1 (0.6)
QTcF	>450 msec	n (%)	0	11 (10.0)	5 (4.5)	1 (3.7)	17 (6.7)	11 (6.2)
	>480 msec	n (%)	0	0	0	0	0	2 (1.1)
	>500 msec	n (%)	0	0	0	0	0	0
QT	>30 msec increase from BL	n (%)	1 (20.0)	21 (19.1)	27 (24.1)	6 (22.2)	55 (21.7)	26 (14.6)
	>60 msec increase from BL	n (%)	0	3 (2.7)	3 (2.7)	2 (7.4)	8 (3.1)	5 (2.8)
QTcF	>30 msec increase from BL	n (%)	0	3 (2.7)	6 (5.4)	2 (7.4)	11 (4.3)	11 (6.2)
	>60 msec increase from BL	n (%)	0	1 (0.9)	0	0	1 (0.4)	1 (0.6)

BL = Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854 and the 80 mg column includes doses of 75 mg and 80 mg NBI-98854.
Note: Thresholds for each parameter are based on either the highest value or largest increase from baseline reported from Day 1 through Week 6. Subjects are counted only once within each threshold category.

5.3.5.3－2 Table 1.4.9.1 より引用

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Baseline	Actual	n	200	230	210	430
		Mean(SD)	73.7(12.61)	75.0(13.05)	75.0(13.06)	74.4(12.85)
		SEM	0.89	0.86	0.90	0.62
		Median	72.8	74.7	74.7	74.0
		Min, Max	45, 108	37, 112	37, 112	37, 112
Week 2	Actual	n	112	72	67	184
		Mean(SD)	71.1(11.92)	68.8(12.50)	68.9(12.61)	70.2(12.17)
		SEM	1.13	1.47	1.54	0.90
		Median	72.3	67.8	68.0	70.3
		Min, Max	45, 106	45, 101	45, 101	45, 106
	Change	n	112	72	67	184
		Mean(SD)	-2.4(9.86)	-5.3(9.91)	-5.6(10.12)	-3.6(9.95)
		SEM	0.93	1.17	1.24	0.73
		Median	-1.8	-6.0	-6.7	-3.0
		Min, Max	-36, 17	-26, 42	-26, 42	-36, 42
Week 4	Actual	n	100	187	171	287
		Mean(SD)	71.9(12.40)	72.4(12.05)	72.5(12.17)	72.2(12.16)
		SEM	1.24	0.88	0.93	0.72
		Median	72.2	71.7	72.0	72.0
		Min, Max	46, 105	45, 109	45, 109	45, 109

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 4	Change	n	100	187	171	287
		Mean(SD)	-2.4(9.97)	-3.2(10.65)	-3.1(10.95)	-2.9(10.41)
		SEM	1.00	0.78	0.84	0.61
		Median	-1.7	-2.3	-2.3	-2.3
		Min, Max	-26, 34	-49, 35	-49, 35	-49, 35
Week 6	Actual	n	101	66	61	167
		Mean(SD)	71.7(12.54)	69.4(12.32)	69.5(12.31)	70.8(12.47)
		SEM	1.25	1.52	1.58	0.96
		Median	70.3	70.0	69.3	70.3
		Min, Max	46, 110	43, 94	43, 94	43, 110
	Change	n	101	66	61	167
		Mean(SD)	-2.6(11.85)	-4.5(9.31)	-4.9(9.15)	-3.4(10.92)
		SEM	1.18	1.15	1.17	0.85
		Median	-1.7	-5.5	-5.7	-2.7
		Min, Max	-38, 33	-31, 17	-31, 13	-38, 33
Week 8	Actual	n	159	206	186	365
		Mean(SD)	70.6(11.51)	71.7(12.00)	71.2(11.97)	71.2(11.78)
		SEM	0.91	0.84	0.88	0.62
		Median	69.7	70.2	69.7	70.0
		Min, Max	45, 102	46, 110	46, 110	45, 110

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 8	Change	n	159	206	186	365
		Mean(SD)	-3.8(10.64)	-3.1(10.82)	-3.5(11.03)	-3.4(10.73)
		SEM	0.84	0.75	0.81	0.56
		Median	-3.7	-3.7	-4.3	-3.7
		Min, Max	-42, 32	-39, 40	-39, 40	-42, 40
Week 12	Actual	n	140	196	178	336
		Mean(SD)	71.5(11.46)	73.6(11.72)	73.3(11.75)	72.7(11.64)
		SEM	0.97	0.84	0.88	0.64
		Median	70.8	73.0	72.5	72.0
		Min, Max	43, 98	46, 109	46, 109	43, 109
	Change	n	140	196	178	336
		Mean(SD)	-2.9(11.47)	-1.1(11.35)	-1.3(11.37)	-1.8(11.42)
		SEM	0.97	0.81	0.85	0.62
		Median	-1.8	-1.0	-1.0	-1.3
		Min, Max	-44, 25	-34, 47	-34, 47	-44, 47
Week 24	Actual	n	93	156	146	249
		Mean(SD)	70.3(11.90)	72.1(12.24)	72.1(12.48)	71.4(12.12)
		SEM	1.23	0.98	1.03	0.77
		Median	68.0	71.7	71.7	70.7
		Min, Max	45, 100	46, 101	46, 101	45, 101

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 24	Change	n	93	156	146	249
		Mean(SD)	-3.5(11.87)	-2.4(10.85)	-2.6(10.87)	-2.8(11.23)
		SEM	1.23	0.87	0.90	0.71
		Median	-3.0	-2.2	-2.7	-2.3
		Min, Max	-41, 19	-34, 35	-34, 35	-41, 35
Week 36	Actual	n	75	118	111	193
		Mean(SD)	71.5(11.43)	72.4(12.91)	72.7(12.88)	72.1(12.33)
		SEM	1.32	1.19	1.22	0.89
		Median	71.7	71.2	72.0	71.7
		Min, Max	42, 95	43, 100	43, 100	42, 100
	Change	n	75	118	111	193
		Mean(SD)	-2.1(12.40)	-1.6(12.00)	-1.7(12.28)	-1.8(12.13)
		SEM	1.43	1.10	1.17	0.87
		Median	-1.7	-1.8	-2.3	-1.7
		Min, Max	-39, 32	-38, 39	-38, 39	-39, 39
Week 48	Actual	n	68	87	83	155
		Mean(SD)	71.8(11.88)	72.5(11.53)	72.6(11.72)	72.2(11.65)
		SEM	1.44	1.24	1.29	0.94
		Median	69.3	71.3	71.3	70.7
		Min, Max	48, 106	47, 101	47, 101	47, 106

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: ECG Heart Rate (beats/min)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 48	Change	n	68	87	83	155
		Mean(SD)	-2.3(11.56)	-2.7(12.32)	-3.1(12.35)	-2.5(11.95)
		SEM	1.40	1.32	1.36	0.96
		Median	-1.5	-4.0	-4.0	-3.0
		Min, Max	-36, 23	-27, 32	-27, 32	-36, 32
Week 52	Actual	n	67	81	77	148
		Mean(SD)	72.3(12.60)	75.1(13.57)	75.8(13.45)	73.8(13.17)
		SEM	1.54	1.51	1.53	1.08
		Median	72.0	76.0	76.3	74.2
		Min, Max	43, 99	47, 114	47, 114	43, 114
	Change	n	67	81	77	148
		Mean(SD)	-1.6(11.96)	0.3(11.18)	0.5(11.38)	-0.5(11.54)
		SEM	1.46	1.24	1.30	0.95
		Median	-0.7	0.3	0.3	-0.3
		Min, Max	-37, 26	-29, 29	-29, 29	-37, 29

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Baseline	Actual	n	199	230	210	429
		Mean(SD)	157.5(24.54)	159.2(25.37)	158.5(25.41)	158.4(24.97)
		SEM	1.74	1.67	1.75	1.21
		Median	154.3	155.3	154.7	154.7
		Min, Max	94, 301	93, 257	93, 257	93, 301
Week 2	Actual	n	111	72	67	183
		Mean(SD)	157.8(24.02)	157.5(26.93)	155.9(25.73)	157.7(25.13)
		SEM	2.28	3.17	3.14	1.86
		Median	154.7	154.5	154.3	154.7
		Min, Max	103, 293	87, 240	87, 240	87, 293
	Change	n	111	72	67	183
		Mean(SD)	1.1(9.37)	2.7(13.10)	2.2(12.34)	1.7(10.98)
		SEM	0.89	1.54	1.51	0.81
		Median	1.0	0.8	1.3	1.0
		Min, Max	-30, 25	-48, 47	-48, 42	-48, 47
Week 4	Actual	n	98	187	171	285
		Mean(SD)	158.4(23.10)	161.0(24.61)	160.3(24.50)	160.1(24.09)
		SEM	2.33	1.80	1.87	1.43
		Median	157.8	158.7	158.0	158.3
		Min, Max	99, 215	85, 251	85, 251	85, 251

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 4	Change	n	98	187	171	285
		Mean(SD)	3.1(10.79)	0.7(11.41)	0.6(11.64)	1.6(11.24)
		SEM	1.09	0.83	0.89	0.67
		Median	2.5	0.3	0.0	1.7
		Min, Max	-29, 43	-48, 42	-48, 42	-48, 43
Week 6	Actual	n	100	66	61	166
		Mean(SD)	157.7(24.94)	157.7(26.41)	157.1(27.11)	157.7(25.45)
		SEM	2.49	3.25	3.47	1.98
		Median	155.0	154.0	153.0	154.7
		Min, Max	111, 277	91, 228	91, 228	91, 277
	Change	n	100	66	61	166
		Mean(SD)	0.7(11.03)	3.9(13.67)	4.7(12.65)	2.0(12.21)
		SEM	1.10	1.68	1.62	0.95
		Median	0.7	2.7	2.7	2.0
		Min, Max	-31, 30	-35, 47	-19, 47	-35, 47
Week 8	Actual	n	157	204	184	361
		Mean(SD)	157.6(23.69)	159.1(24.01)	158.7(23.87)	158.4(23.85)
		SEM	1.89	1.68	1.76	1.26
		Median	155.0	155.7	154.7	155.3
		Min, Max	98, 287	86, 256	86, 256	86, 287

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 8	Change	n	157	204	184	361
		Mean(SD)	0.6(10.83)	-0.1(12.75)	0.3(12.79)	0.2(11.94)
		SEM	0.86	0.89	0.94	0.63
		Median	1.3	-0.5	-0.2	0.7
		Min, Max	-29, 38	-60, 48	-60, 48	-60, 48
Week 12	Actual	n	138	196	178	334
		Mean(SD)	157.5(22.50)	158.7(24.10)	158.3(24.23)	158.2(23.43)
		SEM	1.92	1.72	1.82	1.28
		Median	154.7	156.3	155.5	155.3
		Min, Max	79, 271	91, 256	91, 256	79, 271
	Change	n	138	196	178	334
		Mean(SD)	0.0(12.34)	-0.3(13.20)	0.1(13.42)	-0.1(12.83)
		SEM	1.05	0.94	1.01	0.70
		Median	0.2	0.0	0.0	0.0
		Min, Max	-54, 32	-65, 48	-65, 48	-65, 48
Week 24	Actual	n	93	156	146	249
		Mean(SD)	157.1(20.17)	160.8(26.15)	159.9(25.71)	159.4(24.11)
		SEM	2.09	2.09	2.13	1.53
		Median	153.3	159.7	158.3	156.7
		Min, Max	113, 207	72, 269	72, 269	72, 269

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 24	Change	n	93	156	146	249
		Mean(SD)	0.9(11.02)	1.4(11.49)	1.6(11.63)	1.2(11.30)
		SEM	1.14	0.92	0.96	0.72
		Median	1.3	1.3	1.3	1.3
		Min, Max	-28, 34	-24, 37	-24, 37	-28, 37
Week 36	Actual	n	75	118	111	193
		Mean(SD)	155.8(18.22)	159.8(25.95)	159.1(25.46)	158.2(23.28)
		SEM	2.10	2.39	2.42	1.68
		Median	155.3	158.0	158.0	156.7
		Min, Max	110, 206	88, 274	88, 274	88, 274
	Change	n	75	118	111	193
		Mean(SD)	-0.9(12.73)	3.6(13.21)	3.5(13.02)	1.9(13.19)
		SEM	1.47	1.22	1.24	0.95
		Median	0.3	2.7	2.7	1.3
		Min, Max	-35, 33	-32, 54	-32, 54	-35, 54
Week 48	Actual	n	67	86	83	153
		Mean(SD)	154.9(17.84)	160.9(25.70)	160.9(25.28)	158.3(22.72)
		SEM	2.18	2.77	2.77	1.84
		Median	152.7	157.0	157.3	155.7
		Min, Max	107, 203	90, 261	90, 261	90, 261

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: PR Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 48	Change	n	67	86	83	153
		Mean(SD)	-1.3(12.63)	5.9(13.60)	6.0(13.47)	2.8(13.62)
		SEM	1.54	1.47	1.48	1.10
		Median	0.0	5.0	5.3	3.3
		Min, Max	-27, 36	-31, 54	-31, 54	-31, 54
Week 52	Actual	n	67	81	77	148
		Mean(SD)	155.9(18.64)	157.1(22.63)	156.4(21.69)	156.6(20.86)
		SEM	2.28	2.51	2.47	1.71
		Median	154.3	155.3	155.3	155.0
		Min, Max	99, 209	91, 221	91, 215	91, 221
	Change	n	67	81	77	148
		Mean(SD)	-1.0(12.34)	2.0(15.31)	1.9(15.21)	0.7(14.08)
		SEM	1.51	1.70	1.73	1.16
		Median	2.7	2.7	2.7	2.7
		Min, Max	-34, 19	-55, 51	-55, 51	-55, 51

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Baseline	Actual	n	200	230	210	430
		Mean(SD)	90.0(11.96)	91.7(13.72)	90.8(12.95)	90.9(12.95)
		SEM	0.85	0.90	0.89	0.62
		Median	88.7	90.0	89.5	89.3
		Min, Max	67, 147	56, 144	56, 144	56, 147
Week 2	Actual	n	112	72	67	184
		Mean(SD)	90.3(12.55)	90.0(10.54)	89.9(10.55)	90.2(11.78)
		SEM	1.19	1.24	1.29	0.87
		Median	88.8	91.0	91.3	90.0
		Min, Max	58, 153	58, 119	58, 119	58, 153
	Change	n	112	72	67	184
		Mean(SD)	0.3(6.23)	-0.3(6.14)	-0.6(5.90)	0.1(6.18)
		SEM	0.59	0.72	0.72	0.46
		Median	0.7	0.0	0.0	0.3
		Min, Max	-15, 43	-20, 17	-20, 17	-20, 43
Week 4	Actual	n	100	187	171	287
		Mean(SD)	89.1(13.14)	90.1(12.91)	89.4(11.83)	89.7(12.98)
		SEM	1.31	0.94	0.91	0.77
		Median	87.0	89.3	89.3	89.0
		Min, Max	54, 159	61, 139	61, 139	54, 159

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 4	Change	n	100	187	171	287
		Mean(SD)	-0.9(6.43)	-1.8(7.14)	-1.8(6.88)	-1.5(6.90)
		SEM	0.64	0.52	0.53	0.41
		Median	-0.3	-1.0	-1.0	-0.7
		Min, Max	-30, 16	-41, 16	-41, 16	-41, 16
Week 6	Actual	n	101	66	61	167
		Mean(SD)	88.8(12.05)	89.0(11.34)	89.4(11.58)	88.9(11.74)
		SEM	1.20	1.40	1.48	0.91
		Median	88.0	89.8	90.3	89.0
		Min, Max	61, 157	59, 122	59, 122	59, 157
	Change	n	101	66	61	167
		Mean(SD)	-0.9(6.12)	-1.3(7.65)	-1.2(7.84)	-1.1(6.75)
		SEM	0.61	0.94	1.00	0.52
		Median	0.0	-0.8	-0.7	-0.3
		Min, Max	-23, 16	-37, 23	-37, 23	-37, 23
Week 8	Actual	n	159	206	186	365
		Mean(SD)	89.5(12.36)	91.7(13.70)	90.8(12.90)	90.7(13.16)
		SEM	0.98	0.95	0.95	0.69
		Median	88.7	90.7	90.5	89.3
		Min, Max	62, 153	55, 147	55, 147	55, 153

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 8	Change	n	159	206	186	365
		Mean(SD)	-0.2(5.96)	0.2(8.00)	0.3(7.97)	0.0(7.18)
		SEM	0.47	0.56	0.58	0.38
		Median	0.0	0.2	0.3	0.0
		Min, Max	-20, 21	-31, 47	-30, 47	-31, 47
Week 12	Actual	n	140	196	178	336
		Mean(SD)	89.5(10.52)	91.5(14.23)	90.5(13.29)	90.7(12.84)
		SEM	0.89	1.02	1.00	0.70
		Median	88.8	89.3	89.0	89.3
		Min, Max	66, 143	53, 147	53, 147	53, 147
	Change	n	140	196	178	336
		Mean(SD)	-0.1(6.12)	-0.1(7.71)	-0.1(7.83)	-0.1(7.08)
		SEM	0.52	0.55	0.59	0.39
		Median	0.5	0.0	0.0	0.0
		Min, Max	-24, 29	-30, 45	-30, 45	-30, 45
Week 24	Actual	n	93	156	146	249
		Mean(SD)	89.6(11.16)	91.8(14.06)	91.0(13.21)	91.0(13.07)
		SEM	1.16	1.13	1.09	0.83
		Median	89.3	90.3	89.5	89.7
		Min, Max	66, 144	66, 142	66, 141	66, 144

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 24	Change	n	93	156	146	249
		Mean(SD)	-0.4(6.72)	-0.1(8.37)	0.0(8.40)	-0.2(7.78)
		SEM	0.70	0.67	0.70	0.49
		Median	0.0	-0.3	-0.3	-0.3
		Min, Max	-21, 14	-24, 45	-24, 45	-24, 45
Week 36	Actual	n	75	118	111	193
		Mean(SD)	90.0(12.78)	92.2(17.48)	92.0(17.69)	91.4(15.82)
		SEM	1.48	1.61	1.68	1.14
		Median	89.3	89.3	89.3	89.3
		Min, Max	61, 151	57, 203	57, 203	57, 203
	Change	n	75	118	111	193
		Mean(SD)	-0.4(6.93)	0.6(13.65)	0.7(14.01)	0.2(11.50)
		SEM	0.80	1.26	1.33	0.83
		Median	0.3	-0.7	-0.7	0.0
		Min, Max	-23, 18	-21, 105	-21, 105	-23, 105
Week 48	Actual	n	68	87	83	155
		Mean(SD)	90.1(12.42)	90.5(14.34)	90.5(14.52)	90.4(13.49)
		SEM	1.51	1.54	1.59	1.08
		Median	88.3	90.0	90.0	88.7
		Min, Max	69, 145	55, 153	55, 153	55, 153

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QRS Duration (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 48	Change	n	68	87	83	155
		Mean(SD)	-0.4(6.65)	0.1(11.81)	0.1(12.08)	-0.1(9.86)
		SEM	0.81	1.27	1.33	0.79
		Median	0.7	-0.7	-0.7	0.0
		Min, Max	-19, 13	-21, 54	-21, 54	-21, 54
Week 52	Actual	n	67	81	77	148
		Mean(SD)	90.9(12.44)	90.4(14.39)	90.3(14.57)	90.7(13.50)
		SEM	1.52	1.60	1.66	1.11
		Median	91.3	88.0	88.0	89.3
		Min, Max	64, 142	58, 150	58, 150	58, 150
	Change	n	67	81	77	148
		Mean(SD)	0.3(6.16)	0.0(11.32)	-0.2(11.43)	0.1(9.32)
		SEM	0.75	1.26	1.30	0.77
		Median	1.3	-2.0	-2.0	-0.7
		Min, Max	-16, 14	-21, 52	-21, 52	-21, 52

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Baseline	Actual	n	200	230	210	430
		Mean(SD)	386.0(33.03)	384.7(30.91)	384.7(30.47)	385.3(31.88)
		SEM	2.34	2.04	2.10	1.54
		Median	384.5	386.7	386.7	385.3
		Min, Max	304, 471	305, 467	309, 451	304, 471
Week 2	Actual	n	112	72	67	184
		Mean(SD)	391.8(31.82)	395.9(31.98)	396.4(30.85)	393.4(31.86)
		SEM	3.01	3.77	3.77	2.35
		Median	385.3	398.5	397.7	389.2
		Min, Max	288, 479	321, 459	325, 459	288, 479
	Change	n	112	72	67	184
		Mean(SD)	5.2(23.96)	9.7(23.58)	11.6(22.49)	7.0(23.85)
		SEM	2.26	2.78	2.75	1.76
		Median	6.0	9.3	11.3	7.3
		Min, Max	-54, 66	-79, 70	-79, 70	-79, 70
Week 4	Actual	n	100	187	171	287
		Mean(SD)	393.0(35.83)	389.1(33.55)	388.4(33.41)	390.5(34.35)
		SEM	3.58	2.45	2.55	2.03
		Median	390.3	389.0	388.0	389.7
		Min, Max	318, 489	288, 480	288, 480	288, 489

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 4	Change	n	100	187	171	287
		Mean(SD)	5.5(24.46)	6.3(25.20)	5.6(25.72)	6.0(24.91)
		SEM	2.45	1.84	1.97	1.47
		Median	5.0	4.7	4.7	4.7
		Min, Max	-56, 69	-73, 103	-73, 103	-73, 103
Week 6	Actual	n	101	66	61	167
		Mean(SD)	391.2(33.48)	395.5(30.87)	394.8(30.54)	392.9(32.45)
		SEM	3.33	3.80	3.91	2.51
		Median	387.3	392.7	390.3	388.7
		Min, Max	307, 468	337, 499	337, 499	307, 499
	Change	n	101	66	61	167
		Mean(SD)	5.9(27.93)	9.4(21.85)	10.3(21.10)	7.3(25.69)
		SEM	2.78	2.69	2.70	1.99
		Median	7.3	7.5	7.7	7.3
		Min, Max	-91, 61	-48, 87	-48, 87	-91, 87
Week 8	Actual	n	159	206	186	365
		Mean(SD)	394.1(31.41)	391.6(32.39)	392.2(32.71)	392.7(31.95)
		SEM	2.49	2.26	2.40	1.67
		Median	389.3	390.5	392.0	389.3
		Min, Max	329, 507	293, 471	293, 471	293, 507

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 8	Change	n	159	206	186	365
		Mean(SD)	9.7(24.95)	6.8(25.03)	7.4(25.15)	8.1(25.00)
		SEM	1.98	1.74	1.84	1.31
		Median	9.3	9.0	9.5	9.3
		Min, Max	-100, 80	-78, 75	-78, 75	-100, 80
Week 12	Actual	n	140	196	178	336
		Mean(SD)	391.0(32.08)	389.0(29.70)	388.9(30.25)	389.8(30.68)
		SEM	2.71	2.12	2.27	1.67
		Median	387.0	386.0	386.0	386.7
		Min, Max	312, 475	316, 486	316, 486	312, 486
	Change	n	140	196	178	336
		Mean(SD)	6.9(27.95)	3.4(27.15)	3.2(27.19)	4.9(27.50)
		SEM	2.36	1.94	2.04	1.50
		Median	9.0	2.5	2.2	4.5
		Min, Max	-73, 92	-88, 74	-88, 74	-88, 92
Week 24	Actual	n	93	156	146	249
		Mean(SD)	394.1(30.77)	392.8(33.61)	392.9(34.26)	393.3(32.52)
		SEM	3.19	2.69	2.84	2.06
		Median	396.0	391.8	391.2	392.7
		Min, Max	306, 467	308, 498	308, 498	306, 498

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 24	Change	n	93	156	146	249
		Mean(SD)	7.3(27.62)	5.7(27.15)	7.1(27.14)	6.3(27.28)
		SEM	2.86	2.17	2.25	1.73
		Median	8.7	5.0	7.3	6.0
		Min, Max	-61, 88	-62, 100	-62, 100	-62, 100
Week 36	Actual	n	75	118	111	193
		Mean(SD)	395.2(31.89)	390.8(32.45)	390.2(32.06)	392.5(32.22)
		SEM	3.68	2.99	3.04	2.32
		Median	392.7	391.7	390.7	392.0
		Min, Max	329, 483	313, 466	313, 466	313, 483
	Change	n	75	118	111	193
		Mean(SD)	6.9(29.58)	3.3(28.08)	3.6(28.77)	4.7(28.65)
		SEM	3.42	2.59	2.73	2.06
		Median	10.0	-1.0	0.0	3.3
		Min, Max	-84, 80	-61, 77	-61, 77	-84, 80
Week 48	Actual	n	68	87	83	155
		Mean(SD)	394.9(28.76)	394.2(30.69)	393.8(30.79)	394.5(29.76)
		SEM	3.49	3.29	3.38	2.39
		Median	392.7	392.0	391.3	392.0
		Min, Max	341, 470	336, 466	336, 466	336, 470

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QT Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 48	Change	n	68	87	83	155
		Mean(SD)	7.9(27.03)	6.8(25.79)	7.7(25.93)	7.3(26.26)
		SEM	3.28	2.77	2.85	2.11
		Median	8.7	8.3	9.3	8.7
		Min, Max	-63, 71	-62, 65	-62, 65	-63, 71
Week 52	Actual	n	67	81	77	148
		Mean(SD)	391.3(30.97)	387.2(31.68)	385.8(31.28)	389.1(31.32)
		SEM	3.78	3.52	3.56	2.57
		Median	387.3	386.0	385.3	386.8
		Min, Max	336, 473	321, 476	321, 476	321, 476
	Change	n	67	81	77	148
		Mean(SD)	4.0(27.26)	-0.7(24.50)	-0.7(25.03)	1.4(25.80)
		SEM	3.33	2.72	2.85	2.12
		Median	1.3	-2.0	-2.0	0.3
		Min, Max	-53, 79	-48, 65	-48, 65	-53, 79

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Baseline	Actual	n	200	230	210	430
		Mean(SD)	411.0(21.42)	411.5(22.26)	411.4(21.60)	411.3(21.85)
		SEM	1.51	1.47	1.49	1.05
		Median	409.5	412.8	412.8	411.8
		Min, Max	342, 458	312, 465	312, 465	312, 465
Week 2	Actual	n	112	72	67	184
		Mean(SD)	412.0(20.72)	411.3(22.45)	412.2(21.00)	411.7(21.35)
		SEM	1.96	2.65	2.57	1.57
		Median	411.8	413.7	415.0	412.0
		Min, Max	345, 469	335, 460	366, 460	335, 469
	Change	n	112	72	67	184
		Mean(SD)	0.7(16.23)	0.2(15.88)	1.8(13.39)	0.5(16.06)
		SEM	1.53	1.87	1.64	1.18
		Median	0.3	1.0	1.7	0.3
		Min, Max	-56, 68	-68, 38	-46, 38	-68, 68
Week 4	Actual	n	100	187	171	287
		Mean(SD)	414.3(21.32)	411.5(23.04)	410.9(22.66)	412.5(22.46)
		SEM	2.13	1.68	1.73	1.33
		Median	413.8	412.3	412.3	412.7
		Min, Max	363, 465	323, 478	323, 468	323, 478

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 4	Change	n	100	187	171	287
		Mean(SD)	1.0(14.44)	0.9(17.67)	0.4(17.47)	0.9(16.59)
		SEM	1.44	1.29	1.34	0.98
		Median	-1.0	1.7	0.3	0.3
		Min, Max	-44, 61	-86, 91	-86, 91	-86, 91
Week 6	Actual	n	101	66	61	167
		Mean(SD)	412.1(20.18)	412.3(20.32)	411.7(20.62)	412.2(20.18)
		SEM	2.01	2.50	2.64	1.56
		Median	409.7	409.2	409.0	409.3
		Min, Max	366, 469	373, 469	373, 469	366, 469
	Change	n	101	66	61	167
		Mean(SD)	1.6(17.10)	1.0(15.13)	1.2(14.52)	1.4(16.31)
		SEM	1.70	1.86	1.86	1.26
		Median	0.7	2.2	2.3	1.7
		Min, Max	-48, 51	-37, 53	-37, 53	-48, 53
Week 8	Actual	n	159	206	186	365
		Mean(SD)	413.7(19.81)	413.6(20.75)	413.0(20.58)	413.6(20.32)
		SEM	1.57	1.45	1.51	1.06
		Median	411.0	414.0	413.3	412.7
		Min, Max	371, 474	350, 472	350, 472	350, 474

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 8	Change	n	159	206	186	365
		Mean(SD)	3.7(16.47)	2.1(17.61)	1.6(16.56)	2.8(17.12)
		SEM	1.31	1.23	1.21	0.90
		Median	2.7	1.7	1.2	2.0
		Min, Max	-51, 64	-48, 106	-45, 106	-51, 106
Week 12	Actual	n	140	196	178	336
		Mean(SD)	411.9(21.05)	413.9(20.21)	413.2(19.97)	413.1(20.56)
		SEM	1.78	1.44	1.50	1.12
		Median	411.7	414.3	412.2	412.3
		Min, Max	358, 473	349, 470	349, 470	349, 473
	Change	n	140	196	178	336
		Mean(SD)	2.2(17.66)	1.9(18.64)	1.2(18.15)	2.0(18.21)
		SEM	1.49	1.33	1.36	0.99
		Median	1.7	0.5	0.3	1.3
		Min, Max	-68, 68	-58, 76	-58, 76	-68, 76
Week 24	Actual	n	93	156	146	249
		Mean(SD)	412.8(19.11)	414.7(22.60)	414.7(22.88)	414.0(21.34)
		SEM	1.98	1.81	1.89	1.35
		Median	414.0	413.5	413.5	413.7
		Min, Max	351, 467	333, 500	333, 500	333, 500

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 24	Change	n	93	156	146	249
		Mean(SD)	1.3(13.56)	1.6(18.83)	2.5(18.62)	1.5(17.02)
		SEM	1.41	1.51	1.54	1.08
		Median	1.0	2.3	3.3	2.3
		Min, Max	-31, 49	-62, 94	-62, 94	-62, 94
Week 36	Actual	n	75	118	111	193
		Mean(SD)	416.3(18.90)	413.2(23.32)	413.1(23.48)	414.4(21.71)
		SEM	2.18	2.15	2.23	1.56
		Median	414.0	415.0	415.0	414.7
		Min, Max	371, 461	337, 479	337, 479	337, 479
	Change	n	75	118	111	193
		Mean(SD)	4.0(15.18)	0.6(20.31)	0.9(20.57)	1.9(18.51)
		SEM	1.75	1.87	1.95	1.33
		Median	5.0	2.8	2.7	4.0
		Min, Max	-34, 37	-61, 94	-61, 94	-61, 94
Week 48	Actual	n	68	87	83	155
		Mean(SD)	416.9(19.83)	417.8(22.33)	417.5(22.36)	417.4(21.21)
		SEM	2.40	2.39	2.45	1.70
		Median	415.7	418.0	417.7	416.7
		Min, Max	374, 484	364, 476	364, 476	364, 484

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

表 2.7.4.7－102　各評価時点での心電図パラメータ及びベースラインからの変化量：
MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Parameter: QTcF Interval (msec)

Visit	Actual/ Change from Baseline	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
Week 48	Change	n	68	87	83	155
		Mean(SD)	5.0(19.18)	3.3(17.65)	3.4(18.01)	4.1(18.30)
		SEM	2.33	1.89	1.98	1.47
		Median	4.2	3.3	4.0	4.0
		Min, Max	-63, 53	-73, 60	-73, 60	-73, 60
Week 52	Actual	n	67	81	77	148
		Mean(SD)	413.4(18.78)	414.4(22.40)	414.2(22.81)	413.9(20.78)
		SEM	2.29	2.49	2.60	1.71
		Median	414.3	411.7	411.7	413.2
		Min, Max	365, 463	371, 470	371, 470	365, 470
	Change	n	67	81	77	148
		Mean(SD)	1.8(16.11)	0.0(16.29)	0.3(16.22)	0.8(16.18)
		SEM	1.97	1.81	1.85	1.33
		Median	1.0	0.0	1.0	0.8
		Min, Max	-30, 57	-31, 47	-31, 47	-31, 57

Max = Maximum; Min = Minimum; SD = Standard Deviation; SEM = Standard Error of the Mean.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.

5.3.5.3－3 Table 1.4.8.2 より引用

表 2.7.4.7－103　QTcF 間隔のカテゴリカル解析結果：MT-5199 長期投与期間（海外試験_120-Day Safety Update）

Period: Day 1 to Week 48

Parameter	Category	Statistic	NBI-98854 Dose[a] 40 mg (N=200)	80 mg (N=230)	80 mg Only[b] (N=210)	All NBI-98854 (N=430)
QT	>450 msec	n (%)	16 (8.0)	33 (14.3)	31 (14.8)	49 (11.4)
	>480 msec	n (%)	3 (1.5)	2 (0.9)	2 (1.0)	5 (1.2)
	>500 msec	n (%)	1 (0.5)	2 (0.9)	2 (1.0)	3 (0.7)
QTcF	>450 msec	n (%)	24 (12.0)	37 (16.1)	33 (15.7)	61 (14.2)
	>480 msec	n (%)	2 (1.0)	3 (1.3)	3 (1.4)	5 (1.2)
	>500 msec	n (%)	0	1 (0.4)	1 (0.5)	1 (0.2)
QT	>30 msec increase from BL	n (%)	66 (33.0)	78 (33.9)	72 (34.3)	144 (33.5)
	>60 msec increase from BL	n (%)	17 (8.5)	20 (8.7)	19 (9.0)	37 (8.6)
QTcF	>30 msec increase from BL	n (%)	21 (10.5)	38 (16.5)	33 (15.7)	59 (13.7)
	>60 msec increase from BL	n (%)	3 (1.5)	6 (2.6)	5 (2.4)	9 (2.1)

BL = Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: Thresholds for each parameter are based on either the highest value or largest increase from baseline reported within that treatment period (i.e., Day 1 to Week 48, or > Week 48 to Week 52). Subjects are counted only once within each threshold category.

表 2.7.4.7－103　QTcF 間隔のカテゴリカル解析結果：MT-5199 長期投与期間（海外試験_120-Day Safety Update）（続き）

Period: > Week 48 to Week 52

Parameter	Category	Statistic	NBI-98854 Dose[a] 40 mg (N=68)	80 mg (N=84)	80 mg Only[b] (N=80)	All NBI-98854 (N=152)
QT	>450 msec	n (%)	4 (5.9)	4 (4.8)	3 (3.8)	8 (5.3)
	>480 msec	n (%)	0	0	0	0
	>500 msec	n (%)	0	0	0	0
QTcF	>450 msec	n (%)	1 (1.5)	3 (3.6)	3 (3.8)	4 (2.6)
	>480 msec	n (%)	0	0	0	0
	>500 msec	n (%)	0	0	0	0
QT	>30 msec increase from BL	n (%)	9 (13.2)	9 (10.7)	9 (11.3)	18 (11.8)
	>60 msec increase from BL	n (%)	3 (4.4)	1 (1.2)	1 (1.3)	4 (2.6)
QTcF	>30 msec increase from BL	n (%)	3 (4.4)	4 (4.8)	4 (5.0)	7 (4.6)
	>60 msec increase from BL	n (%)	0	0	0	0

BL = Baseline.
[a] 40 mg column includes doses of 40 mg and 50 mg NBI-98854.
[b] Subjects in the NBI-98854 80 mg column who did not have a dose reduction during the study. For Study 1304, includes subjects in the 80 mg NBI-98854 arm (double-blind and/or extension period) with no dose reduction. For Study 1402, includes subjects with a dose increase to 80 mg NBI-98854 after Week 4 with no dose reduction. These subjects are counted only once in the All NBI-98854 column.
Note: Thresholds for each parameter are based on either the highest value or largest increase from baseline reported within that treatment period (i.e., Day 1 to Week 48, or > Week 48 to Week 52). Subjects are counted only once within each threshold category.

5.3.5.3－3 Table 1.4.9.2 より引用

表 2.7.4.7－104　各評価時点での C-SSRS 評価結果：プラセボ対照二重盲検期間（MT-5199-J02 試験）

Analysis visit	Category Item	Statictics	MT-5199		All MT-5199	Placebo
			40 mg (N=85)	80 mg (N=84)	(N=169)	(N=84)
Any Suicidal Ideation or Suicidal Behavior Post-Baseline		n (%)	8 (9.4)	6 (7.1)	14 (8.3)	7 (8.3)
Lifetime		n	85	84	169	84
	Suicidal Ideation					
	Wish to be Dead	n (%)	33 (38.8)	37 (44.0)	70 (41.4)	32 (38.1)
	Non-Specific Active Suicidal Thoughts	n (%)	16 (18.8)	22 (26.2)	38 (22.5)	20 (23.8)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	14 (16.5)	14 (16.7)	28 (16.6)	16 (19.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	10 (11.8)	7 (8.3)	17 (10.1)	14 (16.7)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	8 (9.4)	7 (8.3)	15 (8.9)	8 (9.5)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	5 (5.9)	4 (4.8)	9 (5.3)	7 (8.3)
	Aborted or Self-Interrupted Attempt	n (%)	6 (7.1)	2 (2.4)	8 (4.7)	4 (4.8)
	Interrupted Attempt	n (%)	5 (5.9)	5 (6.0)	10 (5.9)	4 (4.8)
	Actual Attempt	n (%)	11 (12.9)	14 (16.7)	25 (14.8)	14 (16.7)
	Suicidal Behavior	n (%)	11 (12.9)	16 (19.0)	27 (16.0)	13 (15.5)
	Suicidal Ideation or Suicidal Behavior	n (%)	33 (38.8)	38 (45.2)	71 (42.0)	32 (38.1)
Past 3 Month		n	85	84	169	84
	Suicidal Ideation					
	Wish to be Dead	n (%)	8 (9.4)	6 (7.1)	14 (8.3)	4 (4.8)
	Non-Specific Active Suicidal Thoughts	n (%)	3 (3.5)	1 (1.2)	4 (2.4)	1 (1.2)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	2 (2.4)	1 (1.2)	3 (1.8)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	1 (1.2)	0 (0.0)	1 (0.6)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	9 (10.6)	6 (7.1)	15 (8.9)	4 (4.8)

表 2.7.4.7－104　各評価時点での C-SSRS 評価結果：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=85)	MT-5199 80 mg (N=84)	All MT-5199 (N=169)	Placebo (N=84)
Week 2		n	82	79	161	84
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.1)	4 (5.1)	9 (5.6)	4 (4.8)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.2)	0 (0.0)	1 (0.6)	1 (1.2)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.1)	4 (5.1)	9 (5.6)	4 (4.8)
Week 4		n	77	70	147	80
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.5)	3 (4.3)	8 (5.4)	2 (2.5)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.5)	3 (4.3)	8 (5.4)	2 (2.5)

表 2.7.4.7－104　各評価時点での C-SSRS 評価結果：プラセボ対照二重盲検期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199		All MT-5199	Placebo
			40 mg (N=85)	80 mg (N=84)	(N=169)	(N=84)
Week 6		n	70	59	129	80
	Suicidal Ideation					
	Wish to be Dead	n (%)	3 (4.3)	4 (6.8)	7 (5.4)	3 (3.8)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.4)	0 (0.0)	1 (0.8)	1 (1.3)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	3 (4.3)	4 (6.8)	7 (5.4)	3 (3.8)

5.3.5.1－1 Table 14.3.5.2.1.1 より引用

表 2.7.4.7－105　各評価時点での自殺念慮スコア最大値のシフトテーブル：プラセボ対照二重盲検期間（MT-5199-J02 試験）

Treatment	Total Non-missing	Past 3 Month Score	Maximum Suicidal Ideation Score (Day 1 through Week 6)					
			0	1	2	3	4	5
			n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
MT-5199 40 mg	83	0	73 (88.0)	2 (2.4)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)
		1	0 (0.0)	3 (3.6)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
		3	1 (1.2)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MT-5199 80 mg	82	0	71 (86.6)	5 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		1	4 (4.9)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
All MT-5199	165	0	144 (87.3)	7 (4.2)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)
		1	4 (2.4)	4 (2.4)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
		3	2 (1.2)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Placebo	84	0	76 (90.5)	3 (3.6)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)
		1	1 (1.2)	1 (1.2)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
		2	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Suicidal Ideation Items: 0=No suicidal ideation, 1=Wish to be dead, 2=Non-specific active suicidal thoughts, 3=Active suicidal ideation with any methods (not plan) without intent to act, 4=Active suicidal ideation with some intent to act, without specific plan, 5=Active suicidal ideation with specific plan and intent.

5.3.5.1－1 Table 14.3.5.2.2.1 より引用

表 2.7.4.7－106　自殺念慮又は自殺企図が認められた被験者の一覧：

プラセボ対照二重盲検期間・長期投与期間・長期投与終了後観察期間（MT-5199-J02 試験）

Subject	Treatment	Age	Sex	Preferred Term /Verbatim term	SAE	Severity	Causality	Action taken with study treatment	C-SSRS at Balinse			
									Lifetime		Past 3 Months	
									Suicidal Ideation	Suicidal Behavior	Suicidal Ideation	Suicidal Behavior
[redacted]	MT-5199 40 mg	4[redacted]	Female	Suicidal ideation /Suicide ideation	No	MODERATE	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	No	No	No
[redacted]	MT-5199 40 mg	2[redacted]	Male	Suicide attempt /Suicide attempt	No	MILD	REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
[redacted]	MT-5199 40 mg	2[redacted]	Female	Suicide attempt /Suicide attempt	No	MILD	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	Yes	Yes	Yes	No
[redacted]	MT-5199 80 mg	3[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	NOT APPLICABLE	Yes	Yes	No	No
[redacted]	MT-5199 40 mg	4[redacted]	Male	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	No	No	No	No
		4[redacted]	Male	Suicidal ideation /Suicidal ideation	Yes	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	No	No	No	No
		4[redacted]	Male	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	No	No	No	No
[redacted]	MT-5199 40 mg	4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE REDUCED	Yes	No	No	No
		4[redacted]	Female	Suicidal ideation /Worsening of suicidal ideation	No	SEVERE	REASONABLE POSSIBILITY	DRUG WITHDRAWN	Yes	No	No	No
[redacted]	MT-5199 80 mg	5[redacted]	Male	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	NOT APPLICABLE	No	No	No	No

MedDRA Version 23.0.

表 2.7.4.7－106　自殺念慮又は自殺企図が認められた被験者の一覧：

プラセボ対照二重盲検期間・長期投与期間・長期投与終了後観察期間（MT-5199-J02 試験）（続き）

Subject	Treatment	Age	Sex	Preferred Term /Verbatim term	SAE	Severity	Causality	Action taken with study treatment	C-SSRS at Balinse			
									Lifetime		Past 3 Months	
									Suicidal Ideation	Suicidal Behavior	Suicidal Ideation	Suicidal Behavior
[redacted]	MT-5199 80 mg	4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
		4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
		4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
		4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
		4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	Yes	Yes	No
		4[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	NOT APPLICABLE	Yes	Yes	Yes	No
[redacted]	MT-5199 40 mg	8[redacted]	Female	Suicidal ideation /Suicide feeling	No	MILD	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	No	No	No	No
[redacted]	MT-5199 40 mg	5[redacted]	Female	Suicide attempt /suicide attempt	Yes	MODERATE	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	No	No	No	No
[redacted]	MT-5199 80 mg	5[redacted]	Female	Suicidal ideation /Suicidal ideation	No	MODERATE	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	No	No	No	No
		5[redacted]	Female	Suicidal ideation /suicidal ideation	No	MODERATE	NO REASONABLE POSSIBILITY	NOT APPLICABLE	No	No	No	No

MedDRA Version 23.0.

表 2.7.4.7－106　自殺念慮又は自殺企図が認められた被験者の一覧：

プラセボ対照二重盲検期間・長期投与期間・長期投与終了後観察期間（MT-5199-J02 試験）（続き）

Subject	Treatment	Age	Sex	Preferred Term /Verbatim term	SAE	Severity	Causality	Action taken with study treatment	C-SSRS at Balinse			
									Lifetime		Past 3 Months	
									Suicidal Ideation	Suicidal Behavior	Suicidal Ideation	Suicidal Behavior
[redacted]	MT-5199 40 mg	6[redacted]	Male	Suicidal ideation /Suicidal Thoughts	No	MILD	NO REASONABLE POSSIBILITY	DOSE NOT CHANGED	Yes	No	No	No
[redacted]	MT-5199 40 mg	5[redacted]	Male	Suicidal ideation /Suicidal ideation	No	MILD	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	Yes	Yes	No	No
[redacted]	Placebo	6[redacted]	Female	Suicide attempt /Suicide attempt	Yes	MODERATE	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	Yes	No	No	No
[redacted]	MT-5199 80 mg	7[redacted]	Female	Suicide attempt /Suicidal attempt	No	MODERATE	NO REASONABLE POSSIBILITY	DRUG WITHDRAWN	No	No	No	No

MedDRA Version 23.0.

5.3.5.1－1 Listing 16.2.12 より引用

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Any Suicidal Ideation or Suicidal Behavior Post-Baseline		n (%)	26 (20.6)	20 (16.3)	14 (16.7)	46 (18.5)
Lifetime		n	126	123	84	249
	Suicidal Ideation					
	Wish to be Dead	n (%)	50 (39.7)	50 (40.7)	37 (44.0)	100 (40.2)
	Non-Specific Active Suicidal Thoughts	n (%)	26 (20.6)	31 (25.2)	21 (25.0)	57 (22.9)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	22 (17.5)	22 (17.9)	12 (14.3)	44 (17.7)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	17 (13.5)	13 (10.6)	8 (9.5)	30 (12.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	13 (10.3)	10 (8.1)	7 (8.3)	23 (9.2)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	10 (7.9)	6 (4.9)	3 (3.6)	16 (6.4)
	Aborted or Self-Interrupted Attempt	n (%)	8 (6.3)	4 (3.3)	2 (2.4)	12 (4.8)
	Interrupted Attempt	n (%)	7 (5.6)	7 (5.7)	4 (4.8)	14 (5.6)
	Actual Attempt	n (%)	18 (14.3)	21 (17.1)	15 (17.9)	39 (15.7)
	Suicidal Behavior	n (%)	17 (13.5)	23 (18.7)	16 (19.0)	40 (16.1)
	Suicidal Ideation or Suicidal Behavior	n (%)	50 (39.7)	51 (41.5)	38 (45.2)	101 (40.6)
Past 3 Month		n	126	123	84	249
	Suicidal Ideation					
	Wish to be Dead	n (%)	12 (9.5)	6 (4.9)	6 (7.1)	18 (7.2)
	Non-Specific Active Suicidal Thoughts	n (%)	4 (3.2)	1 (0.8)	1 (1.2)	5 (2.0)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	2 (1.6)	1 (0.8)	1 (1.2)	3 (1.2)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.4)
	Suicidal Ideation or Suicidal Behavior	n (%)	13 (10.3)	6 (4.9)	6 (7.1)	19 (7.6)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 2		n	82	79	59	161
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.1)	4 (5.1)	3 (5.1)	9 (5.6)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.6)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.1)	4 (5.1)	3 (5.1)	9 (5.6)
Week 4		n	77	70	50	147
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.5)	3 (4.3)	2 (4.0)	8 (5.4)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.5)	3 (4.3)	2 (4.0)	8 (5.4)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 6		n	70	59	39	129
	Suicidal Ideation					
	Wish to be Dead	n (%)	3 (4.3)	4 (6.8)	2 (5.1)	7 (5.4)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.8)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	3 (4.3)	4 (6.8)	2 (5.1)	7 (5.4)
Week 8		n	105	93	55	198
	Suicidal Ideation					
	Wish to be Dead	n (%)	7 (6.7)	6 (6.5)	2 (3.6)	13 (6.6)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.5)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	7 (6.7)	6 (6.5)	2 (3.6)	13 (6.6)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 12		n	100	81	47	181
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (5.0)	10 (12.3)	7 (14.9)	15 (8.3)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.0)	2 (2.5)	2 (4.3)	3 (1.7)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Suicidal Behavior	n (%)	1 (1.0)	0 (0.0)	0 (0.0)	1 (0.6)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (5.0)	10 (12.3)	7 (14.9)	15 (8.3)
Week 16		n	95	73	43	168
	Suicidal Ideation					
	Wish to be Dead	n (%)	9 (9.5)	8 (11.0)	6 (14.0)	17 (10.1)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.1)	1 (1.4)	1 (2.3)	2 (1.2)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	1 (1.1)	1 (1.4)	1 (2.3)	2 (1.2)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	9 (9.5)	8 (11.0)	6 (14.0)	17 (10.1)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 20		n	92	67	39	159
	Suicidal Ideation					
	Wish to be Dead	n (%)	6 (6.5)	8 (11.9)	6 (15.4)	14 (8.8)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.1)	1 (1.5)	1 (2.6)	2 (1.3)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	1 (1.1)	1 (1.5)	1 (2.6)	2 (1.3)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	6 (6.5)	8 (11.9)	6 (15.4)	14 (8.8)
Week 24		n	86	65	39	151
	Suicidal Ideation					
	Wish to be Dead	n (%)	7 (8.1)	7 (10.8)	5 (12.8)	14 (9.3)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	7 (8.1)	7 (10.8)	5 (12.8)	14 (9.3)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 28		n	85	61	37	146
	Suicidal Ideation					
	Wish to be Dead	n (%)	7 (8.2)	7 (11.5)	5 (13.5)	14 (9.6)
	Non-Specific Active Suicidal Thoughts	n (%)	2 (2.4)	0 (0.0)	0 (0.0)	2 (1.4)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	2 (2.4)	0 (0.0)	0 (0.0)	2 (1.4)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	2 (2.4)	0 (0.0)	0 (0.0)	2 (1.4)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Suicidal Behavior	n (%)	1 (1.2)	0 (0.0)	0 (0.0)	1 (0.7)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	7 (8.2)	7 (11.5)	5 (13.5)	14 (9.6)
Week 32		n	82	58	35	140
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.1)	6 (10.3)	5 (14.3)	11 (7.9)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.1)	6 (10.3)	5 (14.3)	11 (7.9)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 36		n	77	56	34	133
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (6.5)	6 (10.7)	5 (14.7)	11 (8.3)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	1 (1.8)	1 (2.9)	1 (0.8)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	1 (1.8)	1 (2.9)	1 (0.8)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (6.5)	6 (10.7)	5 (14.7)	11 (8.3)
Week 40		n	71	55	33	126
	Suicidal Ideation					
	Wish to be Dead	n (%)	3 (4.2)	6 (10.9)	5 (15.2)	9 (7.1)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Suicidal Behavior	n (%)	0 (0.0)	1 (1.8)	1 (3.0)	1 (0.8)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	3 (4.2)	6 (10.9)	5 (15.2)	9 (7.1)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 44		n	67	51	29	118
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (7.5)	6 (11.8)	4 (13.8)	11 (9.3)
	Non-Specific Active Suicidal Thoughts	n (%)	1 (1.5)	1 (2.0)	0 (0.0)	2 (1.7)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	1 (2.0)	0 (0.0)	1 (0.8)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	1 (2.0)	0 (0.0)	1 (0.8)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	5 (7.5)	6 (11.8)	4 (13.8)	11 (9.3)
Week 48		n	67	50	29	117
	Suicidal Ideation					
	Wish to be Dead	n (%)	5 (7.5)	8 (16.0)	7 (24.1)	13 (11.1)
	Non-Specific Active Suicidal Thoughts	n (%)	2 (3.0)	1 (2.0)	1 (3.4)	3 (2.6)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	2 (4.0)	2 (6.9)	2 (1.7)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	1 (2.0)	1 (3.4)	1 (0.9)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	1 (1.5)	0 (0.0)	0 (0.0)	1 (0.9)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	6 (9.0)	8 (16.0)	7 (24.1)	14 (12.0)

表 2.7.4.7－107　各評価時点での C-SSRS 評価結果：MT-5199 長期投与期間（MT-5199-J02 試験）（続き）

Analysis visit	Category Item	Statictics	MT-5199 40 mg (N=126)	MT-5199 80 mg (N=123)	MT-5199 80 mg (no dose reduction) (N=84)	All MT-5199 (N=249)
Week 52		n	66	49	28	115
	Suicidal Ideation					
	Wish to be Dead	n (%)	1 (1.5)	7 (14.3)	6 (21.4)	8 (7.0)
	Non-Specific Active Suicidal Thoughts	n (%)	0 (0.0)	3 (6.1)	3 (10.7)	3 (2.6)
	Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Some Intent to Act, without Specific Plan	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Active Suicidal Ideation with Specific Plan and Intent	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior					
	Preparatory Acts or Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Aborted or Self-Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Interrupted Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Actual Attempt	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Behavior	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Completed Suicide	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Suicidal Ideation or Suicidal Behavior	n (%)	1 (1.5)	7 (14.3)	6 (21.4)	8 (7.0)

5.3.5.1－1 Table 14.3.5.2.1.2 より引用

表 2.7.4.7－108　各評価時点での自殺念慮スコア最大値のシフトテーブル：MT-5199 長期投与期間（MT-5199-J02 試験）

Treatment	Total Non-missing	Past 3 Month Score	Maximum Suicidal Ideation Score (Day 1 through Week 48)					
			0	1	2	3	4	5
			n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
MT-5199 40 mg	123	0	95 (77.2)	11 (8.9)	3 (2.4)	1 (0.8)	1 (0.8)	2 (1.6)
		1	1 (0.8)	5 (4.1)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
		3	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.8)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MT-5199 80 mg	121	0	97 (80.2)	12 (9.9)	2 (1.7)	1 (0.8)	3 (2.5)	0 (0.0)
		1	2 (1.7)	2 (1.7)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MT-5199 80 mg (no dose reduction)	82	0	64 (78.0)	7 (8.5)	2 (2.4)	1 (1.2)	2 (2.4)	0 (0.0)
		1	2 (2.4)	2 (2.4)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
All MT-5199	244	0	192 (78.7)	23 (9.4)	5 (2.0)	2 (0.8)	4 (1.6)	2 (0.8)
		1	3 (1.2)	7 (2.9)	1 (0.4)	1 (0.4)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)
		3	1 (0.4)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	1 (0.4)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Suicidal Ideation Items: 0=No suicidal ideation, 1=Wish to be dead, 2=Non-specific active suicidal thoughts, 3=Active suicidal ideation with any methods (not plan) without intent to act, 4=Active suicidal ideation with some intent to act, without specific plan, 5=Active suicidal ideation with specific plan and intent.

5.3.5.1－1 Table 14.3.5.2.2.2 より引用

表 2.7.4.7－109　各評価時点での自殺念慮スコア最大値のシフトテーブル：MT-5199 長期投与終了後観察期間（MT-5199-J02 試験）

Treatment	Total Non-missing	Week 48 Score	Maximum Suicidal Ideation Score (After Week 48 through Week 52)					
			0	1	2	3	4	5
			n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
MT-5199 40 mg	66	0	62 (93.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		1	1 (1.5)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		2	2 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MT-5199 80 mg	49	0	40 (81.6)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)
		1	2 (4.1)	3 (6.1)	2 (4.1)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MT-5199 80 mg (no dose reduction)	28	0	20 (71.4)	0 (0.0)	1 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)
		1	2 (7.1)	2 (7.1)	2 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)
		2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	0 (0.0)	1 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
All MT-5199	115	0	102 (88.7)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
		1	3 (2.6)	4 (3.5)	2 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)
		2	2 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		3	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
		5	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Suicidal Ideation Items: 0=No suicidal ideation, 1=Wish to be dead, 2=Non-specific active suicidal thoughts, 3=Active suicidal ideation with any methods (not plan) without intent to act, 4=Active suicidal ideation with some intent to act, without specific plan, 5=Active suicidal ideation with specific plan and intent.

5.3.5.1－1 Table 14.3.5.2.2.3 より引用